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Abstract 
 
This thesis describes work carried out on the design of new routes to a range of 
bisindolylmaleimide and indolo[2,3-a]carbazole analogs, and investigation of their potential 
as successful anti-cancer agents.   
 
Following initial investigation of classical routes to indolo[2,3-a]pyrrolo[3,4-c]carbazole 
aglycons, a new strategy employing base-mediated condensation of thiourea and guanidine 
with a bisindolyl β-ketoester intermediate afforded novel 5,6-bisindolylpyrimidin-4(3H)-ones 
in moderate yields. Chemical diversity within this H-bonding scaffold was then studied by 
substitution with a panel of biologically relevant electrophiles, and by reductive 
desulfurisation. Optimisation of difficult heterogeneous literature conditions for oxidative 
desulfurisation of thiouracils was also accomplished, enabling a mild route to a novel 5,6-
bisindolyluracil pharmacophore to be developed within this work.  
 
The oxidative cyclisation of selected acyclic bisindolyl systems to form a new planar class of 
indolo[2,3-a]pyrimido[5,4-c]carbazoles was also investigated. Successful conditions for this 
transformation, as well as the limitations currently prevailing for this approach are discussed.  
Synthesis of 3,4-bisindolyl-5-aminopyrazole as a potential isostere of bisindolylmaleimide 
agents was encountered, along with a comprehensive derivatisation study, in order to probe 
the chemical space for potential protein backbone H-bonding interactions. Synthesis of a 
related 3,4-arylindolyl-5-aminopyrazole series was also undertaken, based on identification 
of potent kinase inhibition within a closely related heterocyclic template.  
 
Following synthesis of approximately 50 novel compounds with a diversity of H-bonding 
enzyme-interacting potential within these classes, biological studies confirmed that 
significant topo II inhibition was present for 9 lead compounds, in previously unseen 
pyrazolo[1,5-a]pyrimidine, indolo[2,3-c]carbazole and branched S,N-disubstituted thiouracil 
derivative series. NCI-60 cancer cell line growth inhibition data for 6 representative 
compounds also revealed interesting selectivity differences between each compound class, 
while a new pyrimido[5,4-c]carbazole agent strongly inhibited cancer cell division at 10 µM, 
with appreciable cytotoxic activity observed across several tumour types.  
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Abbreviations/ Definitions 
ABCG2      ATP-binding cassette G2 protein 
Abl             proto-oncogene protein kinase kinase ABL1 
AGC       PKA, PKG and PKC 
ALK       anaplastic lymphoma kinase 
AML       acute myeloid leukemia 
BIM       bisindolylmaleimide 
Boc       tert-butoxycarbonyl group 
Boc2O       t-butoxycarbonic anhydride 
BOM       benzyloxymethyl 
Brk       breast tumour kinase 
n-BuLi       n-butyllithium 
CAMK       calcium/ calmodulin-dependent protein kinases 
CAN                                                                           ceric ammonium nitrate                 
CDK1                                                                         cyclin-dependent kinase 1 (or cdc2) 
ChAT           Cas/Hef1-associated signal transducer protein 
ChK1       checkpoint kinase 1 
CK       casein kinase 
c-KIT       mast/ stem cell growth factor receptor 
c-Met       hepatocyte growth factor receptor 
CMGC      CDK, MAPK, GSK3 and CLK kinases 
CML       chronic myelogenous leukemia 
m-CPBA                                                                     m-chloroperoxybenzoic acid 
CPT       camptothecin 
CSK       c-src tyrosine kinase 
DBU                                                                           1,8-diazabicyclo[5.4.0]undec-7-ene 
DCC       dicyclohexylcarbodiimide 
DCE       1,2-dichloroethane 
DCM       dichloromethane 
DDQ              2,3-dichloro-5,6-dicyano-1,4-benzoquinone 
DMAD      dimethylacetylene dicarboxylate 
DMAP       N,N-dimethylaminopyridine 
DMB       3,4-dimethoxybenzyl 
DMDO      dimethyldioxirane 
DMF                                                                           N,N-dimethylformamide 
DMSO       dimethylsulfoxide 
EGFR       epidermal growth factor receptor 
EPT       ellipticine 
ErbB       erythroblastic leukemia viral oncogene 
FGFR       fibroblast growth factor receptor 
Flt3       fms-like tyrosine kinase receptor-3 
GPCR       G-protein coupled receptor 
GSK       glycogen synthase kinase 
HER2                human epidermal growth factor receptor 2 
HGF/SF      hepatocyte growth factor/ scatter factor 
HMPA       hexamethylphosphoramide 
HNSCC      head and neck squamous cell carcinoma 
IAA       indole-3-acetic acid 
ICZ       indolocarbazole 
IIQ       indenoisoquinoline 
vi 
 
IL-8       interleukin-8 
JAK       Janus kinase 
JNK       c-Jun N-terminal kinase 
KRAS             Kirsten rat sarcoma viral oncogene homolog 
LDA       lithium diisopropylamide 
LiHMDS      lithium hexamethyldisilazide 
MLK       multiple lineage kinase 
MOM       methoxymethyl     
NBS       N-bromosuccinimide 
NCI       National Cancer Institute 
NRTK       non-receptor tyrosine kinase 
NSCLC      non-small cell lung cancer 
PDB       Protein Databank 
PDGFR      platelet-derived growth factor receptor 
PDK       phosphoinositide-dependent kinase 
PIFA       phenyliodine bis(trifluoroacetate) 
PI3K       phosphoinositide-3-kinase 
PKB       Protein kinase B (or Akt) 
PKC       Protein kinase C 
PMB       p-methoxybenzyl 
POCl3       phosphorus oxychloride 
PPSE       polyphosphoric acid trimethylsilyl ester 
pp60
v-rsc
     proto-oncogene protein 60 (Rous sarcoma virus) 
RACK       receptor for activated C-kinase 
REB       rebeccamycin 
rt       room temperature 
SAR       structure-activity relationship 
SEM                 [2-(trimethylsilyl)ethoxy]methyl 
STA       staurosporine 
STE          homologs of yeast Sterile 7, 11 and 20 kinases 
TBAB       tetrabutylammonium bromide 
TBAF       tetrabutylammonium fluoride 
TBDMS      tert-butyldimethylsilyl 
Teoc       2-(trimethylsilyl)ethoxycarbonyl 
TFA       trifluoroacetic acid 
THF       tetrahydrofuran 
THP       tetrahydropyran 
TIPS       triisopropylsilyl 
TK       tyrosine kinases 
TKL       tyrosine kinase-like kinases 
T.M       transition metal 
TMS       trimethylsilyl 
Ts       p-toluenesulfonyl group 
p-TSA       p-toluenesulfonic acid 
U.V                                                                             ultra-violet 
VEGFR              vascular endothelial growth factor receptor 
ZAP-70      zeta-chain-associated protein kinase 70 
Δ       heat 
h       electromagnetic radiation 
W       microwave 
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“A man is as great as the thoughts he thinks,  
as the worth he has attained;  
As the fountains at which his spirit drinks,  
and the insight he has gained” 
- C.E. Flynn 
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1.0 Biological Introduction 
1.1 Cancer 
 
Cancer is a pernicious affliction which affects up to 1 in 3 people at some stage in life. It will 
also have an increasingly negative impact on global public health based on current trends of 
higher average life expectancy and elevated incidence of age-related diseases. According to 
a study by the NCRI, the number of new cases of invasive cancer in Ireland increased from 
17,148 in 1994 to 22,775 in 2005, an annual increase of 2.7%; the age-adjusted incidence 
rate (cases per 100,000 of population) increased by 1.1% annually for women and 0.9% for 
men over the same period. The largest increases in rate were in prostate cancer (7.1% annual 
increase), melanoma (3.3%) and breast cancer (2.4%), while increased mortality was also 
observed in melanoma (4.2%) and colorectal cancer (1.7%).
1
 Based on recent projections, 
the number of new cancer cases in Ireland will double between 2000 and 2020. 
 
The term cancer is applied specifically to a malignant neoplasm. Cells are deemed neoplastic 
when they fail to respond normally to the usual regulatory signals dictating cell growth.
2,3
 
This loss of cell control tends to result in excessive, unregulated cell proliferation - forming a 
lump or tissue mass in solid tumours called a neoplasm. Two types of neoplasm exist: 
benign and malignant, with the latter requiring that tumour cells attain several capacities, 
including hyper-proliferation, anchorage and growth-factor independency, evasion of 
apoptosis, angiogenesis and metastasis. 
 
The continuing quest to unearth a cure or prophylactic vaccine for this formidable collection 
of over 200 diseases in various tissues is one which has exercised the medicinal chemistry 
field over the past half-century. However, progress in this area has been rendered 
painstakingly slow due to the high toxicity of most front-line anti-cancer drug families, non-
selective killing of normal somatic cells, and increasingly, development of innate 
chemotherapeutic resistance, by means of drug efflux pumps and drug metabolism.
4-8
 
Multidrug efflux pumps, for example, p-glycoprotein, are perhaps the most important 
contributor to multidrug resistance and are capable of expelling multiple drug classes from 
within the cell environment. The expression of these pumps can also be upregulated by 
exposure to a single chemotherapeutic agent.
9-11
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Indolo[2,3-a]carbazole (ICZ) 1 was observed over the course of several screening programs 
to represent a privileged multiple site target scaffold (Fig. 1.1). Interest in anti-cancer ICZ 
drug discovery has arisen due to the untapped potential of these potent „lead‟ compounds to 
intervene through novel mechanisms in tumourigenesis signaling pathways, cell cycle 
surveillance, tumour perfusion and even in mediation of multi-drug resistance reversal. The 
normal roles of these cellular targets are altered in some cancers, wherein dysfunctions have 
been related to uncontrolled proliferation.
12-20
 
 
 
 
                                                                      1 
Fig. 1.1 Structure of indolo[2,3-a]carbazole 1 
1.2 Importance of indolocarbazole alkaloids 
 
“Progress lies not in enhancing what is, but in advancing toward what will be.” 
- Kahlil Gibran 
 
Initial interest in the possible use of indolocarbazole alkaloids as clinical anti-tumour agents 
began as a result of the discovery in 1977, by Omura and co-workers, of a natural product 
aminoglycoside, initially termed AM-2282, and later reclassified as staurosporine 2, from 
soil samples containing the actinomycete Streptomyces staurosporeus, a filamentous Gram-
positive microbe belonging to the phylum Actinobacteria (Fig. 1.2).
21
  
 
 
 
 
 
 
 
Fig. 1.2                                                                              2 
 
Actinomycetes are widely distributed in terrestrial and aquatic ecosystems, being involved in 
soil biodegradation and humus formation by the recycling of decomposing organic polymers 
such as keratin, lignocelluloses and chitin.
22,23
 Around 23,000 bioactive microbial natural 
products have been reported to date; 10,000 of these compounds are produced by 
actinomycetes, and around 75% of these are derived from Streptomyces species - the primary 
antibiotic-producing organisms in the pharmaceutical industry.
24
 Members of this group also  
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produce clinically useful anti-tumour drugs such as anthracyclines (aclarubicin, daunomycin 
and doxorubicin), peptides (bleomycin and actinomycin D), mitomycins and others.
25
 
 
Over the last 30 years, metabolites comprising the characteristic indolo[2,3-a]pyrrolo[3,4-
c]carbazole chromophore 3 have also been isolated from bacteria, fungi and invertebrates in 
diverse geographical locations (Fig. 1.3). In addition to fermentation of other producer 
strains such as Streptomyces hygroscopicus C39280-450-9 (ATCC 53730), Streptomyces sp. 
TP-A0274 and Streptomyces lividus ATCC 21178, staurosporine 2  has also been repeatedly 
isolated from field samples such as marine invertebrates Eudistoma toealensis (tunicate) and 
its predatory flatworm Pseudoceros sp.
16,26
 In 1992, Kinnel and Scheuer also extracted 11-
hydroxystaurosporine 4 and 3,11-dihydroxystaurosporine 5 (minor component) from the 
Pohnpei tunicate (Eudistoma sp.), which were the first ICZs isolated from a marine organism 
or animal. Both compounds were active against cancer cells, and 11-hydroxystaurosporine 4 
was more potent than STA 2 in PKC inhibition.
16,27
 K-252c 6 and arcyriaflavin A 7 are 
important indolo[2,3-a]carbazoles produced by the marine actinomycete strain Z2039-2; 
arcyriaflavin A 7 induced almost 70% apoptosis in a human chronic myelogenous leukemia 
K562 cell line at 100 μM, while more active K-252c 6 was found to induce greater than 50% 
apoptosis at 10 μM and nearly 100% at 100 μM, in the same assay (Fig. 1.3).25,28,29  
 
 
 
 
 
 
 
                         3                                                                                          R3=CH2 6    
                                                                                                                      R3=CO 7  
     R1=R2=H 2   
    R1=OH; R2=H 4  
Fig. 1.3    R1=OH; R2=OH 5 
 
Actinomycetes are ubiquitous from marine sources, being found in symbiosis with different 
invertebrates, especially sponges, or bioaccumulated through filter-feeding. The relatively 
unexplored marine ecosystem is a natural laboratory enveloping almost 70% of the Earth‟s 
surface and contains a multitude of microbial lifeforms with unique metabolic capabilities 
evolved over far longer timescales than terrestrial biology. In addition to producing 
metabolites with anti-tumour and other pharmacological activities, to modulate the chemical 
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effects of salinity, pressure and temperature in this environment, these compounds also 
mediate potent biochemical effects on marine eukaryotic organisms, including mammals.
25,30
 
Staurosporine 2 has been isolated, together with two natural analogues, 4‟-N-methyl-5‟-
hydroxystaurosporine 8 and 5‟-hydroxystaurosporine 9 from Micromonospora sp. L-31-
CLCO-002, obtained from a homogenate of the sponge Clathrina coriacea collected from 
Fuerteventura Island in the Canary Islands, and were five times more active than 
staurosporine 2 in vitro against colon adenocarcinoma HT29 cell line (Fig. 1.4).
31
 
 
 
 
 
 
                      R1=R2=H 2  
                       R1=OH; R2=CH3 8 
Fig. 1.4                                                                                    R1=OH; R2=H 9                                
 
Total synthesis of indolocarbazole analogues derived from actinomycetes is of critical 
importance due to ongoing pharmaceutical research into their SAR profiles, as well as 
practical difficulties in bioprospecting and culturing inefficient producer microorganisms, in 
order to access these congeners in sufficient multigram quantities for clinical trials.  
1.2.1 Staurosporine – a promiscuous lead for new inhibitor development 
 
Biosynthesis of 2 from two units of tryptophan, along with a glycosyl residue derived from 
glucose and methionine, is widespread among actinomycetes and has been frequently 
„rediscovered‟ in various natural product screening assays due to the wide range of 
biological potencies across multiple targets displayed by this compound.
25
 These effects 
include strong anti-fungal and hypotensive activity, inhibition of platelet aggregation and 
potent cytotoxicity in cell cultures of murine macrophage P388D1 (IC50 = 0.01 μg/mL), 
human lung adenocarcinoma A549 (IC50 = 0.0005 μg/mL) and melanoma SK-MEL-28 cell 
lines (IC50 = 0.001 μg/mL).
31
 Additionally, natural and synthetic analogues of staurosporine 
2 have been implicated in other mechanisms of neuroprotection, insecticidal activity, 
immunosuppression and reversal of multidrug resistance.
20,21,32-35
 An important breakthrough 
in this field was achieved in 1986, when 2 was found to be a nanomolar PKC inhibitor in 
vitro, and subsequently exhibited non-specific activity against at least 12 kinase targets 
including GSK-3β, CDK-2, MAPKK and PI3K.33 
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This high level of nonspecific toxicity is due to the fact that the catalytic domain of PKC is 
highly homologous to similar domains found in other protein kinases (e.g. pp60
v-src
, cAMP-
dependent protein kinase A, casein kinase etc.), each of which is critical for normal cell 
operation.
34,36
 Following determination of its absolute configuration by X-ray 
crystallography, staurosporine 2 was identified to closely mimic adenosine within the 
conserved ATP binding pocket, interfering in ATP-dependent cell homeostatic processes, 
and thus eliciting complex biological activity and toxicity profiles in vivo.
16,37,38
 
 
     
 
 
                                                        
                                                                                               10                                    
 
Fig. 1.5                
Illustrating the pharmaceutical potential derived from modified biosynthetic pathways, a 
blocked mutant of S. longisporoflavus R19 afforded 3‟-desmethylstaurosporine  10 – a less 
potent PKC inhibitor than 2, which selectively inhibited PKC subtypes α, β-2 and γ (Fig. 
1.5).
39
 Synthetic endeavours have also derived numerous active congeners with improved 
solubility, cell permeability and enhanced tumour cell line specificity. However, translation 
of indolocarbazole agents to the clinical milieu has been impaired due to an absence of 
complete molecular biology data for these compounds, as current deficiencies in the 
pharmacological profiles of these candidates extend to a lack of target enzyme specificity, as 
will be described, and perhaps other as yet unidentified modes of action in vivo.
40-43
 
1.3 Mechanisms of action of indolocarbazoles at the molecular level 
 
Active ICZ analogues possess immense potential to mediate anti-cancer effects through 
either kinase or topoisomerase inhibition. Since these enzymes perform a wide variety of 
regulatory roles orchestrating a vast repertoire of cellular responses, a discussion of how 
specific small-molecule inhibitors achieve desirable therapeutic outcomes is of immense 
benefit for design of selective ICZ analogues imparting improved therapeutic results based 
on these effects.  
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1.3.1 Protein kinase inhibition: From clinical challenges to selective candidates 
 
In the field of target identification there has been a great deal of enthusiasm for the prospect 
of identifying novel drug targets based on knowledge of key signal transduction components 
and their links to disease. Protein kinases modulate intracellular signal transmission by 
phosphorylating a hydroxyl group of residues in target proteins which are involved in signal 
pathways, with acute relevance to cancer, diabetes, immune system disorders, 
neurodegenerative disorders, cardiovascular disease and inflammation (Fig. 1.6).
44,45
 
 
(a)    (b) 
Fig. 1.6 (a) Transmembrane structure of HER (RTK); (b) Molecular model of staurosporine 2 within 
CDK2 binding pocket.
46,47
  
 
 Protein kinases constitute 22% of the medicinal genome, and a critical drug target in the 
post-genomic 21
st
 century landscape. As knowledge of the 518 enzymes that comprise the 
human „kinome‟ advances towards clinical applications, small-molecule kinase inhibition is 
now at the forefront of anti-cancer drug development, due to the current urgent need for 
versatile „single-target‟ anti-tumour therapies to overcome resistant cancers.45,48,49 
 
Signal transduction therapy achieves this aim by modulating individual upstream kinases 
across a number of families, discussed below, which participate in errant pathways leading 
to cancer progression, hyperproliferation and cell cycle evasion, with minimal interference 
on normal cell processes involving other kinases, and thus reducing the overall burden of 
systemic cytotoxicity within normally dividing somatic cells.
50,51
  
1.3.1.1 Classification of protein kinases: a target for signal transduction therapy 
 
Genes coding for protein kinases constitute 1.7% of the total number of human genes and are 
one of the largest and most functionally disparate gene families in nature, as they control the 
location and synchronised function of proteins, maintaining cellular homeostasis and 
orchestrating the flow of ubiquitous cellular processes. Kinases regulate normal signal 
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transduction from extracellular stimuli to intracellular signalling pathways by catalysing the 
transfer of the γ-phosphate group of adenosine triphosphate (ATP) 11 to the hydroxyl group 
of a peptide residue, affording a new phosphopeptide and adenosine diphosphate (ADP) 
12.
52
 In the case of membrane-bound RTKs, binding of a ligand to the extracellular domain 
induces receptor dimerisation and ATP-mediated mutual transphosphorylation of a 
phosphate-acceptor tyrosine residue (E-OH→E-PO4
3-
). The active enzyme phosphorylates 
downstream signalling proteins (i.e. protein „X‟ in Fig. 1.7) via its intracellular catalytic site 
and thus, elicits a vast array of cellular responses through initiation of multiple pathways. 
Activation of a corresponding transcription factor results in enhanced cell growth and 
proliferation, and in aberrant oncogene expression, this chain of events is a key influence on 
tumourigenesis (Fig. 1.7).
50
 
 
 
 
 
 
 
 
 
 
 
 
 
                        12                                   11 
 
 
 
Fig. 1.7: Molecular and supramolecular regulation of signal transduction by kinase-mediated protein 
phosphorylation (RTK) in the presence of ATP. 
 
The importance of kinase activity in cell metabolism was recognized in 1992, when Krebs 
and Fischer were awarded the Nobel Prize in physiology/medicine „for their discoveries 
concerning reversible protein phosphorylation as a biological regulatory mechanism‟.  
 
The absolute indispensability of kinase functions is demonstrated by the conservation of over 
50 distinct kinase families through sequence alignment between yeast, invertebrate and 
mammalian kinomes (Fig. 1.8). Of the 518 human protein kinases, 478 constitute the 
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„typical‟ kinase superfamily, known through sequence homology and their ability to transfer 
a phosphate group via conserved catalytic domains. 
 
Fig. 1.8: Phylogenetic relationship between human protein kinases, illustrating the location of critical 
targets for kinase modulating therapy.
35
 
 
Further phylogenetic studies led to differentiation of these kinases into 6 distinct groups 
catalysing phosphorylation of a Ser/Thr residue, and tyrosine kinases (TKs), that catalyse 
transfer of a phosphate group from ATP to a tyrosine residue of a substrate peptide (Fig. 
1.8).
53
 
 
Furthermore, each group can be sub-divided into families and sub-families, e.g. based on 
sequence identity, substrate type and structure of extracellular domains. A genetic map 
known as a dendrogram graphically illustrates this classification; the distance between two 
main branches correlates with mutual evolutionary divergence, and variation of catalytic site 
sequences. In the context of this discussion, ICZ congeners have been observed to confer 
inhibition across a wide variety of enzyme families, from distinct kinase groups.
33,35,38,54,55
 
1.3.1.2 Structural basis of ATP-competitive protein kinase inhibition 
 
Eukaryotic protein kinases comprise approximately 250-300 amino acid residues, and are 
characterised by the appearance of a number of highly conserved functional subdomains.
56
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Fig. 1.9: Crystal structure of ATP 11 bound within kinase site (substrate peptide is coloured blue).57 
 
Numerous X-ray crystal structures of kinases have identified discrete N and C-terminal 
lobes, with both ATP 11 and substrate-binding sites located in the interlobular cleft (hinge 
region) (Fig. 1.9).
58
 Of particular interest, e.g. in PKA, is the flexible glycine-rich loop as 
well as Lys72 (catalytic region) and Glu91 (activation segment) residues which form a salt 
bridge within the enzyme active site, with an important regulatory role in correctly 
orientating ATP for kinase activity (Fig. 1.10).
52,53
  
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.10: Schematic of kinase phosphorylation activity and critical active site interactions in PKA.
52
 
 
Other essential residues in the „DFG‟ motif (magnesium binding loop), e.g. Asp184 in PKA, 
also confer a strong conformational influence, by co-ordinating Mg
2+ 
within the ATP
 
phosphate binding region, as illustrated in Fig. 1.10. In addition, the HRD catalytic motif 
(Arg165 and Asp 166 in PKA), catalytic loop and α-C helix also comprise residues 
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maintaining the catalytic orientation of the ATP 11 γ-phosphate, and several regulatory 
autophosphorylation sites are also located within the activation loop region.
52,56
  
The ATP-binding pocket consists of the 38 residues known to interact with protein kinase 
inhibitors through multiple alignment of PDB kinase crystal structures in complex with these 
agents.
58
 These residues are close in space but not necessarily close in primary sequence. 
The adenine binding region, ribose pocket and phosphate region were identified based on 
crystal structures containing ATP 11. The surrounding hydrophobic pocket I, hydrophobic 
pocket II or „gatekeeper‟ pocket, and solvent accessible regions were discovered in kinase 
crystal structures with ATP-competitive inhibitors (Fig. 1.11).  
 
 
 
 
 
 
 
 
 
 
 
                                                                         11 
                
 
 
Fig. 1.11: Schematic of ATP 11 binding motif present in catalytic sites of protein kinases.
45
 
 
An expanded region of the ATP-binding site displayed in Fig. 1.11 contains an essential 
adenine pocket which forms two H-bonds to the protein backbone, ribose and phosphate 
binding sites, and two hydrophobic regions, containing less conserved, non-polar residues.  
 
Following initial kinase catalytic activation, docking of associated signaling proteins 
potentiates downstream signalling cascades, invoking their biological response.
59
 In the 
inactive kinase conformation, residues within the activation loop motif are orientated 
towards the „activation segment‟ and occlude ATP 11-Mg2+ binding. However, ligand-
induced phosphorylation may release this constraint by directing these residues away from 
the active site, ordering stable formation of other activating non-covalent interactions (Fig. 
1.12).
45,60
  
 
Binding of inhibitors to inactive kinase conformations is highly attractive as they incorporate 
more structural diversity even within kinase subfamilies than their corresponding active 
conformations and therefore demonstrate increased scope for innate selectivity.
61
 However, 
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development of novel kinase inhibitors of this type has been difficult due to the lack of 
available binding assays and mechanistic data regarding binding sites of inactive 
conformations.
45
  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.12: Conformational effect of „activation loop‟ phosphorylation on kinase catalysis.45 
1.3.1.3 Structural features of staurosporine: an ICZ kinase inhibitor template 
 
As mentioned previously, due to its extended planar chromophore and propitious hydrogen 
bonding network, staurosporine 2 occupies the nucleotide-binding region and closely mimics 
the hydrogen bonding network of adenine with conserved hinge region residues. In addition 
extensive hydrophobic contacts are formed with relatively variable non-polar side chains in 
buried domains not occupying ATP 11 (c.f. Fig. 1.11).
57
  
 
Accommodation of optimised ligands in these unique buried regions and induced-fit 
interactions with flexible loop regions (activation loop, glycine-rich loop, e.g. pyranose ring 
O in 2 with Gly365 in the ZAP-70 complex, etc.) are the two major determinants of inhibitor 
selectivity.
62-64
 The three nucleotide-binding (adenine, sugar and phosphate) domains are not 
characterized by large amino acid variability and thus constitute a poor target for obtaining 
overall specificity.
35,45,65
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                                            2 
    
Fig. 1.13: Orientation of inhibitor 2 within ATP-binding protein kinase active site (ZAP-70).
35
 
 
Conceptual concerns regarding enhanced specificity of staurosporine 2 analogues have been 
somewhat allayed by recent three-dimensional crystallographic (>40 kinase domains co-
crystallised with 2 are reported in the PDB) and site-directed mutagenesis studies, 
illustrating universal characteristics of inhibition.
35
 These highly conserved molecular 
interactions include hydrogen bonds involving backbone atoms (CO and NH) of two hinge 
residues, (one of which is highly conserved as glutamate) anchoring the lactam or maleimide 
ring moiety to the enzyme hinge region.
57
 Other essential hydrogen bonds involve the 
methylamino nitrogen of the perpendicular glycosidic ring bound in its active boat 
conformation: one to the backbone of a catalytic loop residue, and the other to a polar side-
chain from a residue C-terminal to the hinge (Fig. 1.13).
35
  
 
1.3.1.4 Selectivity profile of staurosporine 
 
Despite its promiscuous binding nature, staurosporine 2 also exhibits a pattern of selectivity 
between some closely related protein kinases, and the origin of these effects may permit 
design of more selective ICZ analogues.
35
 The position of 2 in the ATP-binding pocket of 
CSK almost exactly matches the relative position of this chromophore (as well as 
perpendicular conformations of aminopyranose moiety) in the PKA structure described by 
Prade et al., yet micromolar inhibitor concentrations are necessary to reduce CSK enzyme 
activity by 50% (IC50) whereas only nanomolar concentrations of 2 are required for 
equipotent inhibition of PKA or CDK2 (Fig. 1.14).
47,65
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Fig. 1.14: Inhibitory binding mode of 2 within co-crystallised CSK and CDK2 protein complexes.
58,66
 
 
The enhanced interaction energy resulting from more stable inhibitor hydrogen bonding is a 
fundamental contribution to >10
3
-fold greater binding affinity in PKA. Staurosporine 2 can 
only make three hydrogen-bond contacts with CSK as opposed to the four possible in PKA 
(c.f. CSK structure (a), Fig. 1.14). These are the lactam carbonyl group O30 to the backbone 
amide group of Met269 (equivalent to Val123 in PKA), the N19 lactam ring amide hydrogen 
bond donating to the Glu267 backbone carbonyl group (equivalent to Glu121 in PKA) and 
the methylamino, N31 hydrogen bond donating to the Arg318 backbone carbonyl group 
(equivalent to Glu170 in PKA). The missing hydrogen bond would be formed between N31 
and the side-chain of Glu127 in PKA and Asp86 in CDK2.
66,67
 
 
Similarly, STA 2 is a low nanomolar inhibitor of CDK2/cyclin A (IC50 = 8 nM), but only 
inhibits casein kinase I (CKI) with an IC50 value of 3.4 µM (CDK2 structure (b), Fig. 1.14).
58
 
Structural changes in CKI, reducing STA 2 affinity, to account for this difference include:  
 
 Substitution of bulkier Ile26 (CKI) for highly conserved Val18 (CDK2)  
 Substitution of a rare and less flexible Pro69 (CKI) for Val64 (CDK2)58 
 
In addition, despite substantial sequence similarity in two tyrosine kinases (EGFR and 
HER2), EGFR is inhibited by 2 at low nM concentrations, but HER2 remains unbound even 
at 10
5
 nM concentration, perhaps due to conformational changes disfavouring inhibitor 
binding.
35
   
The ability of ATP-competitive staurosporine 2 analogues to predominantly afford polar 
interactions with highly conserved backbone amide bonds, including an induced fit between 
CSK 
STA CDK2
22 
STA 
(a) 
(b) 
STA C=O ---
backbone NH Leu83 STA NH ---
backbone CO Glu81 
Leu83 
Glu81 
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the backbone amide of the first glycine of a glycine-rich loop and the ether oxygen of the 
glycosidic ring present in 2 is a key component of its unselective inhibition.
33,57
 Conversely, 
hydrophobic interactions within the ATP-binding region involve more variable side-chain 
groups, indicating that regioselective installation of lipophilic substituents at key positions of 
the chromophore, affirmed to interact with these recognition residues may confer optimal 
selectivity.
45,58,68
 Thus, global analysis of kinase domains in complex with staurosporine 2 
has shown that binding affinity is intimately correlated with two factors: the size of the 
„gatekeeper‟ residue (hydrophobic pocket II), and the distance between the first Gly of the 
glycine-rich loop and the Asp of the DFG loop – a measure of the closure of both lobes.35,65 
 
 Further investigation into why staurosporine 2 does not inhibit certain kinases may also 
reveal how low potency can be overcome through mediation of novel structural 
reorganisation proximal to the ATP 11 binding site. In 2009, Shomin et al. reported that 
STA 2 covalently linked to a cyclic PKA substrate peptide displayed >60 times greater 
potency towards PKA, compared to staurosporine 2 alone. This bivalent linker (BL) strategy 
was also reported to be readily applicable to user defined warhead fragments, i.e. more 
selective small-molecule inhibitors, and exhibited activity employing long linkers, indicating 
that the peptide moiety may be binding to allosteric sites rather than an adjacent substrate 
site – a novel mode of inhibition with the capacity to discriminate between kinases while 
exploiting avid ATP-competitive binding within the ICZ chemical class.
69,70
 
1.3.1.5 Non-STA indolocarbazole TK inhibitors 
 
Due to its promiscuous kinase inhibition, staurosporine 2 possesses therapeutic limitations 
due to its off-target effects. However, extensive investigation of the indolocarbazole scaffold 
has identified several derivatives with advantageous kinase activity profiles. An important 
target for a number of these compounds is the TK family, comprising several kinases with 
dysfunctions implicated in cancer. Tyrosine kinases can be classified into receptor and non-
receptor types, and over 20 members of this class are currently being evaluated for 
therapeutic inhibition in malignant and non-malignant diseases.
3,49,71,72
 
 
1.3.1.5.1 K-252a – c-Met kinase inhibitor  
 
An important RTK, c-Met, constitutes an attractive target in cancer therapy, owing to 
involvement in migration, angiogenesis, invasion and metastasis. An activating point 
mutation of the receptor has been suggested to exist in aggressive hereditary papillary renal 
carcinoma, as well as metastatic HNSCC and gastric carcinoma, associated with a poor 
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prognosis.
49
 Cyclofuranosylated indolocarbazole K-252a 13 has recently been demonstrated 
to inhibit c-Met phosphorylation in a cellular assay, and causes reversion of tumorigenicity 
in fibroblasts transformed with an oncogenic form of c-Met. K-252a 13 binds in the adenine 
pocket of c-Met in a similar F-ring manner to structures of PKA and CDK2 co-crystallised 
with staurosporine 2. However, the c-Met-K-252a 13 complex possesses three additional 
hydrogen bonds, unique to the ribofuranosylated fragment in contrast to the 4‟-methylamino-
pyranose moiety in 2, as illustrated in Fig. 1.15. In common with STA 2 binding, the 
glycosyl ring oxygen also approaches within 3.7Å of the α-carbon of Gly-1085 within the 
catalytic glycine-rich loop, affording a possible CH-O polar interaction.
60,73
  
 
                                            K-252a 13 
 
Fig. 1.15: Crystal structure of c-Met in complex with K-252a 13
60
 
 
1.3.1.5.2 C-3 and C-9 substituted indolocarbazoles – JAK inhibitors  
 
Janus kinases (JAKs) are important soluble NRTKs that play a role in cytokine-mediated 
lymphocyte development and correspondingly, inhibition may be therapeutically useful in 
immunological defects such as organ transplant rejection, allergy and asthma.
68,74
 In 2006, 
Yang et al. successfully elaborated the JAK inhibitory pharmacophore of the pan-kinase 
inhibitor, stauosporine 2, by means of ring simplification and indole ring substitutions (C-3 
and C-9). This endeavour resulted in formation of indolocarbazole 14, which inhibited JAK 
3 with an IC50 value of 3 nM, albeit with poor solubility.
68
 
 
Modeling indicated that 14 adopted a typical bidentate hydrogen-bonding mode with the 
JAK3 backbone at the ATP 11 adenine binding segment (hinge region); the lactam NH 
interacts with the carbonyl oxygen of Glu903, while the carbonyl oxygen contacts the amide 
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nitrogen of Leu905. The hydroxymethyl on the aliphatic ring within 14 forms a hydrogen 
bond with the side chain of Arg953, and the C-9 hydroxymethyl side chain was implicated 
with this low single digit nanomolar activity due to its orientation inside a small binding 
pocket to form hydrogen bonds with Glu871 and Phe968 (Fig. 1.16).
68
 
 
 
                                                                                                          14     
Fig. 1.16: Selectivity pattern illustrated by crystal structure of 14 in complex with JAK3 active site.
68
   
 
1.3.1.5.3 Clinical indolocarbazole candidates as Flt3 inhibitors 
 
Indolo[2,3-a]carbazoles are notably effective against several tumours characterized by 
genetic abnormalities, such as CML, where approximately 30% of patients, with poor 
prognosis, have a hyper-activating gain of function (GOF) mutation in RTK Flt3. CEP-701 
15 and midostaurin 16 are currently in phase I and II trials against AML, due to their 
attractive anti-proliferative activity in Flt3-mutant receptor cells, with no adverse effects on 
cells expressing the wild-type enzyme (Fig. 1.17).
49,75
 Preliminary results also indicate that 
disease remission is highly successful in the presence of Flt3 dysfunction.
76
 In addition, 
midostaurin 16 has entered phase I trials in the treatment of solid tumours.
77
  
 
 
 
 
 
 
 
 
 
                                 CEP-701 15   
midostaurin 16  
Fig. 1.17                                                                                    
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1.3.1.6 Indolocarbazole derivatives as modulators of aberrant cell cycle activity   
 
Recognition that protein phosphorylation events underpin control of cell cycle transitions in 
a precisely co-ordinated and sequential fashion in dividing somatic cells dates back to the 
1970s, with the ground-breaking research of Lee Hartwell, Paul Nurse and Tim Hunt.
78,79
 
 
Cell cycle regulatory kinases display complex, synchronised roles in normal cell-cycle 
modulation, with cell cycle kinase perturbation having causal links to cancer (Fig. 1.18).
2,80
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.18: Cancers associated with specific genetic alterations of cell cycle-related enzymes; CDK 
inhibitors (G1, S, G2), ChK inhibitors (G1, G2), Topo I (S), Topo II (S, G2). 
 
Illustrating this phenomenon, inhibition of cyclin D1-CDK4 results in selective G1 arrest, 
prior to S phase, thus preventing replication of damaged DNA.
81
 It was also reported that 
IC50 values for indolocarbazole inhibitors of purified cyclin D1-CDK4 correlated with anti-
proliferative IC50 values against colon carcinoma cell line, HCT-116, following incubation 
for 24 hours.
82
   
  
       
 
  
 
 
                                                                           
Fig. 1.19                       SB-218078 17                                            18                                                                                                                                                                                                                                                             
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SB-218078 17, a ChK1 (Ki = 15 nM) and PKC inhibitor, also demonstrated a potent D1-
CDK4 inhibitory effect (IC50 = 0.54 µM) (Fig. 1.19).
35
 Sanchez-Martinez and co-workers 
also reported that aromatized ICZ congeners conferred between 8 and 42 times greater cyclin 
D1/CDK4 potency than their corresponding BIM analogues, e.g. 3-hydroxypropyl BIM 18 
(D1/CDK4 IC50 = 1.17 µM), compared with the indolocarbazole derivative 19 (D1/CDK4 
IC50 = 0.07 µM).  
 
Flow cytometry analysis also demonstrated that active ICZs elicited G1 arrest and a decrease 
in S and G2/M populations, within 24 hours, whereas BIMs produced G2/M accumulation.
82
 
A crystal structure of the ATP binding pocket of another cell cycle kinase, CDK2, in the 
presence of 19 (cyclin E/CDK2 IC50 = 0.18 µM) revealed the bidentate hydrogen bonding 
between the maleimide carbonyl group and backbone NH of Leu83, as well as interaction of 
the imide NH with the backbone carbonyl group of Glu81 (Fig. 1.20).
82
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Fig. 1.20: Structure of CDK2 co-crystallised in the presence of hydroxypropyl ICZ analogue 19.
82
 
 
 
Another natural metabolite from Streptomyces species, 7-hydroxystaurosporine (UCN-01) 
20, is a potent PKC inhibitor (IC50 = 30 nM). It also selectively targets tumour suppressor 
p53 deficient, G1 checkpoint-defective cancer cells resulting in S or G2 checkpoint-mediated 
arrest and mitotic catastrophe via accumulation of irreparable DNA damage (Fig. 1.21). 
Similar to STA 2 and SB218078 17, UCN-01 20 is also a potent inhibitor of ChK1 (Ki = 5.6 
nM), but interestingly, confers decreased activity against CDKs (CDK1; Ki = 95 nM, CDK2; 
Ki = 30 nM, CDK4; Ki = 3.6 µM).
35
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                    K-252c 6                                                UCN-01 20              fascaplysin 21 
Fig. 1.21 
 
The origin of this selectivity is the energetically favourable hydrogen bond formed with 
Ser147 in ChK1.
64
 This interaction is absent in both staurosporine 2 and SB-218078 17 
inhibitor complexes. In addition, the 7-OH group in 20 forms an unfavourable hydrophilic-
hydrophobic contact within the CDK2 hinge region, while UCN-01 20 is also unable to 
stabilise the activation loop through formation of any sugar-residue hydrogen bonds (Fig. 
1.22).
35
 In contrast to UCN-01 20 and STA 2, SB218078 17 possesses a tetrahydrofuran ring 
and does not have a H-bonding methylamine group. However, SB218078 17 is almost as 
potent as STA 2 in inhibiting ChK1 and CDK2 activity, indicating that retention of a 
lactam/maleimide H-bonding scaffold and hydrophobic planarity is most essential for 
efficacious inhibition.
35,63
 
 
(a) (b) 
Fig. 1.22:(a) Origin of UCN-01 20 selectivity in ChK1; (b) STA 2 lacks key C7 H-bond donor.
63
 
 
Various compounds derived from the indolo[2,3-a]carbazole framework present in 
staurosporine, e.g. K-252c 6, have also been reported as potential CDK inhibitors, leading to 
significant G2 arrest, presumably due to inhibition of downstream cell cycle-related 
kinases.
18,82
 Structurally related to this chemical series, the marine sponge pigment, 
fascaplysin 21, has also been identified as a CDK4-selective inhibitor (Fig. 1.21).
83
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It may be possible to overcome the limitations of high cellular ATP concentration ([ATP]i = 
3 mM) imposed upon conventional kinase inhibitors, as well as the inherent selectivity 
problem, by introducing bivalent inhibitors combining an active „anchor‟ inhibitor tethered 
to a short peptide sequence incorporating a recognition motif via flexible spacer groups. This 
approach affords a dual high affinity competitive inhibitor of both ATP 11 and peptide 
substrates (Fig. 1.23).
69,70
 Introduction of peptide pseudosubstrate into compound 22 
significantly enhanced anti-CDK1 activity; in vitro potency of 22 (IC50 = 285 µM) was 
improved to 4.5 µM by 23. Spacer chain length was critical for efficient inhibition, as both 
individual components each displayed only negligible CDK1 inhibition (IC50 >1 mM).
70
   
 
 
                                                                                               
                                                                                              
 
 
 
 
                    22                                                     23                                                
 
Fig. 1.23 
 
1.3.1.7 PKC inhibition: a new anti-tumour strategy 
 
Members of the AGC serine/threonine kinase group constitute another class with important 
downstream signal capability in diverse cell growth and differentiation, following 
extracellular activation of RTKs. The most important family is PKC, comprising 10 
isoforms, implicated in various tumour types.
84-86
 
 
Long term activation of PKC modulates several processes such as immune response, 
memory/learning, and receptor desensitization. In 2010, Abrams et al. reported that VEGF 
stimulated PKC-βII activity in chronic lymphocytic leukemia cells.87 PKC is also a key 
effector of ERK activation under the influence of VEGF and upregulated transcription factor 
activation in unabated growth responses has been reported in several malignancies in vivo.
77
 
Based on these observations, initial discovery of the nanomolar inhibitory efficacy of STA 2 
towards PKC (IC50 = 2.7 nM) has precipitated a surge in development of important BIM and 
ICZ analogues, some of which have successfully progressed to clinical trials (Fig. 1.24). 
However, activity within these derivatives is still not known to exclusively stem from PKC 
inhibition, another kinase (e.g. PKA) or perhaps even a combination.
34,38,55
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Fig. 1.24: Crystal diagram of PKC in complex with staurosporine 2
35
 
 
The absence of consistent inhibitor selectivity profiles is also a significant stumbling block 
to clinical progress. Ro-318220 24 is a potent inhibitor of PKC isoforms α, β and µ, but only 
inhibits the closely related PKCξ at much higher concentrations, despite having considerable 
potency against less sequentially homologous kinases (Fig. 1.25).
88
 
                                                                                               
 
 
 
 
                       24                                                       25                        
 
                                                                                                          R1=H; R2=CH; R3=NEt2 26                           
                                                                                                          R1=Ar, Het; R2=N, R3=NEt2,    
                                                                                                                    morpholinyl, piperazinyl 27                              
Fig. 1.25 
 
Endothelial PKC inhibition constitutes an important strategy for impairing solid tumour 
metastasis, due to the reduction in VEGF-induced vasculogenesis by diverse PKC inhibitors 
in vitro. In an endothelial cell co-culture assay, VEGF-induced angiogenesis was markedly 
inhibited by the BIM, GF-109203x 26 (PKC IC50 = 10 nM).
89
 In 2005, BIM analogue 
indolylindazolylmaleimides 27 were also reported as low nanomolar inhibitors of PKC-β, 
blocking release of a proinflammatory cytokine IL-8, also associated with promotion of 
metastasis, enhanced survival, and angiogenesis, induced by PKC-βII (IC50 = 20-25 nM), 
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while possessing enviable selectivity against other PKC isoforms and structurally analogous 
GSK-3β (Fig. 1.25).90  
 
Mechanistic studies within this inhibitor class have also confirmed that Gӧ7612 25 
competitively inhibited PKC, with respect to ATP 11 binding in vitro. Experimental Km 
values were ascertained to shift to higher ATP 11 concentrations in the presence of 
increasing concentrations of Gӧ7612 25, while vmax remained relatively unchanged.
84
 These 
workers also reported that for imide PKC inhibitors, methyl and 
dimethylaminohydroxypropyl groups at the indolyl nitrogens were most beneficial for 
potency and selectivity, and the presence of the hydroxyl group in this alkyl chain has a 
substantial effect in reducing off-target MLCK inhibition.
84
 In 1993, synthesis of non-
glycosidic indolo[2,3-a]carbazole, Gӧ6976 28 was reported, which displayed selective PKC 
inhibition, as well as activity against human immunodeficiency virus 1 (HIV-1).
91,92
 In 
addition to Gӧ7612 25, planar ring substitution has also been reported to enhance kinase 
inhibition in a number of ICZ derivatives possessing extremely favourable pre-clinical 
activity, such as CEP-7055 29 (VEGFR) and CEP-1347 30 (ChAT, JNK, and MLKs), due to 
„gatekeeper-induced selectivity‟ (Fig. 1.26).16,49,93 
 
 
 
 
 
 
 
                                  Gӧ 6976 28                                         CEP-7055 29                
Fig. 1.26 
  
This phenomenon describes the nature of a single gatekeeper residue within the buried 
hydrophobic pocket adjacent to the ATP-binding site (Fig. 1.27); the size of this residue is a 
critical determinant of inhibitor selectivity. Interestingly, 50% of tyrosine kinases have a 
threonine gatekeeper, but only 10% of serine-threonine kinases have this residue; serine-
threonine kinases are thus relatively cross-resistant to tyrosine kinase inhibitors.
45
 
 
Further SAR work has revealed that glycosidic ICZ analogues comprising an F-ring lactam 
moiety rather than an imide system preferentially inhibit PKC, whereas in aglycon systems, 
the maleimide F-ring is more favourably indicated for activity.
16
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                               CEP-1347 30                   
Fig. 1.27: Structural basis of the residue „gatekeeper‟ mechanism for selective kinase inhibition.                                                        
 
Nanomolar inhibition of other serine/threonine kinases containing structural homology 
within the adenine-binding region, e.g. protein kinase D (PKD) associated with gastric 
tumours, by non-specific PKC inhibitors, such as K-252a 13, is intriguing, but further insight 
into the nature of this target may be required prior to full scale clinical target identification 
based on these results.
94
 
1.3.1.8 Indolocarbazoles as GSK-3β inhibitors 
 
Glycogen synthase kinase (GSK) 3β - a member of the CMGC group of kinases, has an 
interesting range of biological effects including regulation of cardiac hypertrophy. It has also 
been pursued as a treatment for insulin-resistant type II diabetes due to its intrinsic role in 
glycogen synthesis.
95
  
 
 
 
 
 
 
 
                       13                                                        31                               32                           
 Fig. 1.28     
                                                                                               
The observation that GSK-3β activity is associated with promoting apoptosis in a protective 
anti-tumourigenic role, initially suggested that enzyme inhibition would be highly 
undesirable. However, due to complex conflicting pro-tumour effects, kinase inhibition in 
GSK-3β over-expressing ovarian cell lines has been demonstrated to have significant anti-
proliferative effects in vivo. Following a study into new inhibitors of PKC-γ, Kuo et al. 
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discovered that polyoxygenated macrocyclic BIM analogues 31 conferred enviable GSK-3β 
potency, while replacement of both indoles with 7-azaindole moieties resulted in almost no 
inhibition across a panel of 50 protein kinases, but retained sub-micromolar selective activity 
against this GSK isoform.
96,97
 In 2008, several 3-azaindolocarbazole derivatives also 
inhibited two cancer cell lines with activity in the submicromolar range. The synthetic lead 
candidate 32 inhibited the L1210 leukaemia cell line with an IC50 of 195 nM, while 
compounds with unsubstituted F-ring moieties were most active in purified ChK1 assays, 
possessing IC50 values as low as 14 nM within this series (Fig. 1.28).
98
 
1.3.1.9 Conclusion 
 
According to the Sanger Institute, over 300 proto-oncogenes associated with cancer 
progression exist within the genome, and many of these gene products are protein kinases or 
their endogenous ligands.
2
 Nascent awareness of small-molecule kinase inhibition has 
coincided with an observation of the acute significance of aberrant protein phosphorylation 
and protein-protein interaction (PPI) in affecting cellular homeostasis, and therefore, its 
causative role in mediating several disease states.
44
 At present over 30 kinase inhibitors are 
in clinical trials for their therapeutic applications and 8 kinase inhibitors, including AML 
front-line agent imitanib 3, which demonstrates tumour regression in 90% of cases involving 
the Philadelphia chromosome, have achieved full FDA approval for clinical use.
49
  
 
A fundamental limitation for ICZ congeners in their common mode of action is the 
competitive nature of their binding within the ATP-binding domain of the kinase hinge 
region.
35
 Exploitation of subtle conformational differences for unique binding profiles will 
undoubtedly attract increasing attention as clinical success emerges in the field of small-
molecule kinase inhibition. Assessment of kinase selectivity by in vitro screening is intrinsic 
to future development of novel inhibitors, but does not address critical issues of metabolic 
deactivation, cell permeability and adverse off-target effects.
45
 IC50 values also vary 
enormously between laboratories depending on the ATP 11 concentrations employed in 
purified enzyme assays. Concentrations of ATP 11 in vivo are approximately 3 mM, while 
most tyrosine kinases possess extremely high affinity for ATP (Km = 10 - 150 M), thus 
highlighting the difficulty of identifying new lead chemical scaffolds eliciting significant 
ATP-competitive inhibitory effects. Thus, theoretical potency may be difficult to correlate 
with studies performed in vivo, with increased complexity arising from fluctuating kinase 
expression, endogenous inhibition and effects on alternate targets in tumourigenesis.
44,57,84
 
Anti-vascular inhibition of PKC, VEGFR and FGFR represents an attractive alternative to 
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non-selective cytotoxic drugs with a complementary spectrum of activity including 
improving intravenous drug delivery due to normalisation of abnormal vessel development.
99
  
 
In addition to further elucidation of activity in individual kinases, and novel strategies for 
signal transduction therapy, development of markers of kinase mutation in tumour 
phenotypes as well as identification of germ-line mutations indicating pre-disposition to 
cancer, e.g. c-Met mutation in familial renal cell carcinoma, will ultimately allow 
administration of selective inhibitors tailored for specific kinase abnormalities.
4,45,49
 Future 
breakthroughs in kinase research leading to successful therapeutic strategies have the 
potential to transform cancer from an acute crisis into a chronic disorder, where abnormal 
tumour growth signaling has effectively ceased by targeting individual dysregulated kinases. 
 
1.3.2 Topoisomerase I inhibition and putative intercalative effects 
 
The recently digitized human genome is a revolutionary genetic repository located at the 
forefront of biology, set to redefine the blueprint for medicine in the 21
st
 century. The human 
genome comprises approximately 4 billion base pairs of DNA integrated into 44 somatic and 
2 sex chromosomes. Although this genetic material is only 20 Å in diameter, if total DNA 
from the nuclei of all 10
13 
cells within the body were laid end-to-end, it would equal the 
distance of almost 70 round trips between Earth and the Sun. 
 
Fig. 1.29: Critical non-covalent DNA-topo I interactions involved in „cleavage complex‟ 
formation.
100
  
 
In order to compact this overwhelming amount of DNA more than 200,000 fold, ubiquitous 
eukaryotic nuclear enzymes known as DNA topoisomerases control helical torsional strain 
by catalysing the concerted breaking and religating of supercoiled DNA. This topological 
adaptability is exerted over DNA during essential metabolic processes, including 
Chapter 1                                                                                                                     Biological Introduction 
__________________________________________________________________________ 
                                                                         27 
transcription, replication, recombination, chromosome condensation and mitotic 
chromosomal segregation.
101-105 
 
In humans, there are 6 topoisomerase genes coding for nuclear topoisomerase I (topo I) and 
mitochondrial topo I, along with topoisomerases IIα, IIβ, IIIα, IIIβ.106 Topo I is a 
monomeric protein (765 residues), consisting of four major domains: a C-terminus
 
catalytic 
region that contains the active nucleophilic tyrosine residue, a non-conserved
 
"linker" 
domain, a conserved "core" domain, and an N-terminus
 
domain that contains a nuclear 
localization signal (NLS).
106,107
 Topo I clamps DNA at its sequence recognition point, prior 
to relaxing local superhelical stress by nicking and rejoining a single strand of DNA, in the 
absence of energetic co-factors or metal ions (Fig. 1.29). In contrast, topo II enzymes are 
dimeric, break both strands of a duplex DNA (using catalytic Tyr residues from each 
monomer), and pass an intact DNA duplex through this transient double-stranded break.
101
 
 
The catalytic cycle of eukaryotic topo I can be divided into four main steps and is initiated 
by the binding of the enzyme to DNA (Fig. 1.30). The second step of the cycle encompasses 
nicking of one DNA strand by transesterification of an active-site tyrosine (Tyr723 in human 
topo I) at a DNA phosphodiester bond, prefiguring formation of a covalent 3'-
phosphotyrosine DNA break (cleavage complex).  Base activation of the nucleophilic 
Tyr723 residue is required in order for it to attack the 3′-phosphate group. This activation is 
thought to occur by means of a deprotonated water molecule as no other residues have been 
found in close enough proximity to carry out this function. The third step in the catalytic 
cycle invokes superhelical relaxation and more than likely occurs via a mechanism of 
“controlled rotation” in which the intact strand remains stationary and the cleaved strand 
interacts through transient electrostatic interactions with positively charged regions of the 
topo I enzyme that are in close proximity to the downstream DNA. 
 
The final step in the catalytic cycle is DNA religation and occurs when the released 5'-OH of 
the broken strand reattacks the phosphotyrosine intermediate in a second transesterification 
reaction to release the DNA constraints.
108
 In kinetic terms, the rate of religation in this 
reversible process has been determined to be normally much faster than the initial rate of 
DNA uncoiling, indicating that the steady state concentration of the covalent 3'-
phosphotyrosyl topo I–DNA complex is extremely low.109 As a result of unique activity, 
topo I can modulate DNA underwinding and overwinding, but cannot resolve knots or 
tangles from double stranded DNA.
101,108
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Fig. 1.30: Schematic representation of the stepwise mechanism of topo I activity in DNA (for clarity, 
DNA strands are represented in black, while topo I residues are coloured purple) 
 
Several DNA mutations (e.g. mutation expressing A718T residue substitution in topo I) and 
inhibitory drugs have been shown to stabilize the covalent 3'-phosphotyrosyl intermediate, 
and induce extensive DNA strand fragmentation, in vitro (Fig. 1.31).
109,110
 Elevated topo I 
expression, relative to baseline cell levels, reported by Giovanella et al., in advanced human 
colon cancer also reinforces a link beween topo I targeting and anti-cancer therapy.
111
  
 
 
 
 
 
 
 
 
 
Fig. 1.31: Cellular responses to drug-mediated topo I poisoning/DNA lesion formation. 
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A particular classification system for the mode of action mediated by specific anti-
topoisomerase agents incorporates a number of mechanistic classes based on their sites of 
action. Topoisomerase suppressors act on either DNA or topo I, and do not bind to the 
transient „covalent complex‟. Alternatively, uncompetitive inhibitors which bind to this 
DNA-enzyme complex are known as topo I poisons, and this approach is of acute clinical 
relevance to current anti-cancer research.
112,113
  In each case, disruption of the catalytic cycle 
results in persistent strand breakage during DNA synthesis (S) phase and elicits massive 
DNA damage from replication fork and transcription complex collisions, leading to ultimate 
cell death, if not repaired (Fig. 1.31).
109,110
 
1.3.2.1 Topo I „poisons‟ at the DNA-enzyme interface: a potent anti-cancer lead 
 
The DNA-topo I macromolecular complex was the intrinsic nuclear target for the potent 
anti-cancer natural product camptothecin 33 isolated by Wall and Wani from the Chinese 
tree Camptotheca acuminata, subsequently found to promote accumulation of DNA-topo I 
adducts and inhibit DNA synthesis for up to 8 hours following drug removal. The natural 
alkaloid 33 is the 20S-enantiomer which is active against topo I and experimental cancers, 
whereas the synthetic 20R-enantiomer lacks both activities (Fig. 1.32).
114
  
Camptothecin 33 does not bind to either DNA or purified topo 1 alone; the uncompetitive 
nature of inhibitor binding to the transient cleavable complex extends some mechanistic 
limitations to formulation of a full binding model due to the fact that no equilibrium 
constants have been determined for 33 or analogues, such as silatecan 34. However, it can be 
surmised that CPT-like agents must act in a concentration dependent manner, due to 
interaction of each drug molecule with one topo I enzyme to afford a single DNA lesion.
110
 
 
 
 
 
 
 
 
 
Fig. 1.32: Camptothecin 33 (R1-R3=H) family of topoisomerase I poisons, including silatecan 34 (R1 
= TBDMS; R2 = H; R3 = OH) and approved chemotherapeutic congeners, topotecan 35 (R1 = H; R2 = 
CH2N(CH3)2; R3 = OH) and irinotecan 36 (R1 = CH2CH3; R2 = H; R3 = OCON(CH2)4N(CH2)5). 
 
CPT 33 activates cell cycle S and G2 checkpoints, as well as p53/p21 pathways in response 
to DNA damage, halting mitosis (preferentially targeting rapidly dividing tumour cells with 
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over-expressed topo I), increasing DNA repair, and preventing amplification of replicative 
errors (c.f. Fig. 1.31).
109,112
  
 
Two FDA-approved water soluble CPT 33 analogues are now routinely used for intravenous 
(IV) administration in human cancer therapy: topotecan 35 (Hycamtin
®
, GSK) in small cell 
lung cancer as well as for second-line treatment of advanced ovarian cancer and irinotecan 
36 (CPT-11, Camptosar
®
, Yakult Honsha KK) used for treatment of colorectal cancers (Fig. 
1.32).
20
 Haemotological toxicity is a common side effect of camptothecin derivatives due to 
the destruction of bone marrow progenitors. However, the major clinical limitation of these 
analogues relates to the rapid metabolic inactivation of the lactam E-ring to the inactive 
serum protein-sequestered carboxylate form.
5,115
  
 
1.3.2.2 Indenoisoquinolines – polycyclic non-CPT intercalatory topo I inhibitors 
 
A number of topo I inhibitors from a range of chemical classes share close target analogy 
with CPT 33 analogues, and thus, may possess different spectra of clinical activity, with 
complementary efficacy against diverse tumour types in vivo. Over 300 indenoisoquinoline 
(IIQ) derivatives such as MJ-238 37 have been synthesised to date, following investigation 
into agents resembling CPT 33 in their activity profiles against 60 human cancer cell lines.
114
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Fig. 1.33: Schematic representation of key hydrogen bond networks between two interfacial 
inhibitors (CPT 33; MJ-238 37) and catalytic topo I amino acid residues in drug-topo I-DNA 
complexes.
114
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In contrast to camptothecin 33, IIQs, e.g. 37, are chemically stable and do not contain the 
labile hydroxylactone E-ring characteristic of CPTs. In addition, „trapped‟ ternary complexes 
within this series are much more stable than those formed by CPTs (Fig. 1.33). Key 
hydrophobic stacking (intercalation) between successive base pairs flanking the DNA 
cleavage site and formation of critical hydrogen bonds with topo I amino acid residues, also 
reveals a common interfacial binding mode between CPT 33 and IIQ 37 inhibition.
114
 
 
1.3.2.2 DNA binding and topo I poisoning activities of rebeccamycin-type ICZs 
 
Indolocarbazoles represent the most advanced non-CPT topo I inhibitor class encountered to 
date, with a well studied mechanism of action and a number of derivatives in current clinical 
development.
14,112
 Interest in this field began in 1985, when a new ICZ possessing the 
conserved indolo[2,3-a]carbazole framework was isolated from cultures of Lechevalieria 
aerocolonigenes, so termed rebeccamycin (REB) 38 for the daughter of the scientist who 
isolated the compound.
116
 It is arguably the most important derivative of the indolo[2,3-
a]carbazole family, due to the vast amount of synthesis, relating to design of novel clinical 
congeners based on this privileged topo I inhibitory lead, reported in scientific 
literature.
14,40,41,117-122
 38-40 
 
 
 
 
 
 
 
 
                          R1=R2=Cl 38                                   
                        R1=H; R2=Cl 39                              R1=Cl; R2=CH3 41        R1=Cl; R2=H 42                        
                       R1=Br; R2=Br 40                                R1=H; R2=CH3 43           R1=R2=H 44                                                                                            
Fig. 1.34 
 
This water insoluble compound was found to inhibit topo I with an IC50 value of 1.75 µM, 
but unlike STA 2, is virtually inactive towards topo II and PKC (IC50 >100 µM).
41,122
 The 
primary structural features of REB 38 and its anti-cancer analogue, 11-
dechlororebeccamycin 39, also isolated from this microbial source, include the presence of a 
carbohydrate moiety (4-O-methylglucose) attached in an „open‟ orientation via a β-N-
glucosyl bond to a single indole nitrogen and unsubstituted maleimide F-ring (Fig. 1.34). 
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In 1987, rebeccamycin 38 was reported to induce prolongation of survival of leukaemic mice 
(P388 leukaemia/ L1210 leukaemia) at a wide dose range, from 8 – 256 mg/ kg. In vitro anti-
proliferative activities against murine B16 melanoma and P388 leukaemia cell lines were 
0.48 µM and 1.22 µM, respectively, while growth of human lung adenocarcinoma cells was 
also suppressed via topo I inhibition and production of single DNA strand breaks.
117,122
 
Although structurally related to other microbial indolocarbazoles, rebeccamycin 38 is 
unusual in that it can be isolated in large quantities from fermentation, e.g. in a 30 L 
fermentor, a yield of 663 mg/L was observed.
41
 In 1991, the water soluble, potent anti-
tumour derivative, bromorebeccamycin 40 was also successfully cultured in the presence of 
bromide ions.
123
  
 
Tight intercalation and the observation of growth inhibition in leukaemic cell lines, 
discovered by Facompre et al., stemming from DNA complexation within the AT2433 
aminodisaccharides (AT2433-A1 41, AT2433-A2 42, AT2433-B1 43 and AT2433-B2 44), 
isolated from Actinomadura melliaura, comprising an N-methylimide, also represent a novel 
DNA unwinding lead within this series.
124 
These derivatives 41-44 were investigated in 
clinical trials for the treatment of a wide range of malignancies, including refractory 
pediatric neuroblastoma, advanced renal cell carcinoma, metastatic or locally recurrent 
colorectal and stage IIIB or IV breast cancer.
125
 Two anti-topo I compounds, BMS-250749 
45 and edotecarin 46, from the mono-N-glycosidic indolo[2,3-a]carbazole class are also 
currently in phase III human clinical trials; full disclosure as to their future therapeutic 
applicability is currently being awaited (Fig. 1.35).
126,127
 
 
 
 
 
 
 
 
 
                             45                                                       46                                    
Fig. 1.35 
 
 
Interestingly, development of topo I inhibitors in the ICZ series retains a high degree of 
structural fidelity to the indolopyrrolocarbazole 3 glycoside template represented by REB 
38; kinase inhibition based on STA 2 tolerates structural diversity to a much larger extent. 
Chapter 1                                                                                                                     Biological Introduction 
__________________________________________________________________________ 
                                                                         33 
However, there is also evidence of exploitable structural overlap between these drug targets, 
as the proportion of persistent „nicked‟ DNA produced by the PKC active, K-252a 13 
derivative, KT-6006 47 was >50% of substrate DNA or comparable to CPT 33, with DNA 
relaxation and cleavage activities also being similar to the camptothecins 33, 35-36 (i.e. no 
cleavage observed in absence of topo I or in the presence of topo II) (Fig. 1.36).
14,114,128 
 
 
 
 
 
 
 
  
                                                   R1=R2=H; R3=CH3 13 K-252a      
                                                 R1=R2=OH; R3=CH3 47 KT-6006    
Fig. 1.36 
                                                                             
The reduction in this DNA cleavage, following thermal denaturation (65°C) indicates the 
involvement of a disrupted reversible DNA-enzyme complex, i.e. „poisoning‟ effect.28 The 
weakly intercalating lactam ICZ compound 48 reported by Yamashita et al. also induced 
topo I-mediated DNA cleavage in a dose-dependent manner up to 50 μM, at comparable 
levels, in vitro, to camptothecin (Fig. 1.37).
128
  
 
 
 
 
 
 
  
                                                       48                                                 49 
 
Fig. 1.37 
 
Additionally, topo I confers dual activity as it has recently been shown to phosphorylate 
serine/arginine (S/R) residues in substrate proteins. As well as having DNA affinity and 
CPT-like topo I poisoning, ICZ compound R-3 49 displays discrete anti-topo I kinase 
activity in the absence of DNA (IC50 = 1-2 µM), independently of its DNA cleavage capacity 
in a knockout Y723F mutant (Fig. 1.37). Interestingly, CPT 33 required DNA to inhibit topo 
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I kinase function, and could not confer inhibition in the absence of DNA even at 
concentrations as high as 500 µM. This DNA-independent anti-kinase activity may evolve to 
be a fertile new target for pharmaceutical mediation due to its prodigious selectivity (R-3 49 
is 10
4 
times less potent than STA 2 for PKC), as it exhibits a differential pharmacological 
trait between ICZ agents and CPT analogues 33, 35-36 that interact via analogous binding 
modes within DNA.
129
  
 
In alternative indications, staurosporine 2 aglycon, K-252c 6 and arcyriaflavin A 7, 
containing a maleimide F-ring, also diminished relative resistance of cells transfected with 
ABCG2 - a drug transporter comprising an ATP-binding motif, strongly implicated in cancer 
chemoresistance, to irinotecan 36 in vitro.
130
 This observation may be important for future 
adjuvant therapies as topotecan 35 and irinotecan 36 are also substrates of drug efflux pumps 
such as P-glycoprotein (P-gp) and breast cancer resistant protein (BCRP) in vivo.
112,130
 
1.3.2.3 Overview of SAR in ICZ topo I inhibition 
 
The semi-synthetic, but only sparingly water-soluble rebeccamycin analogue, NB-506 50, 
discovered from natural product screening of a Streptoverticillium culture, and endowed 
with in vivo anti-cancer activity has undergone clinical trials, with positive clinical Phase I 
results, especially against taxol-resistant breast and ovarian cancers, as well as lung and 
colon cancer indications.
131
 Based on work by Ohkubo et al., it is now postulated that NB-
506 50, as a prime exemplar of this class, contains three indispensable functional domains 
for anti-topo I activity (Fig. 1.38).
132
 
 
These structural segments facilitate maleimide ring DNA major groove and protein side-
chain contacts, interfacial intercalation between successive DNA bases at GC-rich sites 
(cleaving TG linkages), through an extended planar chromophore and DNA accommodation 
of a glycosyl side-chain by means of minor groove insertion.
133-137
 
 
Observed tumour sensitivity to ICZ glycosides may also be due to the crucial role of the 
glycosyl residue in mediating cellular uptake via passive diffusion through the plasma 
membrane.
138
 In addition, hydrophilic F-ring N-imide substituents are also necessary for 
effective topo I inhibition.
121,132
 Despite profound structural differences, glycosylated ICZs,    
IIQs and camptothecin classes share common steric and electronic features, recognising 
similar structural elements to specifically stabilise the topo I-DNA-drug ternary complex.
114
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Fig. 1.38: Three functional domains of NB-506 50, a model glycosidic ICZ topo I inhibitor. 
A = Enzyme-interacting domain.
 
B = Planar DNA-binding domain. 
C = Minor groove DNA-binding domain. 
 
This conclusion was supported by X-ray crystallographic analysis of the topo I-DNA 
complex bound to either CPT 33, IIQ congener, MJ-238 37 or the 2,10-dihydroxylated, 
SA315F 51, which demonstrated that distinct intercalative modes prevailed for each class, 
along with common features including mimicking of a DNA base pair at the cleavage site 
and multiple contact stabilisation of the ternary complex. Co-axial interfacial stacking 
interactions between -1 (nucleotide covalently linked to topo I) and +1 (nucleotide at free 5‟-
OH terminus) base pairs at the topo I cleavage site following binding of SA315F 51 results 
in DNA unwinding due to the increased distance between flanking base pairs required to 
accommodate the intercalated molecule. It was also observed that the protein-interacting 
maleimide ring was orientated into the major groove of DNA, while the hydrophilic 
deoxyribose unit was accommodated in the minor groove (Fig. 1.39).
114
  
 
 
 
 
 
 
 
 
                                                    51 
 
Fig. 1.39: Crystal structure of SA315F 51 bound to a stabilised DNA-topo I covalent complex.
139
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The glycosylated indole ring stacked with bases on the intact strand, while the unsubstituted 
ring intercalated with the cleaved DNA complement. Essential active site residues also 
interacted with a hydroxyl of the sugar moiety, with one of the carbonyls at the maleimide 
ring, and with both hydroxyl substituents of the planar ring system.
114
 Additionally, it was 
determined that alkyl-substitution of the non-glycosylated indole nitrogen totally abolished 
topo I inhibition; in addition, peripheral ring substituents have also been shown to either 
abolish or enhance anti-topo I activity, and are also highly correlated with DNA intercalation 
and anti-tumour cell line selectivity.
40,136,140
 
52 
Thus, ED-110 53, a glucosylated derivative of a 1,11-dihydroxylated dual topo I/II inhibitor 
(both IC50 = 2 µM), BE-13793c 52, exhibited in vitro cytotoxicity across a wide spectrum of 
cancer cell lines and pre-clinical in vivo activity in xenotransplanted nude mice (Fig. 
1.40).
141-144
 
 
 
 
 
 
 
                                                                      
                                       52                                                                       53                                                           
         
 
                                                                                                   
Fig. 1.40: Enzymatic transformation of BE-13793c 52 to D-glucosylated derivative ED-110 53.  
                                                                                                                                    
As displayed in Fig. 1.41, a regioisomeric derivative 54 was reported to be ten-fold more 
active than ED-110 53 against topo I and 5 to 35 times more active against cancer cell lines, 
such as colon HT29 (IC50 = 0.84 µM; 54, c.f. >10 µM; 53) and prostate DU-145 (IC50 = 
0.067 µM (54), c.f. 2.3 µM (53)).
145
 In 1999, Bailly et al. also reported how ICZ analogues 
with ten-fold greater DNA binding affinities exhibited no improvement on topo I inhibition, 
illustrating that intercalation and topo I poisoning comprise two distinct modes of 
action.
135,140,146
 
 
The action of ICZ inhibitors is also similar to camptothecin 33 with respect to the stability of 
the drug-induced cleavable complex, and in a comparison study of camptothecin with the 
intercalating R-3 49 both preferred binding sites were in the 361-364 amino acid „lip‟ region 
of topo I. 
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Fig. 1.41: DNA cleavage site of topo I in the presence of co-axial DNA intercalator SA315F 51, 
illustrating planar intercalating motif and DNA supercoil unwinding effect (increased distance 
between -1 and +1, compared with +1 to +2), and structure of topo I intercalatory inhibitor 54.
114
 
 
This region is essential for covalent and non-covalent contacts in DNA cleavage activity, and 
cross-resistance to derivative 49 was also demonstrated following alteration of a common 
critical residue in a F361S topo I mutant.
147
 The absolutely essential requirement of correct 
orientation for the sugar linkage is necessary for an appreciable DNA binding affinity.
148
 In 
fact, inversion of configuration at C1 of a galactose residue attached to a close rebeccamycin 
38 analogue has been reported to abolish effective minor-groove DNA binding in vitro, 
based on fluorescence energy-transfer experiments.
147
 
1.3.2.4 Conclusion  
 
In summary, previously asserted structural differences between different chemical classes of 
topoisomerase I inhibitors, such as CPTs, IIQs and ICZs may now be exploited for novel 
pharmacophore design, based on converging stereochemical features.
114
 Rational design of 
more potent topo I inhibitors as clinical agents and valuable mechanistic probes has 
accelerated  following the advent of powerful in silico techniques, along with insights arising 
from isolation of crystal structures of small-molecule inhibitors in complex with topo 
I.
40,41,147,148
 Cleavage site mapping studies have also recently been employed for estimating 
in vivo anti-tumour activity from the electrophoretic properties of structurally related 
derivatives possessing closely aligned DNA cleavage capacities, and thus, similar sites of 
action.
149 
 
Important work must also complete the full SAR profile determining how topoisomerase 
disruption, conferred by novel indolocarbazole compounds containing hydrophilic 
maleimide F-ring substituents can be clinically exploited. Various substitutions, in addition 
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to attractive imide substitutions have also been exhibited to exert potent effects on 
cytotoxicity.
41
 
 
 
Fig. 1.42: Intercalative binding mode of anti-cancer indolocarbazole topo I inhibitors.
114
 
 
Anti-proliferative effects of topo I inactive ICZ analogues must be attributable to alternative 
cellular targets such as DNA interaction and phosphotransferase activity; this has been 
corroborated by assays where actual cytotoxicity for members of this series could not be 
correlated with in vitro topo I inhibitory efficacy in CPT-resistant (expressing low topo I 
levels) murine leukaemic cell lines (CPT 33 = 10
5 
loss of activity, c.f. NB-506 50 = 2-10 fold 
reduction). It has also been established that 2‟-aminoglucose substituted ICZ 55 reinforces 
much stronger affinity for DNA than 2‟-OH congener 56, at low pH, yet both possess similar 
ability to inhibit topo I. Thus, DNA intercalation and topo I inhibition are not necessarily 
inter-related and can both contribute to an overall anti-cancer activity profile (Fig. 1.42).
129
  
 
 
 
 
 
 
                                                                    
              R = NH2 55 
               R = OH 56 
                                                                                                                       57 
Fig. 1.43  
In fact, tight binding to DNA can be detrimental for trapping the covalent DNA-topo I 
complexes.
118,140
 In addition, the mode of binding of the carbohydrate moiety rather than the 
binding affinity may be a crucial determinant, as evident from the incorporation of a 
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methylaminoxylose carbohydrate unit which reinforced DNA interaction but abolished anti-
topo I activity, whereas modifying an inactive disaccharide unit to another epimer may 
induce the correct drug-enzyme contacts to stabilise the transient ternary complex.
147,148
  
 Future work in this series may elaborate on the unique biological properties of 1,11-aza-
rebeccamycin derivatives. Marminon and co-workers have recently reported that an anti-
proliferative derivative 57, for which 66% of cells in the L1210 murine leukemic cell line 
were arrested in G2/M at a concentration of 0.25 µM (IC50 = 0.067 µM), was much more 
active than rebeccamycin 38 (IC50 = 0.14 µM) yet possessed diminished activity against 
other cell lines (A549 IC50 = 41.5 µM; 57), suggesting that related analogues may have 
improved toxicity profiles in vivo (Fig. 1.43).
150
 Also, alkyl substitution of the non-
glycosidic nitrogen in most REB-like anti-topo I ICZs is not tolerated, due to active β-N-
glycosidic conformations comprising a bifurcated intramolecular H-bonding network 
between donor NH and pyranose oxygen/6‟-OH positions.136 In the corresponding mono-
azaindole series, it was also disclosed that incorporation of the sugar on the indolic ring 
confers higher affinity for DNA and improved anti-topo I capacities than on the 7-azaindole 
moiety, within aza-rebeccamycin congeners.
140
     
1.4 Significant milestones in ICZ research 
 
The indolocarbazole family consists of 5 isomeric classes, of which the indolo[2,3-
a]carbazole 1 series is the most important as most indolocarbazole alkaloids isolated from 
natural sources to date, exist in this orientation. Isomeric analogues mimicking other 
bioactive compounds, such as aza-derivatives of indolo[3,2-b]carbazole 58 have also been 
reported to display affinity for the aryl hydrocarbon (Ah) or 2,3,7,8-tetrachlorodibenzo-p-
dioxin 59 (TCDD) receptor, possibly due to the presence of a shared planar, polycyclic 
binding motif (Fig. 1.44).
151
 
  
 
        
 Fig. 1.44                                        58                                           59 
 
In this overview, the initial development of classical indolo[2,3-a]pyrrolo[3,4-c]carbazoles 
as improved congeners of STA 2 and REB 38 in terms of their topo I, kinase inhibition or 
other modes of action, will be assessed. Biological activity of the closely related, 
unaromatised bisindolylmaleimide family will then be described, as well as heterocyclic 
modifications accomplished on the indolo[2,3-a]carbazole 1 template in order to 
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contextualize the synthetic work undertaken during this project. The following section will 
then explore the status of up to date research on therapeutic candidates within these classes 
undergoing clinical phase I-III trials. 
1.4.1 Introduction to the structure-bioactivity paradigm within ICZs 
 
Following initial identification of the exceptional biological potency of ICZ alkaloids in 
nature, it was also deemed beneficial to characterize the provenance of specific biological 
roles via SAR patterns of critically conserved structural motifs. On comparison of 
cytotoxicity data from this class, it was noted that target enzyme selectivity seemed to derive 
from two significant structural differences between REB 38 (topo I active, without efficacy 
towards PKA/PKC) and STA 2 (non-selective PKC inhibitor, topo I inactive) congeners:  
 
 imide H-bonding network for active REB 38 derivatives, replacing lactam 
functionality within potent PKC inhibitor STA 2 analogues, in the F-ring position.  
 glycosyl moiety linked to only one indole nitrogen in REB 38 (c.f. doubly linked N-
glycosidic linkage in STA 2), essential for DNA minor groove binding and cell 
permeability.
15
  
 
A recently enhanced awareness of how more subtle changes in molecular functionality 
within the indolo[2,3-a]pyrrolo[3,4-c]carbazole framework 3 can potentiate an extraordinary 
range of biological activities through its polyheterocyclic framework derives from an array 
of sources. Fermentation (actinomycetes, cyanobacteria, β-proteobacteria etc.), 
combinatorial biosynthesis, collection of eukaryotic field samples (myxomycetes, slime 
moulds, marine invertebrates), and an explosion of synthetic endeavour in the last 15 years, 
have all assisted compilation of the tantalizing SAR within this chemical family over that 
time.
16,152,153
 In the following sub-sections, the properties of several important ICZ classes 
distinct from the STA 2 and REB 38 template, including those derivatives bearing no F-ring, 
a cyclofuranosylated/ modified pyranose sugar linkage and the clinically attractive non-
planar bisindolylmaleimide scaffold will be discussed with respect to distinct bioactivity 
profiles within selected members of each series.  
1.4.1.1 Bioactivity of ICZs lacking an F-ring   
 
The necessity of an annelated pyrrolo[3,4-c] structural motif for biological effects associated 
with STA 2 congeners has been investigated by several workers. Thus, glycosidic tjipanazole 
A1 60 which lacks any indolo[2,3-a]carbazole F-ring has been demonstrated to be PKC-
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inactive and lack cytotoxic activity, but has been reported to possess phytopathogenic anti-
fungal action (Fig. 1.45).
154
 
 
 
 
 
 
 
                                                             60                          R1 = H; R2 = CH3 61 
                                                                                           R1 = CH3; R2 = H 62 
                                                                                             R1 = H; R2 = H 63                                                                                                                                            
Fig. 1.45                                                                                           
 
 
In 1990, ICZ metabolites were isolated for the first time from cyanobacteria (blue-green 
algae). Extracts from cultures of Nostoc sphaericum EX-5-1 possessed moderate antiviral 
activity against herpes simplex virus type 2 (HSV-2) and weak, non-selective cytotoxicity 
against human cancer cell lines. This biological activity was attributable to the presence of 5-
cyano-6-methoxy-11-methylindolo[2,3-a]carbazole 61 (major product), its regioisomer 62, 
and desmethyl analogue 63 (Fig. 1.45).
155,156
 
 
In 2009, Guo and co-workers synthesised a panel of these derivatives and reported their anti-
bacterial activity against B. anthracis and M. tuberculosis. The necessity of indole methyl 
substitution, as well as the nature of substituents at both 5 and 6-positions were also 
investigated, and activity within novel analogues was compared to that of 61 against both 
bacterial strains. The results of SAR within this series confirmed that inhibitory activity was 
improved where R4 = H, and was adversely affected by alkyl substitution on R1 (Fig. 1.46).  
 
 
 
 
 
                                              
                                                   64                                                                                               
Fig. 1.46       
                                                                                         
The most active congener in this screen was determined to be 64 (MIC50 B. anthracis = 1.6 
µM; MIC50 M. tuberculosis = 15.0 µM), compared with reduced inhibitory activity in the 
natural product 61 (MIC50 B. anthracis = >200 µM; MIC50 M. tuberculosis = >128 µM).                                                            
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1.4.1.2 F-ring variants of ICZs with bridged ribofuranose linkages 
 
In 1986, the isolation of a series of novel ICZs, K-252a 13, K-252b 65 and STA aglycon K-
252c 6, was reported from Nocardiopsis sp. K-290 providing further insight into the 
preponderance of the indolo[2,3-a]carbazole scaffold 1 as an immutable and diversifiable 
biological motif (Fig. 1.47).
157
 These three compounds were strongly cytotoxic and 
conferred weak anti-microbial capacities; K-252a 13 possessed a 3‟-ester substituted 
ribofuranose ring and mediated weak anti-bacterial and anti-fungal effects, including a 
prophylactic effect on rice plants against bacterial infection, in addition to potent PKC 
inhibition, also observed in K-252b 65.
151,158
 
 
Indolocarbazole platforms offer unique opportunities for imbuing specific biological 
capacities with subtly graduated alterations to overall molecular structure. Due to this 
property, indocarbazostatin 66 was successfully identified as a potent inhibitor of NGF-
induced neuronal outgrowth from PC12 cells, yet remarkably, while K-252a 13 was a 
weaker inhibitor, STA 2 actually induced neurite outgrowth in the same cell line.
159,160
 
 
 
 
 
 
 
                   
                       R1=R2=                    2 
                                                                                     R3=R4=H; R5=CH3 K-252a 13                
                        R1=R2=H  K-252c 6                         R3=R4=OH; R5=CH3  KT-6006 47                  
                                                                                       R3=R4=H; R5=H K-252b 65  
 
 
 
 
 
 
 
                                              66                                       R6=NH2 67 KT-6124   
                                 Indocarbazostatin                            R6=OH 68 KT-6528    
Fig. 1.47  
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Prudhomme et al. also described in 1996 the development of a K-252a 13 structural 
congener, KT-6006 47, with competitive antagonism at the ATP-binding site of PKC, while 
similar ribofuranosylated analogues to KT-6006 47, differing only in F-ring imide 
substitution, KT-6124 67 and KT-6528 68 displayed much less potent PKC activity, but 
exhibited broad spectrum anti-proliferative activity against human tumour cell lines in vitro 
due to their attractive topo I inhibition profiles (Fig. 1.47).
161,162
  
1.4.1.3 STA analogues containing modified pyranose moieties  
 
In the mid-1990‟s, interesting work from several groups produced structures for two 
biologically relevant STA derivatives, namely, the PKC-active anti-tumour metabolite 10-
methoxystaurosporine, TAN-999 69, derived from the soil bacterium Nocardiopsis 
dassonvillei, as well as a 4‟-oxime analogue, (-)-TAN-1030a 70, from Streptomyces sp. C-
71799, with both possessing significant macrophage activation ability.
17
 The synthetic 
derivative (+)-RK-286c 71 was equipotent to STA 2 as an inhibitor of platelet aggregation, 
and differs from staurosporine 2 via its 4‟-hydroxy substitution, yet was only a weak 
inhibitor of PKC, as was its epimeric PKC inhibitor RK-1409B 72 (Fig. 1.48).
163,164
  
 
 
 
 
 
                                                                                           
              
                       TAN-999 69                (-)-TAN-1030a 70     R1=H; R2=OCH3 (+)-RK-286c 71 
 Fig. 1.48                                                                                 R1=OCH3; R2=H RK-1409B 72       
 
Thus, when a corresponding rhamnose sugar was inserted into the STA framework, (+)-
MLR-52 73 afforded almost identical in vitro platelet inhibitory activity to (+)-RK-286c 71 
and STA 2, as well as conferring micromolar PKC inhibition.
165
 In addition, a natural 3‟-
demethylated analogue of (+)-MLR-52 73, K-252d 74 lacked the doubly linked sugar 
configuration, and contained a REB-type mono-α-L-rhamnose linkage, yet also conserved 
kinase inhibitory activity (Fig. 1.49).
157
  
 
In 1999, a 5‟-deoxyaminohexose derivative of K-252d 74 isolated from the marine 
actinomycete strain N96C-47, holyrine A 75, was also reported to exhibit potent and quite 
selective kinase inhibition.
166
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               MLR-52 73                                  K-252d 74                            holyrine A 75    
Fig. 1.49: Deconvolution of sugar configuration in active mono and di-N-glycosidic indolocarbazole 
natural product kinase inhibitors conserving a lactam F-ring heterocyclic moiety. 
 
An interesting result in this area concerns the recent isolation of the 4‟-N-formyl 76 and 4‟-
N-carboxamido 77 derivatives of STA 2 from Streptomyces sp. QD518 and testing against a 
number of solid tumour cell lines. 4‟-N-Carboxamido staurosporine 77 was determined to be 
the most active compound with a mean IC50 of 0.016 µg/mL, while 4‟-N-formyl-
staurosporine 76 was also highly active in vitro (IC50 = 0.063 µg/mL) (Fig. 1.50).
167
  
 
It may also be possible to constrain and align certain optimised sugar orientations, with the 
goal of creating potent kinase inhibitors through novel non-covalent stabilising contacts with 
residues in the hydrophilic region of the ATP-binding domain. A putative lead compound 
which could be exploited through this strategy is the novel oxazolone-fused pyran system 
(perhaps mimicking a backbone interaction in the kinase ATP pocket) in the naturally 
occurring marine indolo[2,3-a]carbazole ZHD-0501 78 from Actinomadura sp. 007.
25
 
 
 
 
 
 
 
 
 
                          R1=H 76                          ZHD-0501 78                     UCN-01 20   
Fig. 1.50          R1=NH2 77     
       
At 1 µM concentration, this metabolite 78 inhibited the proliferation of human lung 
adenocarcinoma A549 and pro-myelocytic leukemia HL60 cancer cell lines with inhibition 
rates of 82.6% and 76.1%. It also exhibited strong anti-proliferative activity against mouse 
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mammary cancer tsFT210 cells by eliciting mitotic catastrophe via accumulation of cells in 
the G2/M phase.
168
 This spectrum of activity is similar to the previously discussed anti-
cancer agent, UCN-01 20, potent in p53-deficient (G1-evading) tumours due to inhibition of 
various cell cycle-related kinases such as ChK1, PDK1 and various CDKs (Fig. 1.50).
35
  
 
1.4.1.4 Heterocyclic ring modifications in ICZs 
 
1.4.1.4.1 Bisindolymaleimide (BIM) derivatives: acyclic C-ring analogues 
 
As previously discussed, the broad spectrum of biological activity displayed by STA 2 was 
rationalized in 1986 to be due to its behaviour as a non-specific ATP-competitive kinase 
inhibitor, exhibiting strong cytotoxic activity against cancer cell lines due to its nanomolar 
PKC activity, as well as CDK inhibition, in vitro.
33,38
 As biogenetic ICZ precursors, the 
bisindolylmaleimide (3,4-di-1H-indol-3-yl-1H-pyrrole-2,5-dione) scaffold based on the anti-
fungal metabolite arcyriarubin A 79, which was isolated as the pigment from myxomycetes 
such as Arcyria denudata and A. nutans, may also represent a novel template for selective 
PKC inhibition and anti-angiogenesis activity via effects on VEGFR.
169,170
  
 
 
 
 
 
 
 
                  R1 = R2 = H 79                                            
      R1 = H; R2 = (CH2)3N(CH3)2 26                           
                                                                         80                                       81 
Fig. 1.51 
 
Compounds of this type are also associated with suppression of cultured cancer cell line 
progression, while displaying a narrow therapeutic window, as well as having vast clinical 
potential for treatment of autoimmune diseases.
171,172
 As will be discussed in Section 1.5, 
selective PKC-β inhibitors ruboxistaurin 80 and enzastaurin 81 possess extremely attractive 
potential as clinical agents against cancer and other indications (Fig. 1.51). 
Bisindolylmaleimide congener GF109203x 26 was also identified to display extremely 
potent activity against PKC (IC50 = 10 nM), although kinase selectivity issues later 
emerged.
173-175
 In terms of overcoming innate chemotherapeutic resistance, active
 
bisindolylmaleimides (BIMs) have also been described as ABCG2 transporter inhibitors, 
thus increasing the oral bioavailability of co-administered ABCG2 substrate cytotoxic 
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agents, in order to potentiate an effective therapeutic response and significantly improve 
subsequent clinical outcome.
130
 
 
Due to their close biosynthetic and structural relationships with ICZs and BIMs, a number of 
other related alkaloids with interesting biological applications have been encountered from 
natural product screening. Lynamycin E 82 is a member of a family of bisindole pyrroles 
related to BIMs that all demonstrate potent anti-microbial activity against staphylococci and 
enterococci and was initially isolated from Marinispora sp. NPS12745, present in marine 
sediment collected off the coast of San Diego, California.
25,176,177
 Its dechloro derivative, 
lycogarubin C 83 was isolated in the slime mold Lycogala epidendrum, and possessed 
moderate anti-viral activity against human simplex virus type 1 (HSV-1) (Fig. 1.52).
178,179
  
 
Several complex analogues of simple indole alkaloids are also formed from alternative minor 
biosynthesis pathways via oxygenation and cyclisation steps.
16
 Thus, cinereapyrroles A 84 
and B 85 were present, together with arcyriarubin A 79, in Arcyria cinerea, and 
regioisomeric annelation product arcyriacyanin A 86 was isolated, along with arcyriarubin A 
79, aromatised arcyriaflavin A 7, dihydroarcyriarubin B 87 and arcyriaverdin C 88, in the 
brightly coloured slime mold Arcyria denudata (Figs. 1.52 and 1.53).
16,169,180
 
 
 
 
 
         
R1=H; R2=CO2CH3; R3=Cl 82     R1=H; R2=OH; R3=OH 84                           89 
R1=R3=H; R2=CO2CH3 83           R1=H; R2=H; R3=OH 85   
     
Fig. 1.52                                                                         
Anti-cancer effects were reported by Brãna et al. within BIM analogue N,N-
dimethylaminoethyl-substituted pyrazolone 89, which induced 43% apoptosis within HeLa 
cells at 100 µM.
181
 Interestingly, arcyriacyanin A 86 also exhibited anti-proliferative effects 
on several human tumour cell lines, as well as inhibiting PKC and protein tyrosine kinase.
182
 
Thus, initial condensation of two tryptophan units and F-ring diversity affords a disparate 
variety of bisindolyl metabolites with attractive medicinal characteristics, in which the 
indolo[2,3-a]carbazoles are present within modified heterocyclic scaffolds (Fig. 1.53).
16,30,183
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                    86                                           87                                               88 
Fig. 1.53 
 
 
1.4.1.4.2 Peripheral ring modification: substituted D/E-rings in BIMs and ICZs 
 
In addition to non-carbazole (acyclic) BIM derivatives, recent work, has revealed that 
chemical modification of advanced bisindolylethene chromophores may derive unique 
ligand binding interactions within an ATP-binding pocket, with enhanced target selectivity, 
due to increased conformational flexibility.
184,185
 Thus, replacement of an indolic ring with a 
benzofuran heterocycle in 90 has been reported to confer potent GSK-3β inhibition.186 SAR 
also revealed that lactam regiochemistry and retention of aryl rings B and E are important in 
development of potent cell-permeable MLK1/3 family selective inhibitors. Accordingly, the 
non-planar fused pyrrolocarbazole dihydronaphthyl[3,4-a]pyrrolo[3,4-c]carbazole-7-one 91 
was determined to be a comparable MLK1/MLK3 inhibitor to K-252a 13, and was 3 times 
more active than K-252c 6 (Fig. 1.54).
187
 
 
 
 
 
 
                                                 90                                                       91 
 
 
 
 
 
Fig. 1.54                                 92                                                                93                                                      
 
Maintaining the arcyriaflavin A 7 framework, several workers have also recently synthesised 
other related fused carbazole analogues retaining either maleimide or imide F-ring systems, 
including naphtho and phenylcarbazoles, while the development of 1,11-azaindolocarbazoles 
92, including anti-topo I derivative 57 will have important future significance in cognisance 
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of their reported biological effects to date.
98,152,188,189
 The attractive, partially hydrogenated 
4H-tetrahydrostaurosporine 93 is a more soluble non-planar STA 2 analogue, possessing 
reduced aromatic E-ring character (Fig. 1.54). It has also been co-crystallised with Abl 
kinase and JAK3, binding in a distinct mode deep in the ATP pocket.
35,74
 
 
A water-soluble 5-oxoindeno[2,1-a]pyrrolo[3,4-c]carbazole derivative CEP-7055 29 was 
also observed to exhibit anti-angiogenic properties through metabolic esterase activation of 
the prodrug to the VEGF inhibitor CEP-5214 94 (Fig. 1.55). CEP-7055 29 entered phase I/II 
clinical trials for solid tumours but pre-clinical assessment of the drug apparently ceased in 
2005.
16,93
 
 
 
 
 
 
 
 
 
 
 
               CEP-7055 29                               CEP-5214 94                          BMS-251873 95  
Fig. 1.55: Metabolic conversion of CEP-7055 29 to its active form, CEP-5214 94 and structure of 
topo I inhibitor 95.   
 
                                                                 
Finally, to demonstrate the utility of indolic ring replacement for non-kinase targeting 
agents, Saulnier and co-workers recently reported synthesis of a putative clinical target – the 
highly active fluorinated rebeccamycin 38 analogue, BMS-251873 95, containing a 
contiguous thiophene-fused carbazole core and 6‟-aminoglycosylated system, which 
possessed potent in vitro anti-tumour activity due to efficient promotion of topo I-mediated 
DNA cleavage.
126,190
  
 
1.4.2 Conclusion 
In conclusion, it seems that, in the case of a non-glycosylated system, any specific structure–
activity relationships seem to operate only for a particular protein kinase and a given ICZ 
type, and are also limited in scope by the non-specific basis of their understood modes of 
action.
16
 Specific biological functions within this series may be encoded within distinct 
structural domains, and perhaps, the ability to decouple structural („modular‟) traits 
corresponding to anti-tumour or immunosuppressive ability may lead to less toxic, mono-
purpose clinical agents incorporating a rationally designed indolo[2,3-a]carbazole 1 
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skeleton. These results suggest that major alterations to the initial aminohexose configuration 
of STA 2, (including mono-N-linkage, ring contraction and 3‟-NHCH3 replacement) could 
selectively modulate interesting biological effects (e.g. neurological treatment), but does not 
constitutively abolish PKC inhibition; the corresponding aglycon K-252c 6 still conferred 
significant PKC inhibition, if slightly weaker than both glycosides, K-252a 13 and K-252b 
65.
34,157,164,165,191
  
 
Analysis of the activity of biosynthetic precursors may also benefit SAR within this series, 
due to the large number of closely related structures isolated in nature to date. In the case of 
clinical development of K-252c 6, therefore, the vital necessity for N-glycosylation should 
be explored, as aqueous solubility of the non-glycosylated kinase-inhibitory pharmacophore 
could also be enhanced via efficacious alkylation/ carbohydrate modification.
120,190
 
 
The synthetic endeavours encountered herein feature comprehensive efforts to apply 
synergistic advantages from the exciting strategies which underpin current research in 
relation to cancer. Thus, K-252c 6 and 3,4-diarylmaleimide (e.g. arcyriaflavin A 7) 
investigation will culminate in design and synthesis of novel anti-cancer agents 
incorporating unique heterocyclic F-ring and indole ring subunits, with well defined 
biological potential. Unique opportunities arising from elaboration of a basic 1,2-bisindolyl-
cis-ethene pharmacophore will thus be exploited to afford novel bioactive „bridge-head‟ 
structural motifs, fully consistent with the basic indolo[2,3-a]pyrrolo[3,4-c]carbazole 
template 3. 
1.5 Current development of indolocarbazoles as clinical therapeutic agents 
In recent years, several industrial indolocarbazole derivatives have been developed in order 
to optimize their intrinsic pharmacological activity, while limiting undesirable activity at 
other target sites.
13,15,152,192
 Following a number of pre-clinical studies on REB 38 and STA 2 
analogues, advanced candidates were investigated to possess attractive therapeutic and 
physicochemical characteristics (log P, molecular weight etc.). Based on these results, 
effective congeners which possessed low toxicity through enviable selectivity profiles, 
effective dosage regimens and acceptable drug metabolic fates in target tissue have now 
progressed to current clinical trials.
16,193
 
1.5.1 Bisindolylmaleimides (BIMs) 
 
Recent progress in the development of PKC isoform-selective inhibitors has been 
highlighted by the drug application submitted to the FDA by Eli Lilly, in February 2006, 
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following successful clinical phase III trials, for the macrocyclic bisindolylmaleimide, 
ruboxistaurin mesylate (Arxxant
®
) 80 (Fig. 1.56).
16,194
 
 
 
 
 
 
 
 
                   
                                                      80                                                                   81 
Fig. 1.56 
                                                                                            
Interestingly, compound 80 was reported to confer quite discrete enzyme selectivity; IC50 
values for PKC-β1 and β2 (4.7 and 5.9 nM, respectively), are more than 40-fold greater than 
for other PKC isoforms, and thousands-fold more potent than against other ATP-dependent 
kinases, e.g. Src tyrosine kinase.
195,196
 This clinical candidate possesses attractive efficacy in 
reducing vision loss in patients with diabetic peripheral retinopathy, and is currently defined 
as the first chemotherapeutic treatment for this serious complication of diabetes.
85,197
 The 
orally-administered enzastaurin 81 has also been evaluated favorably in clinical trials for the 
treatment of glioblastoma and colo-rectal cancer, and is described to operate via induction of 
apoptosis and inhibition of VEGF-mediated angiogenesis.
198,199
 Preliminary phase I/II data 
published to date also supports the potential of 81 as a component of adjuvant therapies for 
diffuse large B-cell lymphoma and refractive Akt-mediated diseases, such as breast and 
ovarian cancers due to its highly attractive PKCβ and AKT/PI3 activity (Fig. 1.56).200-202 
1.5.2 Staurosporine derivatives 
 
In 1987, Takahashi and co-workers isolated the epimeric 7-hydroxystaurosporine UCN-01 
20 from Streptomyces sp. N-126 – which is unique as the only natural indolo[2,3-a]carbazole 
to be in current clinical trials.
203,204
 This compound is now finding application against 
haematological and advanced solid tumours, melanoma, and small-cell lung cancer, 
especially in combination with DNA-damaging agents, topo I poisons or radiotherapy, due 
to synergistic inhibition of various PKCs and cell cycle-related kinases.
77,205-208
 The 
stereochemical configuration of the hydroxyl group in 20 is unstable in low or high pH 
solution and is found to exist in equilibrium with epimeric UCN-02 96 (Fig. 1.57).
209
 Active 
UCN-01 20, possesses poor tissue distribution and a prolonged half-life of elimination 
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(600h) following 72h infusion, due to high affinity for α1-acid glycoprotein. Additional 
refinement may be required in order to overcome this pharmacokinetic limitation.
204,209-211
 
 
 
 
 
 
 
 
                                                  20                                                96                                                                                                                                           
Fig. 1.57: Configurational instability of UCN-01 20 in aqueous acidic or basic media. 
 
Based on crystallographic data, the ability of 20 to potently inhibit ChK1 (Ki = 5.6 nM), 
PDK (IC50 = 5 nM) and PKC-β (IC50 = 10 nM) and abrogate G2/M checkpoint induced by 
DNA-damaging agents was ascertained by flexible conformational interactions in the 
adenine domain, glycine-rich and activation loops and hydrophobic pockets.
35,63,64
 
Furthermore, UCN-01 20 polypharmacology may also extend to anti-tumour activity based 
on disruption of Akt pathways arising from upstream PDK-1 inhibition.
212
 In addition, UCN-
01 20 exhibits enhanced cytotoxicity in commonly refractory HT-29 and CA-46 cancer cell 
lines due to a down-regulated or mutated p53 tumour suppressor gene. G1 phase cell cycle 
arrest in a head and neck carcinoma cell line (HN12) has also been reported for 20, but does 
not seem to be associated with p53, or maintaining hypophosphorylation of Rb protein, 
based on the conclusions of Shimizu et al., following a review of its effects in lung 
cancer.
204,213
 Future exploration of the pyrrolo[3,4-c]ring ring system present in UCN-01 20  
may also focus on semi-synthetic and chemical derivatisation of tjipanazole J 97, a 
fungicidal indolo[2,3-a]carbazole produced by the blue-green alga, tolypothrix 
tjiapanasensis, which has relatively little biological data reported to date (Fig. 1.58).
16,154
  
         
 
 
 
 
 
                                                                                          tjipanazole J 97            
Fig. 1.58                           16  
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 The relatively non-specific kinase inhibitor and orally administered midostaurin 16, has 
entered phase I/II trial in patients with acute myeloid leukaemia, due to its potent inhibition 
of Flt-3, which is mutated in approximately 30% of these cancers.
12,214-216
 Its use has also 
been positively indicated in clinical phase I/II trials for B-chronic lymphocytic leukaemia, 
acute myeloid leukemia (AML) and non-cancer disorders such as diabetic macular edema, 
based upon the recognised ability of midostaurin 16 to potently inhibit kinases including 
VEGFR2, PDGFR and c-Kit, involved in development of aberrant microvascularisation 
associated with this complication of diabetes (Fig. 1.58).
16,76,217
  
1.5.3 K-252a derivatives 
 
Lestaurtinib (CEP-701) 98 and CEP-751 99 have also been found to possess intrinsic anti-
tumour activity via inhibition of neurotrophin-specific trk-receptors, in addition to kinases 
including PDGFR and Flt-3, and have entered phase II/ III clinical trials against refractive 
AML in patients with mutated copies of Flt-3.
218-220
  
In April 2006, lestaurtinib 98 was granted orphan drug designation against AML, and is 
currently undergoing various trial protocols for additional treatment of myelofibrosis and 
prostate cancer, in addition to early human trials in children with high risk neuroblastoma 
and patients with severe psoriasis (Fig. 1.59).
16,35
 
 
A 3,9-bis(ethylthiomethyl) derivative of K-252a 13, orally active CEP-1347 30 was also 
found to possess pre-clinical neuroprotective activity due to its inhibition of MLK kinases, 
which are key modulators within the JNK signalling pathway implicated in 
neurodegeneration and apoptosis.
221,222
 
 
 
 
 
 
 
 
 
     
              R1=H 98 lestaurtinib   
              R1=CH3 99 CEP-751                                                      CEP-1347 30  
Fig. 1.59 
 
CEP-1347 30 thus represents a rational target for suppression of Parkinson‟s disease, via 
disruption of pathogenesis.
16
 Subsequently, in May 2005, clinical studies were discontinued 
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due to the lack of an observable therapeutic dividend arising from 30 (Fig. 1.59). However, it 
is still an intriguing development and further research could elucidate precise 
neuroprotective pathways affected by similar compounds. Perhaps, more effective ICZ 
derivatives could be found through combination therapy with another inhibitory agent or 
improving pharmacokinetics within this poorly aqueous soluble drug class by engineering a 
prodrug containing a labile water-soluble fragment, increasing bioavailability, prior to 
enzymatic cleavage and localisation of the active moiety within the target site. 
1.5.4 Rebeccamycin derivatives 
 
Due to the aqueous insolubility of rebeccamycin 38, subsequent structural analogues of 
clinical relevance within this series have incorporated improved hydrophilic functionality, in 
addition to their enhanced spectra of activity and improved toxicity profiles.
41,120,138
  
 
 
 
 
 
 
  
                                             
      
Fig. 1.60                                     100                                                    45              
                           
This anti-cancer compound, becatecarin 100, unlike REB 38, can act through tight DNA 
intercalation. Thus, it is active as a topo I poison mediating extensive strand fragmentation, 
and potently inhibits topo II by preventing correct DNA binding of the enzyme. In addition, 
100 also induces expression of ABCG2 drug transporter, implicated in mechanisms of 
cancer chemoresistance against other ABCG2 substrate drugs.
120,223
 A fluorinated analogue, 
BMS-250749 45, entered human trials as a result of effective topo I-mediated DNA 
cleavage, following a biocombinatorial study involving addition of starting 
fluorotryptophans to a culture of L. aerocolonigenes, to afford the corresponding 
fluoroindolocarbazoles (Fig. 1.60).
126,190
  
 
The difficulty of predicting putative modes of action of de novo synthetic indolocarbazoles 
can be encapsulated by the unique biological characteristics of the 2,10-dihydroxylated 
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congener, arcyriaflavin C 101, produced by the slime mold, Tubifera casparyi.
224
 
Arcyriaflavin C 101 induced cell-cycle arrest at lower concentrations, while displaying 
cytotoxicity at higher concentrations, along with no observable effect on bacterial topo 1 
activity. Interestingly, the arcyriaflavin C 101 1,11-dihydroxylated regioisomer and potent 
dual topo I/II inhibitor, BE-13793C 52 (aglycon of ED-110 53) also overcomes conventional  
drug resistance phenomena in that it inhibits the growth of P388/ADR cells, which are 
refractive towards doxorubicin, part of a well-known family of DNA intercalating topo II 
suppressors (Fig. 1.61).
144
  
 
Due to its hydrophobic, polyheteroaromatic core, derivative 52 demonstrated the significant 
drawback of low water solubility, and thus a clinical study set about evaluating analogues 
with improved physico-chemical parameters, through glycosylation and imide substitution. 
The resultant glucosylated anti-cancer derivative ED-110 53 also possessed a significantly 
lower log P value and interestingly, inhibited topo I while being topo II inactive (Fig. 
1.61).
141-143
 
 
 
 
 
 
 
                        
                        
                      101                                                                                                46 edotecarin 
 
                                                            R1=H 53 ED-110  
Fig. 1.61                                        R1=NHCHO 50 NB-506 
                                                    
In 1994, another more soluble, semi-synthetic 6-N-formylamino derivative, NB-506 50 
progressed to clinical trials for treatment of solid tumours.
131,225
 This 1,11-dihydroxylated 
ICZ 50 was an effective anti-topo I congener, preserving its capacity for DNA binding, in 
addition to inhibition of its dual DNA relaxing and SR kinase activity.
16
 These multiple 
mechanisms contribute to the limited resistance seen for 50 on camptothecin-resistant cancer 
cell lines; it was observed that camptothecin 33 induced greater than 100-fold reduction in 
anti-cancer activity, while NB-506 50 only elicited less than 10-fold decrease in cytotoxicity 
against cell strains also resistant to NB-506 50 topo I inhibition.
226
 Developmental work 
culminated in a positive phase I outcome for NB-506 50  against estrogen sensitive ovarian 
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and breast cancers resistant to vinca alkaloid anti-mitotics, but further advanced clinical 
trials were ultimately unsuccessful.
131
  
 
Another cytotoxic derivative of 50, edotecarin 46, also afforded topo I-mediated persistent 
single strand breakage and DNA lesion formation more effectively than either camptothecin 
33 or NB-506 50, and improved its pharmacokinetic and efficacy profile further by replacing 
the formylamino group of 50 with a more hydrophilic 1,3-dihydroxyisopropylamino moiety, 
and adjusting the hydroxylation pattern of the planar chromophore (2-OH and 10-OH).
112,227
 
These structural alterations result in non-covalent stabilisation of H-bonding interactions 
within the DNA stacking or protein side-chain regions of the drug-DNA-topo I ternary 
complex. Following initial human tumour xenograft testing against CNS, colon and breast 
neoplasms, edotecarin 46 was revealed to exert dose-limiting haematologic toxicity and 
subsequently entered advanced clinical trials as an intravenous infusion, for the treatment of 
breast, gastric and metastatic colo-rectal cancer, and is currently in phase III studies against 
glioblastoma multiforme.
228-230
 
 
1.6 Final perspective on future indolocarbazole development 
 
Critical insights from the validated bioactivity of natural product and synthetic ICZs denote 
an exciting launching pad for new chemical research into formation of diverse analogues as a 
potential new anti-cancer class with a multitude of biological applications.  
 
Originally isolated from microbial sources, indolocarbazoles display important effects in 
morphogenesis and developmental processes, such as cell differentiation within marine 
actinomycetes; it has been speculated that potent activity at discrete eukaryotic targets also 
confers an acute defence mechanism against attack.
16
 The primary biological targets probed 
by current novel indolo[2,3-a]pyrrolo[3,4-c]carbazole development are inhibition of protein 
kinases (characterised by an unsubstituted lactam/maleimide F-ring), which constitute 22% 
of the total medicinal genome, as well as distinct topo I poisoning using hydrophilic, 
branched F-ring analogues, unrelated to tyrosine kinase inhibition.  
 
Stabilisation of the DNA-topoisomerase covalent catalytic intermediate or „cleavable 
complex‟ and avid DNA binding by 2,10-dihydroxylated (A/E-ring) indolocarbazoles also 
disrupts critical cell processes such as transcription and replication, in a relatively complex 
fashion, also possibly related to intrinsic topo I kinase (phosphotransferase) inhibition.
129
 
The contribution of other mechanisms to overall anti-cancer activity was also illustrated by 
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only partial correlation between the in vitro S-phase cytotoxicity and G2-M cell cycle arrest 
induced by rebeccamycin 38 derivatives and their corresponding topo I inhibitory activity or 
magnitude of drug-DNA binding.
41,112,226
 Thus, it is evident that no mono-modal or single 
target activity paradigm underpins the fusion of biological effects transmitted by the diverse 
spectrum of indolo[2,3-a]carbazole agents. 
Indolocarbazole derivatives possessing an essential bidentate hydrogen bonding network and 
hydrophobic heterocyclic scaffold, are now fully recognised as constituting a versatile anti-
cancer class with novel synthetic congeners yielding noteworthy success in a multitude of 
clinical trials within the last 15 years, against diverse cancer states, with successful BIM 
investigational compounds ruboxistaurin 80 and enzastaurin 81, attracting intense clinical 
interest within diabetic retinopathy chemotherapy and Parkinson‟s disease, due to 
specifically targeting PKC-β and MLK, respectively.16,77 Relatively structurally diverse 
indolocarbazole scaffolds have also been employed to derive relatively specific PKC 
inhibitors, with possible application to non-cytotoxic anti-angiogenesis therapies, as well as 
cell cycle modulating roles due to inhibition of CDK, PDK1 and ChK1 enzymes. With 
respect to carbohydrate substitution, the necessity of an active mono-glycosyl conformation 
with an adjacent indole NH, for topo I inhibition within this series was outlined by Facompre 
and co-workers. However, for general kinase inhibition, active glycosidic derivatives favour 
the presence of a lactam F-ring moiety, while non-glycosidic congeners comprising an imide 
heterocyclic nucleus generally exhibit enhanced activity.  
 
Kinase inhibition is more tolerant of functional group variation and simplification; acyclic  
bisindolylmaleimide analogues are believed to bind in a more flexible mode within the 
adenosine-binding hinge region of the ATP pocket, in unique conformations exploiting 
selective non-covalent ligand interactions.
82,136,185
 In concert with the enviable pre-clinical 
activity observed for UCN-01 20 (containing a modified 5-hydroxypyrrol-2-one F-ring 
system) against a range of solid and haematological tumours, these underpinning structural 
relationships clearly demonstrate how bisindolylmaleimide and indolocarbazole derivatives 
possessing desirable pyrrol-2-one (maleimide/lactam) isosteres may impart improved anti-
cancer potency and target selectivity. However, few workers to date have comprehensively 
investigated heterocyclic modification of the crucial F-ring pyrrole moiety and its associated 
potential for accessing new molecular targets, or an enhanced array of anti-cancer properties.   
 
The illustrious history of indolocarbazole anti-cancer research and underlying clinical 
benefits accruing from defining new robust analogues within this privileged bioactive 1,2-
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bis(indol-3-yl)-cis-ethene scaffold offers unique opportunities ripe for exploration over the 
course of this work. 
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2.0 Chemical Introduction 
2.1 Development of chemical routes to indolo[2,3-a]carbazoles 
 
Indolo[2,3-a]carbazoles comprise a core pentacyclic scaffold consisting of a carbazole 
moiety fused to an indole ring unit via its five-membered ring.
1
 Privileged approaches to 
derivatisation of this skeleton utilising a multitude of heterocyclic strategies involving ICZ 
ring assembly and B/C/D/F-ring annulation have propelled the ongoing quest for synthetic 
analogues with attractive biological applications.
2-4
 
 
 
 
 
 
 
 
                                                                       
 
                                                                                            102 
 
 
 
 
 
Fig. 2.1: Classical methods of indolo[2,3-a]carbazole 102 synthesis 
 
As illustrated in Fig. 2.1, retrosynthetic routes to construction of the indolo[2,3-a]carbazole 
nucleus (102) can be classified according to the site of final ICZ ring formation. Several 
workers have reported Fischer cyclisation and Cadogan nitrene insertion processes as 
peripheral B and D-ring forming methodologies while Diels-Alder cycloaddition has also 
been employed by several workers in B/C-ring annulation, in addition to targeting versatile 
carbon-carbon bond formation within advanced ICZ intermediates.
5,6
 A wide diversity of C-
ring routes is characterised by coupling of indole moieties to activated F-ring precursors, 
followed by oxidative ring closure, or ring dehydrogenation in the case of a 2,2-biindolyl 
dienophile tandem cyclisation approach. It should also be remarked that this review 
primarily addresses the study of current methodologies available for synthesising regio-
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analogues of indolo[2,3-a]carbazoles bearing diverse F-ring functionality, and will serve as a 
critical launching pad for our novel investigations in this relatively unexplored field. 
2.2 Overview of current strategies for indolocarbazole synthesis  
 
Chemical diversity observed within complex indolo[2,3-a]carbazole natural products reflect 
the wide range and overwhelming impact of biological roles mediated by this chemical class 
(Section 1.0; Biological Introduction).
7-9
 Discussion of these strategies will comprise initial 
approaches to the indolocarbazole nucleus as well as F-ring containing derivatives, prior to 
investigating individual C, B/D and F-ring forming reaction types classified by means of 
their highlighted ring cyclisation step.    
2.2.1 Early efforts in synthesis of indolo[2,3-a]carbazoles 
 
Prior to initial isolation of these alkaloids from natural sources and discovery of their 
biological potential, derivatisation of the conserved indolo[2,3-a]carbazole scaffold received 
scant attention from medicinal chemists.  
 
 
                                 103            104                                        105 
                                                                                    
                                          
                                106               104                                        1 
Scheme 2.1 
 
In 1956, Tomlinson reported the first synthesis of the indolo[2,3-a]carbazole core as an N-
methyl derivative 105, following condensation of 8-amino-1,2,3,4-tetrahydro-9-methyl-9H-
carbazole 103 with acyloin 104, followed by dehydrogenation (Scheme 2.1).
10
 However, an 
analogous approach to form the demethylated indolo[2,3-a]carbazole 1 was unsuccessful. 
However, Mann and co-workers employed stepwise Fischer indolisation of acyloin 104 with 
phenylhydrazine 106 to afford the unsubstituted skeleton, following cyclisation of both 
indole rings, prior to final aromatisation to yield 1.
11
  
 
Winterfeldt and co-workers reported the first synthesis of pyrrolo[3,4-c] analogue, K-252c 6, 
paving the way for continuing synthetic endeavours in the field of F-ring head group 
derivatisation.
12,13
 Starting from bisindolyl amide 107, DDQ oxidation in aqueous THF 
afforded intermediate trione 108, which was partially reduced following treatment with 
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NaBH4, to 109. Polyacetylation was then carried out to form intermediate 110, prior to 
titanium-induced reduction. Following indole deacetylation to afford 111 under basic 
conditions, final oxidative ring closure was performed under photocyclisation conditions to 
afford compound 6 in 65% yield (Scheme 2.2). 
 
 
 
                      107                                              108                                             109 
110-111 
 
                                  6 
 
 
                                                                      111                                                    110 
Scheme 2.2 
2.2.2 C-Ring forming routes 
2.2.2.1 Electrophilic strategies to ICZs 
 
These reaction types exploit the nucleophilic C-3 reactivity of indole with electrophilic 
reagents, in order to afford advanced intermediates which can subsequently be cyclised to 
form the indolo[2,3-a]carbazole core. 
 
2.2.2.1.1 Indole C-3 electrophilic addition  
 
Cai and Snieckus reported an elegant C-ring condensation approach, invoking early 2,2‟-
bond formation via Stille cross-coupling of both indolic fragments 112 and 113.
14
 2,2‟-
Biindolyl 114 then undergoes C-3 attack from a dialkyliminium electrophile on treatment 
with Eschenmoser‟s salt, to provide gramine derivative 115 (Scheme 2.3). 
  
Methylation and cyanide addition then resulted in formation of key nitrile intermediate 116, 
which, following base-induced ring closure and diazomethane-mediated etherification, 
completed synthesis of cytotoxic 5-cyano-6-methoxy-11-methylindolo[2,3-a]carbazole 61, 
lacking an F-ring moiety (Section 1.4.1.1).
15
 
 
61, 116 
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                 112                              113                                           114 
 
 
 
 
                    61                                              116                                                115                         
Scheme 2.3 
 
Recently, a ruthenium catalysed indolocarbazole synthesis has been published which is 
based on Grubbs‟ celebrated metathesis reaction. This rather limited approach to 
indolocarbazole design was fully realised by Pelly et al. in 2005, when synthesis of the 
pentacyclic indolocarbazole core 1 and a sulfur analogue of furostifoline 117 were 
completed (Scheme 2.4).
16
  
 
 
                      118                                            119                                                  
                                                                        
 
  
                                                                                                        117                                                    
                        1                                                      120 
Scheme 2.4 
                                                                                                                                                                                                                               
Similar to other benzannulation approaches, a feature of this method is the early formation of 
the 2,2‟-biindolyl bond; the central carbocyclic ring is then rendered by ring-closing 
metathesis (RCM) reaction. Conversion of starting biindolyl 118 to dialdehyde 119 was 
achieved using the Vilsmeier-Haack protocol and, following double Boc-protection, 
converted to the corresponding diene 120, by means of a Wittig reaction. Exposure of 120 to  
the Grubbs second-generation catalyst in toluene at 80
o
C for 24 hours gave the anticipated 
product 1 in overall combined yield of 47%. 
 
 
 
            121                                        122                                                 1 
Scheme 2.5 
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A more straightforward route has recently been suggested, involving 2,2‟-dimerisation of 
indole-3-carboxaldehyde 121 with the single-electron transfer reagent, SmI2, followed by 
annulation of the resulting product 122 with hydrazine in refluxing THF, leading to 
indolocarbazole 1 via ultimate extrusion of nitrogen (Scheme 2.5).
17,18
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126-127 
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                                                                                                                               126 
                                                                                                                                    61 
                           129                                             130 
Scheme 2.6     
 
An alternative route to interesting polycyclic analogues involving a readily available, 
symmetrical starting material and critical C3 electrophilic aromatic substitution step was 
reported by Somei et al, in 59% yield over six steps.
19,20
 Starting from indigo 123, initial 
reduction by tin in acetic acid/acetic anhydride afforded an initial 3-acetoxylated precursor, 
which was heated with dichloroacetyl chloride to form the C-3 acylated 2,2‟-bisindolyl 
derivative 124 (67% yield over two steps); treatment with ammonia to form 125, followed 
by N-methylation, cyanation and O-methylation of 126, provided natural product 5-cyano-6-
methoxy-11-methylindolo[2,3-a]carbazole 61, which was identical to the anti-viral 
compound synthesised by Cai et al., and originally isolated from a blue-green alga by Moore 
and co-workers in 1990.
14,15
 In 2007, McErlean et al. co-opted this route for a biomimetic 
synthesis of a structurally related pentacyclic indolo[3,2-j]phenanthridine natural product, 
calothrixin A 130.
21,22
 Reduction of intermediate 125 to 5-hydroxyindolo[2,3-a]carbazole 
127 was followed by Vilsmeier-Haack formylation and universal MOM-protection steps. 
CAN-induced rearrangement of intermediate 128 to 129 was then performed in a yield of 
31%, prior to HCl deprotection and mild peroxyacid oxidation to afford 130 (Scheme 2.6).  
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2.2.2.1.2 Mannich cyclisation of 1,2-bisindolylethane derivatives 
 
An efficient biomimetic route to indolocarbazole construction involved base-mediated 
condensation of gramine methiodide 131 and N-protected indole-3-acetonitrile 132, to afford 
bisindole derivative 133; TFA-induced Mannich cyclisation and subsequent DDQ oxidation 
of the non-aromatic 134 produced indolocarbazole 135 (Scheme 2.7).
23
 
135-137  
 
 
      131                 132                                     133                                                 134 
 
 
 
 
 
                   137                                            136                                                    135 
Scheme 2.7 
 
Reduction of the aryl nitrile 135, followed by reductive amination employing 3,4,5-
trimethoxybenzaldehyde afforded 5-aminomethyl substituted derivative 136, which was 
employed to access the lactam-bearing indolo[2,3-a]pyrrolo[3,4-c]carbazole ring system 
137, via palladium-catalysed carbonylation reaction, in the presence of copper acetate and 
carbon monoxide, in DMSO, at 110
o
C (50%). This rection step also represents a significant 
improvement on the route of Magnus et al. that employed gaseous phosgene along with a 
strong Lewis acid, TiCl4, in order to complete F-ring pyrrol-2-one synthesis (c.f. Section 
2.2.5.2).
24
  
 
 
 
                                                                                                            
                138                                        139                                              140 
 
 
Scheme 2.8 
 
The key TFA-promoted Mannich cyclisation step is a versatile approach to the partially 
saturated polyheteroaromatic nucleus, being essential to Van Vranken‟s tjipanazole F2 140 
synthesis via 1,2-bis(indol-3-yl)ethane 138, which was transformed to 139 under acidic 
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conditions, prior to mono-N-glycosylation, aromatisation and chlorination, to furnish 140, in 
72% yield over three steps (Scheme 2.8).
25
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Scheme 2.9 
 
In 2000, a similar method was applied in order to derive a total synthesis of AT-2433-A1 41, 
comprising linked methylglucose and deoxyaminopyranose moieties, featuring 
hydrogenation of the corresponding aglycon 141 to Mannich substrate bisindolylsuccinimide 
142, prior to methanesulfonic acid-induced cyclisation to provide the hexacyclic derivative 
143.
26,27
 This indoline derivative constitutes a privileged aminodisaccharide coupling 
precursor, and readily undergoes acid-promoted regioselective β-N-glycosylation.28 Final 
treatment with DBU and iodine thus afforded the fully aromatised silyl-protected analogue 
144, which was converted to glycoside 41, on reaction with TBAF, in 78% yield (Scheme 
2.9).
27
 
  
2.2.2.1.3 Electrophilic cyclisation of 2,2‟-biindolyl derivatives  
 
Synthesis of the central C-ring within unsymmetrical indolo[2,3-a]carbazoles has been 
facilitated by recent developments, characterised by heterocyclic elaboration of simple 
precursors containing desired functionality.
5
 An elegant contribution was reported by Bartoli 
et al. following condensation of TMS-substituted nitrotoluene derivative 145 with indole-2-
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carboxaldehyde 146, in the presence of TBAF, prior to base-induced elimination, affording 
styrene intermediate 147 (Scheme 2.10).
29,30
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Scheme 2.10 
151 
Conversion to the hetero-substituted 2,2-biindolyl 148 was smoothly achieved under 
Cadogan conditions, and was subsequently annulated to the chlorinated tjipanazole I 149 on 
heating with dimethyl aminoacetaldehyde diethyl acetal 150 in acetic acid.
30,31
 Application 
of reagent 150 in the ultimate central ring formation step derived from intermediate 152, to 
afford 153 was also demonstrated by Chang et al., following initial copper-mediated double 
intramolecular cyclisation of diyne 151 (Scheme 2.11).
32
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Scheme 2.11 
2.2.2.2 Base-mediated synthesis of indolo[2,3-a]carbazole analogues 
 
These reaction types constitute a type of indole electrophilic substitution reaction, where 
initial indole reaction with an organometallic base or LiHMDS results in enhanced C-3 
nucleophilicity prior to stepwise substitution reaction with 3,4-dihalomaleimide reactants, 
and subsequent C-ring aromatisation. 
 
2.2.2.2.1 Grignard-mediated 3,4-dihalomaleimide substitution  
 
The majority of versatile syntheses of K-252c 6 (and related congeners) employing a key 
base-promoted indole coupling strategy can be classified into two carbon-carbon bond 
forming stages:
33
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 Formation of a 3,4-bisindolyl substituted pyrrol-2-one/pyrrol-2,5-dione scaffold by 
nucleophilic substitution of an electrophilic F-ring precursor. 
 Oxidative cyclisation to form the ultimate biindolyl 2,2‟-bond, with concomitant 
formation of the planar indolocarbazole chromophore. 154-157 
 
The classical base-mediated route employed by Weinreb
34
 in 1984 utilised indole coupling 
reaction, under Grignard conditions, in the presence of N-benzyl-3,4-dibromomaleimide 157, 
to provide intermediate bisindolylmaleimide 155, as well as pioneering F-ring 
desymmetrisation by means of Clemmensen reduction, also encountered by Hughes and 
Raphael
35
, to afford benzylated lactam 156. However, in an improvement on the palladium-
mediated oxidative cyclisation route of Hill
36
, the penultimate ring-closing step was 
accomplished by reaction with DDQ, along with p-TSA, in an aromatic hydrocarbon as 
solvent. Under these optimised conditions, Joyce and co-workers employed 
indolylmagnesium bromide 154, along with HMPA, heated in the presence of 157 for 44 
hours, and high-yielding DDQ cyclisation to isolate ICZ 156 (Scheme 2.12).  
 
                          157 
 
 
 
    
              154                                      155                                                        156 
Scheme 2.12    
 
In an investigation of the oxidative cycliation step, Faul and Sullivan also evaluated 
alternative mild conditions utilising PIFA, in combination with BF3.Et2O, for aromatisation 
of N-benzyl bisindolylmaleimide 155 and demonstrated that C-ring formation occurred at 
best in modest yields only, and with a limited scope for substrate applicability (c.f. Section 
4.7.1).
37
 In 2005, Witulski et al. also successfully cyclised N-benzyl-3,4-
bisindolylmaleimide 155 using the catalyst, RhCl3.3H2O (10 mol%), in the presence of 1.1 
equiv of Cu(OAc)2.H2O, in reproducibly high yields.
38
 Excellent results have also been 
reported for annulations of similar substrates with Pd(OAc)2 (5 mol%) and CuCl2 (1 equiv), 
heated in DMF in the presence of air.
39
  
158-160 
Kaneko and Clardy also utilised similar base methodology employing 7-
chloroindolylmagnesium bromide 158 and BOM-protected dibromomaleimide 161 to 
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prepare the appropriately protected bisindolylmaleimide analogue 159, which was 
subsequently cyclised and reduced to the corresponding N-protected REB aglycon 160, 
bearing a lactam BOM substituent and 1,11-dichlorinated chromophore, by U.V. irradiation 
in benzene followed by Clemmensen reduction (Scheme 2.13).
40
  
 
                        161 
 
 
 
              158                                     159                                                       160 
                                                                                                                                         
Scheme 2.13 
 
In 1994, Xie and Lown also demonstrated this procedure to form N-benzylstaurosporinone 
156, from acyclic precursor 155, via reaction of starting 154, along with an improved 
synthesis of N-benzyl-3,4-dibromomaleimide 157 in a yield of 92% by condensation of 
dibromomaleic acid 162 with benzylamine, in the presence of DCC, and catalytic DMAP.
41
 
Kirilovsky‟s modification of the Weinreb approach involved KOH-mediated conversion of 
benzylated arcyriarubin A analogue 155 to the corresponding maleic anhydride 163.
42
 This 
step was followed by U.V-mediated conversion to 164, prior to treatment with ammonium 
acetate at 150
o
C, affording 7, and final reduction with Zn amalgam. K-252c 6 was obtained 
in a yield of 25%, over six steps, from dibromomaleic acid 162 (Scheme 2.14).
41
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Scheme 2.14 
79, 165-169 
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As previously mentioned, an alternative approach to the penultimate acyclic precursor was 
proposed by Hill and co-workers, where aromatisation of arcyriarubin A 79, constituted the 
key step towards K-252c 6 formation. Synthesis of 79 was realised in a single step without 
protection of the imide nitrogen by heating of dibromomaleimide (R = Br; 167) with 4 
equivalents of indolylmagnesium bromide 154 in benzene (Scheme 2.15).
36
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Scheme 2.15 
 
Oxidative cyclisation employing 1 eq. of palladium acetate in acetic acid and careful hydride 
reduction (LiAlH4) to afford monohydroxy intermediate 165 followed by hydrogenation 
afforded K-252c 6 in an overall yield of 14%, over 4 steps. In 1995, Faul et al. disclosed an 
optimised route to K-252c 6 based on the Hill protocol, replacing dibromomaleimide 167 
with dichloromaleimide (R = Cl; 168) to produce 6 in an enhanced yield of 34% over these 
four steps.
43
 In 2000, Burtin and co-workers also applied Hill‟s route to synthesise the KT-
5823 aglycon 166 from N-methyl-3,4-dichloromaleimide 169 and indolylmagnesium 
bromide 154, in four steps and 36% cumulative yield (Scheme 2.15).
44
  
 
2.2.2.2.2 LiHMDS-mediated route to arcyriaflavin B 
170 
During the course of research into the reactivity of indole 171 as Grignard acceptor, 
activating the C3 position towards electrophilic substitution, it was apparent that two-fold 
molar excess of reactant 154 was required in order to afford synthesis of indolocarbazole 
precursors such as 6-methylarcyriarubin A 172, arising from a competing side-reaction.
45
 
 
 Formation of monoindolyl substituted intermediate 170 is postulated to occur following 
initial bromide displacement from 173 by indolylmagnesium bromide 154. However, 
another equivalent of this nucleophilic indole Grignard reagent has limited reactivity in 
displacement of the second bromine leaving group from 170 (Scheme 2.16). Successful 
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reactions of this type are thus characterised by several drawbacks such as extended reflux, 
inefficient excess of coupling reagent, as well as necessity for additives such as carcinogenic 
HMPA. Therefore, an alternative milder base methodology was sought in order to form 
indole derivatives activated towards electrophilic C-3 attack.
34,40,42,45
 
   
                                       173 
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Scheme 2.16 
 
In 1996, Ohkubo et al. reported an optimised Grignard-mediated route to unsymmetrical 
arcyriaflavin B 174, eliminating the problems associated with indolylmagnesium bromide 
154, and which was derived from initial formation of precursor bisindolylmaleimide via 
reaction of a lithiated indole salt, followed by oxidative 2,2‟-bond formation as the terminal 
ring-closing step. In an application of this approach utilising reaction of 6-benzyloxyindolyl 
175 anion with N-methyl-3,4-dibromomaleimide 173, clean monoindolylation to afford 176 
was achieved in 93% yield, under stoichiometric conditions.
46
 
 
Following Boc-protection of monoindolyl derivative 176, the second LiHMDS-mediated 
indolylation to form 177 was accomplished in 70% yield, prior to high yielding amine-
promoted protecting group removal. Cyclisation of 178 was accomplished by exposure to 
DDQ, prior to O-debenzylation. Employing Kirilovsky conditions, arcyriaflavin B 174 was 
afforded via initial alkaline imide hydrolysis, followed by amination of the resultant maleic 
anhydride moiety 179 with ammonium acetate at 140
o
C, in a yield of 62% (Scheme 2.17).
46
 
Interestingly, smooth one-pot conversion to the corresponding N-benzyl-3,4-
bisindolylmaleimide 155 has also been reported following heating of the lithium salt of 
indole 171 in the presence of N-benzyl-3,4-dibromomaleimide 157 for 12 hours at reflux.
38
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Scheme 2.17 
180-182 
2.2.3 B and D-Ring forming routes 
2.2.3.1 Cadogan cyclisation 
 
These routes are characterised by a nitrated biphenyl ICZ precursor, which undergoes nitrene 
insertion to the central C-ring to yield the full carbazole ring moiety.  
In 1990, Raphael and co-workers proffered a modification of their earlier plan towards 
formation of K-252c 6 incorporating cycloaddition of N-benzylmaleimide 183 to 1,4-
diarylbutadiene 181 derived from Wittig reaction of 180 and 182, to afford terphenyl imide 
184. Subsequent conversion to 6 was unsuccessful due to the resistance of the N-benzyl 
imide protecting group within 156 to facile cleavage conditions (Scheme 2.18; Route B).
35
 
 
Employing DMAD as dienophile, conversion of the resultant anhydride to the unprotected 
imide 185 and subsequent 7-deoxygenation by NaBH4/triethylsilylhydride treatment to 
lactam 186 prefigured final cyclisation by a Cadogan double nitrene insertion.
47
 
Unfortunately, only an inseparable complex of K-252c 6 and triphenylphosphine oxide could 
be formed at the conclusion of this route; attachment of a THP protecting group (187) prior 
to bisannulation, and final acidic deprotection afforded K-252c 6 (Scheme 2.18; Route A).
35
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Scheme 2.18 
 
 
Lowinger and co-workers at Bayer subsequently improved Kirilovsky-type conversion to 
maleic anhydride 164, by initial cycloaddition of N-methylmaleimide 188 prior to refluxing 
of triaryl 189 in the presence of triphenylphosphine and collidine, and basic hydrolysis, to 
complete the ICZ scaffold, easily ammonolysed to arcyriaflavin A 7 (Scheme 2.19).
48
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Scheme 2.19 
190 191 192 193 
Also in 1990, Moody and Rahimtoola disclosed intramolecular Diels-Alder reaction of 
pyrano[4,3-b]indol-3-one 194 in bromobenzene, with subsequent aromatization to key 
intermediate 195, via CO2 extrusion and air oxidation.
49
 Cinnamylamine 190 was initially 
prepared in three steps from commercial 2-nitrocinnamaldehyde 180; reaction of ethyl 
indole-2-acetate 191 with oxalyl chloride, followed by condensation with 190 afforded 
glyoxamide 192, which was hydrolysed in virtually quantitative yield to 193, and cyclised in 
the presence of acetic anhydride to form 194 (Scheme 2.20). A final nitrene insertion step 
following triethylphosphite-induced deoxygenation then afforded K-252c 6, in an overall 
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yield of 23% over six steps. Interestingly, this route is distinguished by a substitution pattern 
capable of differentiating both indole nitrogens and thus, may also allow regioselective 
introduction of a carbohydrate moiety.
50
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Scheme 2.20 
 
In 2000, the intensely studied model indolo[2,3-a]pyrrolo[3,4-c]carbazole, arcyriaflavin A 7 
was prepared by Tomé et al. by means of an elegant route from 2-nitrobenzaldehyde 196,  
involving stepwise Diels-Alder cycloaddition, Fischer methodology and nitrene insertion 
(Scheme 2.21).
51,52
 196-202 
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Scheme 2.21 
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Wittig reaction of 2-nitrobenzaldehyde 196 with ketone 197, followed by carbonyl group 
protection to TBDMS-enol derivative 198 preceded [4+2] cycloaddition with maleimide 199 
to afford the initial cycloaddition adduct, in quantitative yield; acidic hydrolysis then 
afforded desilylated cyclohexanone derivative 200, which was configured for Fischer 
indolisation with phenylhydrazine, providing correct regioisomer 201 and undesirable 202 in 
a 2:1 ratio, under acidic conditions. DDQ-induced oxidation of major isomer 201, followed 
by Cadogan annulation in the presence of triethyl phosphite gave access to arcyriaflavin A 7 
in a yield of 42% over two steps.
52
 
2.2.3.2 Fischer indole synthesis 
 
This synthetic approach targets the fully aromatised indolo[2,3-a]carbazole ring system via 
reaction of phenylhydrazine with cyclohexanone derivatives. As the C-ring structure is 
already established, these routes efficiently target B/D ring formation.   
 
Synthesis of indolo[2,3-a]carbazole 1 was initially reported by Bhide and Mann derived 
from one-pot bisphenylhydrazone (osazone) formation and acid-promoted oxidation of 2-
hydroxycyclohexanone 104 (Scheme 2.1).
11,53
 In 1989, Bergman and Pelcman disclosed how 
their strategy employing double Fischer methodology resulted in synthesis of arcyriaflavin A 
7 scaffold, over four steps.
54
  
 
These workers also demonstrated the potential of this process for facile synthesis of a panel 
of unsymmetrical indolocarbazole alkaloids, based on the nature of these bis-
phenylhydrazone derivatives.
54,55
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Scheme 2.22 
208-210 
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Preparation of the TMS-protected dione 205 substrate was achieved via [4+2] cycloaddition 
of 2,3-bis(trimethysilyloxy)butadiene 204, prepared by thermal ring-opening of 203, with 
maleimide 199 (90%), and condensed with phenylhydrazine under acidic conditions to 
afford osazone 206 (91%).
56
 
 Double Fischer indolisation employing PPSE in nitromethane led to dihydroarcyriaflavin A 
207, which could be dehydrogenated in situ to arcyriaflavin A 7 (Scheme 2.22).
54,57
 Gribble 
and co-workers independently developed a variant of this route to form 6-
methylarcyriaflavin A 210 (aglycon of synthetic AT2433-B topo I inhibitor class), by Diels-
Alder reaction of 204  with N-methylmaleimide 188 to provide intermediate 208, prior to 
hydrazone formation (209) and conversion to 6-methylarcyriaflavin A 210 in almost 
identical overall yield to that achieved by Bergman (Scheme 2.23).
55
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Scheme 2.23 
 
 In 1992, Gribble and Berthel also described a shorter but lower yielding two-step route to 
both arcyriaflavin A 7 and 210. Reductive ozonolysis of the commercial 
tetrahydrophthalimide 211 resulted in formation of a labile dialdehyde, prior to conversion 
with 2 equivalents of phenylhydrazine to afford bis(phenyl)hydrazone 212 (Scheme 2.24).
55
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Scheme 2.24 
 
Following treatment with other arylhydrazines, it was noted that considerable stability issues 
were present. Exposure to Lewis acid catalyst, polyphosphoric acid trimethylsilyl ester 
(PPSE) in refluxing nitromethane, resulted predominantly in decomposition, but in the case 
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of unsubstituted phenylhydrazine, the fully aromatised indolocarbazole 7 could be isolated in 
10% yield, following chromatography.
55
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Scheme 2.25 
 
Interestingly, an ultimately unsuccessful attempt to block the premature cyclisation of 
bisphenylhydrazone 212 (leading to decomposition products) was carried out by means of 
NBS treatment in THF to give the putative bis-hydrazonyl bromide 213. However, when 
applied to the succinimide derivative 212 in THF/ pyridine at −10oC, this route afforded an 
enhanced, high-yielding route to dihydroarcyriaflavin A 207 (66%) and thus, following 
PPSE-induced indolisation and full cyclodehydrogenation, employing 10% Pd/C in refluxing 
diglyme (63%), elicited a novel pathway to indolo[2,3-a]carbazoles congeners, under 
Bergman cyclisation conditions (PPSE, MeNO2), as displayed in Scheme 2.25.
54,55
  
 
In 2005, Hu and Chen demonstrated that exposure of amino-substituted cyclohexanone 214 
to 4-chlorophenylhydrazine 215 in a mixture of acetic acid and TFA yielded the 
corresponding modified indolo[2,3-a]carbazole 216 (Scheme 2.26).
58
  
                                                                   
                                                                                                   216 
 
 
                     214               215 
Scheme 2.26 
215, 217-218 
Similarly, the double Fischer indolisation between cyclohexane-1,2-dione derivatives and 
substituted hydrazines may also constitute a key route to construction of symmetric 3,8 or 
1,10-disubstituted indolo[2,3-a]carbazoles, via a protocol initially proposed by Curiel et al.
59
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This approach was also utilised by Bonjouklian and co-workers in order to introduce the 3,8-
dichloro substitution pattern present within tjipanazole D 219, without the need for any 
protecting groups or regioselectivity concerns.
31
 
 
 
 
                             217                                                                                218                   
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                                                                                                219 
Scheme 2.27 
 
In this route, cyclohexane-1,2-dione 217 was condensed with 4-chlorophenylhydrazine 215 
in the presence of H2SO4 to afford the hydrazone derivative 218 (72%), which was then 
converted under acidic conditions to the desired natural product 219 (Scheme 2.27).     
2.2.4 F-Ring Routes 
2.2.4.1 Perkin condensation approach  
 
These reaction types involve either the combination of an indole-3-glyoxylate or related 
glyoxylyl chloride with an indole-3-acetic acid derivative, or homocoupling reaction of an 
indole-3-acetic acid followed by amidation. 220-223 
 
In 2003, Garaeva and co-workers published an efficient synthesis of indolocarbazole β-N-
ribofuranoside 223, starting from indoline 220 and 2,3,5-triacetylated bromofuranose 
derivative 224, was then converted to a 1-(2,3,5-tri-O-acetyl)-β-D-ribofuranosylated indole 
precursor, in the presence of DDQ.
60
  
 
                        224                               225 
                      
 
 
  220 
                               221                                           222                                               223 
Scheme 2.28 
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Following oxalyl chloride-mediated glyoxylyl chloride 221 synthesis, base-induced 
condensation with N-methyl indole-3-acetic acid 225 resulted in formation of tri-O-
acetylated bisindolylfuran-2,5-dione 222, in a yield of 44%. Following oxidative cyclisation, 
exposure to ammonia provided access to deacetylated pyrrole-2,5-dione 223 in a yield of 
73% (Scheme 2.28). These workers also investigated the biological nature of novel sugars 
possessing distinct hydrogen bonding character, attached to the indolocarbazole nucleus. In 
the case of 2-deoxyribofuranoside derivatives, initial 1-(β-D-2-deoxyribofuranosyl)indole-3-
glyoxylyl chloride analogue 226 condensation with 225 also effected anomerisation, yielding 
a 1:1 diastereomeric mixture of furanosylation products due to in situ generation of HCl. 
Fortunately, addition of silver carbonate to the reaction mixture was reported to suppress this 
phenomenon, and subsequent cyclisation of the 2‟-deoxy-β-N-glycoside 227 afforded the 
corresponding indolocarbazole 228 in moderate yield (Scheme 2.29).
60
  
                                   225 
 
 
 
 
           226                                                          227                                                228 
 
              Scheme 2.29229-232 
  
Faul‟s methodology permitted one-pot synthesis of a range of disubstituted maleimides and 
avoided any ammonolysis step.
61
 These reactions have also been shown to be highly tolerant 
to substrate variation and affords quantitative conversion to arcyriarubin A 79, without the 
need for protecting groups. Addition of strong base to a reaction mixture in THF at 0
o
C, 
comprising indole-3-acetamide 230, isolated following hydrolysis of the corresponding 
nitrile 229, along with labile glyoxylate ester 232, formed in two steps, from indole 171 via 
glyoxylyl chloride 231 afforded 79 in quantitative yield (Scheme 2.30).
61,62
 
 
 
 
                       229                                     230  
        
                                                                                                                           79 
                                                                                    
          171                                   231                                    232 
Scheme 2.30 
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2.2.4.2 Iodine-mediated indole coupling reactions 
 
Employing this biomimetic approach,  deprotonation of 233 with 2 equivalents of n-
butyllithium and 1 equivalent of tert-butyllithium successively, enabled formation of the  
indole-3-acetic acid trianion 234, prior to oxidative coupling to form 235.
63,64
 Refluxing in 
acetic anhydride afforded derivative 236, whereas diazomethane treatment resulted in 
formation of diester 237. Iodine-promoted dimerisation of dianion 238 obtained from methyl 
indole-3-acetate 239 following addition of 2 equiv of LDA constituted an improved yield of 
this ester 237 (85%). Reaction of succinic anhydride 236 or diester 237 with benzylamine 
resulted in isolation of N-benzyl bisindolyl analogue 240 in a yield of 80%, which could then 
be efficiently oxidised by DDQ in benzene to the corresponding fully aromatised 
pyrrolo[3,4-c]carbazole product 241 in a yield of 90% (Scheme 2.31).
63,65
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                                                                                                                                  241 
                                                                                              240 
Scheme 2.31 
 
In 2007, Hinze et al. reported a related biomimetic oxidative annulation sequence involving 
n-butyllithium/iodine radical dimerisation of pyruvic acid 242 at −78oC, prior to 
condensation with gaseous ammonia, to afford 3,4-bisindolylpyrrole-2,5-dicarboxylic acid 
243 (36%). Subsequent oxidative ring-closure in aqueous KOH, in the presence of potassium 
ferricyanide resulted in formation of arcyriaflavin A 7; however, no yield was reported for 
this final cyclisation step (Scheme 2.32).
66
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Scheme 2.32 
2.2.5 Successful multiple ring forming strategies  
2.2.5.1 [4+2] Diels-Alder cycloaddition in B/D/F-ring formation  
 
Numerous workers have reported Diels-Alder carbon-carbon bond forming reactions as key 
points in diverse syntheses of ICZs. Recent examples of this versatile C-ring forming 
process for intermediate steps are illustrated in Fig. 2.2, and include Moody‟s ICZ route 
involving decarboxylative carbazole ring aromatisation
49
 within 194 (Scheme 2.20), 
Raphael‟s dienophile addition35 to 1,4-bisarylbutadiene precursor 181 (Scheme 2.18), 
Tomé‟s strategy52 employing cycloaddition of maleimide 199 to 2-nitrostyrene derivative 
198 (Scheme 2.21), and Bergman‟s Fischer route from 2,3-bis(trimethylsilyloxy)butadiene 
204 (Scheme 2.22).
55
  
                                                                                                                 
                                                                                                                          199 
                                                                                                    
                                                                                                                               198 
                                     194                                                                     
                                                                                                                    
                                                                           102                                                199 
         181 
                                                                                                           204 
                                          199                                                                                                
Fig. 2.2 
2.2.5.2 B/C-ring formation employing Diels-Alder cycloaddition  
244-250 
In 1983, Magnus and co-workers reported the first synthesis of more complex F-ring 
substituted ICZs by intramolecular Diels-Alder cycloaddition of indole-2,3-quinodimethane 
analogue 246, formed following initial conversion of tryptamine derivative 244 to N-
protected 2-formyl analogue 245 and subsequent 2-aminostyrene 250 condensation.
24
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Formation of target compound 249 then occurred in 5 steps from 246; intramolecular Diels-
Alder ring-closure occurred under thermal conditions to provide carbamate-protected 
intermediate 247, which then underwent DDQ-induced aromatisation and phthalimide 
deprotection forming 248, prior to successive phosgene-mediated cyclocarbonylation in the 
presence of a Ti(IV) Lewis acid catalyst and final detosylation, to provide lactam 249, in a 
yield of 65% over the final two steps (Scheme 2.33).
24
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Scheme 2.33 
 
2.2.5.3 Retro Diels-Alder route: C-ring formation 
251-253 
In 1999 and 2000, Lobo and co-workers disclosed two methods employing electrocyclic 
removal of S2 as a key step in their synthetic procedure.
67,68
 A one-step synthesis of 3-
chlorinated K-252c derivative 254 in 36% yield, following treatment of 2,2‟-biindolyl-3,3‟-
dithiete 251 with maleimide 199 in 1,2-dichlorobenzene at high temperature. This reaction is 
believed to feature initial Diels Alder cycloadduct 252, followed by elegant retro Diels-Alder 
formation of intermediate 253, prior to air oxidation to aromatised 254 (Scheme 2.34).
67
  
                                                                         199 
 
 
                                       251                                                         254 
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Scheme 2.34 
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2.2.5.4 Tandem conjugate addition reactions 
255-257 
 The involvement of 6π-electrocyclisation events within diverse routes to ICZ formation and 
closely related Michael addition/cyclisation reactions of 2,2‟-biindolyl 118, have been 
disclosed as a relatively unversatile C-ring forming reaction for generation of the indolo[2,3-
a]carbazole nucleus 1. In 1992, Somei and Kodama employed this [4+2] cycloaddition-type 
strategy utilising N-phenylmaleimide 258 to afford an intermediate adduct, which was 
subsequently dehydrogenated to 6-phenylarcyriaflavin A 257, in a yield of 30%.
69
    
 
 
                                                                                     258                                                                         
              255                                                      256                                          257 
                                                                       118 
Scheme 2.35 
  
These workers also employed a novel ultrasound-induced oxidative coupling of 2-lithiated 
N-methoxyindole 255, with anhydrous copper(II) sulfate under oxygen atmosphere to 
provide 2,2-biindolyl 118, following reductive demethoxylation of 256, in overall 43% yield 
(Scheme 2.35). Unfortunately, subsequent attempts by several workers to effect facile 
cycloaddition between a panel of functionalised dienophiles and 2,2‟-biindolyl 118, in order 
to develop a direct route to indolo[2,3-a]carbazoles have been beset by low yields and 
limited success under conventional high-temperature conditions.
5,69-72
  
                                                               199 
                                                            
 
                                                          259 
                                 118                                                                260 
 
Scheme 2.36 
  261-262   
In the case of unsubstituted biindolyl 118, Hudkins and Diebold also reported unanticipated 
formation of a K-252c 6 regio-analogue, 260 via acid-catalysed tandem Michael addition, 
following exposure to either maleimide 199 or ethyl cis-β-cyanoacrylate 259 in the presence 
of trifluoroacetic acid or ethylaluminium dichloride, respectively (Scheme 2.36).
73
 These 
reactions are thus believed to progress via a mechanism of conjugate 1,4-addition, followed 
by nucleophilic addition and dehydrogenation, rather than formal concerted [4+2] 
electrocyclization. Exploiting this stepwise Michael condensation-cyclisation rationale, 
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Kuethe et al. also recently developed an innovative one-pot route to the unprotected 
indolo[2,3-a]carbazole scaffold within 262 by heating mono-N-protected 2,2‟-biindolyl 261 
to high temperature in the presence of N-benzylmaleimide 183.
74
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                                   261 
                                                                                                 262 
 
 
 
 
 
Scheme 2.37 
 
Under these harsh conditions, thermal cyclisation of 261 is facilitated by the electron-
withdrawing N-substituent; dehydrogenation to form 9-chloro-N-benzylarcyriaflavin A 262 
then proceeds with in situ elimination of the N-phenylsulfonyl group (Scheme 2.37).
74
 In 
terms of analogous glycosidic chemistry, Somei et al. illustrated that mono-N-
glucopyranosylated 2,2‟-biindolyls also exhibit moderate reactivity with DMAD in 
nitrobenzene, to afford the corresponding indolo[2,3-a]carbazoles in low yields.
75
 
Consequently, these non-facile cycloaddition approaches are limited in scope, due to the 
absence of robust chemistry to diverse chemical scaffolds, application of harsh reaction 
conditions and requirement for auxiliary indole functionality to enhance reactivity.
68,74,76
  
2.2.5.5 Transition metal-mediated routes 
 
Although stringently limited in substrate scope and product derivatisation capacity, few 
constructions of the central indolocarbazole core still display such elegance as the diverse 
range of transition metal-mediated routes, employing relatively mild conditions as well as 
one-pot conversion of simple starting materials to complex polycyclic products through 
regioselective control of concerted bond-forming reactions.
77-82
 Up to relatively recent times, 
three alternative strategies were adopted through this methodology: 
(i) Pd(0)-catalysed benzannulation route 
(ii) Annulation of Fischer carbene intermediates 
(iii) Pd(0)-mediated 1,3-diacetylene double cyclisation  263-266 
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2.2.5.5.1 C-Ring formation: Benzannulation route  
Merlic and colleagues disclosed regioisomeric synthesis of indolocarbazole analogues  265 
and 266, derived from indole utilising a key Pd-induced benzanulation step.
83
 Following the 
Bergman/Venemalm strategy, quantitative N-methylation of readily available 2-iodoindole 
267 was performed, prior to conversion in situ to the corresponding indole-2-boronic ester. 
Suzuki cross-coupling with 2-iodoindole 267 in the presence of Pd(PPh3)4 (268), prior to 3‟-
iodination and tosylation of the NH unsubstituted indole ring then provided access to 3-iodo-
2,2‟-bisindolyl derivative 264.76,84-86 Unsymmetrical intermediate 264 afforded a mixture of 
ICZ regioisomers 265 and 266 in a ratio of 2:1, in moderate yields, via palladium(0)-
catalysed benzannulation reaction with phenylacetylene ester reactant 263 (Scheme 2.38).
83
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                                                              268     
 
Scheme 2.38 
 
2.2.5.5.2 C-Ring formation: annulation of Fischer carbene intermediates 
269-270 
Fischer chromium carbene methodology also constitutes an important transition metal route 
involving benzannulation of 2,2‟-biindolyl chromium carbene complexes, also derived from 
3-iodo-2,2‟-bisindolyl precursors to form products in a single step.83,87 
 
Preparation of carbene complex 270 from corresponding 269, was readily accomplished by 
means of standard metal-halogen exchange with n-butyllithium, followed by addition to 
chromium hexacarbonyl and methylation with methyl triflate.  
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Scheme 2.39 
273-276 
Cyclisation of 270 (R1=allyl, R2=MOM) to yield the desired benzannulation products was 
accomplished by a photochemical method in the presence of carbon monoxide, employing 
toluene or THF as solvent via a ketene intermediate to form 271
 
in 63% yield or conversely, 
following aminobenzannulation reaction occurring with tert-butylisocyanide – forming an 
intermediate ketenimine complex capable of undergoing thermal 6π-electrocyclisation to 
provide 272 in a yield of 74%. (Scheme 2.39).
77,87
 Comparative yields reported in this study 
were 71% (photochemical) for 276 as opposed to 68% in boiling toluene for 275; R1=MOM, 
R2=Boc, and 57% for irradiated reaction to afford 274, along with a highest yield of 89% for 
thermal transformation to 273 (R1=R2=CH3; Scheme 2.40).
87
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                             273                                                                                               274 
                             275                                                                                               276 
                   Scheme 2.40           277-281 
 
2.2.5.5.3 B/C/D-ring formation: 1,3-diacetylene double cyclisation 
This strategy developed by Saulnier and co-workers involves assembly of the indolo[2,3-
a]carbazole framework via a polyannulation methodology wherein both indole B and D-
rings, and central C-ring are formed in a one-pot process from the 1,3-diacetylene precursor 
280.
88,89  
Starting from 2-iodoaniline 277, this was readily converted to 2-ethynylaniline 278 and then 
to trifluoroacetanilide 279, under Cacchi conditions, in reported 70% yield (Scheme 2.41).
79 
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Scheme 2.41 
However, under typical Sondheimer conditions none of the desired 280 could be obtained. 
Fortunately, direct transformation of 278 to intermediate 281 under similar coupling 
conditions (63%), followed by trifluoroacetylation provided access to the desired 
bistrifluoroacetanilide 280 in 93% yield for this step.
88
  
 
 
    
            157 
            
      280 
 
 
 
 
       241 
 
 
Scheme 2.42 
 
Coupling of 280 with 157 in the presence of potassium carbonate and 
tetrakis(triphenylphosphine)palladium (7 mol%) at 50
o
C overnight, afforded the 
corresponding 6-benzylarcyriaflavin A 241 in 52% yield. The putative mechanism for this 
polyannulation implicates the activity of the readily cleavable trifluoroacetyl group in 
attenuating nitrogen nucleophilicity – thus favouring subsequent C(3)-Pd attack (Scheme 
2.42).
88 
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In other work, Beccalli et al. disclosed a route to K-252c 6 incorporating a pivotal 
palladium-mediated Stille reaction step. Starting from readily accessible ethyl 3-cyano-2-
hydroxy-3-(1H-indol-3-yl)acrylate 282, reaction with ethyl chloroformate to form 283 and 
selective O-deprotection under mildly basic conditions, followed by trifylation employing 
Hunig‟s base provided the Stille precursor 284.90 
285-287 
 
                                     
                              282                                      283                                           284                    
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                        6                                               287                                             286 
Scheme 2.43 
 
Coupling of triflate 284 with 1-phenylsulfonyl-3-tributylstannylindole 285 led to 1,2-
bisindolyl-cis-alkene 286 in 89% yield. Following indolic deprotection and U.V. 
aromatisation, reductive amidation of 287 in a methanolic mixture containing NaBH4 and 
CoCl2 gave lactam 6 (92%), as illustrated in Scheme 2.43.
90,91
  
 
Finally, according to the elegant carbenoid protocol of Wood et al., treatment of 2,2‟-
biindolyl 118 with the diazo compound 288 in the presence of catalytic Rh2(OAc)4 and 
degassed pinacolone as solvent, directly afforded K-252c analogue 289 in a yield of 62%.
92
 
This reaction has been postulated to proceed by sequential C-H insertion, electrocyclization, 
and aromatization (Scheme 2.44).
93
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Scheme 2.44 
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2.3 Strategies for synthesis of N-glycosidic linkages in natural ICZs  
2.3.1 Importance of sugars in indolocarbazole alkaloids 
2, 13, 70, 74 
Indolocarbazole glycosides possessing modified sugar units possess a wider range of 
biological activity than their corresponding aglycon analogues, due to the increased aqueous 
solubility of these derivatives, as well as the recognised ability of these glycosyl units to 
mediate important structural interactions within target enzyme active sites.
7,94
 These 
compounds can be broadly classified into two classes based on the mode of sugar 
attachment. Single β-N-glycosidic ICZ linkages, as present in rebeccamycin 38, are essential 
to topo I-mediated DNA strand breakage and intercalatory capacity, with the sugar moiety 
being accommodated within the minor groove of DNA and greatly contributing to energetic 
stabilisation of the drug-DNA-topo I cellular „poison‟.95-97 The ability of a sugar unit to form 
hydrogen bonds with the unsubstituted indole nitrogen within these systems also potentiates 
an active warhead alignment of the enzyme-interacting F-ring within the topo I pocket.
98
  
 
In addition, double β-N-glycosidic linkages, such as those present in cycloglycosylated 
staurosporine 2 and K-252a 13 have also been described to enhance ATP-competitive kinase 
inhibition within this class, due to the formation of an extended non-covalent bonding 
network where the glycosyl residue mimics important ATP phosphate contacts within the 
kinase ATP-binding domain.
99,100
 Crystallographic data also indicates that sugar moieties 
may adopt a binding mode perpendicular to the planar indolocarbazole ring, and interact 
with several residues within the activation loop, in a unique phenomenon also contributing to 
attractive kinase selectivity.
100-102
 Thus, derivatisation work within glycosidic congeners 
constitutes a crucial element within overall design of more potent ICZs. Isolation of these 
compounds has been achieved by fermentation, based on modification of natural 
biosynthetic pathways, as well as total synthesis of complex analogues bearing a range of 
sugar sub-units. These innovative chemical glycosidation strategies will now be discussed 
for important analogues within a highlighted panel of mono and di-β-N-glycosidic 
derivatives.  
2.3.2 Biosynthetic origin of indolocarbazole sugar moieties 
 
Endogenous functionalisation of natural products provides important clues for 
biocombinatorial synthesis of novel derivatives, as well as for innovative synthetic strategies 
capable of mimicking critical enzymic transformations in vivo.
4,103,104
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Fig. 2.3 
 
Recent insights into the biosynthetic gene clusters of ICZ producing microorganisms have 
revealed several conserved features within their glycosidation strategies: (a) close alignment 
of absolute configurations of sugar moieties within co-produced ICZ metabolites possessing 
disparate indole-N-glycosidic linkages, e.g. stereochemistry at positions C-4‟ and C-5‟ of L-
rhamnose in K252d 74 is identical to C-3‟ and C-2‟ of the deoxyaminopyranose moiety in 
staurosporine 2, and (b) TAN-1030a 70 and staurosporine 2 retain identical absolute 
stereochemistry as ribofuranosylated K-252a 13 at the bridging anomeric carbons (Fig. 2.3). 
In addition, synthetic studies have also determined that carbohydrate moieties undergo 
remarkably stereoselective ring modification pathways.
4,105-107
 
 
An important transition enabling commitment of indolocarbazole precursors to a specific 
metabolic fate occurs within the biosynthetic pathway starting from tryptophan 290-derived 
chromopyrrolic acid 243 following production of K-252c 6 (Scheme 2.45).
108,109
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Scheme 2.45 
 
Under the influence of the gene product of StaG, regiospecific incorporation of a mono-N-
glycosylated aminosugar (e.g. NDP-L-ristosamine) results in formation of precursor holyrine 
A 75 and may subsequently permit formation of a second glycosidic linkage via enzymatic 
C-N bond formation. Alternatively, following initial transfer of a non-nitrogenated 
carbohydrate unit, analogues such as K-252d 74 may be produced, in addition to ring-
contraction leading to ribofuranosylated derivatives related to K-252a 13. Six-carbon 
carboxyfuranosylated derivatives are thus postulated to be formed from rearrangement of 
six-membered pyranose derivatives such as TAN-1030a 70 – a K-252a 13 biosynthetic 
precursor via an intermediate 3‟-amino analogue 291 (Scheme 2.45).4 
2.3.3 Semi-synthesis of natural bioactive indolocarbazole glycosides  
292 
Wood and co-workers established an elegant derivatisation protocol towards a panel of 
indolo[2,3-a]carbazole analogues including (+)-2 and (-)-70 based on biomimetic 
diversification of a common precursor, α-hydroxy ketone (+)-293, possessing all essential 
stereogenic centres in place.
106,110
 Final imide deprotection of each DMB-protected congener 
was performed in a mixture of TFA and anisole to afford the parent natural compound in 
each case (Scheme 2.46). 
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Scheme 2.46 
 
Regioselective reduction of K-252a derivative 292 followed by regioselective Lewis acid-
mediated Demjanov-Tiffeneau-type ring expansion provided intermediate α-hydroxy ketone 
293 over three steps. Semi-synthetic routes involving key reductive amination of this 
glycosylated precursor afforded staurosporine 2 in 88% yield over 5 steps, while 
regioselective O-methylation and oxime transformation also led to synthesis of TAN-1030a 
70, in 4 steps and in overall yield of 3.5%, due to difficult DMB group removal (Scheme 
2.46).
110
 
 
2.3.4 Chemical routes to mono-N-glycosides 
 
Development of chemical strategies to mono-N-glycosylated ICZ congeners involve 
application of classical routes to the correspsonding aglycon prior to a stereoselective sugar 
coupling step to afford the target compound. 
2.3.4.1 Total synthesis of rebeccamycin  
38, 294-297 
In 1985, Kaneko and co-workers reported the first total synthesis of topo I inhibitory natural 
product rebeccamycin 38, according to a strategy involving double 7-chloroindole 294 
substitution of BOM-protected dibromomaleimide 161, to afford bisindolylmaleimide 295 
according to Weinreb‟s Grignard base-mediated procedure, followed by iodine-induced 
photocyclisation in a yield of 65% (Scheme 2.47).
40
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Scheme 2.47 
 
Koenigs-Knorr coupling of aglycon 296 with 1-bromo-2,3,6-tri-O-acetyl-4-O-methylglucose 
298, in the presence of Ag2O afforded 297, and was transformed to the title N-glycosidic 
compound 38 in 30% yield, upon removal of the BOM group by hydrogenolysis and full 
ammonolytic 2,3,6-tri-O-deacetylation (Scheme 2.47).
40
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Scheme 2.48 
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In 1993, Danishefsky reported development of glycal chemistry as an improved strategy 
towards formation of analogues comprising an N-glycosidic monolinkage (Scheme 2.48).
111
 
Initial monosubstitution of Kaneko precursor, BOM-protected dibromomaleimide 161, 
formed in an excellent yield of 91% at room temperature, permitted selective indole nitrogen 
SEM-protection (299), prior to bromine displacement with another equivalent of the 
Grignard salt of 7-chloroindole 294 in benzene. Glycosidation of the sodium salt of 300 with 
α-1,2-anhydrosugar 301, obtained from commercially available tri-O-acetyl-D-glucal, gave 
access to the β-glucopyranoside 302 in 48% yield. Following fluoride-induced SEM 
deprotection, construction of the central carbocyclic ring was achieved by U.V.-irradiation. 
The final two steps in this synthesis comprised BOM hydrogenolysis employing Pearlman‟s 
Pd(OH)2 catalyst and ammonolysis to afford 38. The monochlorinated ICZ side-product was 
also reported in 14% yield under these hydrogenation conditions. The major advantage of 
this method involves the novel application of stereoselective glycal epoxide ring-opening to 
form intermediate 302, as well as utilising the bisindolylmaleimide precursor 300, prior to 
photocyclisation, as a superior glycosyl acceptor (44% yield), compared with Kaneko‟s 
pathway employing the aromatised indolocarbazole core within 296 (Scheme 2.48).
40,111
  
 
 
         
 
                                                                                               
                                            303       
                                                                 301                          304                                                         
                                           
Scheme 2.49 
 
Subsequent to discovery of their condensation method for bisindolylmaleimide synthesis, 
Faul et al. also published their total synthesis of rebeccamycin 38  including application of 
their pioneering step involving reaction of N-glycosylated 7-chloroindole-3-acetamide 304 
with methyl 7-chloroindole-3-glyoxylate 305 to afford the anticipated di-O-benzyl derivative 
306.
61,112
 The carbohydrate-linked acetamide 304 was stereoselectively synthesised via 
Danishefsky‟s methodology; reaction of the 1-indolyl anion of 303 with dibenzylated 
precursor 301 proceeded in a yield of 40%, and the desired β-epimer 304 (16:1 β/α-
selectivity) was isolated in >98% diastereomeric purity (Scheme 2.49).
111,112
 Following 
condensation to afford β-N-glucosylated bisindolylmaleimide in 86% yield, oxidative 
cyclisation employing palladium(II) trifluoroacetate at high temperature, followed by 
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debenzylation revealed the natural product rebeccamycin 38 in three steps and 47% 
cumulative yield (Scheme 2.50).
112
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Scheme 2.50 
This base-promoted route also constitutes a more efficient synthesis of 38, compared with 
those of Danishefsky or Kaneko, as it requires no maleimide protection, obviating indole 
deprotection or imide deprotection steps, necessary for masking acidic sites under Grignard-
mediated coupling routes to furnishing BIM compounds.  
 
In addition, Prudhomme described a route envisaged as degradation of this natural product 
38, to afford K-252c 6, in two steps. Reduction of the 7-oxo functionality followed by 
perchlorate-induced carbohydrate cleavage resulted in formation of 1,11-
dichlorostaurosporinone analogue 307, in a yield of 47%. Palladium-mediated dechlorination 
under acidic conditions then provided 6 in 30% yield (Scheme 2.51).
113
 
 
 
 
 
                                                                        307                                                6 
                        38 
                    Scheme 2.5150, 308-312 
2.3.4.2 Synthesis of rebeccamycin analogues: NB-506, ED-110 and J-109 404  
Ohkubo and co-workers utilised initial indole coupling chemistry to develop a route to the 
aglycon precursor of the clinical analogue, NB-506 50, from 7-benzyloxyindole 308  and 
3,4-dibromo-N-methylmaleimide 173, in five steps and 34% yield.
46
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Glycosylation of the potassium salt of precursor 309 with 2,3,4,6-tetra-O-benzyl-α-D-
glucopyranosyl chloride 312 was accomplished with enviable stereoselectivity (α/β = 1:37). 
Following full debenzylation to intermediate 310 and imide hydrolysis, exposure of 311 to 
formic hydrazide provided NB-506 50 in a final step yield of 76% (Scheme 2.52).
114
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Scheme 2.52 
 
Alternatively, treatment of the electrophilic precursor 311 with hydrazine or amine 
derivatives resulted in 6-N-amino substituted analogues of 50, including the anti-cancer 
compound, J-109 404 313, with a 1,3-dihydroxyisopropyl group in place of the N-formyl 
group, and formation of a panel of dihydroxylated anti-topo I congeners.
115-117
  53, 314-316 
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Scheme 2.53 
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ED-110 53 synthesis reported by Zembower et al. in 1999 employed Danishefsky‟s stepwise 
formation of BOM-protected bis(1,11-dibenzyloxyindolyl)maleimide 315 via successive 
Grignard-mediated 3-indolylation steps (Scheme 2.53).
111,118
 Transformation of 
monoindolylbromomaleimide 314 to the corresponding bisindole-N-glycoside 315 was 
accomplished with 2,3,4,6-tetra-O-benzyl-α-D-glucose 317, under Mitsunobu conditions, 
prior to bromine displacement by addition of the Grignard salt of 7-benzyloxyindole 308.
119
 
Palladium-mediated oxidation of 315 under acidic conditions afforded derivative 316, which 
could be deprotected by hydrogenolysis to access ED-110 53 (Scheme 2.53). 
 
2.3.5 Chemical routes to di-N-glycosides 
 
A common feature of strategies for natural product di-β-N-glycoside ICZ formation is the 
initial indole coupling of a complex electrophilic sugar derivative to a protected BIM or ICZ 
intermediate. These complex, multi-step routes also require activation of mono-N-
glycosylated precursors prior to late-stage chemistry to furnish the second C-N linkage.  
2.3.5.1 Total synthesis of staurosporine  
 
Elegant contributions to steresoselctive carbohydrate synthesis in the field of ICZ research 
have been instrumental concerning preparation of the aminohexose ring system in 2 from 
simple starting blocks. Employing these carbohydrate synthons requires several steps to 
afford the final ICZ natural product culminating in aglycon formation, mono-N-
glycosylation and subsequent intramolecular electrophilic cyclisation via attack of the 
unsubstituted indole nitrogen on the modified sugar moiety. 
2.3.5.1.1 Staurosporine carbohydrate development 
 
In 1993, Danishefsky reported that base-induced epoxysugar ring opening constituted an 
effective N-glycosylation methodology towards preparation of 2.
120
  
 
 
 
 
 
                    318                           319                      320                           321                                                          
Scheme 2.54 
 
Subsequently, in 1995, L-glucal derivative 318 was utilised as a key starting material for 
total synthesis of 2 based on stepwise formation of oxazoline 319 via Schmidt reaction, 
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conversion to oxazolidinone 320 and treatment of this intermediate with Murry‟s dioxirane 
reagent, to yield the glycal epoxide derivative 321. This compound 321 has subsequently 
gained application as an effective glycosyl donor in further elaboration of the staurosporine 2 
indolocarbazole skeleton (Scheme 2.54).
120,121
 
2.3.5.1.2 Sugar-aglycon coupling route for total synthesis of staurosporine  
 
 Synthesis of the selectively protected aglycon 322 was initially achieved in three steps and 
57% yield.
111
 Formation of the first N-glycosidic linkage occurred by reaction of the sodium 
salt of 322 with sugar precursor 321, to afford 323, prior to C2‟-hydroxyl removal from the 
glycosyl moiety by Barton deoxygenation.
120-122
 Two-step elimination of the PMB and SEM 
protecting groups was followed by photocyclisation, in order to provide N-protected imide 
congener 324 (73%).
123
 Conversion of C6‟-hydroxyl group to the iodo derivative 325 
enabled dehydroiodination under the influence of DBU, to provide exo-glycal derivative 
326.  
326-329 
Base-induced intramolecular coupling of this activated mono-β-N-glycosyl derivative 326 
via attack of indole nitrogen on C5‟ of the electrophilic terminal alkene in the presence of 
iodine afforded cyclopyranosylated indolocarbazole intermediate 327, which was initially 
deiodinated under radical hydrodehalogenation conditions.
120-122
 Subsequent oxazolidinone 
ring cleavage to form 329 necessitated a three-step protection strategy. BOM hydrogenolysis 
over Pearlman‟s catalyst, followed by regioselective oxazolidinone Boc protection and 
concluding imide BOM-reprotection achieved initial conversion to analogue 328.
124
 Smooth 
hydrolysis of the labile Boc-protected oxazolidinone ring moiety was subsequently 
accomplished by stirring with cesium carbonate to provide the corresponding 
deoxyaminosugar 329 in a yield of 93%.  
 
A series of functional group modifications involving N,O-dimethylation with 
dimethylsulfate, followed by BOM-deprotection and Boc removal resulted in formation of 7-
oxostaurosporine 330 in 70% yield over three steps. Transformation by NaBH4 reduction to 
the intermediate lactol ring followed by deoxygenation with phenylselenol in the presence of 
a catalytic amount of p-TSA, resulted in non-stereospecific desymmetrisation of the 7-oxo 
precursor and formation of equivalent amounts of both desired (+)-STA 2 (39%) and 
isomeric isostaurosporine 331 (39%), in combined 78% yield from 330 (Scheme 2.55).
121,125
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Scheme 2.55 
2.3.5.2 Total synthesis of K-252a  
 
Synthetic cyclofuranosylation methodologies have also been developed to access bioactive 
ICZ, K-252a 13. In this section, two alternative approaches, employing electrophilic 
dimethoxyfuranose coupling and modified Danishefsky cycloglycosylation will be 
discussed.    
 
2.3.5.2.1 Route to electrophilic K-252a furanose precursor  
332-339 
An asymmetric synthesis of the (-)-diastereomer of dimethoxyfuranose 338, starting from a  
transformation of (R)-(-)-1-nonen-3-ol 332 to intermediate acetoacetate 337, was initially 
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accomplished following treatment with methyl 2-diazo-3-oxobutyrate 340, in the presence of 
Rh2(OAc)4, via tandem [3,3]-Claisen rearrangement of initial O-H insertion product α-
allyloxy ketone 333 to form the R-enantiomer of α-ketoester 335 (ee = 95%) and final Lewis 
acid-promoted α-ketol rearrangement (Scheme 2.56).92,126 334, 336, 339 
 
                                        340 
 
                  332                                            337                              338 
                                                                                                                                     339 
 
                            333                            335 
                                                           
                                                                                 336 
                                            
 
                                                           334 
 
 
Scheme 2.56 
 
Induction of the observed stereochemical outcome is thought to be mediated by a preferred 
Z-enol chair conformation, avoiding unfavourable steric interactions present within the [3,3]-
transition state 334. Similarly, the necessity for a syn-periplanar relationship between the 
hydroxyl and α-carbonyl groups within 335 also correlates with a high degree of (S)-
stereoselectivity within 337 (ee = 92%). Hydroxyl group activation by BF3.Et2O 
complexation is thought to promote intramolecular carbonyl protonation through enhancing 
alcohol acidity, thus favouring the „pseudo-chelated‟ transition state maintained in 336.  
One-pot synthesis of the desired K-252a sugar residue was effected by reductive ozonolysis, 
followed by acid-mediated cyclisation, to afford a mixture of carbohydrate synthon, (-)-338 
and side product (+)-339 in an overall yield of 80%.
127
  
2.3.5.2.2 Acid-mediated cyclofuranosylation route to K-252a 
 
According to McCombie‟s original procedure, acid-catalysed cyclofuranosylation is 
hypothesised to proceed via stepwise formation of an aminoacetal intermediate, which then 
undergoes further nucleophilic indole nitrogen attack and acid-promoted intramolecular 
cyclisation.
128
 Exposure of DMB-protected 289 to carbohydrate precursor 338, generated 
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from methyl acetoacetate 341 via intermediate 342, as per the route outlined in Scheme 2.57, 
in the presence of CSA, afforded a regioisomeric mixture of K-252a analogues 292 and 343, 
in a ratio of 2:1, and overall yield of 80%.        
 
                                                                                                
                                         341 
                                                                                  342              338 
 
                                            338 
                                                                                           
                   289                                                            
                                                                                                                               
                                                                                                                                     13           
                                                    343                      292                       
Scheme 2.57 
 
Following chromatographic purification, final imide protecting group removal similar to the 
2,4-DMB peptidic deprotection procedure initially refined by Steglich et al., was carried out 
to afford natural product (+)-K-252a 13, in 83% yield following treatment of major 
regioisomer 292 with TFA, for 6 hours (Scheme 2.57).
92,127,129
  
 
2.3.5.2.3 Fukuyama total synthesis of K-252a employing Danishefsky glycosidation strategy 
 
 In 1999, Fukuyama and co-workers reported an elegant total synthesis of (+)-K-252a 13 
starting from indole-3-acetic acid 233.
130
 Initial O-allylation was then followed by indole    
C-2 bromination at room temperature, in 79% yield over two steps. Employing an analogous 
approach to the NB-506 50 methodology developed by Ohkubo et al., initial deprotonation, 
followed by addition of p-toluoyl protected furanose derivative 344 then provided β-N-
glycoside 345 as sole product in 97% yield.
131
 Diacetylated compound 346 was produced in 
four steps and 52% yield following allyl ester hydrolysis, amide formation, regioselective 
benzylic oxidation to ketone and N-acetylation of both indole and amide nitrogens. DBU-
catalysed formation of lactam 347 in the presence of 4Å molecular sieves proceeded in 92% 
yield, prior to annulation by irradiation in the presence of DIPEA, leading to the 
dehydrobrominated pyrrolo[3,4-c]carbazole analogue 348 in almost quantitative yield (96%). 
Complete masking group deprotection under alkaline conditions followed by chemoselective 
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iodination of the resultant primary alcohol also provided access to intermediate 349 in high 
yield (Scheme 2.58).
130,132
 350-355 
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Scheme 2.58 
Four-step conversion to alkene 350 employed initial diphenylselenide treatment, followed by 
reacetylation, oxidation and triethylamine-induced elimination/olefination steps. Application 
of Danishefsky‟s di-N-glycoside cyclisation method, employing iodine, KI, and DBU as 
base (351), followed by radical deiodination afforded cyclofuranosylated congener 352.
133
 
Conventional K2CO3-mediated deacetylation of the C3‟-hydroxy group to fully deprotected 
353, prior to regioselective Moffatt-Pfitzner oxidation was then followed by addition of 
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HCN and acetic anhydride to afford elegant conversion to the single acetylcyanohydrin 
diastereoisomer 354, under mild conditions. 
Following acidic conversion to amide 355, KOH hydrolysis elicited formation of the 
corresponding acid, which was finally esterified to give (+)-K-252a 13 in 23 steps and 
cumulative yield of 10% starting from indole-3-acetic acid 233 (Scheme 2.58).
130
    
     
2.4 Chemical modification of the indolo[2,3-a]carbazole nucleus 
 
During the course of this project, chemical studies based on ICZ heterocyclic replacement 
were of paramount importance. Literature results based on sugar modification, 
indolocarbazole A/E-ring substitution and indole B/D-ring replacement with 7-azaindole 
isosteres are important contributions in this area. Derivatisation routes focusing on F-ring 
diversity remain relatively unexplored, but will be addressed in the present work (vide infra). 
2.4.1 Sugar substitution: synthesis of ICZ-bridged cyclopentanes 
 
In order to investigate the effects of regioselective non-glycosidic alkylations on specific 
kinase activity, much synthetic effort has also been concerned with structural modifications 
of the indolocarbazole glycosyl moiety, leading to clinical development of functionalised 
macrocyclic analogues possessing attractive PKC activity.
42,134-136
 
 
Alkylation of indolo[2,3-a]pyrrolo[3,4-c]carbazoles, comprising all three unprotected 
nitrogens constitutes a formidable challenge, with respect to regioselective mono-N-
alkylation. In the course of accessing N-alkylated indolocarbazoles as effective inhibitors of 
human cytomegalovirus replication, it was reported that treatment of arcyriaflavin A 7 with 
Boc anhydride in the presence of NaH, afforded the regioselectively diprotected compound 
356 in 70% yield.
137
 Subsequent indolic nitrogen alkylation and full deprotection, forming 
12-methyl analogue 357 thus represented a privileged route to a panel of monoalkylated 
derivatives.
137
 Interestingly, application of less electrophilic alkylating agents gave more 
complex mixtures, postulated to be due to protecting group instability under harsher 
conditions.
138
 Application of 7 along with KOH/iodomethane in acetone also afforded the 
corresponding tri-alkylated congener 358 (Scheme 2.59).
139
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Scheme 2.59 
 
In addition, reaction of arcyriaflavin A 7 with cis-dibromocyclopentene 359 only afforded a 
modest amount of the anticipated cyclic derivative 360, whereas following attachment of a 
6-PMB group, the analogous reaction of 361 proceeded to give cyclopentene-bridged 362 in 
a yield of 73% (Scheme 2.60). Masking of the reactive imide group is an important feature 
of indolocarbazole chemistry, due to the reagent incompatibility and poor solubility of the 
corresponding N-H analogues under a wide range of synthetic conditions.
140
 Introduction of 
the readily cleavable, modified PMB group has also been described by many groups, 
including Wood and Moffat, to be beneficial due to its stability and increased solubility, as 
well avoiding the exigencies associated with removal of the N-Bn group.  
                                                              359 
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                                               361                                                                  362                              
Scheme 2.60 
 
In 2005, Moffat and co-workers reported transformations based on alkene 362 leading to 
construction of a range of ICZ-bridged cyclopentane congeners (Scheme 2.61).
140
 363-366 
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Scheme 2.61 
 
Azidoalcohol 365 formation could be realised by either m-CPBA epoxidation of starting 
362, to yield epoxide 364 followed by addition of TMS-azide and BF3.Et2O, in overall 40% 
yield, or alternatively, dihydroxylation of 362 with OsO4, followed by treatment of the 
resulting diol with sulfuryl diimidazole, gave the cyclic sulfate derivative 363, which could 
be further converted to the desired azidoalcohol 365. This intermediate 365 was readily 
convertible to the corresponding amino derivative 366 following hydrogenation. 
Diastereoselective hydroboration to form precursor alcohol 367, prior to Dess-Martin 
periodinane-mediated oxidation also afforded cyclopentanone intermediate 368 (Scheme 
2.61).
140
  
369-372 
An innovative route to novel N,N-cyclohexyl analogues of staurosporine 2, was also 
elucidated by cyclopentanone ring-expansion to form a key α-hydroxyketone product 373 
derived from vinylmagnesium bromide addition to ketone 369, subsequent TMS protection 
of alcohol 370, ozonolysis of alkene 371 and Lewis acid-mediated α-ketol rearrangement of 
aldehyde 372 (Scheme 2.62; c.f. Section 2.10.5.2.1).
106,110,140
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Scheme 2.62 
2.4.2 Indolocarbazole A/E ring substitution 
 
A convenient means to directly functionalise ICZs usually involves incorporation of 
appropriately substituted indole units in conventional Fischer indolisation routes, 
incorporation of substituted indoles in dibromomaleimide coupling or Diels-Alder 
cycloaddition/tandem electrocyclisation of substituted 2,2-biindolyl analogues
46,112,118
 
However, an important transformation concerns electrophilic indole substitution and 
subsequent modifications investigated to refine bioactivity and improve solubility.
4,141-143
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Scheme 2.63 
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In 2007, development of elegant synthetic methodology for targeted modification of critical 
C-3 and C-9 indole positions within JAK3 inhibitors structurally related to phase II/III 
VEGFR-active analogues, was reported by Yang et al.
4,62
 Regioselective NBS bromination 
of ICZ pyrrol-2-one 374 occurs preferentially at C-3, followed by Lewis acid-mediated 
formylation of 375 employing dichloromethyl methyl ether proceeds at C-9 to afford 
intermediate 376 (83%). Hydride reduction of unsymmetrical aldehyde 376 then afforded C-
9 hydroxymethyl bromo-derivative 377 (72%), which was converted, on reaction with 378, 
to the corresponding C-3 allyl imidazole-substituted compound 379 (JAK3; IC50 = 3 nM) in 
moderate yield under Heck microwave conditions (Scheme 2.63).
62,80
 
2.4.3 1-Azaindolocarbazoles 
 
Synthetic efforts in the field of indole ring isosteric replacement have also recently described 
desirably selective cytotoxicity profiles associated with a panel of 1-azarebeccamycin 
analogues.
144-146
 380-387 
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Scheme 2.64 
 
Replacement of an indole unit with an azaindole moiety introduces novel basic character 
capable of modifying inherent pharmacological properties of ICZs, while also enhancing 
drug-complex affinity by formation of hydrogen bonds orientated within the active site of 
target enzymes and/or DNA.
147,148
 Symmetrical 1,11-azaindolocarbazole synthesis was 
reported by Routier et al. under Grignard conditions, starting from 7-azaindole 380 reaction 
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with 3,4-dibromo-N-methylmaleimide 173 at 50
o
C for 24 hours, to afford 381 in 64% yield. 
Interestingly, this transformation was strongly base-dependent and the regioisomeric N-
substituted analogue 382 was formed in 25% yield, following stirring of 380 along with 173 
in LiHMDS, for 3 hours. However, following N-phenylsulfonyl protection, sterically 
favoured C-3 substitution of the 7-azaindole lithium salt rapidly provided bis(7-
azaindolyl)maleimide 383, then transformed to protected 384, prior to selective deprotection 
to the mono-Boc derivative 385. Following subsequent U.V. ring-closure, 386 was treated 
with formic acid to afford indolocarbazole 387 in 74% yield, over two steps (Scheme 
2.64).
145,146
 57, 388-393 
 
In 2003, Marminon and co-workers introduced a carbohydrate moiety within BOM-
protected 1,11-azarebeccamycin 392 following reaction of BOM-protected 
bisazaindolylmaleimide 388 with 2,3,4,6-penta-O-acetyl-α-D-glucopyranose 389 under 
standard Mitsunobu coupling conditions to give 390, and overall accessed β-N-glycosidic 
ICZ 57 following initial PhSO2 group removal (391), cyclisation (392), BOM hydrogenation 
to yield compound 393 and ammonolysis to provide the potent anti-proliferative compound 
57 (Scheme 2.65).
147
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2.5 Synthesis of arylindolyl derivatives related to indolocarbazoles 
 
Due to vast interest in development of novel bioactive compounds structurally related to 
staurosporine 2, incorporation of diverse arylindolylmaleimide heterocyclic functionality has 
become an essential target for current research related to the ability of modified 
indolocarbazole chromophores to exhibit potent kinase inhibition.
16,149-154
  
 
2.5.1 Synthesis of 3,4-bisarylmaleimides via Perkin condensation  
 
In 1998, a new and robust preparation of arcyriarubin A 79 was revealed, utilising base-
induced Perkin-type condensation; this versatile methodology has also been successfully 
applied to synthesis of unsymmetrical bisindolyl analogues, as well as diverse 
arylindolylmaleimides (Section 2.2.4.1).
61,62,155
 In 2006, Peifer and co-workers efficiently 
employed this approach in order to synthesise a panel of asymmetrically substituted 3,4-
bisarylmaleimides, as potent VEGFR2 inhibitors.
156,157
 In each case, one-pot condensation of 
acetamide and an excess of an indole glyoxylate ester, prepared via Friedel-Crafts acylation 
or treatment of indolylmagnesium bromide 154 with diethyl oxalate at low temperature, 
occurred following reaction in the presence of potassium tert-butoxide in THF. Application 
of this method involving ethyl indole-3-glyoxylate 394 and 3,4,5-
trimethoxyphenylacetamide 395 afforded 3-(indol-3-yl)-4-(3,4,5-trimethoxyphenyl)-1H-
pyrrole-2,5-dione 396, subsequently determined to inhibit VEGFR2 (IC50 of 2.5 nM), in 
54% yield (Scheme 2.66).
157
 Based on molecular modelling rationale, this group 
subsequently published the synthesis of lactam 397, conserving a critical pyrrole-2-one H-
bonding motif.
158
 398-401 
                            
           394                              395                         396        
                                                                
 
                                                                                                     397 
 
                                                                                                                                     400 
                                                                                                                                      401 
 
                                            398 
                                             399 
Scheme 2.66 
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Due to the reported difficulty associated with regiospecific maleimide carbonyl reduction of 
compound 396 to derivative 397, a modified Knoevenagel condensation of precursor 399, 
isolated following SEM-protection of 398, afforded the aldol precursor, which was self-
condensed, to yield the corresponding pyrrole-2-one 400. Heating of 400 along with a 
catalytic amount of HCl, resulted in isolation of hemiaminal 401 (46%). The desired 
analogue 397, was then synthesised following elimination of formaldehyde, in 47% yield. 
Interestingly, while reaction of 400 under acidic catalysis afforded predominantly 401, 10% 
of the target pyrrole-2-one 397 was also detected as the minor component of the final 
product mixture (Scheme 2.66).
158
  
2.5.2 Planar ring modification: formation of heteroarylcarbazole derivatives 
 
In 2005, Meggers and co-workers suggested that application of pentacyclic pyrido[2,3-
a]pyrrolo[3,4-c]carbazoles constituted an interesting bioisostere of active classical 
indolo[2,3-a]carbazole analogues.
155
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                 403                                              404                                              405 
                                                                                                                        406 
Scheme 2.67 
 
The initial route selected for synthesis of compound 406, involved Faul-type condensation to 
yield 404, utilising pyridine-3-acetamide 402 and SEM-protected methyl indole-3-glyoxylate 
403, followed by photoinduced annulation to finally give 406 after ultimate deprotection 
(Scheme 2.67).
155
  
 
However, due to the insolubility of 406 in most organic solvents, an alternative strategy was 
developed, which avoided the necessity for indole nitrogen protection, and was analogous to 
the 2,2‟-biindolyl 118 cycloaddition approach. This method encompassed initial hydrazone 
formation between 2-acetylpyridine 407 and phenylhydrazine 106, resulting in formation of 
2,2‟-pyridoindole 408, following exposure of intermediate 409 to PPSE at reflux (Scheme 
2.68).
155
 However, addition of TBDMS-protected dibromomaleimide 410 does not proceed 
via the thermal one-pot cyclisation mechanism proposed by Bergman et al. similar to the 
bisindolyl series; in this case, LiHMDS-mediated indole-maleimide C-C bond formation 
(411) is followed by U.V.-induced oxidative dehydrobromination, to form 412.
5,155
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Scheme 2.68 
These workers also designed an elaborate cyclometalation strategy, permitting formation of a 
unique ligand sphere within a water and air-stable metal complex capable of potent 
interactions with specific ATP-binding site residues.
159
 Heating of TBDMS-protected 
intermediate 412 with [RuCp(CO)(CH3CN)2]
+
PF6
-
 complex, along with K2CO3, formed a 
ruthenium complex 413, which, following TBS deprotection, possessed prodigious IC50 
activity against GSK-3α (0.3 nM); formation of 413 proceeded via co-ordination of the 
pyridyl nitrogen, followed by indole attack and subsequent deprotonation.
155
 414-425 
 
In 2008, Bourderioux et al. developed an alternative and versatile palladium-mediated route 
to pyrido- and other heteroarylcarbazoles, beginning from trimethylstannylation of 1-
phenylsulfonylindole 415 to form precursor 416 in 83% yield, prior to Stille coupling with a 
2-bromopyridine derivative 414 (R‟=H, OMe) in the presence of 10 mol% of Pd(PPh3)4, and 
CuI, in DMA at high temperature, to afford unsubstituted 417  and methoxy analogue 418, 
respectively.
154
 The corresponding intermediate 2,2-pyridoindoles 419 and 420, were then 
isolated in >90% yields following TBAF deprotection. Following formation of the 
maleimide-fused intermediate 422 via reaction of 419 and 173 under basic conditions, 
nucleophilic formation of a ring-constrained pyridinium salt 423, was also reported by these 
workers. In addition, 2-hydroxypyridine derivative 421, initially formed by HBr-acetic acid 
demethylation of 2-methoxypyridine derivative 420 (89%) could be thermally cyclised to 
pyrido[2,3-a]carbazole congener 425 by a facile addition-elimination mechanism via its 
pyridone tautomer 424 (Scheme 2.69).
154
 416, 426-430 
 
 
 
 
Chapter 2                                                                                                                      Chemical Introduction 
__________________________________________________________________________ 
                                                                         120 
                                               414-425    
                                                     414 
                                                                                                              419 
                                        415                             417                                 420                           
                                                  416                     418 
                                                                                                                                      421 
                                           173 
                                                                                                      423 
 
                         419                                         422 
                                            173 
                                                                                                      425                     
 
                       421                                         424 
Scheme 2.69   
 
Reaction of bromobenzene 426 with 2-trimethylstannylindole 416 resulted in formation of 2-
phenylated analogue 427, which was desulfonylated in quantitative yield (428), prior to 
LiHMDS-mediated 1,4-conjugate addition with N-methyl-3,4-dibromomaleimide 173 to 
produce 2,3-disubstituted indole derivative 429.
74
 Heck arylation of bromoalkene 429 was 
successfully achieved, in the presence of stoichiometric Pd(OAc)2, to afford annulated 
benzo[a]carbazole 430 in a yield of 70% after 7 hours (Scheme 2.70).  
                                           426 
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Scheme 2.70 
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These workers also reported that strongly electron-withdrawing phenyl substituents retarded 
the progress of this reaction; presumably, the nature of this phenomenon is due to the 
deactivating influence of these groups on the critical C-Pd bond insertion step within the Pd-
induced intramolecular Heck reaction.
80,154
 
2.5.3 Granulatimide cycloaddition  
431-439 
In 2007, Prudhomme demonstrated novel applications involving Diels-Alder cycloaddition 
of 3-indolylmaleimide 432 and cyclopent-2-enone 435 to form cyclised non-carbazole 
precursor 433, which was subsequently dehydrogenated to the carbocyclic pyrrolo[3,4-
c]carbazole 434 (25%), based on the structure of the ChK1 inhibitor granulatimide 431 
(Scheme 2.71).
160,161
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                                            435                                  
 
 
                      432                                        433                                         434 
 
 
                                     439                                                       199 
 
 
          436                                                 437                                                 438        
Scheme 2.71 
 
In addition, palladium-mediated Suzuki coupling of Boc-protected 2-indoleboronic acid 436 
with 3-bromocyclopent-2-enone 439 afforded 2-substituted indole 437. Condensation with 
maleimide 199 as Diels-Alder dienophile, at 140
o
C for 3 days provided cycloadduct 438, 
following DDQ-induced aromatisation in a two-step yield of 66%, and thus providing the 
regioisomeric carbonyl group orientation to 434 (Scheme 2.71).
161
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2.6 Conclusion 
 
The observed structural complexity present in the indolopyrrolocarbazole chemical class has 
given rise to diverse strategies for versatile construction of a wide range of structural 
congeners.
2,5,6
 However, a number of critical carbon-carbon bond forming events such as 
tandem conjugate cycloaddition, base-mediated indole coupling and palladium-catalysed 
diyne cyclisation have been described as attractive routes to indolo[2,3-a]pyrrolo[3,4-
c]carbazole analogues.
65,74,78,138
 Fischer indolisation methodologies suffer from a 
regiochemical limitation of employing only 2 or 4-substituted phenylhydrazine substrates as 
indolocarbazole precursors, while in many routes, poor organic solubility of unmasked polar 
heterocyclic functionality, as well as non-facile central benzene ring closure issues have also 
been recognised as significant challenges towards formation of this heterocyclic 
scaffold.
38,54,155,162
  
Other recent routes to indolocarbazole aglycon precursors also include base-mediated Perkin 
condensation to afford an attractive one-pot route to unsymmetrical bisindolylmaleimides.
61
 
Biomimetic approaches have also been reported based on complex enzymatic pathways to 
indolocarbazole alkaloids, illustrated by iodine-mediated oxidative coupling of indole-3-
acetic acid trianion 234, as well as diverse semi-synthetic routes from versatile common 
intermediates such as ketone derivatives 293 and 373, analogous to compounds isolated from 
biosynthetic pathways.
63,107,110,140
  
 
In addition, application of disparate glycosidation strategies exploit the nucleophilic 
reactivity of indole moieties in order to couple electrophilic sugar units capable of 
subsequent transformation to a range of mono and di-N-glycosidic derivatives. Danishefsky 
and co-workers utilised a glycal intermediate 321 as a key staurosporine 2 aminohexose 
synthon, which could then be converted to a doubly linked carbohydrate unit, following 
base-mediated electrophilic cyclisation of an alkene intermediate 326.
120,121
 This group also 
employed similar 1,2-anhydrosugar methodology to synthesise the β-N-glycosidic mono-
linkage within an anti-topo I lead natural product, rebeccamycin 38.
111
 In these cases, the 
conventional base-induced 3,4-dibromomaleimide substitution initially developed by 
Steglich and Weinreb was demonstrated to efficiently furnish the bisindolylmaleimide 
precursor prior to regioselective sugar coupling.
33,34
 An important feature of these routes also 
concerned the enhanced reactivity of bisindole intermediates compared with the 
corresponding indolocarbazoles, as initial glycosyl acceptors, prior to aromatisation.  
Synthetic challenges were also overcome in the synthesis of cyclofuranosylated K-252a 13; 
Fukuyama‟s elegant stereoselective route employed halosugar substitution, DBU-mediated 
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lactam ring formation and oxidative dehydrobromination steps, as well as displaying 
Danishefsky‟s di-N-glycosylation protocol.130 Wood and co-workers also demonstrated 
synthesis of 13 by means of a multi-step route to a dimethoxyfuranose derivative 338 that 
was subsequently coupled to an N6-protected K-252c derivative 289 via CSA-promoted 
cyclofuranosylation.
127,163
 Utilisation of stereoselectively β-N-glycosylated indoline 
precursors subsequently oxidised to the corresponding indole analogues within routes to 
novel sugar-linked indolo[2,3-a]carbazole compounds have also been recently reported by 
Garaeva et al., but this approach is hindered by the lack of functionalised starting materials, 
as well as having an extra oxidation step.
60
 
    
Based on the wide spectrum of biological profiles of natural indolocarbazole alkaloids, as 
described in Section 1, recent synthetic focus has also shifted to altered heteroarylcarbazole 
derivatives maintaining a central polyheteroaromatic system, fused to a hydrogen-bonding 
pyrrole head group.
145,154
 Synthetic strategies employed to investigate these peripheral 
molecular characteristics include incorporation of 7-azaindole 380 moieties within unique 
topo I inhibitors and application of Meggers‟ elegant organometallic ruthenium-complexed 
pyridocarbazole nucleus 413 with attractive GSK-3α kinase inhibition.147,148,155 However, it 
can be noted that few workers in this area have attempted to derivatise the constituent 
pyrrole-2,5-dione F-ring, to explore its potential effects on kinase inhibition or conferring 
novel modes of biological activity based on enhanced solubility or new hydrogen bonding 
profiles.
145
  
 
In order to fully contextualise these major pharmaceutical advances with respect to 
innovation of unique biological profiles within this chemical family, it is also necessary to 
identify new opportunities for synthetic exploitation which may not be sufficiently addressed 
by workers in this field, to date. Thus, a beneficial requirement for extensive derivatisation 
work, designed to evoke new structural insights into the bioactive indolocarbazole aglycon 
still behoves continuing development of a wide array of innovative strategies supporting 
their total synthesis, especially for novel F-ring analogues, currently unexplored in pre-
clinical cancer chemotherapy. 
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3.0 Aims and Objectives 
3.1 Project outline 
 
Nature can be envisaged as a useful ally to the intrepid medicinal chemist, providing a wide 
range of active compounds from ubiquitous sources. Natural bisindole alkaloids have 
recently been revealed to constitute an important class, based on their ability to modulate 
important biological functions, often with interesting activity profiles.  
 
 
 
 
 
 
                                                                       440                                                                        
Fig. 3.1: General structure of heterocyclic scaffold utilised for design of novel anti-cancer derivatives 
 
 
Preliminary screening work within the group has identified a group of compounds based on 
the natural product indolo[2,3-a]carbazoles, staurosporine 2 and rebeccamycin 38, 
incorporating five or six-membered heterocyclic ring systems (440) between the two indole 
rings as a lead structure capable of delivering novel anti-cancer activity. In addition, a 
rational approach to diversity-oriented synthesis (DOS) has the potential to yield new small 
molecule kinase inhibitors, overcoming the low availability and dose-limiting side-effects of 
current agents (Fig. 3.1).
1-6
  
 
Refinement of this pharmacophore is envisaged to generate multiple biochemical hits against 
an array of validated molecular targets in cancer and other disorders, with beneficial effects 
in potency and enzyme selectivity. Derivatisation of this H-bonding protein-interacting 
scaffold will also achieve improvements in physico-chemical parameters such as 
enhancement of aqueous solubility, by introduction of biologically relevant polar 
functionality.
7
  441 
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Fig. 3.2 
 
Statement of aims: 
At the outset of this work, a synthetic strategy was outlined which incorporated the 
following project output goals: 
 
(a) Design and synthesis of novel 5,6-bisindolylpyrimidin-4(3H)-ones as potential 
bisindolylmaleimide analogues and investigation of routes to the planar indolo[2,3-
a]pyrimido[5,4-c]carbazol-4(3H)-one 441 series. 
(b) Exploration of heterocyclic derivatisation methodology towards development of 
novel anti-cancer activity and topoisomerase inhibition by isosteric replacement of 
inhibitory structural motifs.  
(c) Evaluation of optimal routes and key intermediates for future development of novel 
heterocyclic derivatives in related aryl/bisindolyl compound screening panels.  
 
Overview of objectives 
 
In the following section, a brief SAR background to the aims of this project will be provided. 
In summary, the known chemical diversity of kinase inhibitors, and related ability of a wide 
number of indolocarbazole derivatives to exhibit biological versatility underpins this project. 
Following investigation of literature in this area, a number of structural leads for enzyme 
inhibition by modified structures have been identified. In addition, very little work has been 
carried out by workers in the area of modifying the key H-bonding lactam/maleimide ring 
within active aglycons of STA 2 and REB 38. This insight has led us to develop several 
strategies targeting innovative F-ring installation in new bioactive BIMs and ICZs. 
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Bisindolylmaleimide 443 was demonstrated by Davis et al. to inhibit PKC with an IC50 value 
of 0.11 µM, while monoindolyl Meridianin D 444, isolated from the marine tunicate 
Aplidium meridianum, displayed modest cytotoxicity towards LMM3 (murine mammarian 
adenocarcinoma cell line), with an IC50 value of 33.9 µM, as well as being an inhibitor of 
several protein kinases.
8,9
 Extrapolating from this structural evidence, novel bisindolyl 
heterocycles related to compound 445, where X = NH2, containing a 1,2-(bisindolyl)-cis-
ethene scaffold and H-bonding pyrimidinone core would be of immense interest as elaborate 
isosteres containing a similar bidentate acceptor-donor heterocyclic H-bond motif (Fig. 3.3).   
 
                  
 
 
 
 
 
 
                     443                                              444                                                445 
Fig. 3.3 
 
 
Investigation of conformationally rigid heterocycles and alkylated analogues would also 
extensively probe the molecular space within proposed binding pockets. As a benchmark 
compound, the new planar indolo[2,3-a]carbazole structure 441 would allow us determine if 
new interactions with enzyme residues by this six-membered ring series correlates with 
improved inhibitory activity, in comparison to the highly active, five-membered indolo[2,3-
a]pyrrolo[3,4-c]carbazoles. In particular, the 2-aminopyrimidine-4-one (isocytosine) subunit 
fused to the indolocarbazole (X = NH2; 442), would be appealing since analogous pyrimidine 
moieties form a component of nucleoside bases, which play a powerful role in biological 
systems (Fig. 3.2).
10-12
  
80, 446 
A major objective of this work was transfer of distinct structural features of related 
heterocyclic compounds into emerging lead architectures obtainable from key intermediates. 
This concept has been pursued by targeting modification of the cytotoxic marine bisindole 
pyrrole alkaloid – nortopsentin A 446.13 Synthesis of 3,4-bisindolylpyrazol-5-amine 447 and 
complementary analogues have not been previously described, and this chimeric system has 
the potential to augment the attractive H-bonding network within bioactive anti-cancer 
bisindolylmaleimide derivatives such as ruboxistaurin 80 (Fig. 3.4).
14-16
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      446                                               80                                         447 
Fig. 3.4 
 
It was anticipated that work based on the VEGFR2 inhibitor 3-(indol-3-yl)-4-(3,4,5-
trimethoxyphenyl)-1H-pyrrole-2,5-dione 396 would also afford a number of novel congeners 
of general structure 448, retaining an arylindolyl system, while comprising a new H-bonding 
enzyme-interacting template with immense biological potential in this series (Fig. 3.5).
17,18
    
 
 
 
 
 
                                          396                                                         448 
Fig. 3.5 
 
The final element of this work involved initiating development of routes to novel chemical 
classes attracting future research within the group. Development of a new route to 
imidazo[4,5-c]indolo[2,3-a]carbazoles 449 - a new synthetic template based on the 3,4-
diarylimidazole class reported by Laufer et al., and exemplified by the p38 MAP kinase 
inhibitor 450 (Fig. 3.6).
19,20
 Devising new approaches to indolo[2,3-c]carbazoles 451 and 
preliminary investigation of heterocyclic variation within this regio-series constituted work 
focused on the future identification of diverse ICZ leads with enviable biological activity. 
 
 
 
 
 
 
 
 
           449                                                   450                                            451 
Fig. 3.6 
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4.0 Chemical Results and Discussion 
4.1 Synthesis of 3,4-bisindolylmaleimides 
 
Any individual method for the construction of the indolo[2,3-a]pyrrolo[3,4-c]carbazole 3 
core, as well as regio-analogues, must be selected according to the structural nature of the 
target of interest. In recent times, a number of versatile approaches to these systems have 
been exploited, with a common motif observed for these routes including the late-stage 
bisindolylmaleimide ring closure to form the central carbocyclic ring.
1-3
  
 
4.1.1 Indole substitution reactions 
 
A classical approach to indolo[2,3-a]carbazole 1 alkaloids involves oxidative cyclisation of 
an appropriately derivatised 3,4-bisindolymaleimide intermediate 155 via double coupling of 
preformed indole 171 to a dihalo substituted maleimide precursor 157.
4,5
  
 
 
                                                                                                     171 
 
        452                           453 
 
 
                                                                            157                                          155 
                                                                                                        
                                          183 
 
 
 
 
                                                                             1                                                                               
                                                                                                                             241 
 
Reagents and conditions: (i) Br2, AlCl3, 120
oC, 16h, 453 = 90%; (ii) Bn-NH2, AcOH, 120
oC, 3h, 157 = 60%; 
(iii)(a) Bn-NH2, AcOH, 120
oC, 2h, (b) Br2, NaOAc, 0
oC - 120oC, 2h, 157 = 60%; (iv) LiHMDS, -78oC - 100oC, 
toluene, 16h, 155 = 42% (crude); (v) DDQ, cat. p-TSA, toluene, 100oC, 1h     
 
Scheme 4.1 
 
As an initial effort to develop a versatile method of indolocarbazole formation, a trial route 
was initiated with N-benzyl-3,4-dibromomaleimide 157 as electrophile, with a view to its 
replacement by other dihalogenated heterocycles within new chemical series (Section 4.2.2).
6
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Dibromination of maleic anhydride 452, using 1.5 equivalents of bromine in DMF, stirred for 
3 days at 55°C was attempted with limited success. Consequently, according to the approach 
outlined by Dubernet et al.
 
(Route
 
A), a mixture containing precursor 452 and bromine, along 
with a catalytic amount of aluminium chloride, was heated in a sealed vessel at 120°C for 16 
hours. Following work-up, 2,3-dibromomaleic anhydride 453 was isolated in a yield of 90%. 
Conversion of this intermediate to N-benzyl-3,4-dibromomaleimide 157 was achieved 
through amination with 1.1 equivalents of benzylamine, and following chromatography, the 
desired product 157 was isolated, as an off-white solid, in a yield of 60% (Scheme 4.1).
6,7
  
 
Interestingly, another method employed to good synthetic effect was the one-pot preparation 
of 157, via intermediate 183, first reported by Choi et al.
 
(Route B), which afforded 157 in a 
yield of 60%, in our hands. However, the non-facile issue of the efficient open-vessel 
heating of volatile bromine limited this route in comparison to Dubernet‟s robust 
methodology.
8
 
 
The penultimate step consisted of the nucleophilic displacement of both bromine atoms in 
intermediate 157, by two indolyl anions, to yield the acyclic bisindolylmaleimide core 
155.
9,10
 Heating of a mixture of 2.5 equivalents of indolemagnesium bromide and the N-
benzyl-3,4-dibromomaleimide 157, in the presence of transmetallating ZnCl2 solution, in 
diethyl ether, did not yield 155, under these conditions. However, other workers attempting 
this transformation have also employed LiHMDS, to furnish this bisindolylmaleimide 155. 
To a solution of LiHMDS formed in situ, at 0°C, 2 equivalents of 171 in toluene were added, 
at −78°C. On addition of a solution of protected dibrominated maleimide 157 to the flask, a 
dark blue colour initially appeared, that changed to a red mixture following heating 
overnight. The resultant crude yield of the bisindolylmaleimide product 155 was 42%, but 
unfortunately, this process was strongly affected by product solubility and work-up issues.
11
 
 
The final stage in this process required full aromatisation of the indolocarbazole nucleus, via 
oxidative cyclisation. Applying the method of Joyce et al.,
 
oxidative cyclisation was carried 
out by heating a mixture of DDQ and crude bisindolylmaleimide 155, along with a catalytic 
amount of p-TSA, in toluene.
9
 Fractions containing a fluorescent spot consistent with N-
benzyl indolocarbazole 241 formation were observed, but could only be recovered in a yield 
of <5%, on a 100 mg scale reaction. Several complex fractions were also collected, 
indicating that perhaps competing side-reactions suppressed the formation of 
indolocarbazole 241; this result suggested that it may be necessary to adopt alternative 
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milder aromatisation methodologies in order to provide access to analogous compounds in 
higher yields.
2,12,13
 The poor profile of this route also necessitated further work on an 
efficacious route to classical indolo[2,3-a]pyrrolo[3,4-c]carbazole derivatives. 
4.1.2 Perkin condensation 
172, 454-457 
Given the inherent difficulties and lack of versatility of the indolic substitution approach, a 
further route to derive di-N-methyl protected arcyriarubin A 172 was explored via a base-
mediated Perkin condensation of N-methyl indole-3-acetamide 455 and N-methyl indole-3-
glyoxylate 457, according to the procedure reported by Faul et al.
14-16
 Treatment of 3-
indolylacetonitrile 454 with 30% hydrogen peroxide and 1M aqueous NaOH solution, along 
with TBAB, in DCM overnight at room temperature was thus found to afford acetamide 455 
in a yield of 52%, following purification (Scheme 4.2).
15
  
 
 
 
 
 
 
                                                     
          454                                       455                             
 
 
 
                                                                                                                                                   172 
  
 
 
           456                                  457 
 
 
Reagents and conditions: (i) 30% H2O2, aq. NaOH, cat. TBAB, DCM, rt, 16h; (ii) (a)(COCl)2, Et2O, 30 min.; 
(b) 25% NaOMe, -65oC - rt; (c) H2O; (iii)(a) 3 eq. 1M KOt-Bu, THF, rt, 3h; (b) 5% HCl, 0
oC  
 
Scheme 4.2 
 
Reaction of N-methylindole 456 with 1.1 equivalents of oxalyl chloride at -65
o
C, followed 
by addition of sodium methoxide solution, and work-up involving water quenching, 
successfully isolated the corresponding N-methyl methyl indole-3-glyoxylate ester 457 in a 
yield of 42%. Following stirring of a bright-red suspension of acetamide 455 and glyoxylate 
457, in THF at 0
o
C, in the presence of potassium tert-butoxide, bisindolylmaleimide 
derivative 172 was afforded as an amorphous red powder in a yield of 67% (Scheme 4.2). 
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Formation of arcyriarubin A derivative 172 represented an attractive indolo[2,3-a]carbazole 
1 „benchmark‟ compound, important as a standard in order to assess the relative potency and 
modes of action of structurally related novel bisindolyl analogues, referenced during this 
investigation.
4,5,14,17-19
       
 
4.2 Modified classical routes to 5,6-bisindolyl-substituted pyrimidin-4-ones 
Due to the non-versatile nature of the Perkin condensation, initial investigation of alternate 
BIM-forming methodologies which could be modified for accessing 5,6-
bisindolylpyrimidin-4-one congeners classified Diels-Alder cycloaddition and base-mediated 
indole coupling to 5,6-dihalouracil derivatives as potential routes to this new chemical class.  
4.2.1 Diels-Alder reaction 
 
An alternative methodology was considered for the formation of indolo[2,3-a]carbazole 458, 
which involved the Diels-Alder [4+2] cycloaddition reaction of 2,2‟-biindolyl 118 and 
maleimide 199, as a heterocyclic dienophile. Unfortunately, while literature references to the 
preparation of 118 are surprisingly rare and constitute a series of uniformly unattractive 
routes, its potential procurement from commercial sources was also deemed to be 
prohibitively expensive. Madelung cyclisation of an N,N‟-bis(O-tolyl)oxamide 459 under 
extremely forcing conditions (>300°C) was known to provide 118 in moderate yield.
20
  
 
The bisamide intermediate 459 was prepared in a facile fashion following reaction of a 
mixture of o-toluidine 460, triethylamine and oxalyl chloride in 1,4-dioxane, maintained at 
0
o
C. Following work-up, the reaction mixture was filtered to cleanly isolate the toluidide 459 
in a yield of 75% as an off-white solid.
21
 Treatment of 459 with 5 equivalents of potassium 
tert-butoxide, in the presence of tert-butanol, at 280°C, only resulted in the recovery of 
starting material. This reaction has not been documented to proceed below 300°C and the 
apparatus at our disposal could not achieve the necessarily harsh conditions required 
(Scheme 4.3). The capricious nature of this indole-forming reaction has been previously 
documented, yet few improvements, in achieving this conversion under milder conditions 
have been described to date.
22
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                                     460                                                       459 
 
 
 
 
                                458                                                                   118 
Scheme 4.3 
 
This route was therefore abandoned due to the high degree of difficulty in obtaining starting 
material and potential lack of viability of the Diels-Alder method. Due to the absence of an 
array of heterocycles capable of behaving as effective dienophiles, the scope of this 
methodology would also be incapable of sustaining a wider program of indolocarbazole 
derivatisation. Following completion of this work, Tsuchimoto and co-workers have 
reported the utilisation of Fischer indole cyclisation, via 1-(indol-2-yl)ethanone 
phenylhydrazone, in 28% yield, while 2,2‟-biindolyl formation has also been accomplished 
by transition metal-mediated routes not investigated in the present work.
23,24
  
 
4.2.2 Base-mediated indole coupling 
 
In contrast to 2,2-biindolyl 118, 2,4,6-trichloropyrimidine 461 could be cheaply sourced and 
hydrolysed readily to 6-chlorouracil 462, under aqueous alkaline conditions at 100
o
C. 
Employing a protocol derived from the work of Murray et al., reaction of 462 in the presence 
of bromine water at 60
o
C, did not yield any of the anticipated 5-brominated derivative 463 
(Scheme 4.4).
25
 On detailed inspection of the literature in this area, it was noted that use of 
5,6-dihalouracils, in general, was exceedingly rare. No work-up was available in any 
available scientific literature, and interestingly, while C-6 attack by pyridine to form 
pyridinium salts etc. have been previously documented, no references were found to any 
reaction in which nucleophilic attacks have been reported occurring simultaneously on both 
the C-5 and C-6 positions of the uracil ring. Therefore, it was established that an innovative 
retrosynthetic plan was required for accessing novel 5,6-bisindolyluracil 464 derivatives. 
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                                                                                                                      464 
Scheme 4.4 
4.3 Synthesis of indolo[2,3-c]carbazoles 
 
Different arrangements of indole 171 and carbazole moieties have been reported to form 5 
possible isomeric ring systems. However, the vast preponderance of indolocarbazoles 
isolated from natural sources are indolo[2,3-a]carbazoles 1 and therefore, most research 
attention in this area has been focused on analogues which comprise this heterocyclic 
system.  
465-468 
It was decided that two congeners bearing the indolo[2,3-c]carbazole 465 chromophore 
would initially be produced in order to effect direct comparison with a panel of indolo[2,3-
a]carbazole derivatives, as well as for the development of novel indolocarbazole analogues 
within this series. These compounds could be formed via cycloaddition of 3,3-biindolyl 466 
and maleimide 199 for synthesis of 468, or with maleic anhydride 452 as dienophile in order 
to access compound 467, as reported by Bergman et al. (Fig. 4.1).
26
    
   
 
 
                                                                                                                                           467 
   
 
                                                                                                                                           468 
             466                                                                        465 
Fig. 4.1: Cycloaddition route to indolo[2,3-c]carbazoles 
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4.3.1 Synthesis of 3,3-biindolyl  
 
Based on Bergman‟s procedure, to a mixture of indole 171 and an equivalent amount of 
isatin 469, was added a small volume of 98% diethylamine solution, along with absolute 
ethanol. Following overnight reaction and addition of water during work-up, 3-(3‟-
hydroxyindolin-2‟-one)indole 470, was isolated by filtration and recrystallised from 
methanol, to afford a single crop of 466, as light pink crystals, in a yield of 91%.
27
 
 
3-(3‟-Hydroxyindolin-2‟-one)indole 470 was initially charged to a mixture of sodium 
borohydride and 1,2-dimethoxyethane (DME). A solution of BF3.Et2O complex in DME 
solution was then added to the beige-coloured, vigorously stirred reaction over 30 minutes. 
During this period, the flask initially assumed a light-green appearance, which transformed 
into a straw-coloured slurry on full reagent addition. Following work-up and cooling to 0
o
C, 
the slurry was filtered and washed with DCM, to yield 3,3‟-biindolyl 466, as silver plate-like 
crystals, in a yield of 41% (Scheme 4.5).
26,27
  
 
 
                                        469 
 
 
         171                                                    470                                                             466 
Scheme 4.5 
 
4.3.2 Diels-Alder [4+2] cycloadditions 
 
Thermal electrocyclisation of 3,3‟-biindolyl 466 with a heterocyclic dienophile was reported 
to successfully generate indolo[2,3-c]carbazole 465 functionality, and unlike Diels-Alder 
approaches for the corresponding indolo[2,3-a]carbazole 1 series, was detailed to proceed in 
excellent yield, under relatively mild conditions (Section 4.2.1). Following heating of maleic 
anhydride 452 and 3,3-biindolyl 466, in the presence of glacial acetic acid, for 60 hours at 
120
o
C, the dark red mixture was filtered to yield furo[3,4-a]indolo[2,3-c]carbazole-
6,8(5H,9H)-dione 467 (68%). Under similar reaction conditions, employing 2 equivalents of 
maleimide 199 stirred in acetic acid for 36 hours at 120
o
C, 5H-indolo[2,3-c]pyrrolo[3,4-
a]carbazole-6,8(7H,9H)-dione 468 was isolated after work-up, as a dark-red amorphous 
solid, in a yield of 62% (Scheme 4.6).
26
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                                                                                   466 
 
              467                                                                                                                468 
Scheme 4.6 
 
4.3.3 Attempted derivatisation of indolo[2,3-c]carbazole  
 
A Knoevenagel reaction was attempted between 467 and 1,3-dimethylbarbituric acid 471, 
carried out by stirring one equivalent of each reactant at 80
o
C, in the presence of ethanol 
containing a catalytic amount of either pyridine or piperidine, acting as base (Scheme 4.7).  
 
 
 
 
    471 
 
 
 
                                 467                                                                           472                                                                   
 
 
Scheme 4.7 
 
Unfortunately, no reaction to form 472 occurred under these conditions, and only starting 
material could be detected even after 72 hours. Nucleophilic ring-opening of 467 utilising 
hydrazine in acetic acid, heated at reflux overnight, successfully afforded 7,8-
dihydroindolo[2,3-c]pyridazino[4,5-a]carbazole-6,9(5H,10H)-dione 473, as a brown powder, 
in a yield of 70%, following addition of water, and filtration of the reaction mixture (Scheme 
4.8).
28
 This novel indolocarbazole 473 represents the first example of a six-membered F-ring 
moiety within this series and future work in this area will exploit this route for further 
derivatisation. 
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                                   467                                                                   473 
 
Scheme 4.8 
4.3.4 Attempted Curtius rearrangement 
 
Based on literature precedent in this area and the initial success of hydrazine-mediated 
pyridazin-3,6-dione 473 formation, it was postulated that azide-induced Curtius 
rearrangement of 467 proffered a route to other novel heterocyclic derivatives.
29
 However, 
reaction of 467 with a number of nucleophilic azide donors, in polar aprotic solvents, known 
to mediate this transformation, failed to yield the desired acyl azide 474 intermediate or final 
oxazine product 475, via Curtius product 476, after 24 hours (Table 4.1). Ammonolysis of 
467 in aqueous ammonia solution overnight at 80
o
C, in order to produce the corresponding 
carboxyamide 477 was attempted, but could not be effected under these hydrolytic 
degradation conditions. Indolocarbazole 468 was also stirred along with a solution of sodium 
hypochlorite, at 0
o
C, for 2 hours, followed by heating at 70
o
C overnight; however, only 
starting material was recovered, due to the poor oxidative efficiency of this transformation 
(Scheme 4.9).  
 
Table 4.1: Conditions employed for attempted indolo[2,3-c]carbazole (467)* Curtius 
rearrangement to yield a novel oxazine intermediate (475)  
 
Reagent Equiv. ICZ reactant Solvent Reflux Product
† 
             
NaN3 10 467 DMF 110
o
C/ 24h n.r 
NaN3 10 467 DMSO 150
o
C/ 24h n.r 
NaN3
#
 20 467 DMF 110
o
C/ 24h n.r 
TMS-N3 10 467 DMF 110
o
C/ 24h n.r 
TMS-N3 10 467 DMSO 150
o
C/ 24h n.r  
*Reaction monitored by TLC and ESI-MS analysis. 
†
Predominantly starting material was recovered after completion of each reaction run, with minor degradation 
evident (n.r = no reaction). 
#
In
 
the presence of a catalytic amount of activated azide donor reagent, TMS-N3 (trimethylsilyl azide). 
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               468                                       477                                                               475 
Scheme 4.9 
 
4.4 Formation of β-ketoesters 
 
At the outset of this work, an optimal retrosynthetic strategy was investigated for assembly 
of novel 5 and 6-membered H-bonding frameworks 441 as new analogues of bioactive BIMs 
(c.f. Section 4.1).  
 
 
 
 
 
 
                             441                                                                   R1 = OH; R2 = OCH3 478 
 
 
 
 
 
                                                                                         479                          480 
Fig. 4.2: Retrosynthetic strategy employed for design of novel indolocarbazoles 
 
Initial investigation revealed that modification of pre-existing, classical indolocarbazole 
routes was impractical; a new strategy was devised, gaining access to advanced dicarbonyl 
precursors, prior to ring condensation and formation of the central carbocyclic ring, as final 
steps (Fig. 4.2). This putative route was also deemed attractive as a versatile method for the 
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preparation of unsymmetrically substituted indolocarbazoles, which are of keen interest 
within the research group. Chemical studies carried out to fully validate bi-nucleophile 
addition to an β-ketoester intermediate 478, formed by condensation between 480 and 479, 
as a viable new route to a panel of novel 5,6-bisindolylpyrimidin-4-ones will now be 
discussed. 
 
4.4.1 Esterification of indole-3-acetic acid (IAA)  
 
Starting from the commercially available indole-3-acetic acid 233, the one-pot preparation of 
the N-methyl protected methyl indole-3-acetic acid ester 480, as a dark yellow oil, was 
achieved in satisfactory yield of 82%, via use of dimethyl carbonate as methylating agent, 
along with potassium carbonate, stirred in dry DMF, at 130
o
C overnight.
30
 
 
The conditions for this reaction were reported by Zhang et al.
 
as a clean, efficient method, 
which avoided the use of toxic dimethyl sulfate or iodomethane, and avoided a two-step 
esterification/protection strategy.
30
 The literature conditions were initially optimised, as a 
stoichiometric amount of potassium carbonate was used in our case, rather than the 50 mol% 
reported (due to reduction of yields of 480 to 45-50%, when those conditions prevailed), and 
the reaction time, at 130
o
C, was extended from 3 to 20 hours, in order to maximise 
conversion to the desired ester 480. It was also determined that methyl indol-3-yl acetate 239 
was formed as a recyclable side-product, in a proportion that could be minimised to 
approximately 10%, by employing 233 along with 3 equivalents of dimethyl carbonate 
(Scheme 4.10). 
 
 
 
 
 
 
                                    233                                                   239                        480 
    
 
 
 
Reagents and conditions: (i) K2CO3, (CH3)2CO3, DMF, 130
oC, 12h, 480 = 82%, 239 = 10%; (ii)(a) SOCl2, 
MeOH, -65oC – rt, 16h, 239 = 99%; (b) NaH, MeI, DMF, 0oC – rt, 16h, 480 = 92%  
 
Scheme 4.10 
 
The corresponding two-step sequence to the protected ester 480 involved reaction of acid 
233  and thionyl chloride, in distilled methanol at −65oC for one hour, prior to warming to 
20
o
C overnight, to form mono O-methylated 239 as a violet oil in a yield of 99%. 
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Alternatively, when this reaction was attempted at room temperature for 3 hours, a small 
amount of starting material persisted, leading to a poorer overall product profile. 
Intermediate 239 was then reacted with NaH, at 0
o
C, followed by addition of iodomethane, 
in dry DMF; stirring of the light green mixture at room temperature yielded ester 480, 
isolated by chromatography, in an overall yield of 90% (Scheme 4.10).
31
 
 
4.4.2 Synthesis of indole-3-carbonyl chloride  
 
Following a series of literature preparations, synthesis of N-methyl indol-3-yl carbonyl 
chloride 479 began with the standard Vilsmeier-Haack formylation of indole 171 at the C-3 
position, carried out by the addition of a solution of indole 171 in DMF at 5
o
C to a mixture 
of POCl3 and DMF cooled to 0
o
C for 35 minutes. Following successive basification and 
acidification steps, the light orange crude indole-3-carboxaldehyde 121 was filtered and 
recrystallised as light-yellow needles, from a mixture of DMF/H2O in a yield of 79% 
(Scheme 4.11). Formation of 3-cyanoindole 481 was carried out by reaction of aldehyde 121 
with hydroxylamine hydrochloride, in DMF, at 90
o
C, for 15 minutes (61%).
32
 However, 
derivative 481 could not be hydrolysed to the acid 482, following heating under a range of 
strongly basic or acidic conditions, as determined by IR spectroscopy. 
 
 
 
                     171                          121                         481                                   482    
 
 
 
 
 
                       456                                          483                                      484 
Reagents and conditions: (i) POCl3, DMF, 0
oC - 45oC, 2h, 121 = 79%; (ii) NH2OH.HCl, DMF, 130
oC, 16h, 
481 = 61%; (iii) OH- or H+, Δ, 16h, n.r; (iv) K2CO3, (CH3)2CO3, DMF, 130
oC, 12h, 456 = 88%; (v) NaH/ MeI, 
DMF, 0oC - rt, 16h, 483 = 92%; (vi) POCl3, DMF, 0
oC - 45oC, 2h, 483 = 28%; (vii)(a) 40% aq. KMnO4, 
acetone, rt, 16h; (b) H2O2, 484 = 83% 
 
Scheme 4.11 
 
As an alternative strategy, initial N-methylation of 121 was accomplished by NaH/MeI 
reaction, in order to afford N-methyl indol-3-yl carboxaldehyde 483 as a viscous dark oil 
(92%). The synthesis of this precursor 483 was also successful following treatment of indole 
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171 with potassium carbonate along with dimethyl carbonate, in DMF at 130
o
C for 5 hours, 
to provide N-methyl indole 456, as a dark brown oil, in a yield of 88%. Formation of 483 
could then be achieved by direct 3-formylation of 456, under Vilsmeier-Haack conditions, in 
a yield of 28% for this step.
32
 Oxidation of aldehyde 483 to the corresponding N-methyl 
indol-3-yl carboxylic acid 484 was attempted with sodium chlorite, stirred in 1,4-dioxane 
overnight, in the presence of TBAB, but this yielded only starting material 483 after 24 
hours (Scheme 4.11).
33
  
 
Fortunately, on stirring of aldehyde 483 with a 40% aqueous solution of potassium 
permanganate in acetone at 35
o
C for 20 hours, a dark mixture was obtained, from which N-
methyl indol-3-yl carboxylic acid 484 was filtered as an off-white powder (83%), following 
acidic work-up and readily identified by its characteristic IR carbonyl stretch at 1750 cm
-1
. 
Unfortunately, this reaction worked well at sub-gram scales but was not amenable to up-
scaling, due to the use and disposal of large potassium permanganate/hydrogen peroxide 
volumes and subsequent low yields of product. 
 
Synthesis of N-methyl indol-3-yl carbonyl chloride 479, from 484, in quantitative yield, was 
reported by Braña and co-workers, employing 20 equivalents of thionyl chloride as solvent, 
along with stirring of 484 for 24 hours, at ambient temperature (Scheme 4.12; Method A).
34
 
Under these conditions, an unusual chlorine fragmentation pattern in the mass spectrum of 
the resultant crude acid chloride 479 was observed, consistent with incorporation of another 
chlorine atom at the C-2 indole position. According to a literature procedure, this N-methyl 
2-chloro indol-3-yl carbonyl chloride 485 derivative could be synthesised by heating of 484 
in neat thionyl chloride, at 80
o
C for 24 hours prior to evaporation to a light red residue.
34
 The 
appearance of this 2-chloro impurity 485, in addition to 479, at room temperature, in our 
work, suggests that regioselective temperature control of this step may be more problematic 
than initially proposed.  
 
 
 
 
 
 
 
 
                                 484                                              479                                 485 
 
Reagents and conditions: Method A: (i) 20 eq. SOCl2, rt, 24h, 479+485 = 99%; Method B: (ii) 1.1 eq. 
COCl2, DCM, rt, 1.25h, 479 = 99% 
Scheme 4.12 
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Future work in the research group may focus on the synthetic applications of this useful 
intermediate 485 as both an electrophile and novel halo-aryl substrate for palladium-
mediated arylation chemistry.
35,36
 In any case, this desired transformation was finally 
achieved under mild conditions, when the procedure of Hutchins et al. was adopted; 484 was 
thus successfully converted to 479, abolishing any side-formation of 485, in quantitative 
yield (99%), following stirring with oxalyl chloride in dry DCM, at room temperature, for 75 
minutes (Scheme 4.12; Method B).
37
 The resultant pink solid residue was used successfully 
in further reactions without any purification, and was identified by its characteristic IR 
carbonyl stretch which was altered from that in acid 484 to 1850 cm
-1
.   
 
4.4.3 Synthesis of 2,3-bisindolyl methyl-3-oxopropionate  
 
Construction of the novel advanced β-dicarbonyl intermediate 478 was achieved via the α-
deprotonated ester of 480,
 
which underwent modified Claisen reaction with 479 to yield the 
corresponding β-ketoester 478 (Scheme 4.13).  
 
 
 
                                                  479 
  
                                                                                                                                   486 
 
          480                                                                 478 
 
Scheme 4.13 
 
A solution of the methyl ester 480 was slowly charged to a flask containing 2.2 equivalents 
of LDA in dry THF, maintained at −78oC; the resultant α-anion remained stable in situ at 
this temperature, while the dark mixture was allowed to stir for 90 minutes to ensure full 
deprotonation had occurred. Formation of the self-condensation side-product 486, was 
effectively suppressed under these conditions, but it was observed that if an unreactive or 
poorly soluble electrophile was present under identical conditions, 486 could be detected in 
low yields (<10%). Fortunately, no solubility issues were encountered with acid chloride 
479, and a solution of 479 in THF was added dropwise over several minutes to the reaction 
vessel, while maintaining an internal temperature of below −65oC. The dark mixture was 
allowed to warm to room temperature over 16 hours, at which point the desired β-ketoester 
478 was formed exclusively, in the absence of any starting 480. Following work-up and 
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chromatography, product fractions were combined and evaporated to form a brown foam, 
which upon drying afforded title compound 478 as a golden crystalline solid (Scheme 4.13).  
 
The optimisation protocols developed for this process are outlined below in Table 4.2. 
Following work carried out to investigate the conditions for this route, the anticipated 
reaction yield for this step was increased from 53%, as recently described for analogous 
literature conditions, to 80%.
34
 
 
 Table 4.2: Optimisation study of conditions employed in formation of 2,3-bisindolyl 
alkyl-3-oxopropionate (478)*   
 
Reaction property Original conditions (lit.)
34
 Optimised conditions 
Acid chloride 479 formation SOCl2, rt, 24h (COCl)2, DCM, rt, 1.25h 
Ester 480 deprotonation; <-70°C 1h 1.5h 
Initial reactant concentration
#
 1 mmol: 4 mL THF 1 mmol: 1.8 mL THF 
Aq. reaction quench (work-up) H2O NH4Cl/ H2O 
Rate of acid chloride addition
‡
 1.1 eq./ 30 min 1.3 eq./ 15 min 
Chromatographic purification 30% ethyl acetate/ 70% hexane 10% - 100% ethyl acetate 
 
* Reaction successfully performed up to 10 g scale (480); optimal yield (80%): 6 g ester 480. 
# Dilution of N-methyl methyl indole-3-acetic acid ester 480 in initial volume of THF, prior to addition of LDA. 
‡Added as acid chloride 479 (1 g)/7 mL THF, based on full conversion of N-methyl indole-3-carboxylic acid 
484. 
 
 
4.4.5 Attempted reductive amination 
 
A number of reactions were carried out in order to convert β-ketoester 478 to its 
corresponding β-enaminoester 487, via imine formation. Reaction of 478 with 10 equivalents 
of ammonium acetate in dry ethanol, was carried out in the presence of 1.1 equivalents of 
tetraethyl orthosilicate – a Lewis acid catalyst and water scavenger, shifting the equilibrium 
position of this reaction towards β-enaminoester 487 formation. Unfortunately, following 
heating for 24 hours, only starting material 478 could be detected (Scheme 4.14).  
 
Similarly, reaction of 478 with 10 equivalents of ammonium acetate, stirred in ethanol, in the 
presence of 3 equivalents of sodium triacetoxyborohydride for 16 hours at reflux, afforded 
none of the reduced β-aminoester 488. Reaction with benzylamine under identical reductive 
amination conditions, yielded only starting material 478, in the absence of anticipated 489, 
following heating for 24 hours. 
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                             490                                                                                             489     
Reagents and conditions: (i) 10 eq. NH4OAc, 1.1 eq. Si(OEt)4, EtOH, N2, Δ, 24h; (ii) 10 eq. NH4OAc, 3 eq. 
NaBH(OAc)3, EtOH, N2, Δ,  16h; (iii) 10 eq. Bn-NH2,  3 eq. NaBH(OAc)3, EtOH, Δ, 16h; (iv) 10 eq. Bn-NH2, 
1.1 eq. Si(OEt)4, EtOH, Δ, 24h 
Scheme 4.14 
 
Interestingly, when β-ketoester 478 was heated in neat benzylamine along with a catalytic 
amount of tetraethyl orthosilicate overnight in order to produce 490, starting material 478 
was fully consumed, along with appearance of a dark brown, fluorescent material with a 
significantly higher Rf value (Scheme 4.15). This property was consistent with incorporation 
of aromatic substituents and corresponded to formation of the dibenzyl protected analogue 
491, as confirmed by HRMS analysis (m/z = 525).  
 
 
 
 
 
 
 
 
 
                       478                                              491                                               492 
 
Reagents and conditions: 1 eq. Si(OEt)4, Bn-NH2, 120
oC, 16h, 491 = 50%; (ii) 1 eq. (CCl3)2CO3, DCE, 80
oC, 
24h; (iii) NH2CONH2, 170
oC, 20h   
 
Scheme 4.15 
 
Unfortunately, β-enaminoamide 491 could not be isolated pure, as a result of its 
decomposition during silica gel chromatography. Reaction of crude 491 with 1 equivalent of 
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triphosgene (a safer, solid alternative to the use of gaseous phosgene), in 1,2-dichloroethane, 
at 80
o
C, for 24 hours, could not successfully form any of the desired 1,3-benzylated uracil 
analogue 492.
38
 Reaction of 491 under solvent-free conditions along with urea at 170
o
C 
similarly yielded only decomposition products. However, future applications of this 
approach to related systems may provide an accessible route to new compounds. Application 
of new electrophiles and further investigation of the stability of these enaminoamide 
synthetic intermediates will also be necessary.   
4.4.6 Synthesis of methyl 3-chloro-2,3-bisindolylacrylate  
 
In order to modulate the apparent limited reactivity of the ketoester nucleus, a strategy was 
adopted whereby 478 was converted to novel β-chloroacrylate 493, formed as an inseparable 
mixture of E and Z-isomers as identified by NMR analysis, in a yield of 65%, following 
reaction with PCl5, in DMF overnight at 110
o
C (Scheme 4.16).  
 
As the stated synthetic goals necessitated introduction of heterocyclic character into an 
advanced bisindolyl precursor, modification of this intermediate 493 was attempted by 
heating with benzylamine to form 490 or thiourea in order to afford 494; however, only 
starting material 493 could be recovered in each case. Reactivity at the β-chloro site is 
postulated to be diminished due to the bulk steric effects of both indolyl substituents 
blocking access to the electrophilic sp
2
 carbon centre. Future work will also employ superior 
nucleophiles in order to maximise reactivity. In this regard, utilisation of reactants such as 
hydrazine or azide may proffer distinct advantages in pursuing the full potential of this route.     
 
 
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                     
                                                                                                                                                 490 
 
 
 
 
                            478                                            493 
 
 
 
 
                                                                                                                                                 494 
 
Reagents and conditions: (i) 1.5 eq. PCl5, DMF, 110
oC, 20h, 493 = 65%; (ii) 5 eq. Bn-NH2, Et3N, EtOH, 
reflux, 24h; (iii) 2.2 eq. NH2CSNH2, Et3N, EtOH, reflux, 24h   
 
Scheme 4.16 
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4.5 Cyclocondensation with urea 
Employing urea as a primary nucleophile, conditions for corresponding uracil synthesis were 
studied under a range of conditions, in the presence of electrophilic bisindolyl derivatives. 
As discussed, solvent-free thermal heating of urea along with β-enaminoamide 491 was 
unsuccessful, and thus, similar conversion of dicarbonyl intermediates by efficient 
microwave heating, and thermal heating of urea in the presence of base were investigated.    
4.5.1 Attempted microwave-mediated synthesis of uracils 
 
The primary method for converting a nominal alkyl β-ketoester 495 to the corresponding 
pyrimidin-2,4-dione 496 moiety involves exposure of the substrate to either urea or thiourea, 
in the presence of sodium alkoxide in alcohol, and heating of this mixture for an extended 
period.
39,40
 Microwave-assisted organic synthesis (MAOS) represents a recent alternative to 
conventional (convection) heating, and constitutes an important new methodology in the area 
of heterocycle synthesis, with a major advantage deriving from efficient thermal heating and 
enhanced concentration effects. Therefore, yields and impurity profiles can be improved 
across a range of reaction types, while reaction times are also typically short. In 2002, it was 
first reported that simple β-ketoester 495 precursors could be transformed directly to the 
respective 5,6-alkyl substituted uracils 496 by conventional microwave irradiation in the 
presence of urea, under solvent-free conditions.
41
  
 
Unfortunately, successful reaction conditions could not be easily prescribed for development 
of a robust, versatile microwave protocol, due to the quite disparate nature of the 5,6-alkyl 
substituents in the study by Mojtahedi et al., and so the versatility of this technique to allow 
formation of 5,6-bis(aryl) pyrimidin-2,4-diones such as 464 remains uncertain.
41
 497-498 
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         499                                                         497                                                           500 
 
Scheme 4.17 
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Preliminary data indicates that this method may be fruitful, but possesses critical limitations 
including thermal decomposition, low electrophilic reactivity and poor reaction 
reproducibility.  
In order to validate this microwave route, the synthesis of novel 3,4,5-trimethoxyphenyl 
ethyl 3-oxoalkanoate 497 was carried out and its reactivity under trial microwave conditions 
was investigated. Following initial KOH-mediated conversion of diethyl malonate to 
potassium monoethyl malonate 498, 2 equivalents of this salt were then stirred at 15
o
C in 
acetonitrile, along with triethylamine and anhydrous magnesium chloride, at which point the 
suspension was warmed to room temperature and maintained for 2.5 hours. The resultant 
milky slurry was cooled to 0
o
C and a solution of 3,4,5-trimethoxybenzoyl chloride 499 in 
acetonitrile was added dropwise over 15 minutes. Following further triethylamine addition, 
the reaction mixture was then stirred for 20 hours at room temperature. Following acidic 
work-up, novel β-ketoester 497 was isolated as an off-white solid in a yield of 71% (Scheme 
4.17). 
 
Employing harsh microwave conditions, intermediate 497 was pre-mixed with 5 equivalents 
of urea, and heated under solvent-free conditions, at a power level of 300W, at 170°C for 25 
minutes, including a 5 minute ramp time. On completion, the resultant urea „melt‟ was 
dissolved in water; the resultant white crystalline precipitate was then filtered and washed 
with diethyl ether in order to fully eliminate starting material 497. Following 
recrystallisation from absolute ethanol, novel 6-(3,4,5-trimethoxyphenyl)uracil 500 was 
successfully isolated in high purity, as an off-white crystalline solid, in a moderate yield of 
20% (Scheme 4.17).  
4.5.2 Reaction of urea with β-ketoesters in routes to 5,6-bisindolyluracils 
   
Following this initial success, synthesis of a novel bisindolyl β-ketoester derivative 501 
containing labile protecting groups was carried out, as an analogous substrate for pyrimidin-
2,4-dione ring formation. Ethyl indol-3-yl acetate 502 was simply derived from the 
corresponding indole-3-acetic acid 233, which was initially stirred in dry ethanol, in the 
presence of thionyl chloride, at -60°C, and then allowed to warm to 20
o
C overnight. 
Protection of the indolic nitrogen of ester 502 was then completed under phase-transfer 
conditions. Conversion to N-carbamate ester 503, was accomplished by treatment with 
aqueous NaOH in DCM, in the presence of ethyl chloroformate, along with catalytic TBAB, 
and then stirred at 0
o
C for one hour, prior to warming to room temperature overnight. The 
crude residue was then purified to afford 503 as a colourless oil in 76% yield (Scheme 
4.18).
42
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                                                                              503                                                                                
            
                               233 
                               502 
                                                                                                                                                 
                                                                                                                                                       501 
                                                                                                                  504 
 
            171                         505  
 
Reagents and conditions: (i) SOCl2, dry EtOH, -78
oC - rt, 16h, 502 = quant; (ii) 1.1 eq. ClCO2Et, 30% aq. 
NaOH, cat. TBAB, DCM, 0oC - rt, 16h, 503 = 76%; (iii) 1.5 eq. p-TolSO2Cl, 50% aq. NaOH, 0.2 eq. TBAHS, 
toluene, 0oC - rt, 16h, 505 = 96%; (iv) 3 eq. (COCl)2, 1 eq. AlCl3, DCM, 0
oC - 20oC, 3h, 504 = quant; (v) 2.2 
eq. 1.8M LDA, 504, THF, -78
o
C - rt, 20h, 501  = 25%. 
  
Scheme 4.18 
 
Synthesis of N-toluenesulfonyl indole-3-carbonyl chloride 504 required initial formation of 
p-toluenesulfonyl indole 505, by addition of a 50% aqueous NaOH solution to indole 171, 
which was stirred in toluene, in the presence of TBAHS. p-Toluenesulfonyl chloride was 
then added to the mixture at 0
o
C, prior to stirring at room temperature overnight. On work-
up, p-toluenesulfonyl indole 505 was identified by means of its characteristic IR 
spectroscopic SO2 bond stretches at 1168 and 1379 cm
-1
 and was isolated as a light pink 
solid in a yield of 96%. Under Friedel-Crafts conditions, acid chloride 504 was formed 
quantitatively, upon addition of 505 to a mixture of 3 equivalents of oxalyl chloride and 
AlCl3 stirred at 0
o
C and stirring of the subsequent black suspension for a further 3 hours at 
room temperature. The crude acid chloride 504 was isolated as a viscous brown oil following 
work-up, and was used directly in the following step (Scheme 4.18).
43,44
 
  
The corresponding bisindolyl β-ketoester 501 was isolated as a light brown crystalline solid 
in a yield of 25%, by reaction of precursors 503 and 504 under optimised Claisen conditions, 
followed by ammonium chloride quench. Purification of crude 501 could be effected either 
by ethyl acetate/ hexane column chromatography or by direct crystallisation from a mixture 
of 95% ethanol and water.   
 
Unfortunately, the success of microwave reaction for simple alkyl (495) and monoaryl (497) 
compounds to afford corresponding pyrimidine-2,4-diones 496 and 500 respectively, could 
not be replicated for 501 following solvent-free microwave heating with urea at 150
o
C for 20 
minutes (Scheme 4.19). The dark brown reaction „melt‟ was not found to contain any uracil 
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506, but a mixture of starting material and assorted decomposition products formed by loss 
of the cleavable carbamate and tosyl N-protecting groups. The desired transformation also 
did not occur when these reactants were subjected to conventional heating at reflux for 16 
hours in ethanol, in the presence of excess sodium ethoxide. Alternatively, microwave 
irradiation of 478 in the presence of 10 equivalents of urea avoided certain limitations due to 
incorporation of very stable N-methyl groups, but also failed to yield any trace of the 
anticipated pyrimidin-2,4-dione product 507 (Scheme 4.19).     
 
Unfortunately, application of p-TSA and camphoric acid, in order to activate the reactant 
towards nucleophilic urea attack also failed to yield benefits for this microwave synthesis. 
 
 
 
 
 
 
 
 
                                                       501                                               506 
 
 
 
 
 
 
 
 
                                                       478                                                 507 
 
Reagents and conditions: (i) 10 eq. NH2CONH2, 300W, 160
oC, 20 min (W); (ii) 10 eq. NH2CONH2, 300W, 
160
o
C, 2.2 eq. camphoric acid, 20 min (W); (iii) 10 eq. NH2CONH2, 2.2 eq. p-TSA, 300W, 160
o
C, 20 min 
(W); (iv) 10 eq. NH2CONH2, NaOMe, MeOH, reflux, 16h 
 
Scheme 4.19 
 
Under forcing microwave conditions, heating of excess urea along with 478 and 2.2 
equivalents of acid resulted in only decomposition in each case, and it was evident that under 
harsh conditions, side-reactions predominate over the desired cyclisation process (Scheme 
4.19). Interestingly, reaction of an alternative protected β-ketoester 508, derived from base-
mediated reaction of 479 and 503 (with reduced conformational and steric bulk compared to 
501) employing optimised microwave settings, with 10 equivalents of urea and 2.2 
equivalents of p-TSA, under solvent-free conditions resulted in isolation of a trace amount of 
the desired uracil derivative 509, as identified by mass spectroscopic analysis, along with 
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disappearance of the characteristic β-ketoester α-proton in the crude 1H spectrum in the 
region of 5.7 ppm (Scheme 4.20). 
  
This reaction has been found to be relatively non-reproducible, largely due to the capricious 
nature of a „reaction melt‟, and whether these intense conditions can suppress decomposition 
pathways relative to attractive product formation. Future work in this area will optimise 
individual reaction parameters in order to yield a single-step, versatile and robust method for 
gaining access to novel heterocyclic analogues, following this template. In the next section, 
the thermal reactivity of more nucleophilic bidentate nitrogen nucleophiles will be 
thoroughly explored, in the context of fully realising the rich potential of transformations of 
this type.  
 
 
 
                                                        479 
 
 
 
 
                   503                                                             508                                                 509 
 
Reagents and conditions: (i) 2.2 eq. 1.8M LDA, THF, -78oC - rt, 20h, 508 = 34% (ii) 10 eq. NH2CONH2, 2.2 
eq. p-TSA, 300W, 160oC, 20 min (W) 
 
Scheme 4.20 
 
4.6 Other cyclocondensations in routes to bisindolyl heterocycles
45
 
   
In pursuit of the synthesis of new bioactive 1,2-bisindolyl-cis-ethene heterocycles with novel 
bridgehead functionality (general structure 441), development of cyclocondensation 
chemistry involving bisindolyl dicarbonyl intermediate 478 was deemed highly attractive. 
Following initial indication of the poor reactivity of urea as a potential nitrogen nucleophile, 
comprehensive studies into the utility of a panel of substituted urea analogues to produce 
novel conversions of this type were undertaken (Fig. 4.3).  
 
 
 
 
 
 
                                   478                                                                   441 
Fig. 4.3 
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4.6.1 Reaction with hydrazines 
4.6.1.1 Synthesis of pyrazolone derivatives 
 
During the course of this work, conditions for the efficient synthesis of 4,5-bisindolyl 
pyrazol-3-one 510 from reaction of the ethyl ester derivative of 478 with hydrazine were 
reported by Braña and co-workers, following their research into potential anti-cancer activity 
within N,N-diethylaminoalkyl O-substituted analogues derived from Mitsunobu reaction of 
parent diarylpyrazolones.
34
 As an initial test reaction in our study, β-ketoester 478 was 
stirred along with hydrazine hydrate and camphoric acid, at reflux temperature for 3 hours, 
prior to addition of excess hydrazine hydrate and subsequent heating for 21 hours. 
Chromatography afforded the fluorescent, polar pyrazolone product 510 as a grey crystalline 
product in a yield of 68%. The N,O-cycloalkylated product 511 was synthesised in 57% 
yield under mild conditions following treatment of 510 in 1,4-dioxane, containing potassium 
carbonate, 1,2-dibromoethane and TBAB, at 30
o
C for 20 hours.
46
 Novel heterocyclic 
derivative 511 was then isolated as a pale yellow solid yield of 55% (Scheme 4.21). 
 
 
 
 
 
 
 
                           478                                             510                                           511 
 
Reagents and conditions: (i) 4 eq. NH2NH2.H2O, 1 eq. camphoric acid, MeOH, reflux, 24h, 510 = 68%;  
(ii) 2.5 eq. K2CO3, 1.2 eq. BrCH2CH2Br, 1,4-dioxane, 30
oC, 20h, 511 = 57%  
 
Scheme 4.21 
 
Reaction of β-ketoester 478 with phenylhydrazine under identical conditions resulted in 
successful formation of an inseparable isomeric mixture of novel N-phenyl substituted 
pyrazolone analogues (512, 513) in overall 65% yield, with product distribution under 
thermodynamic control. NMR studies illustrated that compounds 512 and 513 were formed 
in the ratio of approximately 2:1, under these reaction conditions (Scheme 4.22).   
 
 
 
 
                   478                                                         512                                      513 
Scheme 4.22 
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4.6.2 Reaction with thiourea  
4.6.2.1 Formation of 5,6-bisindolyl-2-thiopyrimidin-4-one 
 
As a landmark reaction, 2,3-bisindolyl methyl-3-oxopropionate 478 was successfully 
converted, in the presence of methanolic sodium methoxide (10 equivalents) and excess 
thiourea (5 equivalents), to the corresponding novel thiouracil 514, following reflux for 24 
hours. On solvent removal, the crude gummy residue was suspended in water and acidified 
to pH 3 with 10% aq. HCl solution. Gravity filtration of the resultant aqueous slurry was 
inefficient and time-consuming, due to the gummy nature of the dark-orange precipitate. 
Fortunately, it was subsequently observed that decanting of the supernatant layer in place of 
filtration was successful, even on multi-gram scale (Scheme 4.23). 
 
 
 
 
 
          233                               480 
 
 
                                                                 
                                                                                 478                                           514 
 
 
 
         484                                  479 
 
Reagents and conditions: (i) 1 eq. K2CO3, 3 eq. (CH3)2CO3, DMF, 130
oC, 12h, 480 = 82%; (ii)(a) 1.1 eq. 
(COCl)2, DCM, 75 min, 479 = 100%; (iii)(a) 2.2 eq. LDA, 1.5 eq. 479, THF, -78
oC - rt, 16h, (b) NH4Cl/ H2O, 
478 = 80%, (iv) 10 eq. NaOMe, 5 eq. NH2CSNH2, MeOH, reflux, (b) 10% HCl, 514 = 24%. 
   
Scheme 4.23 
 
Initial purification of target compound 514 could be achieved by chromatography employing 
DCM/methanol as eluent. Fortunately, in the course of process optimisation, it was found 
that trituration of crude 514 with boiling absolute ethanol, prior to cooling to 35
o
C, obviated 
any need for chromatography, and novel 514, could be isolated pure, as a pale yellow 
powder, following filtration of the dark brown slurry and washing with diethyl ether 
(Scheme 4.23). The overall yield for this reaction was found to be 20-24%, irrespective of 
whether the reaction time was extended to 72 hours or if a larger excess of base (20 
equivalents) was employed.  
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4.6.2.2 Derivatisation of 5,6-bisindolyl-2-thiopyrimidin-4-one 
 
In order to resolve principal difficulties associated with the poor organic solubility of the 
parent thiopyrimidinone 514, it was established that a panel of alkylated analogues could be 
synthesised under extremely mild phase-transfer conditions (Scheme 4.24).
46
  
 
Reaction of title compound 514 with iodomethane in methanol stirred at 30
o
C, in the 
presence of potassium carbonate isolated sulfide 515 as a straw-coloured powder in a 
moderate yield of 35% following chromatography. 516-517 
 
 
515, 518 
 
 
 
 
 
                   516                                            514                                            515 
 
 
 
 
 
 
 
 
 
                  517                                               518 
 
Reagents and conditions: (i) 1.2 eq. CH3I, 1.5 eq. K2CO3, MeOH, 30
oC, 20h, 515 = 35%; (ii) 1.1 eq. 
Br(CH2)2Br, 3 eq. K2CO3, cat. TBAB, 1,4-dioxane, rt, 16h, 516 = 66%; (iii) 20 eq. m-CPBA, DCM, reflux, 
72h; (iv) 1.5 eq. (CH3CO)2O, C6H5N, 90
o
C, 20h 
Scheme 4.24 
 
Thiouracil 514 was also reacted with 1,2-dibromoethane in the presence of potassium 
carbonate and TBAB, for 16 hours, at room temperature, to yield thiazolo[3,2-a]pyrimidin-
5-one 516; this was identified to be the S,N-dialkylated derivative due to the characteristic 
amide carbonyl absorption occurring at 1644 cm
-1
. Following washing of the crude residue 
with hexane in order to remove unreacted 1,2-dibromoethane and crystallisation with 95% 
ethanol, 516 was isolated as an amorphous yellow powder in 66% yield. Attempted 
oxidation of 516 to the sulfone 517 following reaction in DCM, in the presence of excess m-
CPBA did not proceed even after 3 days at elevated temperature.  
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The thioacetylated compound 518 could not be formed, perhaps due to instability and in situ 
deacetyation of the initially formed derivative, following heating of parent thiouracil 514 
with acetic anhydride in pyridine, at 90
o
C. 
 
Interestingly, the corresponding synthesis of a lactam derivative 519 by reaction of 514 with 
chloroacetyl chloride 520 under identical conditions as for synthesis of 516, was 
unsuccessful. Similarly, reaction of ethyl bromoacetate failed to form any of the anticipated 
thiazolidinone 519, but instead afforded the novel bisalkylated congener 521 (Scheme 4.25, 
(ii); X = OEt) in a yield of 45%. Employing this insight, synthesis of the S,N-bisacetamido-
thiouracil 522 (Scheme 4.25, (ii); X = NH2), was also effected in a yield of 40%, following 
reaction of 514 with α-chloroacetamide 523, a light beige solid, initially prepared by 
treatment of chloroacetyl chloride 520 with aqueous ammonia, for 16 hours. 
 
 
 
 
 
 
 
                       519                                           514                                      521              522                                                                              
 
Reagents and conditions: (i) 2.2 eq. ClCH2COCl (520), 3.5 eq. K2CO3, cat. TBAB, 1,4-dioxane, rt, 16h, (ii) 
2.2 eq. BrCH2CO2Et or ClCH2CONH2 (523), 3.5 eq. K2CO3, cat. TBAB, 1,4-dioxane, rt, 16h , 521 = 45%, 522 
= 40%  
 
Scheme 4.25 
 
4.6.3 Thiouracil derivatisation routes to 5,6-bisindolylpyrimidin-2,4-dione  
 
Chemistry was undertaken in order to convert thiouracil 514, to the attractive pyrimidine-
2,4-dione or uracil ring system 507, which is present in several drug families, e.g. pyrimidine 
anti-metabolites and barbiturates, and whose design was envisaged as a bioisosteric 
replacement of the lactam ring/imide motifs (Section 3.0, Aims and Objectives).
47-52
 
Surprisingly, as far as we are aware, this was the first investigation of the necessary 
conditions for converting a 5,6-bis(heteroaryl)-2-thiopyrimidin-4-one substrate to the 
corresponding 5,6-bis(heteroaryl)pyrimidin-2,4-dione. This transformation involved 
considerable optimisation, with solvent choice being critical; the issue of reaction 
heterogeneity impaired this process until the final resolution was achieved. A summary of 
some oxidative conditions which were investigated for this transformation, and the results of 
these runs are outlined in Table 4.3. 
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Table 4.3: Study of conditions for conversion of 2-thiopyrimidin-4-one (514) to 
pyrimidin-2,4-dione (507)  
 
 
 
 
   
                         514                                                   507 
                                                                
 
Reagent 
 
Quantity 
 
Solvent 
 
Conditions 
   Product formation 
514 507 
ClCH2CO2H 10% w/v H2O 72h/ reflux √ √ 
ClCH2CO2H 10% w/v AcOH 72h/ reflux √ √ 
ClCH2CO2H 10% w/v DMF 72h/ 110
o
C √ √ 
ClCH2CO2H 
aq. H2O2 
5 eq. 
30% w/v 
MeOH 
H2O 
72h/ reflux 
20h/ 70
o
C 
√ 
√ 
- 
- 
BrCH2CO2Et 
BrCH2CO2Et 
1.1 eq. 
1.5 eq. 
MeOH 
DMF 
20h/ reflux 
24h/ 110
o
C 
- 
√ 
17% 
- 
BrCH2CO2Et 2.5 eq. MeOH/H2O 48h/ reflux - 45% 
 
Based on previous literature, this conversion, known as oxidative desulfurisation, is known 
to be carried out under aqueous oxidative conditions, in the presence of 10% w/v 
chloroacetic acid, at high temperatures, to routinely convert simple 5,6-alkyl substituted  
thiouracils to the corresponding uracils in moderate to excellent yields.
53
 Unfortunately, 
aqueous chloroacetic acid could not effect full conversion of thiouracil 514 to the desired 
pyrimidin-2,4-dione 507, even with a prolonged reflux of 72 hours. In most cases, only 
inseparable product mixtures were formed – displaying a set of characteristic peaks from 13C 
NMR corresponding to both compounds, thiouracil (514): 161.3 and 174.3 ppm, and uracil 
(507): 151.1 and 164.3 ppm, and also confirmed by mass spectrometry (see Section 4.8). It 
was postulated that heterogeneous conditions prevented full conversion of the sulfur 
analogue 514 to the desired 507, and even when solvent conditions were changed to increase 
thiouracil 514 solubility (DMF, methanol), the non-aqueous conditions then seemed to 
inhibit the oxidative desulfurisation process. Utilisation of 30% aqueous hydrogen peroxide 
as an alternative oxidant yielded only starting material following heating at 70
o
C overnight 
(Table 4.3).  
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However, following an intensive study, it was discovered that the use of a stoichiometric 
quantity of ethyl bromoacetate - an alternative α-haloacetic acid derivative and a liquid 
reagent at room temperature, in dry methanol, which was heated at reflux for 16 hours, 
yielded the product 507, exclusively, in a moderate yield of 17%, following recrystallisation 
from a mixture of DMF/H2O (5:1).
54
 This process was improved by heating 2.5 equivalents 
of ethyl bromoacetate in the presence of thiouracil 514, in methanol containing a few drops 
of water, for 48 hours. Following solvent removal, the residue was crystallised to yield uracil 
507 exclusively in an enhanced yield of 45% (Scheme 4.26).   
 
                                                                                                                79 
                                                                                                      
                 514                                                   507                                                               
Reagents and conditions: (i)(a) 2.5 eq. BrCH2CO2Et, MeOH, reflux, 48h, (b) H2O, 507 = 45%  
 
Scheme 4.26 
 
As an alternative strategy, the hydrolytic conversion of S-methylthiopyrimidin-4-one 515 to 
bisindolyluracil 507 was also attempted under similar conditions to those reported by Gibson 
et al. for chemistry carried out on a solid support (Scheme 4.27; Method A).
55
 Reaction with 
10 equivalents of oxone
®
 in aqueous 1,4-dioxane for 3 days at 70
o
C, involved the putative 
oxidation of sulfide 515 to its corresponding 4-sulfonyl derivative 524 prior to hydrolysis 
affording 507. Sulfone 524 would be envisaged to readily undergo hydrolytic cleavage as a 
result of the greater electrophilicity at the carbon centre (C-2), due to an inductive electron 
withdrawing effect. Unfortunately, no trace of sulfone 524 was detected following heating 
with oxone
®
 under these conditions and thus, subsequent hydrolysis to form 507 did not 
occur.  
 
According to the procedure of Lu et al., 515 was also heated along with aqueous 30% NaOH 
(Scheme 4.27; Method B) or 10% HCl (Method C); however, transformation to the 
corresponding pyrimidin-2,4-dione 507 did not occur and only starting material 515 could be 
isolated.
56
 Future work in this area should countenance that S-oxidation and hydrolysis be 
attempted in a stepwise manner, in order to fully elucidate the limitations of this strategy.   
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                     515                                                   524                                          507 
 
 
Scheme 4.27 
 
4.6.4 Reaction with guanidine carbonate 
 
Synthesis of 5,6-bisindolyl substituted 2-aminopyrimidin-4-one 445, constituted a highly 
interesting target with potential biological activity.
40,47
 As illustrated in Scheme 4.28, this 
novel bisindolyl-substituted isocytosine derivative 445 was produced from base-mediated 
cyclocondensation of guanidine - liberated in situ from the reaction of guanidine carbonate 
with excess sodium methoxide, with β-ketoester 478. The reaction contents were stirred 
under inert atmosphere, at reflux temperature, for 24 hours, followed by solvent evaporation, 
acidic work-up, filtration and careful chromatography employing DCM/methanol in order to 
elute title compound 445, in an overall yield of 45%. 
 
 
 
 
 
                              478                                                                                 445 
Scheme 4.28 
 
4.6.4.1 Derivatisation of 5,6-bisindolyl-2-aminopyrimidin-4-one 
 
A conventional diazotisation route was initially rationalised to introduce a hydroxyl group in 
place of aryl amine functionality within isocytosine derivative 445.
57
 Attempted reaction of 
the amino group of 445 with sodium nitrite/excess HCl, t-butyl nitrite/ acetic acid or t-butyl 
nitrite/ aqueous 2-propanol, to form a diazonium salt, yielded unreacted 445, in each case, 
following stirring overnight at 0
o
C and warming gradually to room temperature. Similarly, 
hydrolytic reaction of 445 with aqueous 10% HCl at 80
o
C for 7 days resulted in formation of 
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only decomposition products. Treatment of 445 with freshly generated nitrosylsulfuric acid 
under aqueous conditions at 70
o
C or heating of 445 with 40 equivalents of t-butyl nitrite in 
DMF at 100
o
C, also resulted in detection of a complex mixture of degradation material 
(Table 4.4). 
 
Table 4.4: Attempted diazotisation/ hydrolysis of bisindolyl-2-aminopyrimidin-4-one 
congener (445) to form uracil derivative (507)
 †
 
 
  
 
 
 
 
                        445                                          507 
                                                                   
 † In each case, reaction was performed on 150 mg scale. Qualitative 13C and ESI-MS analysis was used to 
determine product formation 
 
Exploration of the potent nature of subtle changes within the parent H-bonding framework to 
modulate key biological activity was also undertaken; a wide range of conditions for 
substitution of the isocytosine nucleus within 445 were assessed, as outlined in Table 4.5. 
The use of potassium carbonate/methanesulfonyl chloride (525), NaH/methanesulfonyl 
chloride (525) or NaH/methyl isothiocyanate (526) mixtures, in DMF at high temperature 
was observed to be ineffective. Reaction with acetic anhydride in pyridine provided the 
acetylated derivative 527, as an amorphous light yellow powder, in a yield of 35% (Table 
4.5). Interestingly, if pyridine was employed as solvent, sulfonamide 525 could not be 
formed following reaction with methanesulfonyl chloride. 
 
 
 
 
Reagent Amount Conditions Time Result 
NaNO2 5.0 eq. AcOH, 0
o
C - rt 20h S.M 
NaNO2 5.0 eq. 10% HCl/ H2O, 0
o
C - 70
o
C 24h S.M 
t-BuONO 5.0 eq.  AcOH, 0oC - rt 20h S.M 
t-BuONO 
[NO]HSO4 
5.0 eq. 
>100 eq. 
IPA/ H2O, 0
o
C - rt 
H2SO4/ H2O, 0
o
C - 70
o
C 
24h 
20h 
S.M 
decomp. 
t-BuONO 40 eq. DMF, 100oC 20h decomp. 
10% HCl >100 eq. H2O, 80
o
C 7d S.M 
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Table 4.5: Condition employed for attempted synthesis of N
2
-alkylated 5,6-
bisindolylisocytosine derivatives (525-531)  
 
 
 
 
 
 
                       445                                          525-531                                                    
                                                                       
† In each case, reaction was performed on 150 mg scale. Qualitative 13C and ESI-MS analysis was used to 
determine product formation 
 
However, reaction of isocytosine 445 with a mixture of trifluoroacetic anhydride and 
trifluoroacetic acid (5:1), stirred at 90
o
C for 20 hours, afforded the corresponding 
trifluoroacetamide 528 as light orange crystals in a yield of 45% following column 
chromatography. The importance of trifluoroacetic acid behaving as a catalyst, protonating 
the carbonyl group of trifluoroacetic anhydride, thus activating it towards nucleophilic 
attack, is illustrated by the lack of any reaction when trifluoroacetic anhydride was instead 
stirred with 445, in acetonitrile, containing a few drops of triethylamine, at 80
o
C for 24 
hours.  
 
A series of reactions with pharmaceutically relevant bidentate electrophiles in order to yield 
a library of cycloalkylated analogues were also unsuccessful in our hands. Employing 
efficacious conditions for aminopyrazole derivatisation (Section 4.9), the parent isocytosine 
445 was reacted with chlorocarbonyl isocyanate, in DCM, containing triethylamine, 
R1  R2 I.D                Conditions Temp Time
* Yield 
SO2CH3 H 525 1.5 eq. K2CO3, 1.2 eq. CH3SO2Cl, DMF 90
o
C 24h S.M 
SO2CH3 H 525 5 eq. NaH, 2.2 eq. CH3SO2Cl, DMF 90
o
C 24h S.M 
CSNH(CH3) H 526 10 eq. NaH, 3.5 eq. CH3NCS, DMF 110
o
C 48h S.M 
SO2CH3 H 525 1.5 eq. CH3SO2Cl, C6H5N 90
o
C 24h S.M 
COCH3 H 527 1.5 eq. (CH3CO)2O, C6H5N 90
o
C 24h 35% 
COCF3 H 528 (CF3CO)2O, CF3CO2H (3:1) 75
o
C 20h 45% 
COCF3 H 528 1.5 eq. (CF3CO)2O, Et3N, CH3CN 80
o
C 24h S.M 
=C(CF3)-    
CH=C(CF3)- 
529 5 eq. CF3COCH2COCF3, AcOH 120
o
C 24h S.M 
-CO-NH-CO- 530 1.1 eq. ClCONCO, Et3N, DCM 20
o
C 20h S.M 
=C(CH3)-
CH=C(CH3)- 
531 3.3 eq. CH3COCH2COCH3, 5% HCl/ H2O 100
o
C 24h S.M 
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overnight.
58
 Following addition of water, the residue was filtered but was found to comprise 
only starting material, with no trace of the anticipated triazinedione derivative 530. 
Attempted routes to pyrimido[1,5-a]pyrimidine analogues 529 and 531 were also 
unsuccessful under the reaction conditions outlined in Table 4.5. 
4.6.5 Attempted reaction with panel of bidentate N-nucleophiles 
 
It has been established that base-mediated cyclocondensation of a dicarbonyl precursor with 
an appropriate nucleophile represents a viable route to heterocyclic systems bearing a 
pyrimidine sub-unit. The versatility of this reaction with related ureas of varying 
nucleophilicity was studied, and the results of this reactant study are described in Scheme 
4.29. Reactions of 478 with hydrazine, thiourea and guanidine carbonate have already been 
discussed and the resulting bisindolyl heterocyclic derivatives represent a validated route to 
this novel class of compounds. 
 
As a baseline starting point for accessing bisindolyluracil 507, reaction of 5 equivalents of 
urea, freshly recrystallised from absolute ethanol, with intermediate 478, heated to reflux 
temperature, in the presence of excess sodium methoxide did not yield any anticipated 
product 507 upon acid work-up, even after 72 hours. 532-536 
 
Reaction of 5 equivalents of O-methyl isourea under identical reaction conditions also 
yielded only starting material 478 following stirring for 36 hours at 70
o
C. Utilising aqueous 
inorganic base-mediated conditions, as reported by Botta et al., conversion to uracil 532 was 
investigated following reaction of 478, but no reaction had occurred.
59
  
 
Reaction of N,N‟-dimethyl thiourea also failed to provide any 533, resulting in isolation of 
only starting material 478 following reaction for 48 hours under these conditions (Scheme 
4.29).  
 
S-Methylisothiouronium hemisulfate 534 was synthesised by heating of thiourea with 
dimethyl sulfate in ethanol, for 2 hours. Following cooling to 0
o
C, filtration and successive 
washing with water and diethyl ether, produced the white crystalline hemisulfate salt 534 in 
a yield of 53%. Unfortunately, reaction of 5 equivalents of 534 with 478 under standard 
methoxide conditions did not result in formation of any product 515, following extended 
reflux for 72 hours. Similarly, when reaction of 5 equivalents of the salt 534, along with 
ketoester 478, in a 10% aqueous KOH solution, was carried out, no reaction was observed. 
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             532                                                                                    507                                                  
 
 
   
                                                                                                                    535 
   
                                                                                                                      
                                                                        478 
 
 
 
                                                    534 
 
                  533 
                                                                                                                         536 
  
 
                                                                           515 
Reagents and conditions: (i) 20 eq. NaOMe/ MeOH, 5 eq. NH2(CX)=NH reagent, reflux, 24-72h; (ii) 
Ca(OH)2, 5 eq. NH2(NH)-X reagent, aq. H2SO4, 80
oC, 36h; (iii) 10% KOH/ H2O, 5 eq. NH2(NH)-X reagent, r.t, 
24h; (iv) 20 eq. KOH, 5 eq. NH2(NH)-X reagent, THF, reflux, 24h  
 
Scheme 4.29 
 
Due to concerns over these heterogeneous reaction conditions, a modified reaction involving 
heating of KOH along with isothiouronium salt 534 and intermediate 478, in THF, for 16 
hours, was attempted, but without any success.
40
 Synthesis of 4-morpholinocarboxamidine 
hemisulfate 535 was carried out in a yield of 78%, by one-pot reaction of S-
methylisothiouronium salt 534  with 1.1 equivalents of morpholine, stirred in 1,4-dioxane for 
20 hours at 90
o
C. However, none of the anticipated morpholino product 536 was formed 
under standard base conditions (Scheme 4.29).  
 
Based on these data, thiourea and guanidine possessed superior nucleophilicity compared 
with alternative urea derivatives. In qualitative terms, this is accounted for by the lower 
electronegativity of the C=N and C=S groups, with respect to the electron withdrawing C=O 
within urea. It was also necessary to be cognisant of the severe problems associated with the 
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apparent lack of reactivity of β-ketoester 478 compared with simple alkyl substituted 
analogues, in many instances. To this end, conversion of 478 to more electrophilic or 
nucleophilic intermediates such as enaminoamide 491 or β-chloroester 493 respectively, has 
been successfully achieved; however, no major advantages have manifested from application 
of these analogues to date. Thus, it can be confirmed that bidentate reactants imbued with 
strong nitrogen nucleophilicity as well as relatively harsh initial ring-forming conditions are 
required for effective heterocycle formation. 
 
The failure of alternate substituted urea analogues to yield the desired products 532-536 in 
the majority of cases was also illuminating with respect to devising an effective 
derivatisation strategy. The critical conclusion to be deduced from this study was that major 
synthetic issues encountered within the pyrimidine derivative series could not be 
satisfactorily resolved through targeting the primary base-mediated condensation step, but 
could instead be undertaken by secondary modification of pre-existing pyrimidine 
functionality.  
 
This provident strategy was clearly demonstrated when confronting challenges associated 
with the formation of a highly interesting lactam derivative - 5,6-bis(1-methyl-1H-indol-3-
yl)pyrimidin-4(3H)-one 537, incorporating an amide H-bonding functionality, similar to 
staurosporine 2, rather than the imide motif conserved in pyrimidin-2,4-dione 507, or in the 
closely related thioimide congener 514. Putative reaction of 478 with formamidine acetate 
and sodium methoxide was initially attempted, but unfortunately, only starting material 478 
was present after 48 hours, in the absence of any desired compound 537 (Scheme 4.30).  
 
 
 
 
 
 
 
 
 
                        478                                             514                                              537 
 
 
 
Reagents and conditions: (i) 10 eq. NaOMe, 5 eq. NH2CSNH2, MeOH, reflux, 24h (b) 10% HCl, 514 = 24%; 
(ii) 5 eq. NiBr2, 15 eq. NaBH4, MeOH, 20
oC, 16h, 537 = 55%; (iii) 10 eq. NaOMe, 5 eq. NHCHNH2.HOAc, 
MeOH, reflux, 48h, n.r 
Scheme 4.30 
 
Conversely, stirring of a dark suspension of 514 and 5 equivalents of nickel bromide in 
distilled methanol, to which was added portionwise, 15 equivalents of sodium borohydride, 
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under ambient conditions, successfully yielded the desulfurised pyrimidinone analogue 537, 
through reductive cleavage of the thiocarbonyl (C=S) bond, in a yield of 55%.
60
  
 
4.7 Oxidative cyclisation of bisindolylpyrimidinone series  
 
Novel bisindolyl derivatives, represented by 5,6-bisindolyl-2-aminopyrimidin-4-one 445,  
constitute an interesting bioisosteric modification of the intrinsic heterocyclic (F ring) H-
bonding network within bisindolylmaleimides (BIMs) known to confer potent anti-PKC 
activity (Section 1; Biological Introduction). The ultimate step in generation of a direct 
staurosporine 2 aglycon analogue within this series was now investigated and involves 
aromatisation of the acyclic precursor 445 to novel, fully planar indolo[2,3-a]pyrimido[5,4-
c]carbazol-4(3H)-one 442 (Fig. 4.4).
61-65
  
 
 
 
 
 
 
 
 
                    445                                               2                                              442 
Fig. 4.4 
 
4.7.1 Indolo[2,3-a]pyrimido[5,4-c]carbazol-4(3H)-one synthesis via 2,2’-ring closure of 
5,6-bisindolyl-2-aminopyrimidin-4-one  
 
Following synthesis of the isocytosine derivative 445, attention turned towards the final C-C 
bond formation step, via oxidative cyclisation, to yield fully aromatised (1-methyl-1H-
indolyl)[2,3-a](2-aminopyrimidin-4-one)[5,6-c]carbazole 442. The three most commonly 
employed oxidants employed in transformations of this type within classical 
bisindolylmaleimide chemistry are (i) DDQ
9,10,66
, (ii) Pd(II)-mediated oxidation
3,67,68 
and (iii) 
U.V. photocyclisation.
6,42,69
 
 
Unfortunately, DDQ oxidations are reported to be of limited utility and do not routinely 
prevail in instances where the indole nitrogens are alkyl-protected, as in our case. Due to its 
limited substrate scope, DDQ was discounted at an early stage from our cyclisation study.   
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4.7.1.1 Attempted transition metal-mediated route  
 
Positive results have been reported in the chemical literature, with palladium-based reagents 
acting as oxidants for the aromatisation of bisindolylmaleimides furnished with a mono-N-
protected indolic nitrogen, and most commonly, for mono-N-glycosylated analogues. 
Palladium(II) acetate is an effective mediator of this type of conversion, and oxidative ring-
closure was attempted under a series of conditions reported in chemical literature. One 
equivalent of this Pd complex was added to dry DMF, containing 445, under inert 
atmosphere, and stirred at 110
o
C for 24 hours. However, no evidence of indolocarbazole 
formation could be detected by LCMS under these conditions. Similarly, reaction of 
bisindolyl precursor 445 with 5 equivalents of Pd(OAc)2 in acetic acid, at 110
o
C for 24 
hours, in the presence of air, yielded no product formation. Disappointingly, the application 
of the more reactive Pd(CF3CO2)2, also failed to achieve this oxidative cyclisation, following 
heating in DMF overnight, under aerobic conditions. 
On consideration of transition metal mediated cyclisations, adverse solubility and 
compatibility issues related to palladium chemistry proffered an obvious obstacle to 
subsequent diversification of any chemical route. An alternative route employing 
K3[Fe(CN6)], which is known to operate as an oxidant under aqueous alkaline conditions, 
afforded only starting material 445 following an extended reaction time.
70
 Similarly, the 
recently reported utility of the hypervalent iodine (V) reagent, 
[bis(trifluoroacetoxy)iodo]benzene (PIFA), to achieve oxidative transformations in a number 
of polycyclic heterocyclic systems did not translate into any success with conversion of 
bisindolyl isocytosine compound 445 to the corresponding indolo[2,3-a]carbazole 442, 
following stirring at room temperature, along with 2.2 equivalents of the oxidative reagent in 
DCM, for 24 hours.
13
  
4.7.1.2 U.V Photocyclisation route 
 
A photocyclisation route was deemed to be an attractive method for achieving the final step 
in this synthetic pathway for design of novel heterocyclic compounds. Previous work 
indicated a wide application for iodine/U.V. light-mediated carbazole cyclisation, tolerating 
a wide range of protected indolic systems; it is also economical and readily applicable to 
diverse chemistry. Initially, following conditions outlined by Garaeva et al., reaction of 445, 
suspended in toluene (1 mg/0.5 mL) in the presence of 1 equivalent of iodine, and irradiated 
for 24 hours with a medium-pressure mercury lamp was carried out (Fig. 4.5).
71
 Analysis of 
the crude residue yielded evidence of a small amount of product formation, but 
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predominantly starting material, presumably due to the low solubility of 5,6-bisindolyl-2-
aminopyrimidin-4-one 445 in toluene.  
 
                     
                       445                          
 
 
   
Fig. 4.5: Mechanisms proposed for U.V.-photocyclisation of bisindolyl precursors. 
 
An important feature of this transformation concerns the initial conformation of both indolyl 
substituents - anticipated to initially display a „non-cisoid‟ hexatriene orientation, and thus 
could disfavour the corresponding transition state. The relative ease of U.V.-promoted 
isomerisation of this system may thus contribute to the difference in reactivity observed for 
individual members across the bisindolylpyrimidinone series. A number of workers have 
reported different mechanisms accounting for the final light-mediated oxidative cyclisation 
step to access indolocarbazole derivatives, as illustrated in Fig. 4.5. Based on Woodward-
Hoffmann criteria, a photochemically induced electrocyclic reaction may be realised via 
conrotatory ring closure of the acyclic precursor. Interestingly, electron releasing 
substituents at the C-2 position (e.g. NH2, 442 or H, 537) were successful candidates for this 
transformation, and this may be due to partial resonance contributions that stabilise both 
indole moieties in a beneficial less hindered, co-planar relationship (Fig. 4.5). Application of 
iodine as oxidant then results in conversion to the fully oxidized product. 
Alternatively, homolytic fission of iodine may be necessary to afford a radical cyclisation 
methodology, in which initial 2,2‟-iodination is followed by double radical abstraction and 
indolyl radical dimerisation to provide the central benzene C-ring. In the case of improving 
these final-step strategies, use of Pd/C as final oxidant, in place of iodine has been reported 
in non-radical routes, and future advantages may thus be conferred by performing this 
modification on unreactive bisindolylpyrimidinone analogues. 
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Fig. 4.6: LCMS analysis of planar indolo[2,3-a]pyrimido[5,4-c]carbazole 442  
In the course of our work, optimisation of the encouraging photocyclisation strategy as a 
viable route to the fully aromatized indolocarbazole 442 determined that an acetonitrile/ 
methanol (3:2) solvent system yielded maximum solubility of the 5,6-disubstituted 
isocytosine 445, at a dilution of 1 mg substrate/2.5 mL solvent mixture. Conditions were also 
varied in order to investigate how oxidation proceeded in the presence or absence of air. In 
the absence of atmospheric oxygen, no reaction occurred when 445 was allowed to stir 
vigorously, while U.V. irradiated for 20 hours, in the presence of catalytic iodine. 
Final product formation was carried out successfully on a 100 mg scale, following reaction 
overnight in an open vessel under our optimized reaction conditions, affording the fully 
aromatized congener 442 exclusively, in 55% yield, following gradient column 
chromatography with DCM/methanol. The reaction was also carried out with a constant 
stream of air being bubbled through the solvent over the course of the reaction. However, no 
difference in yield or reaction profile could be identified by excessive aeration of the 
reaction media by this method – thus, stirring under normal atmospheric conditions was 
deemed to be sufficient for full oxidative cyclisation to reach completion, as outlined in 
Table 4.6.  
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Table 4.6: Summary of cyclisation study for novel pyrimidinoindolocarbazole (442) 
synthesis from acyclic 5,6-bisindolyl-2-aminopyrimidin-4-one (445)
 
 
 
 
 
                     445                                     442 
                                                                                                                                     
Abbreviations: PIFA = PhI(OCF3CO)2  
‡ Anoxic conditions / N2 atmosphere. 
# Refers to stoichiometry of iodine 
¥ Air-bubbling (solvent aeration)  
§ Dilution: 1.0 mg substrate / 2.5 mL solvent 
 
 
At the conclusion of this work, full conversion of precursor 445 to the contiguous 
heteroaromatic indolo[2,3-a]pyrimido[5,4-c]carbazole 442 is described. Utilisation of an 
acetonitrile/ methanol solvent system, in place of previously reported benzene or toluene
10
, 
as reaction medium, also represents an optimisation of the overall efficacy of this 
photochemical route. A robust method for purification and characterization of these reactions 
has been developed, using LCMS; under these effective conditions, the novel 
indolocarbazole 442, was synthesised, in the absence of starting material 445 or oxidation 
side-products (Fig. 4.6). 
 
 
 
 
Reagent Stoichiometry                Conditions Time Product  Yield 
Pd(OAc)2 1.0 eq. DMF, 130
o
C
‡ 20h 445 - 
Pd(OAc)2 5.0 eq. AcOH, 110
o
C 20h 445 - 
Pd(CF3CO2)2 3.0 eq. DMF, 100
o
C
‡ 20h 445 - 
K3[Fe(CN)6] 1.0 eq. 10% KOH / H2O, 100
o
C
‡ 24h 445 - 
PIFA 2.5 eq. DCM, rt‡ 36h 445 - 
hυ / I2 1.0 eq.
# toluene, rt, air 72h 445+442 - 
hυ / I2 0.5 eq.
# CH3CN/MeOH (3:2), rt
‡ 24h 445 - 
hυ / I2 0.5 eq.
# CH3CN/MeOH (3:2), rt, air
§ 16h 442 53% 
hυ / I2 0.5 eq.
# CH3CN/MeOH (3:2), rt, air
¥,§ 16h 442 55% 
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4.7.2 Attempted photocyclisation of other novel heterocycles 
 
Following development of a successful aromatisation strategy, conditions were applied to a 
number of bisindolyl pyrazole and pyrimidinone derivatives, in order to generate a panel of 
corresponding indolocarbazoles, with limited success. In each case, the acyclic substrate was 
dissolved in a mixture of acetonitrile/methanol (3:2), along with a catalytic amount of iodine, 
and irradiated with U.V. light for 20 hours, under atmospheric conditions (Table 4.7).
42
  
 
Employing this procedure, U.V. photocyclisation of the acyclic pyrimidine-4-one precursor 
537, formed initially from thiouracil intermediate 514 provided novel indolocarbazole 538 as 
a light-yellow powder, in a yield of 60% (Scheme 4.31). Interestingly, 538 incorporates a 6-
membered lactam F-ring and bears close similarity to K-252c 6 (staurosporinone) – a 
cytotoxic anti-PKC microbial alkaloid derived from Nocardiopsis sp. K-290.
48,72,73
 
 
 
 
 
 
 
 
                 514                                                     538                                             6 
 
 
Reagents and conditions: 5 eq. NiBr2, 15 eq. NaBH4, MeOH, 20
oC, 16h, 537 = 55%; (ii) hυ, cat. I2, CH3CN/ 
MeOH (3:2), 16h, 538 = 60%  
 
Scheme 4.31 
 
 
As illustrated in Table 4.7, a panel of other related 1,2-bisindolyl-cis-ethene analogues, 
containing diverse bridgehead functionality were also investigated for their potential to 
undergo U.V. and Pd(CO2CF3)2-mediated oxidative cyclisation. In the case of β-ketoester 
478 and chloroacrylate derivative 493, as well as uracil 507, thiouracil 514 and N-
acetylisocytosine 527 heterocyclic congeners, no reaction was observed. Pyrazolone 510 and 
novel 5-aminopyrazole 447 derivatives were also unreactive under U.V. conditions. The 
successful conversion of isocytosine 445 and pyrimidin-4(3H)-one 537 to the corresponding 
ICZs demonstrates the utility of this route, and future work will seek to optimize conditions 
to successfully achieve oxidative ring closure within less reactive acyclic substrates, as well 
as investigating the enhanced potential of demethylated indole analogues within this step. 
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Table 4.7: Conditions for U.V. photocyclisation of novel bisindolyl heterocycles to 
indolo[2,3-a]carbazoles
 
 
 
 
                                    
                                                                                                                                     
Method A: Substrate (100 mg), 3:2 acetonitrile/ MeOH (1 µmol/mL), hυ (254 nm), 16h 
Method B: 300 mol% Pd(CF3CO2)2, DMF, 110
oC, 24h 
*
447 = Section 4.9.2. 
 
 
Compound X-Y Conditions/ [Ox] Product HRMS Yield 
478 
 
A 
 
SM - - 
493 
 
A 
 
SM - - 
507 
 
A 
B 
SM 
decomp. 
- 
- 
- 
- 
514 
 
A 
B 
SM 
decomp. 
- 
- 
- 
- 
445 
 
 
A 
 
 
 
442 
 
368.1511 
(C22H18N5O) 
 
55% 
 
537 
 
A 
 
538 353.1396 
(C22H17N4O) 
60% 
 
527 
 
A 
 
SM - - 
447
* 
 
A 
 
SM - - 
510 
 
A SM 
- - 
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4.8 Spectroscopic analysis of the heteroaromatic region of novel bisindolyl 
heterocyclic derivatives 
 
In this section, characteristic differences in electronic environments between individual 5,6-
bisindolylpyrimidin-4-one analogues will be probed via chemical shift perturbations within 
indole ring systems, attributable to the nature of the pyrimidin-4-one substituent. Synthesis 
of complex pyrimidine-fused bicyclic compounds 539 and 540, not discussed in this section, 
will be described in detail in Sections 4.9 and 4.10, respectively (Fig. 4.7).  
 
 
 
 
 
 
                          478                                      445                                      442 
 
 
 
 
 
 
                           514                                      537                                     538 
 
 
 
 
 
 
 
                           507                                     539                                   540 
 
Fig. 4.7 
 
Initial synthesis of β-ketoester 478 was confirmed by IR spectroscopic analysis from the 
appearance of absorption bands relating to carbonyl group stretching appearing at 1644 cm
-1 
(C=O) and 1732 cm
-1 
(CO2Me). Investigation by 
1
H NMR spectroscopy also reaffirmed this 
structure, and deshielded sharp 1H singlet signal at 5.70 ppm was also observed, 
corresponding to the presence of its characteristic alpha proton (CO-CH-CO2Me).  
 
Synthesis of the panel of 5,6-bisindolylpyrimidin-4-one analogues was successfully 
undertaken, and an overview of the unique NMR properties of a selected panel of novel 
indolocarbazole derivatives can be seen in Tables 4.8 and 4.9. 
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Table 4.8: Selected 
1
H NMR analysis of novel 5,6-bisindolylpyrimidin-4-ones 
 
 
†NMR measurements were made in DMSO-d6 solvent; HRMS data agreed with proposed structures 
 
 
 
 
R1 
 
R2 
 
 
N-CH3 
 
1
H NMR 
(C-H2’) 
 
 
1
H NMR 
(C-H2) 
 
 
1
H NMR 
(C-H4’) 
 
 
1
H NMR 
(C-H4) 
 
 
1
H NMR 
(C-H7’) 
 
 
1
H NMR 
(C-H7) 
 
SH 
(514) 
 
 
J (Hz) 
H 
 
 
 
 
3.63 
3.70 
 
 
- 
7.21 
(1H, s) 
 
 
- 
7.65 
(1H, s) 
 
 
- 
7.24-7.27 
(1H, d) 
 
 
8.2 
7.30-7.33 
(1H, d) 
 
 
8.2 
6.95-7.01 
(1H, m) 
 
 
- 
6.95-7.01 
(1H, m) 
 
 
- 
OH  
(507) 
 
 
J (Hz) 
H 
 
 
 
 
3.63 
3.67 
 
 
- 
7.11 
(1H, s) 
 
 
- 
7.50 
(1H, s) 
 
 
- 
7.24-7.27 
(1H, d) 
 
 
8.2 
7.30-7.33 
(1H, d) 
 
 
8.2 
6.96-7.08 
(1H, m) 
 
 
- 
  6.96-7.08 
(1H, m) 
 
 
- 
NH2  
(445) 
 
 
J (Hz) 
H 
 
 
 
 
3.40 
3.80 
 
 
- 
6.62 
(1H, s) 
 
 
- 
7.11 
(1H, s) 
 
 
- 
7.37-7.39 
(1H, d) 
 
 
6.9 
8.31-8.34 
(1H, d) 
 
 
7.8 
7.02-7.07 
(1H, m) 
 
 
- 
7.24-7.26 
(1H, m) 
 
 
  - 
H  
(537) 
 
 
 
J (Hz) 
H 
 
 
 
 
3.38 
3.74 
 
 
 
- 
6.80 
(1H, s) 
 
 
 
- 
7.35 
(1H, s) 
 
 
 
- 
7.33-7.35 
(1H, d) 
 
 
 
5.9 
7.95-7.98 
(1H, d) 
 
 
 
7.9 
6.84-6.86 
(1H, d) 
 
 
 
7.9 
  7.23-7.25 
(1H, d) 
 
 
 
8.0 
-SCH2CH2- 
(516) 
 
       J (Hz) 
3.52 
3.87 
 
- 
6.89 
(1H, s) 
 
- 
7.39 
(1H, s) 
 
- 
7.47-7.50 
(1H, d) 
 
8.2 
7.97-8.00 
(1H, d) 
 
8.0 
7.02-7.04 
(1H, d) 
 
7.9 
 7.36-7.39 
(1H, d) 
 
8.2 
SCH3 
 (515) 
 
 
J (Hz) 
H 
 
 
 
 
3.46 
3.82 
 
 
- 
6.87 
(1H, s) 
 
 
- 
7.37 
(1H, s) 
 
 
- 
7.41-7.44 
(1H, d) 
 
 
8.2 
8.06-8.09 
(1H, d) 
 
 
8.0 
6.93-7.95 
(1H, d) 
 
 
7.9 
7.32-7.35 
(1H, d) 
 
 
8.1 
SCH2CO2Et 
 (521) 
 
 
J (Hz) 
CH2CO2Et 
 
 
 
 
3.36 
3.84 
 
 
- 
6.73 
(1H, s) 
 
 
- 
7.32 
(1H, s) 
 
 
- 
7.49-7.52 
(1H, d) 
 
 
8.2 
8.16-8.19 
(1H, d) 
 
 
7.9 
7.13-7.21 
(1H, m) 
 
 
  - 
 7.36-7.39 
 (1H, d) 
 
 
8.1 
SCH2CONH2 
 (522) 
 
 
 
J (Hz) 
CH2CONH2 
 
 
 
 
 
3.47 
3.84 
 
 
 
- 
6.78 
(1H, s) 
 
 
 
- 
7.39 
(1H, s) 
 
 
 
- 
7.48-7.51 
(1H, d) 
 
 
 
8.4 
8.13-8.16 
(1H, d) 
 
 
 
7.8 
7.12-7.26 
(1H, m) 
 
 
 
  - 
 7.35-7.37 
(1H, d) 
 
 
 
8.0 
NHCOCH3  
(527) 
 
 
 
J (Hz) 
H 
 
 
 
 
 
3.43 
3.84 
 
 
 
  - 
 6.74 
 (1H, s) 
 
 
 
- 
7.35 
(1H, s) 
 
 
 
- 
 7.43-7.46 
   (1H, d) 
 
 
 
8.2 
 8.36-8.38 
   (1H, d) 
 
 
 
8.0 
6.93-6.96 
(1H, d) 
 
 
 
7.8 
7.32-7.35 
(1H, m) 
 
 
 
  - 
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Table 4.9: Selected 
13
C NMR and IR data of 5,6-bisindolylpyrimidin-4-ones 
 
 
†NMR measurements were made in DMSO-d6 solvent; IR spectra measured as KBr discs 
 
A major question posed at the outset of this study was whether these constitutively similar 
compounds could be differentiated via facile spectroscopic methodology, and determine how 
discrete chemical shift patterns could be ascertained, based on modulation of electron 
delocalisation, as illustrated in Fig. 4.8. 
 
 
 
 
                                                     514 
 
 
 
 
 
Fig. 4.8: Select resonance canonical structures for inequivalent indole substituents in 514 
 
Employing this effect, the distinct chemical environments of the both 5 and 6-indolyl 
substituents on the pyrimidinone ring can be deconvoluted, in addition to providing a 
framework for explaining NMR changes that occur between the acyclic and corresponding 
fully aromatised indolocarbazole derivatives.  
For 5,6-bisindolyl-2-thiopyrimidin-4-one 514, differential shielding/deshielding effects act to 
„desymmetrise‟ both indole substituents, thus permitting full assignment of the otherwise 
 
Structure 
 
 
 
 
 
 
 
 
 
Compound No. 
 
 
514 
 
507 
 
445 
 
537 
13C NMR/ppm δ 
(C=C-CO-NH) 
 
161.3 164.3 161.8 161.7 
13C NMR/ppm δ 
(N=CX-NH) 
 
174.3 151.1 152.7 155.7 
υC=O/ cm
-1 1651 1639, 1703 1686 1633 
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much more complex 
1
H NMR spectrum. As observed in Table 4.8, the 1H singlet for C-H2‟ 
occurred at 7.21 ppm, while the corresponding signal for C-H2 was significantly shifted 
downfield to a position of 7.65 ppm (300 MHz; DMSO-d6). On investigation of its 
13
C NMR 
spectrum, a signal was detected for the carbon of the thiocarbonyl (C=S) group at 174.3 
ppm, while the amide carbonyl C4 occurred at 161.3 ppm (Table 4.9). As observed in Fig. 
4.7, the thiocarbonyl group is adjacent to inductively electron-withdrawing N
1
 and N
3 
thiouracil ring
 
positions and is thus strongly deshielded in this environment. Conversely, 
even though oxygen also exerts a considerable deshielding influence, the amide position is 
subject to inward electron donation via conjugation with the indole nitrogen lone pair and 
partial negative charge localised on the oxygen atom, accounting for its relative upfield shift. 
Several workers have also proposed that systems related to thioimide-bearing thiouracil 514 
may exist predominantly in the „enol‟ or „2-mercaptolactam‟ tautomeric form, analogous to 
the 2-aminopyrimidin-4-one and pyrimidin-4(3H)-one derivatives consistently reported 
within scientific literature in this form.
40,46
 Characteristic 
13
C chemical shift differences 
observed within diverse pyrimidin-4-one ring compounds are also displayed in Fig. 4.9. 
 
 
 
Fig. 4.9: Downfield C-2 and C-4 pyrimidinone fingerprint signals in 
13
C NMR of 5,6-
bisindolylpyrimidin-4-ones: pyrimidin-4(3H)-one 537 = black; thiouracil 514 = green; uracil 507 = 
blue; isocytosine 445 = orange 
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In the case of 5,6-bisindolyl-2-aminopyrimidin-4-one 445, a large shielding phenomenon 
was observed due to the release of electron density via the lone pair of electrons delocalised 
from the 2-amino group of the isocytosine ring. The 1H singlet for C-H2‟ was identified 
upfield at 6.62 ppm, due to this effect, while C-H2 was located at a chemical shift of 7.11 
ppm (Table 4.8). This isocytosine derivative 445 possessed a ΔδH of 0.49 ppm, between 
these two proton environments, which could be rationalised in terms of the increased 
electron density localised at C-H2‟, and the additional electron-withdrawing effect due to 
resonance stabilization on the deshielded indole ring substituent (Fig. 4.10). 
 
 
 
 
    
                                              445 
                                          
 
 
 
 
Fig. 4.10: Resonance effects on unsymmetrical indole rings within isocytosine derivative 445  
 
The 
1
H NMR spectrum of planar compound 442, containing a 2-aminoindolo[2,3-
a]pyrimido[5,4-c]carbazole ring system confirmed that successful oxidative cyclisation had 
occurred, due to the absence of any 1H singlet signals in the C-H2 region.  
 
 
 
Table 4.10: Selected NMR analysis of novel indolo[2,3-a]pyrimido[5,4-c]carbazoles 
 
 
†NMR measurements were made in DMSO-d6 solvent; HRMS data agreed with proposed structures. 
R1 N-CH3 
1
H NMR 
(C-H5) 
 
1
H NMR 
(C-H8) 
 
1
H NMR 
(C-H11) 
 
1
H NMR 
(C-H14) 
 
1
H NMR 
NH-CO 
 
1
H NMR 
(R1) 
 
13
C NMR 
(R1-C=N) 
 
13
C NMR 
(NH-C=O) 
 
NH2 
(442) 
 
J (Hz) 
4.15 
4.23 
 
- 
9.06-9.09 
(1H, d) 
 
10.5 
7.64-7.67 
(1H, d) 
 
8.8 
7.71-7.74 
(1H, d) 
 
8.8 
9.68-9.70 
(1H, d) 
 
7.0 
10.93 
(1H, bs) 
 
  - 
6.41 
(2H, s NH2) 
 
  - 
151.5 
 
 
 
162.0 
 
 
 
H  
(538) 
 
J (Hz) 
4.24 
4.28 
8.98-9.01 
(1H, d) 
 
7.8 
7.71-7.74 
(1H, d) 
 
8.1 
7.76-7.79 
(1H, d) 
 
8.2 
  9.72-9.75 
(1H, d) 
 
8.3 
12.33 
(1H, bs) 
 
- 
8.32-8.33 
(1H, d, C-H) 
 
3.6 
144.0 
 
 
160.7 
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The 2-amino group was observed as a broad singlet at 6.40 ppm. In the downfield region, the 
secondary amide (N
3
) proton was also detected as a characteristic broad singlet at 10.93 ppm 
(Table 4.10). In the 
13
C DEPT 90 NMR spectrum of 442, only 8 signals were present, 
corresponding to the benzenoid ring protons of the indolocarbazole scaffold, and also 
confirming that ring closure had occurred (Fig. 4.11). 
 
 
Fig. 4.11: Partial 
1
H NMR spectrum of 2-aminoindolo[2,3-a]pyrimido[5,4-c]carbazol-4(3H)-one 442 
 
When the corresponding bisindolyl 537 and aromatised pyrimidin-4(3H)-one 538 derivatives 
were analysed, similar effects to those reported for other members of this series were 
observed. In the 
1
H NMR spectrum of acyclic 537, the 1H singlet corresponding to C-H2 was 
observed at 7.35 ppm, while the C-H2‟ signal was located as a 1H singlet at 6.80 ppm.  
 
1
H NMR analysis of the novel indolocarbazole 538 located the characteristic pyrimidin-
4(3H)-one N=C-H signal as a weakly split doublet at 8.32-8.33 ppm, which was confirmed 
by means of a COSY 2D-NMR experiment, identifying a cross-peak with the broad N-H 
singlet appearing at 12.33 ppm (Fig. 4.12). Signals corresponding to C-H7 and C-H12 were 
also identified as a 2H quartet occurring at 7.52-7.60 ppm, which is the result of an overlap 
of two triplets, each integrating for a single proton (Fig. 4.12).  
 
 443 
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Fig. 4.12: 
1
H NMR aromatic spectrum of indolo[2,3-a]pyrimido[5,4-c]carbazol-4(3H)-one 538 
 
4.9 Synthesis of 3,4-bisindolyl-5-aminopyrazoles 
 
During the course of chemical studies on incorporating new heterocyclic diversity derived 
from the 3,4-bisindolylpyrrol-2,5-dione/bisindolylmaleimide molecular template, several 
novel bisindolyl-5-aminopyrazole 447 derivatives of biological interest have also been 
synthesised. This strategy complements the approach adopted to modifying the F-ring 
protein-interacting pharmacophore within six-membered pyrimidine analogues (vide infra), 
by incorporating attractive H-bonding characteristics, constrained in a conventional five-
membered ring system – structurally similar to K-252c 6, a natural product derived from 
Nocardiopsis strains, and the selective PKC inhibitor, GF109203x 26 (Fig. 4.13).
65,72,74,75 
 
 
 
 
 
 
                           447                                          6                                          26 
 
Fig. 4.13 
 
539 
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4.9.1 Synthesis of 2,3-bis(1-methyl-1H-indol-3-yl)-3-oxopropanenitrile 
 
In order to pursue the development of diverse bisindolyl-5-aminopyrazoles as a new 
chemical class with important biological potential, the initial synthesis of novel 2,3-bis(1-
methyl-1H-indol-3-yl)-3-oxopropanenitrile 541 constituted a key electrophilic precursor to 
title compound 447.  
 
Synthesis of 541 began from indole 171, substituted under standard Mannich conditions, 
employing diethylamine and formaldehyde to afford gramine 542, as an off-white powder, in 
62% yield, following crystallisation. 3-Indolylacetonitrile 229 was derived from cyanolysis 
of 542 in methanol, in the presence of potassium cyanide and iodomethane, and was isolated 
as an off-white solid, following chromatography (67%). Appearance of a characteristic weak 
absorption band in the middle IR region (~2200 cm
-1
) confirmed the presence of an aryl-
substituted acetonitrile C≡N stretch. 
Following reaction of 229 with NaH and iodomethane in anhydrous DMF, initially at 0
o
C, 
prior to warming to room temperature, N-methyl indole-3-acetonitrile 454, was isolated as a 
violet coloured oil, in quantitative yield (100%). A similar result was accomplished by 
employing powdered KOH base system, in DMF, to afford 454 cleanly, in a yield of 99%, 
within one hour, at room temperature. The N-methylated arylacetonitrile 454 was 
sufficiently pure to be used without any further purification following acidic work-up 
(Scheme 4.32).
15
 
 
 
 
 
 
                    171                                       542                                      229 
 
 
 
   
                                                                                        479 
 
 
                                                        
                                       541                                                               454                 
                                              
Scheme 4.32 
 
Formation of the corresponding β-ketonitrile 541 was initially attempted by stirring of 454 in 
the presence of triethylamine, in DMF, at room temperature, along with N-methylindol-3-yl 
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carbonyl chloride 479, and which resulted in only starting material present after 24 hours. 
However, when LDA was stirred along with precursor 454 in THF, maintained at −78oC, 
subsequent dropwise addition of a solution of N-methyl indol-3-yl carbonyl chloride 479 in 
THF, followed by warming of the reaction to room temperature overnight, successfully 
achieved this transformation. The dark orange intermediate 541 was purified by careful 
gradient ethyl acetate/hexane chromatography in a yield of 76% from 454 (Scheme 4.32).  
4.9.2 Synthesis of 3,4-bis(1-methyl-1H-indol-3-yl)-5-aminopyrazole 
 
Heterocyclic functionalisation of appropriate precursors represents a versatile and robust 
general method for the delivery of a large number of distinct compound types. A 
cyclocondensation route was chosen in order to access parent 3,4-bisindolylpyrazol-5-amine 
447; no special conditions or protecting groups were required, as the key heterocyclic 
nucleus was furnished in the final step. This conversion was initially realised by stirring 541 
in distilled methanol, along with addition of one equivalent of camphoric acid and three 
equivalents of hydrazine, initially refluxed for 2 hours, at which point a further three 
equivalents of hydrazine were added to the reaction flask and reflux was extended for 24 
hours. However, only 600 mg of the polar, fluorescent compound 447 could be isolated 
when this route was performed on a 3 gram scale (20%).
34
 Fortunately, aminopyrazole 447 
formation proceeded in enhanced yields of 40-45% when β-ketonitrile precursor 541 was 
heated with catalytic glacial acetic acid and excess hydrazine monohydrate in absolute 
ethanol for 24 hours, prior to isolating as a light brown powder, characteristically identified 
as the final fraction during column chromatography with 100% ethyl acetate (Scheme 4.33).  
 
 
 
 
 
 
                                 541                                                                       447 
Scheme 4.33 
 
The nature of this synthesis depended on the acid catalyst employed; addition of a few drops 
of acetic acid demonstrated a substantial yield enhancement (and observed darkening of the 
reaction mixture following catalyst addition), when compared with catalyst-free reaction (no 
reaction after 24 hours), or utilising camphoric acid. The apparent mechanism of this 
reaction is outlined in Fig. 4.14, and the addition of acid clearly promotes initial hydrazone 
formation prior to cyclisation.  The predominant product of this reaction after 24 hours was 
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447, along with minimal unreacted 541; prolonged reflux for 72 hours offered no further 
yield dividend.  
 
 
 
 
 
                   541 
 
 
 
 
 
 
 
 
 
 
 
                                               447 
Scheme 4.34 
                                             
4.9.3 Reactivity of 3,4-bis(1-methyl-1H-indol-3-yl)-5-aminopyrazole 
 
A series of pharmaceutically relevant derivatisation studies were conducted in order to 
expand the library of bisindolyl-5-aminopyrazoles available for biological study. A number 
of routes were thus developed in order to access novel derivatives of parent compound 447.
76
 
 
 
 
 
 
 
 
 
 
                                                                                447 
 
Fig. 4.14: General structure of substituted 3,4-bisindolyl-5-aminopyrazoles 
 
Chemical routes based on a dual strategy of pyrazole ring substitution and cycloalkylation 
with appropriate electrophiles were chosen to assess H-bonding and potential enzyme 
binding domains of the 5-aminopyrazole ring system (447; Fig. 4.14) within its putative 
binding pocket. Potency and selectivity may also be improved by incorporating diverse 
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chemical functionality in order to create new non-covalent enzyme-inhibitor contacts within 
this series.  
 
4.9.3.1 Mono-N-substitution of aminopyrazole ring  
 
Initial N-acetylation of the aminopyrazole nucleus within 447 was successfully achieved by 
reaction with acetic anhydride in acetonitrile, at reflux, for 20 hours. Following work-up and 
chromatography, the N
1
-acetylated product 543 was isolated as an off-white crystalline solid 
in a yield of 57% (Scheme 4.35). 539, 544-549 
 
 
 
 
                                                                     539 
                        549                                                                                                          
                                                                                                                   543                                                                                                                                                                                                                       
 
                             546  
                         
                                                                     447 
   
 
 
                                                                                                                          544 
                 547 
 
                                                                     545 
                                                                            
 
 
 
 
 
                 548 
 
Scheme 4.35: Target synthetic routes employed for chemical derivatisation of 3,4-
bisindolyl-5-aminopyrazole 447 nucleus. 
 
 
Following ongoing work to incorporate novel H-bonding networks into these novel anti-
cancer classes, unique thioamide functionality was efficiently introduced following heating 
of aminopyrazole 447 with 1.1 equivalents of methyl isothiocyanate, in refluxing 
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acetonitrile, for 20 hours. The reaction was then quenched with water and stored at 0
o
C for a 
further hour, at which point the light-brown residue was filtered, washed with water and 
diethyl ether, and dried to afford the pure crystalline compound 544 (30%). 
 
Attempted N-sulfonylation employing 1.2 equivalents of methanesulfonyl chloride along 
with triethylamine in DCM, afforded only starting material following stirring at room 
temperature for 48 hours. However, harsher conditions utilising methanesulfonyl chloride in 
pyridine as solvent, stirred at reflux for 20 hours successfully converted 447 to the 
corresponding amino-substituted sulfonamide as a dark brown solid, in a yield of 35%, 
following chromatography.   
 
Expansion of the acetyl (C=O) and thiourea (C=S) themes led to synthesis of a substituted 
pyrazolic derivative 548 bearing the complementary guanidine functional motif (urea 
analogue). Preparation of the pyrazolyl-guanidine core was successfully carried out by initial 
coupling of 447 and (N,N‟-di-tert-butoxycarbonyl)thiourea 546, (generated from reaction of 
thiourea and di-tert-butyl carbonate in 93% yield), in the presence of mercuric chloride, and 
triethylamine, in DCM, warmed from 0
o
C to room temperature overnight, provided the 
relatively non-polar 547, as a beige powder, in overall 37% yield, following work-up and 
chromatography. 
 
                                                                                                     550 
 
                      546                                                                   
 
 
 
 
 
 
 
 
                                         447                                                         547 
 
Scheme 4.36: Mechanism of guanylated-pyrazole 547 formation via electrophilic 
carbodiimide reactive intermediate 550 
 
 
This mechanism of N
1
-guanylation is believed to proceed through initial formation of a 
reactive Boc-protected carbodiimide species 550 – derived from attack of the nucleophilic 
sulfur of thiourea 546 on mercuric chloride to generate a mercury complex 
(thermodynamically driven by the high affinity of sulfur for mercury in the bond-forming 
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event), which then undergoes concerted intramolecular cleavage to produce the final 
electrophilic carbodiimide intermediate 550 and insoluble side-product (Fig. 4.16).  
Final deprotection of compound 547 was carried out with a mixture of TFA in DCM, stirred 
at room temperature for 16 hours; the title trifluoroacetate salt 548 was isolated following 
drying under high vacuum overnight, in quantitative yield (Scheme 4.35).
77
   
 
4.9.3.2 Pyrazolo[1,5-a]pyrimidine heterocycle formation 
 
Development of routes to bisindolyl-substituted pyrazolopyrimidine derivatives was 
undertaken, due to their resemblance to the adenine moiety, within ATP, and thus to 
investigate the biological potential underpinning the application of bicyclic 1,2-bisindolyl-
cis-ethene bridging ring systems within future anti-cancer compounds (Section 6.0, 
Biological Results and Discussion).  
 
Heating of 447 with excess HFAA in acetic acid at 120
o
C for 20 hours characteristically 
resulted in rapid and persistent appearance of a dark red colour during the reaction. After this 
time, the target pyrazolo[1,5-a]pyrimidine 549 was isolated as a red powder in a satisfactory 
yield of 54% (Scheme 4.35). 
The final derivatisation undertaken in this study was the transformation of aminopyrazole 
447 to the attractive triazinedione congener 539. This derivative was anticipated to be highly 
useful, both as it constitutes a novel planar H-bonding pharmacophore, and also as an 
investigative tool to ascertain whether overall larger ring size or relative spatial distortion of 
the uracil motif (pyrazolo[1,5-a]pyrimidine orientation), within this bicyclic derivative 539 
has any biological effect in comparison to the analogous 6-membered uracil ring system of 
5,6-bisindolylpyrimidin-2,4-dione 507.  
 
 Reaction with 2.2 equivalents of chlorosulfonyl isocyanate in DCM, containing 
triethylamine, at room temperature for 16 hours provided only starting material 447 
following aqueous quenching of the dark reaction mixture. Fortunately, the reaction 
proceeded well once the conditions were altered to employ chlorocarbonyl isocyanate in 
DCM at 0
o
C, in the presence of 447, along with a few drops of triethylamine, followed by 
gentle stirring at room temperature for 16 hours.
58
 Addition of water resulted in precipitation 
of the novel triazinedione product 539, in an excellent yield of 84% following filtration 
(Scheme 4.35). 
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4.9.3.3 Regiochemistry of 5-aminopyrazole monosubstitution 
The observed pattern of electrophile addition to the aminopyrazole ring was observed to be 
strongly dependent on the nature of the electrophile and reaction conditions, and was 
investigated by means of 
1
H NMR spectroscopy. Evidence of N-5 or N-1 substitution is 
given from the presence or absence of signals relating to the amine (2H, broad peak between 
4.5-6.5 ppm) as well as confirmatory evidence from single crystal X-ray structure analysis 
(see Section 4.10.2.1). Consequently it is seen that the amine is functionalized in the case of 
the trifluoroacetamide and the methanesulfonamide, whereas in all other cases the ring 
nitrogen was substituted. Interestingly, in the case of methanesulfonylation, reaction of 447 
with methanesulfonyl chloride in refluxing acetonitrile, containing Et3N was unsuccessful, 
amino substituted derivative 545 was formed in the presence of pyridine at 90
o
C -  indicating 
that thermal conditions may have a role in defining the preferred site of ring attack.  
 
4.10 Synthesis of aryl-substituted indolyl-heterocycles 
 
Recognition of how privileged H-bonding characteristics within diverse aryl-substituted 
indolyl heterocycles may be translated into design of new 3,4-diarylpyrrole protein-
interacting analogues has attracted notable success in the area of kinase inhibition (Fig. 
4.15). Preliminary compound screening by Peifer and co-workers recently identified 
indolylarylmaleimide derivative 396 with an IC50 value of 2.5 nM for VEGFR2, while a 
simplified pyrrole-2-one 397, also exhibited potent VEGF-R2 inhibitory activity (IC50 = 31 
nM).
78,79
  The potential for enzyme selectivity arising from strategic modification of the H-
bonding pyrrole ring system was also confirmed by diminished VEGFR2 inhibition within 
regioisomeric pyrrol-5-one 551 (IC50 = 11 µM), resulting from altered orientation of the 
lactam ring in the ATP-binding pocket, and sets the platform for maleimide ring bioisosteric 
replacement in order to achieve complementary biological activity within this series.  
 
 
 
 
 
 
 
 
 
                            396                                       397                                             551    
                                                                                                                                 
Fig. 4.15: Structures of arylindolyl-substituted PKIs for rational design of new pyrrole analogues. 
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Based on this discovery,  novel asymmetrically substituted 4-(indol-3-yl)-3-(3,4,5-
trimethoxyphenyl)-substituted analogues (pyrazol-5-one 552; pyrazol-5-amine 553) were 
valuable due to their ability to mimic the binary N
1
 H-bond donor – N2 acceptor motif, as 
well as introducing auxiliary H-bonding functionality at the C-5 position (Fig. 4.16). Work 
was also carried out to attempt a convergent cyclocondensation route to novel H-bonding 6-
membered pyrimidin-4-one 554 derivatives. 
 
                                                               552    
                                                               553                                                                         
    
 
 
 
                                                                                                      554 
Fig. 4.16: Potential 3,4-diarylmaleimide binding motif in novel analogues of VEGFR inhibitor 397.  
4.10.1 Synthesis of 4-(1-methyl-1H-indol-3-yl)-5-(3,4,5-trimethoxyphenyl)-pyrazol-3-
one  
 
Reaction of methyl 2-(1-methyl-1H-indol-3-yl)acetate 480, under LDA-mediated conditions 
with a slight excess of 3,4,5-trimethoxybenzoyl chloride 499 in THF at −78oC, afforded 
access to light orange crystalline methyl 2-(1-methyl-1H-indol-3-yl)-3-oxo-3-(3,4,5-
trimethoxyphenyl)propanoate 555 in a yield of 35% following chromatography. This 
intermediate 555 was then heated with hydrazine, along with camphoric acid, in methanol at 
reflux for 24 hours, to provide the novel dark brown pyrazolone derivative 552 in a yield of 
60%, employing 0.5% methanol/DCM chromatography (Scheme 4.37).
34
 
 
Unfortunately, pyrimidin-4-one 554 transformation could not be completed for this series; 
reaction under conventional methoxide-mediated conditions with thiourea or guanidine 
carbonate yielded only starting material 555 following acidic work-up of the crude reaction 
mixture after heating for 48 hours. In combination, the resonance effects of several -OCH3 
groups was theorized to increase the electron density at the carbonyl site, thus significantly 
decreasing or negating its electrophilic reactivity with moderate nucleophiles under these 
conditions (Scheme 4.37). Attempted microwave conversion to 554 under harsh conditions 
was also unsuccessful, in the presence of 2.5 equivalents of camphoric acid, following 
solvent-free heating of 555 and excess thiourea or urea for 25 minutes at 160
o
C.
41
 
 
The observed order of reactivity (NH2NH2 >> thiourea/urea) is consistent with literature 
data, and accounts for the initial success in pyrazolone 552 formation, due to the superior 
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nitrogen nucleophilicity associated with hydrazine attack on the relatively electron rich 
carbonyl group in this system. In addition to the poor reactivity of urea and thiourea, it was 
also postulated that a high barrier to rotation of both flexible aryl substituents may exist, due 
to steric repulsion, in order to prevent desired 5-(indol-3-yl)-6-(3,4,5-trimethoxyphenyl)-
pyrimidin-4-one 554 formation (Scheme 4.37). Future work in this area will investigate this 
phenomenon in order to devise an alternative route to these attractive molecular templates.  
 
 
 
 
 
   
                    480                                   555                                               552 
 
 
 
 
 
 
 
                                                                                                        554 
                                                                                                                     
Reagents and conditions: (i) 2.2 eq. LDA, 1.5 eq. 3,4,5-(O-CH3)3C6H2-COCl, THF, -78
oC - rt, 20h, 3 = 35%; 
(ii) 4 eq. NH2NH2.H2O, 1 eq. camphoric acid, MeOH, reflux, 24h, 4 = 60%; (iii) 20 eq. NaOMe, 5 eq. 
NH2(C=S)NH2 or [NH2(C=NH2)NH2]2CO3, MeOH, reflux, 24h, n.r 
 
Scheme 4.37: Formation and reactivity of methyl 2-(1-methyl-1H-indol-3-yl)-3-oxo-3-
(3,4,5-trimethoxyphenyl)propanoate 555. 
 
4.10.2 Synthesis of 4-(1-methyl-1H-indol-3-yl)-3-(3,4,5-trimethoxyphenyl)-5-
aminopyrazole  
 
The identification of new potential bioisosteres for 4-(indol-3-yl)-3-(3,4,5-
trimethoxyphenyl)-pyrrole-2,5-dione 396 and 4-(indol-3-yl)-3-(3,4,5-trimethoxyphenyl)-
pyrrole-2-one 397 agents as protein kinase drug targets, resulted in development of a 
successful synthetic route to the parent 3,4-diaryl-5-aminopyrazole 553 system (Fig. 4.17).  
                                                                                            
 
 
                                                                                                   553 
 
 
 
                                                                        
Fig. 4.17: General structure of substituted 4-(indol-3-yl)-3-(3,4,5-trimethoxyphenyl) pyrazol-5-amine 
553 core 
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In the initial step, N-methyl indole-3-acetonitrile 454 was cooled to −78oC in the presence of 
LDA, and stirred for 1.5 hours, prior to addition of 3,4,5-trimethoxybenzoyl chloride 499. 
On work-up and chromatography, the novel light orange, crystalline 2-(1-methyl-1H-indol-
3-yl)-3-oxo-3-(3,4,5-trimethoxyphenyl)propanenitrile 556 was formed in a yield of 35% 
(Scheme 4.35). Following reaction of β-ketonitrile 556 with hydrazine monohydrate in 
absolute ethanol, containing a few drops of acetic acid, at 80
o
C for 24 hours, compound 553 
was isolated as a brown powder in a yield of 23% (Scheme 4.38).  
 
 
 
 
 
 
                          
             454                                               556                                                   553 
                                                                      
Reagents and conditions: (i)(a) 1.8M LDA, 3,4,5-(OMe)3C6H2COCl (499), THF, -78
oC - rt, 20h (b) NH4Cl, 
556 = 35%; (ii) 5 eq. NH2NH2.H2O, 1 eq. camphoric acid, MeOH, reflux, 24h, 553 = 62% 
 
Scheme 4.38 
 
In order to overcome improve the yield of this reaction, transformation of intermediate 556 
was also investigated in the presence of one equivalent of hydrazine, along with camphoric 
acid in methanol for 3 hours at reflux. At this point, a small amount of desired product 553, 
was detectable by TLC, along with a large proportion of starting material 556. Following 
rapid addition of 4 equivalents of hydrazine to the reaction flask and vigorous reflux of the 
dark mixture for 24 hours, basic work-up and chromatography of the crude residue afforded 
5-aminopyrazole 553 in a satisfactory yield of 62%, on multi-gram scale.
34
  
4.10.3 Derivatisation of 4-(1-methyl-1H-indol-3-yl)-5-(3,4,5-trimethoxyphenyl)-5-
aminopyrazole  
 
A full comparative library of substituted 4-(1-methyl-1H-indol-3-yl)-3-(3,4,5-
trimethoxyphenyl)-5-aminopyrazole 553 analogues was obtained by diversity-oriented 
methodology (c.f. Section 4.9). This synthetic work has exploited the versatile rationale 
proposed by Peifer et al., by engineering a panel of novel congeners possessing the indole-
substituted combretastatin A-4 stilbene scaffold and diverse heterocyclic bridgehead systems 
in order to explore the chemical space between the H-bonding pyrrole ring and kinase 
backbone, with the potential for accessing new binding modes and attractive biological 
activity (Scheme 4.39).
78-81
  540, 557-563 
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4.10.3.1 Mono-N-substitution of aminopyrazole ring 
 
 
 
 
 
 
                                                                      540                                                                   
 
                     563                                                                                      557                     
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                  561                                                                
                                                                                                                      559 
                                                                      560                                                                                                                          
                                                                         
 
 
 
 
                  562 
Scheme 4.39: Target synthetic routes employed for chemical derivatisation of 4-(indol-3-yl)-3-
(3,4,5-trimethoxyphenyl)-5-aminopyrazole 553 
 
Utilising chemistry previously encountered in the bisindolyl series, the acetyl substituted 
analogue 557 was derived from reaction of acetic anhydride, which was stirred along with 
aminopyrazole 553 in refluxing acetonitrile, overnight. Following basic work-up, compound 
557 was purified by chromatography as an off-white crystalline solid in a yield of 40% 
(Scheme 4.39). Reaction of trifluoroacetic anhydride with parent 553 under similar 
conditions afforded the pyrazolic trifluoroacetamide 558, in identical yield of 40%, as a 
beige crystalline solid.  
Synthesis of a derivative furnishing attractive thioamide functionality was accomplished by 
heating of 553 with methyl isothiocyanate, in acetonitrile for 20 hours.
76
 The reaction was 
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quenched by addition of water and stored at 0
o
C for a further hour. Filtration of the resultant 
slurry afforded a crop of compound 559 as fine orange crystals. Evaporation of the mother 
liquor followed by chromatography of the light brown residue resulted in isolation of N
1
-
carbothioamide 559 in a cumulative yield of 34% (Scheme 4.39). In addition to observing 
the presence of the NH2 signal in 
1
H NMR, N
1
-substitution within this compound was also 
proven by obtaining a single crystal X-ray structure of this novel product (Fig. 4.18). The 
influence of conjugation observed in this structure also confirms the phenomenon of unequal 
electron distribution within these heterocyclic systems, consistent with NMR data. 
 
 
 
 
 
 
 
 
 
                                        559 
 
Fig. 4.18: Molecular structure of N
1
-substituted aminopyrazole derivative 559 
 
Heating of 553 and methanesulfonyl chloride in neat pyridine for 20 hours afforded 
arylsulfonamide 560, which was isolated following acidic work-up and chromatography, in a 
moderate yield of 35%, as a clay-coloured powder (Scheme 4.39).  
 
Synthesis of novel congener 562 possessing a warhead guanidine subunit neatly 
complemented our strategy for targeting bioactivity within compounds comprising varied H-
bonding and diverse enzyme-binding properties. 
 
Reaction of aminopyrazole 553 with (N,N‟-di-tert-butoxycarbonyl)thiourea 546, mercuric 
chloride, and triethylamine, in DCM, for 1 hour at 0
o
C, prior to stirring at room temperature 
overnight, afforded non-polar tert-butyl-[(5-amino-4-{1-methyl-1H-indol-3-yl}-3-(3,4,5-
trimethoxyphenyl)-1H-pyrazol-1-yl)({tert-butoxycarbonyl}amino)methylene] carbamate 
561 (35%), as the first fraction, eluting with 10% ethyl acetate/hexane. Deprotection of 561 
was subsequently carried out employing 10% TFA in DCM, in order to liberate the 
trifluoroacetate salt 562, following drying (Scheme 4.39).
77
  
 
 
 
Chapter 4                                                                                                     Chemical Results and Discussion                         
__________________________________________________________________________ 
                                                                         196 
4.10.3.2 Pyrazolo[1,5-a]pyrimidine heterocycle formation 
 
Formation of the bicyclic pyrazolo[1,5-a]pyrimidine derivative
 
563 was accomplished by 
heating of 553 with HFAA in acetic acid, at 120
o
C, for 16 hours. Following stirring of the 
dark red reaction mixture overnight, TLC analysis indicated formation of an intense red spot, 
corresponding to the heterocyclic product 563. Successful isolation of the pure derivative 
563, as a red crystalline solid, was achieved following hexane/ethyl acetate chromatography, 
in a yield of 45% (Scheme 4.39).  
 
The final reaction in this derivatisation study was undertaken in order to incorporate the 
novel planar H-bonding pyrazolo[1,5-a][1,3,5]triazine-2,4-dione nucleus, following 
conversion of 553 to cyclised congener 540, comprising the biologically relevant uracil 
structural motif.
58
  
Addition of the unsubstituted aminopyrazole 553 to chlorocarbonyl isocyanate, in DCM, 
along with a few drops of triethylamine, for 16 hours, afforded a heterogeneous dark brown 
slurry, and subsequently filtered in order to isolate novel congener 540, as a light brown 
powder, following successive washing with water and diethyl ether. Pure 8-(1-methyl-1H-
indol-3-yl)-7-(3,4,5-trimethoxyphenyl)pyrazolo[1,5-a][1,3,5]triazine-2,4(1H,3H)-dione 540 
was synthesised in an excellent yield of 64%, and required no further purification, under 
these conditions (Scheme 4.39). 
4.11 Synthesis of 4,5-bisindolyl-2-substituted imidazoles 
 
Synthesis of 1,2-bisindolyl-cis-ethene compounds bearing a novel substitution pattern (564) 
was also implemented, following initial design of imidazole bridgehead heterocycles 
incorporating novel indolocarbazole functionality 449 (Fig. 4.18).
12
 Major advantages of this 
route include incorporation of non-protected indole units, rapid access to dione precursor 
565, and the combinatorial nature of the final three-component imidazole-forming reaction.
82
 
Further study to extend the undoubted utility of this chemistry towards imidazo[4,5-
c]indolo[2,3-a]carbazole 449 synthesis is also being undertaken within our research group.  
 
 
 
 
 
                                                564                                               449 
Fig. 4.19: Design of a new imidazole-based indolocarbazole compound class 
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4.11.1 Synthesis of 1,2-bis(1H-indol-3-yl)ethane-1,2-dione 
 
The successful route to bisindolyl ethanedione 565, was accomplished following reaction of 
oxalyl chloride with indole 171, in diethyl ether as solvent, at room temperature, for 30 
minutes, to yield light orange 2-(1H-indol-3-yl)-2-oxoacetyl chloride 231 in a yield of 90%. 
This labile intermediate was prepared and used on the same day, as it could not be stored for 
more than a few hours at room temperature prior to degradation. Employing the conditions 
of Krayushkin et al., glyoxylyl chloride 231 was initially charged portionwise to a mixture 
of heptane and DCE, containing AlCl3. Following vigorous stirring of the heterogeneous 
dark red suspension at room temperature, a solution of 171 in DCE was added dropwise, and 
stirred for 3 hours.
83
 
 
                      171                                                  
  
 
         171                                                 231                                                     565 
 
Scheme 4.40 
 
The yield of compound 565 in this step became variable during up-scaling, but was 
successfully maintained in the range of 45-65%, and could not be improved by extending 
reaction time to 24 hours or by replacement of DCE with DCM. Trituration with 
ether/ethanol (20:1) isolated the desired intermediate 565 as a light brown powder in high 
purity, on multi-gram scale (Scheme 4.40).    
4.11.2 A potential one-pot condensation route to 4,5-bisindolylimidazoles  
 
With a scalable method to synthesise dione 565 in hand, one-pot thermal condensation 
offered a viable one-pot route to the novel 4,5-bisindolyl-2-substituted imidazole 564 
template. Reaction of dione 565 with ammonium acetate, along with an appropriate 
aldehyde, in refluxing acetic acid, for 24 hours, yielded a dark-red solution in each case, 
which, following chromatography, supplied the crude products (566-568) (Scheme 4.41).
82
 
                                                                                                  
                                                                                                                   566 
 
                                                                                                                   567 
                                                                                                      
                   565                                                         566-568                    568                                                                                                                           
Scheme 4.41 
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Using thiophene-2-carboxaldehyde, the product imidazole 566 was isolated as a red powder 
in a yield of 35%, following elution with 1% methanol/DCM. In the case of 
isobutyraldehyde, these conditions yielded 4,5-bisindolyl-2-isopropyl-imidazole 567, as a 
light brown solid (37%) following chromatography. Full purification of these derivatives 
was extremely challenging, and is the subject of current development, including 
investigation of reaction conditions and modes of crystallisation. 
4.11.3 Photochemical synthesis of imidazo[4,5-c]indolo[2,3-a]carbazoles 
 
Following identification of an efficient route to the acyclic bisindolyl imidazole framework 
564, a photochemical cyclisation step successfully furnished crude indolo[2,3-a]carbazoles 
in moderate yields.  
 
   
                                                                                                                         569 
 
                                                                                                                         570 
 
                 566-568                                                         449                            571 
   
Scheme 4.42 
 
Irradiation of 4,5-bisindolyl-2-(thien-2-yl)-substituted imidazole 566 in HPLC-grade 
acetonitrile (1 mg/2.5 mL), containing iodine (50 mol%), for 16 hours afforded cyclised 569 
in a crude yield of 25%. Exposure of 2-isopropyl imidazole 567 to U.V. irradiation, afforded 
indolocarbazole 570 in 33% yield (Scheme 4.42).  
 
Synthesis of a 2-(3,4,5-trimethoxyphenyl)-imidazole analogue was also deemed interesting 
as Caballero et al. previously reported 4-arylpyrrolo[3,4-c]carbazole-1,3-dione 572, with an 
IC50 value of 0.8 µM against mouse lymphoma cancer cell line P-388, with enhanced in vitro 
activity due to introduction of the 3,4,5-trimethoxyphenyl moiety as the key aryl subunit.
84
 
As illustrated in Scheme 4.41, imidazole 568 was initially formed as a red crystalline solid in 
a yield of 80%, prior to U.V. irradiation for 16 hours, to isolate aromatised congener 571 as a 
dark-red crystalline solid, semi-pure, in a yield of 92% after chromatography, along with an 
inseparable variable proportion of contaminating side material which resisted all attempts at 
removal, in order to furnish the fully pure final indolocarbazole derivative (Scheme 4.42).  
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                                                  572 
                                                                                                        571          
 
Fig. 4.20: Comparison beween a novel imidazole compound and anti-cancer 572 
 
This attractive methodology represents an original and economical route to access complex 
substituted indolocarbazole derivatives from indole 171 as a simple building block. 
Preliminary optimisation was carried out on the photocyclisation step, by determining the 
appropriate solvent, dilution level and reaction time. However, full characterization could 
not be achieved for these compounds, due to their difficult purification and LCMS 
purification of these compounds will be undertaken in future research.  
4.12 Conclusion 
 
Protein kinase inhibitors are an attractive goal for new drug therapy (especially in cancer 
chemotherapy). Inhibitors vary widely in structure and have inherent selectivity problems 
due to the wide abundance of the highly conserved ATP-binding pocket in which they bind. 
One of the templates used for kinase inhibition is based on the 3,4-bisindolylmaleimide 
structural motif, illustrated by the clinical PKC-β inhibitor ruboxistaurin 80, which 
comprises a critical enzyme-interacting pyrrol-2,5-dione moiety. The reduced lactam ring is 
also present in several bioactive indolo[2,3-a]carbazoles such as K-252c 6 and in arylindolyl 
systems such as 397 with prodigious inhibitory activity against VEGFR2 (Fig. 4.21). These 
structural classes represent the anti-cancer diarylpyrrole heterocyclic templates which were 
effectively modified over the course of this work.  
 
 
 
 
                80                                                      6                                           397                           
                                     
Fig. 4.21 
Chapter 4                                                                                                     Chemical Results and Discussion                         
__________________________________________________________________________ 
                                                                         200 
Extensive investigations were carried out into establishing a complete protocol for the 
preparation of indolo[2,3-a]pyrimido[5,4-c]carbazole 441 derivatives via a convergent route; 
it was found that a β-ketoester intermediate 478 allowed access to a wide number of 
pyrimidine analogues structurally related to ruboxistaurin 80 via base-mediated 
cyclocondensation (Fig. 4.22; A). 
 
Following work on optimisation of this route, a yield of 80% can now be achieved for         
β-ketoester intermediate 478; the novel bisindolylthiouracil compound 514 was subsequently 
formed in 24% yield, by methoxide-induced reaction of 478 with thiourea. Following 
extensive investigation, the thiouracil moiety was oxidatively desulfurised to yield the 
bisindolyl uracil congener 507, following heating with ethyl bromoacetate, in methanol. 
Additionally, formation of the reduced pyrimidin-4(3H)-one (lactam) 537 system by 
NaBH4/NiBr2 reaction, along with subsequent oxidative cyclisation, afforded an interesting 
indolo[2,3-a]carbazole analogue 538 with close structural similarity to the selective PKC-
inhibitory natural product K-252c 6 (Fig. 4.22; C).  
 
5,6-Bisindolyl-2-aminopyrimidin-4-one 445 was produced in 45% yield by means of a 
similar base-mediated conversion of 478, in the presence of guanidine carbonate.
2
 The 
ultimate aromatisation of this bisindolyl congener 445 to form novel 2-aminoindolocarbazol-
4(3H)-one 442 was studied under a number of reaction conditions which have been 
previously utilised in oxidative ring-closure within classical bisindolylmaleimide 
compounds. It has now been successfully achieved through U.V. irradiation (mercury lamp: 
254 nm/ Pyrex glassware) of a dilute mixture (2.5 mL/mg) of the acyclic isocytosine 445 in a 
3:2 acetonitrile/methanol solvent system, along with a catalytic amount of iodine, in air, for 
16 hours (Fig. 4.22; C). 
                       
 
Based on preliminary molecular modelling studies, new H-bonding networks were explored, 
which conserved key elements of the heterocyclic indolocarbazole pharmacophore. 
Resolving this challenge led to the design of a panel of novel 3,4-bisindolyl-5-
aminopyrazole derivatives within a new anti-cancer class (Fig. 4.22; A). Protection of 3-
indolylacetonitrile 229 as its N-methyl derivative 454 was achieved with NaH/iodomethane 
in 97% yield, which, on reaction with N-methyl indole-3-carbonyl chloride 479, under our 
modified Claisen conditions, enabled synthesis of the corresponding advanced β-ketonitrile 
precursor 541. Final 5-aminopyrazole 447 synthesis involved treatment of intermediate 541 
with excess hydrazine hydrate overnight, in refluxing ethanol, containing an acid catalyst. 
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Complementary work was undertaken to furnish (3,4,5-trimethoxyphenyl)-substituted 
indolylpyrazolone 552 and aminopyrazole 553, closely related to the potent arylindolyl 
VEGFR2 inhibitor 397, by initially employing a modifying Claisen route, along with 3,4,5-
trimethoxyphenyl carbonyl chloride 499 as acylating agent. Synthetic derivatisation of this 
5-aminopyrazole ring moiety was also investigated, in order to explore different pyrazolic H-
bonding orientations with potential anti-kinase activity resulting from enhanced protein 
backbone interactions (Fig. 4.22; B).        
 
 
 
    
 
 
 
                        80                                                  6                                          397                           
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.22: General structures of heterocyclic fused indolo[2,3-a]carbazole derivatives 
 
This work also identified a novel synthetic route towards heteroaryl-substituted bisindolyl 
imidazoles 566-567, 573, which were converted to the corresponding indolo[2,3-
a]carbazoles under optimised U.V. conditions, in the presence of air. However, solubility 
and purification issues have so far precluded their full isolation in high purity (Fig. 4.22; C).                         
 
During the course of this work, over 50 novel compounds have been synthesised by means 
of a range of chemistry previously unreported for the indolo[2,3-a]carbazole class, as well as 
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initiating successful chemistry for exploring the regioisomeric indolo[2,3-c]carbazole series 
via nucleophilic ring-opening, to afford attractive pyridazinedione 473 formation.  
 
Development of a novel route towards formation of 5,6-bisindolylpyrimidin-4-one 
derivatives, prior to transformation of this acyclic template to the fully planar pyrimido[5,4-
c]carbazole chromophore has been completed and dissemination of this work is underway 
through publication in peer-reviewed scientific literature. In order to probe the structural 
basis for arylindolyl kinase activity, constituent heteroaryl character was rationally varied, in 
order to access diverse substituted 4,5-bisindolyl, as well as 4-(N-methyl indol-3-yl)-3-
(3,4,5-trimethoxyphenyl)-5-aminopyrazole congeners.  
 
Finally, a valuable study of the factors affecting successful oxidative closure of novel 
bisindolyl heterocyclic precursors, to yield the final fully contiguous indolo[2,3-a]carbazole 
ring system was successfully accomplished, and this desirable transformation has been 
successfully rendered on a number of novel acyclic bisindolyl substrates by means of 
optimised photochemical methodology. 
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5.0 Experimental 
5.1 General Procedures 
 
All solvents were distilled prior to use as follows: DCM was distilled from phosphorus 
pentoxide, ethyl acetate was distilled from potassium carbonate, hexane was distilled prior to 
use, ethanol and methanol were distilled from magnesium in the presence of iodine and THF 
was distilled from benzophenone ketal. Diethyl ether was obtained pure from Riedel de 
Haen. All commercial reagents, anhydrous DMF and 1,4-dioxane were obtained from 
Aldrich and were used without further purification unless otherwise stated. Molecular sieves 
were dried by heating at >100
o
C overnight. Organic phases were dried using anhydrous 
magnesium sulfate. Thin layer chromatography (TLC) was carried out on precoated silica 
gel 60 (Merck PF254) plates and compounds were visualised either by UV (254 nm) light 
detection, vanillin staining or ceric sulfate staining. Column „dry flash‟ chromatography was 
carried out using Merck PF254 silica gel 60A. 
Melting points were measured in a Thomas Hoover Capillary Melting Point apparatus. 
Infrared (IR) spectra were recorded on a Perkin-Elmer FT-IR Paragon 1000 
spectrophotometer. Liquid samples were examined as thin films interspersed between 
sodium chloride plates. Solid samples were dispersed in potassium bromide and recorded as 
pressed discs. Mass spectra were recorded on a Waters Quattro Micro (QAA1202) in ESI 
positive or negative modes. High resolution mass spectra (HRMS) were recorded on a 
Waters Micromass LCT Premier mass spectrometer (Instrument number KD 160) in ESI 
positive and negative modes. An external reference standard of Leucine enkephalin was 
infused in order to confirm mass accuracy of the MS data acquired and a sulfadimethoxine 
concentration test was performed to ensure the accuracy of peaks in the ion count range 1 x 
e
3
 to 1 x e
6
. 
1
H (300 MHz) and 
13
C NMR (75 MHz) were recorded on a Bruker Avance 300 NMR 
spectrometer. All spectra were recorded at 20
o
C in deuterated chloroform (CDCl3) or DMSO 
(DMSO-d6) with tetramethylsilane (TMS) as internal standard unless otherwise specified. 
Chemical shifts (δH and δC) are expressed in parts per million (ppm), positive shift being 
downfield from TMS; coupling constants (J) are expressed in Hertz (Hz). Splitting patterns 
in 
1
H NMR spectra are designated as s (singlet), bs (broad singlet), d (doublet), dd (doublet 
of doublets), t (triplet), q (quartet) and m (multiplet). For 
13
C NMR spectra, the number of 
attached protons for each signal was determined using the DEPT-90 and DEPT-135 modes. 
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5.2 Chemical Data 
5.2.1 Initial routes to bisindolylmaleimides 
5.2.1.1 N,N’-Bis(o-tolyl)oxalamide 4591 
 
Oxalyl chloride (6.1 mL, 70 mmol) was syringed carefully into a 
reaction vessel containing 1,4-dioxane (20 mL), at 0
o
C. To this 
solution stirred under nitrogen atmosphere, was added o-toluidine 
460 (15 mL, 140 mmol) and triethylamine (19.5 mL, 140 mmol) 
in 1,4-dioxane (30 mL) dropwise, over 30 minutes. The mixture 
was allowed to stir in the ice-bath for a further 2 hours, after which it was warmed up to 
room temperature. Deionised water (100 mL) was added slowly to the reaction, and the 
contents were then transferred to a conical flask. Hot ethyl acetate (100 mL) was added to 
dissolve the slurry and the aqueous layer removed by very careful agitation, in a 500 mL 
separating funnel. The crude bisamide was then filtered and washed successively with 
several cold aliquots of hexane, yielding crystals of an off-white solid product, o-toluidide 
459 (9.811 g, 75%); m.p. 217-220
o
C (lit.
2
 215-216
o
C); νmax/ cm
-1
 (KBr) 3100, 1725, 1590; 
δH (300 MHz, CDCl3) 2.38 [6H, s, 2 × CH3], 6.96-7.16 [2H, m, aromatic C-H], 7.23-7.30 
[4H, m, aromatic C-H], 8.34-8.37 [2H, d, J 7.5, aromatic C-H], 9.67 [2H, bs, 2 × N-H]; δC 
(75 MHz, CDCl3) 17.6 (2CH3, 2 × CH3), 124.9 (2CH, 2 × aromatic CH), 126.2 (4CH, 4 × 
aromatic CH), 130.4 (2CH, 2 × aromatic CH), 132.3 (C, 2 × aromatic C), 135.0 (C, 2 × 
aromatic C), 158.5 (C, 2 × C=O); m/z (ES+) 269.0 [M+H]
+
 (10%), 114.9 (50%).  
 
5.2.1.2 2,2’-Biindolyl 1181                                                                                                                                      
 
Potassium tert-butoxide (1.052 g, 9.34 mmol) was added to 
the o-toluidide 459 (0.503 g, 1.87 mmol) in tert-butanol       
(5 mL). The mixture was heated vigorously and a micro-
distillation apparatus was employed to remove the solvent, 
along with heating up to 250
o
C. A white frothy solid was sublimated at this point. Heating 
could not be sustained to 280
o
C, at which point the cake melts. At maximum heating, 
achieved via sand bath, for 1 hour, the mixture was allowed to cool to room temperature. 
Water (5 mL) was then added and the resulting cake crushed. Ethanol (3 mL) was added to 
the residue and then heated to its boiling point. The solution was then cooled and filtered, 
prior to suction drying. However, the product 2,2‟-biindolyl 118 could not be produced 
under these conditions and this route was abandoned, without any further optimisation. 
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5.2.1.3 3,4-Dibromomaleic anhydride 453
3
 
 
In a pressure-resistant microwave tube was placed a solution of maleic 
anhydride (1.503 g, 15.3 mmol), along with a catalytic amount of 
aluminium chloride (0.028 g, 0.21 mmol) and bromine (1.5 mL, 30.6 
mmol, 2 eq.). The tube was then sealed and heated to 120
o
C for 16 hours. 
On cooling to room temperature, the mixture was taken up in ethyl acetate, filtered and the 
dark brown filtrate concentrated in vacuo to afford 2,3-dibromomaleic anhydride 453 as a 
beige solid (3.520 g, 90%); m.p. 105-107
o
C (lit.
3
 113-114
o
C); νmax/ cm
-1 
(KBr) 1735, 1466; 
δC (75 MHz, CDCl3) 131.8 (2C, 2 × C-Br), 152.1 (2C, 2 × C=O); m/z (ES-) 274.8 [M+H2O-
H]
-
 (5%), 194.9, 192.9 [M+H2O-HBr]
-
 (60%). 
 
5.2.1.4 1-Benzyl 3,4-dibromomaleimide 157
3
 
 
3,4-Dibromomaleic anhydride 453 (1.004 g, 4.43 mmol) was dissolved 
in acetic acid (20 mL) in a nitrogen purged flask. To the stirring solution 
was added benzylamine (0.5 mL, 4.7 mmol, 1.1 eq.) added dropwise 
over a few minutes. Reflux at 120
 o
C was then applied to the vessel for 3 
hours. After removal of the solvent under reduced pressure, flash 
column chromatography using 15% ethyl acetate/ hexane as the eluent yielded a pure 
fraction, confirmed by TLC analysis to be the maleimide product 157 (0.900 g, 60%); m.p. 
115-118
o
C (lit.
3
 107-108
o
C); νmax/ cm
-1
 (KBr) 2916, 1740, 1623, 1438; δH (300 MHz, 
CDCl3) 4.75 [2H, s, CH2], 7.30-7.37 [5H, m, 5 × aromatic C-H]; δC (75 MHz, CDCl3) 43.2 
(CH2, N-CH2), 128.4 (CH, aromatic CH), 128.8 (2CH, 2 × aromatic CH), 128.9 (2CH, 2 × 
aromatic CH), 129.5 (C, aromatic C), 135.2 (2C, 2 × C-Br), 163.6 (2C, 2 × C=O); m/z (ES+) 
114.9 (100%), (ES-) 78.7, 80.8 (100%). 
 
5.2.1.5 1-Benzyl-3,4-bis(1H-indol-3-yl)-1H-pyrrole-2,5-dione 155
4
 
 
A solution of hexamethyldisilazane (0.5 mL, 2.32 mmol), in 
dry toluene (10 mL), was cooled to −78oC, under inert 
atmosphere, prior to the dropwise addition of 2.5 M                 
n-butyllithium (1 mL, 2.4 mmol) over 10 minutes. The stirring 
mixture was then placed in an ice-bath for 10 minutes, followed 
by the addition of indole 171 (0.268 g, 2.32 mmol) in toluene 
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(10 mL), and stirred for a further 30 minutes at –78oC. N-Benzyl 3,4-dibromomaleimide 157 
(0.400 g, 1.16 mmol) was then dissolved in toluene (10 mL) and added to the vessel, 
eliciting formation of a blue solution, then kept at room temperature for 20 minutes. The 
reaction was refluxed for 16 hours and then poured into 0.2 M aqueous HCl (50 mL), 
followed by extraction with ethyl acetate. Following washing with sodium bicarbonate, 
water and brine solution, the dried filtrate was passed through a pad of celite. The mother 
liquor was then concentrated and washed with ethyl acetate to yield a red solid in a yield of 
42%, but which could only be identified by nominal mass spectrometry as containing 
bisindolylmaleimide 155 (along with degradation of starting material); m/z (ES+) 418 
[M+H]
+
 (100%). 
5.2.1.6 2-Benzyl-8,9-dihydro-1H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-1,3(2H)-dione 
241
5
 
 
Crude bisindolyl intermediate 155 (0.101 g, 0.342 g) was added 
to dry toluene (30 mL), along with DDQ (0.085 g, 0.374 mmol). 
A catalytic amount of p-TSA was then added to the stirring 
mixture. The vessel was then heated to reflux for one hour. The 
solvent was then removed under reduced pressure to yield a 
residue, which was redissolved in ethyl acetate, adsorbed on 
celite
®
 and purified by flash chromatography. Employing 25% 
ethyl acetate/ hexane as eluent, fractions containing a yellow fluorescent material were 
isolated, but produced only a negligible amount of the fully aromatised indolocarbazole 241, 
which could not be isolated for further study and was not optimised. 
5.2.1.7 1-Methyl methyl 1H-indol-3-yl glyoxylate 457
6
 
 
To a solution of N-methyl indole 456 (2.011 g, 15.2 mmol) in diethyl 
ether (20 mL), at 0
o
C, oxalyl chloride (3 mL, 34.4 mmol) was added 
dropwise, over 10 minutes. The yellow slurry was stirred at 0
o
C for 30 
minutes, and then cooled to −65oC prior to slow addition of a 25% 
methanolic sodium methoxide solution (15.6 mL, 68.2 mmol) to the 
reaction mixture, while maintaining the internal temperature below −60oC. The reaction was 
allowed to warm to room temperature and then quenched by the addition of water (10 mL). 
The precipitated solid was isolated by filtration and dried under vacuum to give the product 
N-methyl glyoxylate ester 457 as a light brown amorphous powder (1.380 g, 42%); m.p. 
102-104
o
C (lit.
7
 96-97
o
C); νmax/ cm
-1
 (KBr) 2953, 1736, 1634, 1621, 1581, 1509, 1419; δH 
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(300 MHz, DMSO-d6) 3.90 [3H, s, O-CH3], 3.92 [3H, s, N-CH3], 7.30-7.35 [1H, td, J 7.2, 
1.3, aromatic C-H5], 7.35-7.40 [1H, td, J 7.2, 1.5, aromatic C-H6], 7.61-7.64 [1H, dd, J 6.9, 
1.5, aromatic C-H7], 8.17-8.20 [1H, m, aromatic C-H4], 8.51 [1H, s, aromatic C-H2]; δC (75 
MHz, DMSO-d6) 33.5 (CH3, N-CH3), 52.5 (CH3, O-CH3), 111.2 (CH, aromatic CH), 111.2 
(C, aromatic C), 121.3 (CH, aromatic CH), 123.2 (CH, aromatic CH), 123.9 (CH, aromatic 
CH), 125.9 (C, aromatic C), 137.4 (C, aromatic C), 141.6 (CH, aromatic CH), 163.9 (C, 
CO2CH3), 178.0 (C, C=O); m/z (ES+) 218.0 [M+H]
+
 (20%). 
5.2.1.8 1-Methyl 1H-indol-3-yl acetamide 455
6
 
 
To a solution of N-methyl 3-indolylacetonitrile 454 (2.010 g, 11.8 
mmol) and TBAB (0.507 g, 1.6 mmol) in DCM (12 mL), at 0
o
C, was 
added 30% aqueous hydrogen peroxide solution (5 mL), followed by 
20% aqueous NaOH solution (4 mL). The mixture was stirred at room 
temperature for 20 hours. DCM (80 mL) was then added to the reaction 
and washed with 5% aqueous HCl (70 mL), water (70 mL), dried over magnesium sulfate 
and filtered. Following solvent removal, hexane (30 mL) was added to the viscous beige 
slurry and this was then filtered under vacuum. Rinsing the acetamide 455 with DCM/ 
hexane (1:1) (15 mL) afforded the final purified product as a yellow powder (1.151 g, 52%); 
m.p. 181-184
o
C (lit.
8
 182-184
 o
C); νmax/ cm
-1
 (KBr) 3437, 3190, 1650, 1623, 1475; δH (300 
MHz, CDCl3) 3.47 [2H, s, CH2], 3.74 [3H, s, N-CH3], 6.87 [1H, bs, NH], 7.00-7.05 [1H, t, J 
7.8, aromatic C-H5], 7.12-7.17 [1H, t, J 7.2, aromatic C-H6], 7.17 [1H, s, aromatic C-H2], 
7.35 [1H, bs, NH], 7.37-7.40 [1H, d, J 8.2, aromatic C-H7], 7.55-7.58 [1H, d, J 7.8, aromatic 
C-H4]; m/z (ES+) 189.1 [M+H]
+
 (40%).   
5.2.1.9 3,4-Bis(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione 172
6
 
 
To a suspension of the N-methyl indole-3-acetamide 455 
(0.333 g, 1.77 mmol) and N-methyl methyl indole-3-
glyoxylate 457 (0.460 g, 2.12 mmol) in dry THF (5 mL), at 
0
o
C, was added 1M potassium tert-butoxide in THF (5.3 mL, 
5.3 mmol). The reaction was then allowed to stir at room 
temperature for 3 hours, and subsequently quenched by addition of 5% HCl (10 mL). The 
resultant slurry was then cooled to 0
o
C and the purified bisindolylmaleimide 172 was 
isolated by vacuum filtration to yield a bright red crystalline solid. The mother liquor was 
then recovered, recooled and filtered to afford a second crop of N-methyl arcyriarubin A 
derivative 172 (0.230 g), and in an overall yield of 0.420 g (67%); m.p. >300
o
C (lit.
9
 357-
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359
o
C); νmax/ cm
-1
 (KBr) 3411, 1709, 1608, 1523; δH (300 MHz, DMSO-d6) 3.85 [6H, s, 2 × 
N-CH3], 6.63-6.68 [2H, t, J 7.3, aromatic C-H5,5‟], 6.76-6.79 [2H, d, J 8.0, aromatic C-H7,7‟], 
7.02-7.06 [2H, t, J 7.3, aromatic C-H6,6‟], 7.41-7.44 [2H, d, J 8.2, aromatic C-H4,4‟], 7.80 
[2H, s, aromatic C-H2,2‟], 10.91 [1H, bs, NH]; δC (75 MHz, DMSO-d6) 31.7 (2CH3, 2 × N-
CH3), 103.6 (2C, 2 × aromatic C), 108.9 (2CH, 2 × aromatic CH), 118.4 (2CH, 2 × aromatic 
CH), 120.0 (2CH, 2 × aromatic CH), 120.5 (2CH, 2 × aromatic CH), 124.8 (2C, 2 × aromatic 
C), 125.9 (2C, 2 × aromatic C), 131.9 (2CH, 2 × aromatic CH), 135.3 (2C, 2 × aromatic C), 
171.8 (2C, 2 × C=O); m/z (ES+) 356.0 [M+H]
+ 
(25%).  
 
5.2.2 Synthesis of indolo[2,3-c]carbazole analogues  
5.2.2.1 3-(3’-Hydroxyindolin-2’-one)indole 47010 
 
A mixture of indole 171 (5.854 g, 50 mmol), isatin (7.356 g, 50 
mmol), 98% diethylamine solution (1 mL) and absolute ethanol 
(75 mL) was heated at 45
o
C for 3 hours. The dark red solution 
was then stirred vigorously at 25
o
C for a further 20 hours. The 
reaction was then heated to 45
o
C for a further hour, prior to 
cooling to room temperature. Water (200 mL) was added to the clear, red solution and some 
turbidity was observed at this point. Following further cooling to 0
o
C, crystallisation was 
complete and the crude solid (13.723 g) was filtered under vacuum. Recrystallisation of 470 
was achieved from methanol, to afford a crop of light pink crystals (10.821 g, 91%); m.p. 
124-127
o
C (lit.
10
 122-123
o
C); νmax/ cm
-1
 (KBr) 3415, 3208, 3056, 1708, 1617, 1470; δH (300 
MHz, DMSO-d6) 6.37 [1H, s, OH], 6.85-6.90 [1H, t, J 6.9, aromatic C-H5‟], 6.90-6.93 [1H, 
d, J 7.5, aromatic C-H7‟], 6.93-6.99 [1H, t, J 7.5, aromatic C-H6‟], 7.00-7.06 [1H, t, J 7.4, 
aromatic C-H5], 7.08-7.09 [1H, d, J 2.5, aromatic C-H2], 7.23-7.26 [1H, d, J 7.4, aromatic C-
H4‟], 7.23-7.28 [1H, t, J 7.3, aromatic C-H6], 7.33-7.38 [2H, m, aromatic C-H4,7], 10.36 [1H, 
bs, indolic NH], 11.00 [1H, bs, NH-CO]; δC (75 MHz, DMSO-d6) 74.9 (C, C-OH), 109.6 
(CH, aromatic CH), 111.5 (CH, aromatic CH), 115.4 (C, aromatic C), 118.4 (CH, aromatic 
CH), 120.3 (CH, aromatic CH), 121.0 (CH, aromatic CH), 121.7 (CH, aromatic CH), 123.5 
(CH, aromatic CH), 124.7 (CH, aromatic CH), 124.9 (C, aromatic C), 129.0 (CH, aromatic 
CH), 133.4 (C, aromatic C), 136.8 (C, aromatic C), 141.6 (C, aromatic C), 178.4 (C, C=O); 
m/z (ES+) 247.1 [M-H2O+H]
+ 
(100%). (ES-) 263.1 [M-H]
-
 (100%).   
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5.2.2.2 3,3'-Biindolyl 466
10
 
 
1,2-Dimethoxyethane (30 mL) was charged into a nitrogen-purged 
flask containing finely ground sodium borohydride (2.285 g, 60 
mmol) and indolin-2-one derivative 470 (5.611 g, 20 mmol). A 
solution of boron trifluoride-diethyl etherate complex (9.9 mL, 80 
mmol) in 1,2-dimethoxyethane (10 mL) was then added slowly via 
dropping funnel to the straw-coloured, vigorously stirred, reaction mixture. On half-addition, 
the mixture assumed a viscous, light green appearance, but following total addition, a beige 
coloured slurry was observed. At this point, the reaction was allowed to stir for a further 
hour at room temperature; 10% HCl (25 mL) was then added, and the resulting suspension 
was diluted with water (120 mL). The formed solids were filtered, redissolved in THF (30 
mL) at 50
o
C, and rapidly filtered at this temperature. DCM (60 mL) was slowly added to the 
filtrate solution, until turbidity became apparent. On cooling to 0
oC, the light green 3,3‟-
biindolyl 466 precipitated immediately. This was then filtered under vacuum, washed with 
DCM (2 × 5 mL), and dried in air, to yield the product 466 as fine plate crystals (1.925 g, 
41%); m.p. 287-290
o
C (lit.
10
 285-287
o
C); νmax/ cm
-1
 (KBr) 3396, 1615, 1586, 1456, 1410; δH 
(300 MHz, DMSO-d6) 7.06-7.11 [2H, t, J 6.8, aromatic C-H5,5‟], 7.15-7.20 [2H, t, J 7.0, 
aromatic C-H6,6‟], 7.48-7.51 [2H, d, J 7.9, aromatic C-H7,7‟], 7.68 [2H, d, J 2.4, aromatic C-
H2,2‟], 7.81-7.84 [2H, d, J 7.7, aromatic C-H4,4‟], 11.19 [2H, bs, 2 × NH]; δC (75 MHz, 
DMSO-d6) 109.7 (2C, 2 × aromatic C), 111.6 (2CH, 2 × aromatic CH), 118.8 (2CH, 2 × 
aromatic CH), 119.6 (2CH, 2 × aromatic CH), 121.2 (2CH, 2 × aromatic CH), 121.8 (2CH, 2 
× aromatic CH), 126.1 (2C, 2 × aromatic C), 136.4 (2C, 2 × aromatic C); m/z (ES+) 232.1 
[M+H]
+
 (70%). 
5.2.2.3 Furo[3,4-a]indolo[2,3-c]carbazole-6,8(5H,9H)-dione 467
11
 
 
Glacial acetic acid (50 mL) was added to a flask containing 3,3‟-
biindolyl 466 (1.803 g, 7.76 mmol) and maleic anhydride (1.594 
g, 15.5 mmol, 2 eq.). The heterogeneous mixture was stirred 
vigorously and heated to 110
o
C and allowed to reflux. The 
reaction mixture initially assumed a cherry colour and eventually, 
a deep red colour, as heating progressed. The reaction proceeded 
for 60 hours, at which point no starting material was evident. The 
solvent was then evaporated under reduced pressure; toluene (2 × 10 mL) was added to the 
reaction flask and evaporated, followed by the addition and evaporation of DCM (2 × 10 
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mL). Diethyl ether (70 mL) was added to the brown residue, and then filtered under vacuum 
to afford dark red crystals, washed with ether (2 × 7 mL), dried and isolated as the 
indolocarbazole 467 (1.738 g, 68%); m.p. >300
o
C (lit.
11
 >250
o
C); νmax/ cm
-1
 (KBr) 3403, 
3360, 1808, 1741, 1715, 1614, 1460; δH (300 MHz, DMSO-d6) 7.40-7.44 [2H, t, J 7.3, 
aromatic C-H2,12], 7.60-7.65 [2H, t, J 7.4, aromatic C-H3,11], 7.77-7.79 [2H, d, J 8.1, 
aromatic C-H4,10], 8.76-8.79 [2H, d, J 8.2, aromatic C-H1,13], 12.32 [2H, s, 2 × NH]; δC (75 
MHz, DMSO-d6) 109.2 (2C, 2 × aromatic C), 112.5 (2CH, 2 × aromatic CH), 120.2 (2CH, 2 
× aromatic CH), 120.4 (2C, 2 × aromatic C), 123.8 (2CH, 2 × aromatic CH), 127.8 (2CH, 2 
× aromatic CH), 129.1 (2C, 2 × aromatic C), 142.5 (2C, 2 × aromatic C), 163.5 (2C, 2 × 
aromatic C), 172.0 (2C, 2 × C=O); m/z (ES+) 588.2 (100%), 359.0 [M+Na]
+
 (30%). (ES-) 
325.1 [M-H]
-
 (5%).  
5.2.2.4 5H-Indolo[2,3-c]pyrrolo[3,4-a]carbazole-6,8(7H,9H)-dione 468
11
 
 
Glacial acetic acid (50 mL) was added to a flask containing 3,3‟-
biindolyl 466 (1.803 g, 7.76 mmol) and maleimide (1.505 g, 15.5 
mmol, 2 eq.). The heterogeneous mixture was stirred vigorously 
and heated to 110
o
C and allowed to reflux. The reaction mixture 
initially assumed a cherry colour and eventually, a deep red 
colour, as heating progressed. The reaction proceeded for 36 
hours, at which point no starting material 466 was evident. The 
solvent was then evaporated under reduced pressure; toluene (2 × 10 mL) was added to the 
reaction flask and evaporated, followed by the addition and evaporation of DCM (2 × 10 
mL). Diethyl ether (70 mL) was added to the brown residue, and then filtered under vacuum 
to afford dark red crystals, washed with ether (2 × 7 mL), dried and isolated as title 
compound 468 (1.566 g, 62%); m.p. >300
o
C (lit.
11
 >250
o
C); νmax/ cm
-1
 (KBr) 3419, 3361, 
3189, 1739, 1703, 1681, 1459; δH (300 MHz, DMSO-d6) 7.39-7.44 [2H, td, J 7.1, 0.9, 
aromatic C-H2,12], 7.56-7.61 [2H, t, J 7.5, aromatic C-H3,11], 7.79-7.82 [2H, d, J 8.0, 
aromatic C-H4,10], 8.82-8.85 [2H, d, J 8.2, aromatic C-H1,13], 11.09 [1H, bs, CO-NH-CO], 
12.07 [2H, s, 2 × NH]; δC (75 MHz, DMSO-d6) 111.5 (2C, 2 × aromatic C), 112.4 (2CH, 2 × 
aromatic CH), 119.7 (2CH, 2 × aromatic CH), 120.6 (2C, 2 × aromatic C), 122.5 (2C, 2 × 
aromatic C), 123.5 (2CH, 2 × aromatic CH), 127.0 (2CH, 2 × aromatic CH), 128.5 (2C, 2 × 
aromatic C), 142.4 (2C, 2 × aromatic C), 170.1 (2C, 2 × C=O); m/z (ES-) 324.1 [M-H]
-
 
(10%).  
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5.2.2.5 7,8-Dihydroindolo[2,3-c]pyridazino[4,5-a]carbazole-6,9(5H,10H)-dione 473 
 
To a suspension of furo[3,4-a]indolo[2,3-c]carbazole-
6,8(5H,9H)-dione 467 (0.150 g, 0.46 mmol) in acetic acid          
(10 mL), was added hydrazine monohydrate (0.06 mL, 1.01 
mmol, 2.2 eq.). The dark reaction was then stirred at reflux 
temperature for 24 hours, at which point, solvent was removed in 
vacuo and the resultant residue was added to a flask containing 
diethyl ether (35 mL). Following stirring for 15 minutes, the dark 
brown precipitate was filtered and washed with water (2 × 10 mL) and ether (2 × 10 mL) 
successively, prior to drying. This afforded the novel indolo[2,3-c]carbazole 473 as a brown 
amorphous powder (0.111 g, 70%); m.p. >300
o
C; νmax/ cm
-1
 (KBr) 3412, 2923, 1710, 1650, 
1619, 1461, 1326; δH (300 MHz, DMSO-d6) 7.42-7.46 [2H, t, J 7.2, aromatic C-H2,13], 7.56-
7.61 [2H, t, J 7.4, aromatic C-H3,12], 8.03-8.06 [2H, d, J 8.1, aromatic C-H4,11], 8.89-8.92 
[2H, d, J 8.2, aromatic C-H1,14], 11.91 [2H, s, 2 × NH-CO], 12.10 [2H, bs, 2 × NH]; δC (75 
MHz, DMSO-d6) 109.9 (2C, 2 × aromatic C), 112.9 (2CH, 2 × aromatic CH), 118.9 (2C, 2 × 
aromatic C), 119.3 (2CH, 2 × aromatic CH), 120.4 (2C, 2 × aromatic C), 123.0 (2CH, 2 × 
aromatic CH), 126.0 (2CH, 2 × aromatic CH), 129.6 (2C, 2 × aromatic C), 140.4 (2 × 
aromatic C), 168.0 (2C, 2 × C=O); m/z (ES-) 339.1 [M-H]
- 
(40%); HRMS - (ES-) requires: 
339.0882. Found: 339.0898 (C20H11N4O2). 
5.2.2.6 Attempted Curtius rearrangement of furo[3,4-a]indolo[2,3-c]carbazole-
6,8(5H,9H)-dione (467) 
 
 
 
 
 
                                         467                                                             473                                        
Table 5.1 
Reactant Azide source Equiv. Solvent Temp/oC  Time Product  
467 NaN3 10 eq. DMF 110 24h n.r 
467 NaN3 10 eq. DMSO 150 24h n.r 
467 NaN3 10 eq. DMF 110 24h n.r 
467 
467 
TMS-N3 
TMS-N3 
3 eq. 
10 eq. 
DMF 
DMSO 
110 
150 
24h 
24h 
n.r 
n.r 
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General reaction: 
 To a flame-dried flask containing 467 (0.150 g, 0.46 mmol), was added NaN3 
(0.300 g, 4.6 mmol, 10 eq.) or TMS-N3 (0.2 mL, 1.4 mmol, 3 eq.) and anhydrous 
DMF (7 mL), under inert atmosphere, prior to heating to 100
o
C and stirring at 
this temperature for 20 hours. 
Following addition of water (25 mL), the reaction was stirred for 1 hour; however, no 
reaction had occurred and only starting material could be detected following work-up. 
 
5.2.3 Formation and derivatisation of 5,6-bisindolylpyrimidin-4-one derivatives 
5.2.3.1 6-Chlorouracil 462
12
 
 
2,4,6-Trichloropyrimidine 461 (1.001 g, 5.48 mmol) was suspended in 
aqueous NaOH (4 M, 50 mL), prior to stirring at reflux temperature 
overnight. The resulting slurry was filtered in order to remove the residual 
starting material 461, and the resulting filtrate was evaporated under reduced 
pressure to isolate a white solid of 6-chlorouracil 462 (0.646 g, 80%), which was easily 
identified by means of its characteristic IR carbonyl stretches; m.p. 295-298
o
C (lit.
13
 287-
289
o
C); νmax/ cm
-1
 (KBr) 3375, 3220, 1528; m/z (ES-) 144.9 [M-H]
-
 (100%).   
5.2.3.2 Attempted formation of 5-bromo-6-chlorouracil 463 
 
6-Chlorouracil 462 (1.003 g, 6.8 mmol) was reacted with bromine water 
(bromine (0.58 mL, 11 mmol, 1.6 eq.), dissolved in water (50 mL)) and 
heated to 60
o
C overnight. Following evaporation of the solvent, it was noted 
that only starting 462 could be isolated and no reaction had taken place.  
 
5.2.3.3 Microwave approach to pyrimidinone formation 
5.2.3.3.1 Ethyl 1H-indol-3-yl acetate 502 
 
Indole-3-acetic acid 233 (1.002 g, 5.7 mmol) was stirred in the presence of 
dry ethanol (20 mL), and then cooled to −78oC. Thionyl chloride (0.5 mL, 
6.25 mmol) was then delivered slowly into the cooled reaction vessel over 
10 minutes. The reaction was allowed to stir overnight while gradually 
warming to room temperature. Following subsequent removal of solvent, 
and extraction between ethyl acetate and water, ester 502 was isolated pure as a violet oil, 
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which subsequently solidified (1.163 g, 100%); m.p. 45-47
o
C (lit.
14
 41-43
o
C) νmax/ cm
-1
 
(NaCl) 3411, 2982, 1732; δH (300 MHz, CDCl3) 1.24-1.29 [3H, t, J 7.1, CO2CH2CH3], 3.77 
[2H, s, CH2CO2Et], 4.13-4.20 [2H, q, J 7.1, CO2CH2CH3], 7.10-7.16 [1H, td, J 7.1, 1.1, 
aromatic C-H5], 7.17-7.22 [1H, td,  J 7.1, 1.2, aromatic C-H6], 7.17 [1H, s, aromatic C-H2], 
7.34-7.36 [1H, d, J 8.1, aromatic C-H7], 7.61-7.64 [1H, d, J 8.3, aromatic C-H4], 8.11 [1H, 
bs, NH]; m/z (ES+) 204.1 [M+H]
+
 (100%).  
5.2.3.3.2 1-Ethoxycarbonyl ethyl 1H-indol-3-yl acetate 503
15
 
 
Ethyl chloroformate (0.18 mL, 1.81 mmol) was added dropwise over 
a 15 minute period, to a rapidly stirred mixture of ethyl indole-3-
acetate 502 (0.325 g, 1.6 mmol) and TBAB (0.009 g, 0.029 mmol) in 
dry DCM (5 mL) and 30% NaOH solution (5 mL). Following stirring 
for 1 hour at 0
o
C, the two distinct layers were observed to separate. 
Following extraction of the aqueous layer with DCM, the combined 
organic layers were washed successively with water and brine, dried with magnesium sulfate 
and evaporated in vacuo. The crude carbamate 503 was then purified by column 
chromatography, with 20% ethyl acetate/ hexane as eluent, yielding a colourless oil used 
without further purification (0.337 g, 76%); νmax/ cm
-1
 (KBr) 2983, 1738, 1732, 1613, 1574, 
1455; δH (300 MHz, CDCl3) 1.27 [3H, t, J 6.9, CH3 (ester)], 1.46 [3H, t, J 6.9, CH3 
(carbamate)], 3.71 [2H, s, CH2CO2Et], 4.16 [2H, q, J 6.9, CH2 (ester)],  4.18 [3H, q, J 6.9, 
CH2 (carbamate)], 7.24-7.35 [2H, m, aromatic C-H5,6], 7.53-7.55 [1H, m, aromatic C-H7], 
7.62 [1H, s, aromatic C-H2], 8.16-8.19 [1H, m, aromatic C-H4]; (ES+) 276.1 [M+H]
+
 
(100%).  
5.2.3.3.3 1-(p-Toluenesulfonyl)-1H-indole 505
16
 
 
Indole 171 (1.004 g, 8.5 mmol) was added to a rapidly stirring solution 
of TBAHS (0.453 g, 1.28 mmol) in toluene (25 mL) at 0
o
C, was added 
50% aqueous NaOH solution (25 mL), followed by freshly 
recrystallised p-toluenesulfonyl chloride (2.503 g, 12.8 mmol). The 
resultant mixture was then stirred vigorously at room temperature for a 
further 16 hours. The toluene layer was then separated, washed with 
aqueous 1 M HCl (2 × 25 mL), saturated aqueous sodium bicarbonate (2 × 25 mL), water 
(25 mL) and brine (25 mL), followed by drying over magnesium sulfate. The filtrate was 
then evaporated under reduced pressure to yield pure compound 505 as a white solid (2.821 
g, 96%); m.p. 90-92
o
C (lit.
17
 85-86
o
C); νmax/ cm
-1
 (KBr) 1596, 1446, 1369, 1168; δH (300 
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MHz, CDCl3) 2.31 [3H, s, CH3], 6.64-6.65 [1H, dd, J 3.7, 1.0, aromatic C-H3], 7.18-7.24 
[3H, m, aromatic C-H5,3‟,5‟], 7.27-7.33 [1H, td, J 8.4, 1.3, aromatic C-H6], 7.50-7.53 [1H, d, J 
7.6, aromatic C-H7], 7.55-7.56 [1H, d, J 3.7, aromatic C-H2], 7.74-7.77 [2H, d, J 8.4, 
aromatic C-H2‟,6‟], 7.97-8.00 [1H, d, J 8.3, aromatic C-H4]; δC (75 MHz, CDCl3) 21.6 (CH3, 
C-CH3), 109.0 (CH, aromatic CH), 113.5 (CH, aromatic CH), 121.4 (CH, aromatic CH), 
123.3 (CH, aromatic CH), 124.6 (CH, aromatic CH), 126.3 (2CH, 2 × aromatic CH), 126.8 
(2CH, 2 × aromatic CH), 129.9 (CH, aromatic CH), 130.8 (C, aromatic C), 134.8 (C, 
aromatic C), 135.3 (C, aromatic C), 144.9 (C, aromatic C); m/z (ES+) 272.1 [M+H]
+
 
(100%). 
5.2.3.3.4 1-(p-Toluenesulfonyl) 1H-indol-3-yl carbonyl chloride 504
18
 
 
Aluminium chloride (0.252 g, 1.85 mmol) was added to dry DCM (10 
mL), maintained at 0
o
C in an ice-bath. Oxalyl chloride (0.16 mL, 1.85 
mmol) was then added over several minutes, and after a further 30 
minutes, p-toluenesulfonyl indole 505 (0.100 g, 0.37 mmol) in DCM (10 
mL) was added to the reaction mixture and allowed to warm gradually to 
room temperature. Following stirring for an additional 2 hours, crushed 
ice (25 mL) was added and the aqueous layer was extracted with DCM (3 
× 10 mL). The usual work-up, with saturated aqueous sodium bicarbonate (2 × 25 mL), 
water (25 mL) and brine (25 mL), followed by drying with magnesium sulfate and 
concentration in vacuo, produced the acid chloride 504 as a viscous brown oil (0.129 g, 
100%), used without any further purification, following IR analysis; νmax/ cm
-1
 (film) 3350, 
1744, 1532, 1383, 1178.  
5.2.3.3.5 2-(1-Ethoxycarbonyl-1H-indol-3-yl)-3-(1-p-toluenesulfonyl-1H-indol-3-yl) 
ethyl-3-oxopropionate 501 
  
LDA solution (1.8 M, 8.9 mL, 16.1 mmol, 2.2 eq.) was added 
dropwise over a period of 20 minutes, to dry THF (30 mL), at     
−78oC, under nitrogen. A mixture of ester 503 (2.012 g, 7.3 
mmol) in THF (3 mL) was then added to the reaction vessel, at 
a sufficient rate to maintain the internal reaction temperature at 
below −65oC, during addition. The dark brown solution was 
then stirred vigorously for 90 minutes. The p-toluenesulfonyl 
protected acid chloride 504 (2.905 g, 8.7 mmol, 1.2 eq.) was 
then dissolved in dry THF (7 mL) and added to the vessel slowly, over 15 minutes. Stirring 
of the reaction mixture proceeded at room temperature overnight, and, following subsequent 
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solvent removal, was quenched with the addition of saturated aqueous ammonium chloride 
solution. Following the usual ethyl acetate/ water work-up conditions outlined above, a crude 
di-protected ketoester 501 was produced, which was then crystallised from 95% ethanol and 
water, to yield a light brown solid, on vacuum filtration, easily identified by means of its 
characteristic sulfonamide bands in IR, and then dried under high vacuum overnight (0.810 
g, 25%); m.p. 192-196
oC (dec.); νmax/ cm
-1
 (KBr) 2980, 2927, 1739, 1732, 1669, 1455, 1379, 
1175; δH (300 MHz, CDCl3) 1.26 [3H, t, J 7.0, CH3 (ester)], 1.45 [3H, t, J 7.0, CH3 
(carbamate)], 2.32 [3H, s, p-CH3-Ar], 4.28 [2H, q, J 7.0, CH2 (ester)], 4.43-4.50 [2H, m, CH2 
(carbamate)], 5.64 [1H, s, C-H], 7.13-7.16 [2H, m, aromatic C-H], 7.33-7.41 [4H, m, 
aromatic C-H], 7.53-7.56 [2H, m, aromatic C-H], 7.86-7.92 [1H, m, aromatic C-H], 7.86-
7.98 [2H, m, aromatic C-H], 8.23-8.28 [1H, m, aromatic C-H], 8.31-8.36 [2H, m, aromatic 
C-H]; m/z (ES+) 573.1 [M+H]
+
 (100%); HRMS - (ES+) requires: 573.1695. Found: 
573.1674 (C31H29N2O7S).   
5.2.3.3.6 2-(1-Ethoxycarbonyl-1H-indol-3-yl)-3-(1-methyl-1H-indol-3-yl) ethyl-3-
oxopropionate 508 
 
1.8 M LDA solution (8.9 mL, 16.1 mmol, 2.2 eq.) was added 
dropwise over a period of 20 minutes, to THF (30 mL), stored at 
–78oC, under an inert atmosphere. A solution of the carbamate 
protected ester 503 (2.018 g, 7.3 mmol) in THF (3 mL) was 
added to the vessel at a sufficient rate to maintain the internal 
reaction temperature at below –65oC during addition. The dark 
brown solution was then stirred vigorously for 90 minutes, allowing full deprotonation of 
ester 503 to occur. The corresponding methyl protected acid chloride 479 (1.710 g, 8.8 
mmol, 1.2 eq.) was then dissolved in dry THF (5 mL) and added to the vessel over 15 
minutes. Stirring of the reaction mixture proceeded at room temperature overnight, and 
following subsequent solvent removal, was quenched with the addition of saturated aqueous 
ammonium chloride solution. Extraction of the resultant residue with ethyl acetate and 
washing with water and brine, following work-up and drying with anhydrous magnesium 
sulfate, yielded a crude product that was then purified by column chromatography, 
employing 15% ethyl acetate/ hexane as eluent. A light brown solid β-ketoester 508 was then 
isolated following rotary evaporation of the combined product fractions (1.076 g, 34%); m.p. 
117-120
o
C; νmax/ cm
-1
 (KBr) 2926, 1738, 1732, 1643, 1530, 1456; δH (300 MHz, CDCl3) 
1.26 [3H, t, J 7.2, CH3 (ester)], 1.44 [3H, t, J 7.2, CH3 (carbamate)], 3.80 [3H, s, N-CH3], 
4.25 [2H, q, J 7.2, CH2 (ester)], 4.46 [2H, q, J 7.2, CH2 (carbamate)], 5.60 [1H, s, 
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COCHCO2Et], 7.18-7.36 [5H, m, aromatic C-H], 7.59-7.65 [1H, m, aromatic C-H], 7.83-
7.88 [2H, m, aromatic C-H], 8.17-8.21 [1H, m, aromatic C-H], 8.40-8.44 [1H, m, aromatic 
C-H]; δC (75 MHz, CDCl3) 14.5 (CH3, OCH2CH3 (ester)), 14.8 (CH3, OCH2CH3 
(carbamate)), 34.1 (CH3, N-CH3), 53.9 (CH, COCHCO2Et), 62.3 (CH2, OCH2CH3 (ester)), 
63.7 (CH2, OCH2CH3 (carbamate)), 110.1 (CH, aromatic CH), 114.9 (C, aromatic C), 115.4 
(C, aromatic C), 115.8 (CH, aromatic CH), 119.3 (CH, aromatic CH), 123.2 (CH, aromatic 
CH), 123.4 (CH, aromatic CH), 123.5 (CH, aromatic CH), 124.2 (CH, aromatic CH), 125.2 
(CH, aromatic CH), 125.5 (CH, aromatic CH), 127.1 (C, aromatic C), 130.0 (C, aromatic C), 
136.5 (CH, aromatic CH), 136.6 (C, aromatic C), 137.8 (C, aromatic C), 151.5 (C, CO2Et 
(carbamate)),, 169.2 (C, CO2Et (ester)), 187.0 (C-C=O(C)); m/z (ES+) 433.1 [M+H]
+
 
(100%), 259.1 (100%); HRMS - (ES+) requires: 433.1763. Found: 433.1762 (C25H25N2O5). 
5.2.3.3.7 Potassium monoethyl malonate 498
19
 
 
To a vigorously stirring mixture of diethyl malonate (4.002 g, 25 
mmol) in absolute EtOH (25 mL), was added a solution of KOH 
(1.408 g, 25.14 mmol) in absolute EtOH (20 mL), via dropping funnel, 
over 1 hour. After stirring for 3 hours at room temperature, the reaction mixture was allowed 
to stand overnight. On heating to 70
o
C, hot filtration was carried out in order to remove any 
dipotassium malonate. The corresponding monopotassium salt 498 precipitated on cooling to 
0
o
C, prior to isolation by filtration of the milky slurry. The white crystals were washed with 
ether (2 × 10 mL) and dried under vacuum. Concentration of the mother liquor to a volume 
of approximately 30 mL, yielded a second crop of the salt 498, which was isolated overall in 
a yield of 3.157 g (74%), used without further purification; m.p. 184-187
o
C (lit.
19
 175
o
C 
dec.). 
5.2.3.3.8 Ethyl 3-oxo-3-(3,4,5-trimethoxyphenyl)propanoate 497 
 
Potassium monoethyl malonate (1.573 g, 9.25 mmol) and 
acetonitrile (20 mL) were placed in a 100 mL 3-neck round-
bottomed flask, cooled to 15
o
C, and maintained under inert 
atmosphere. Triethylamine (1.3 mL, 9 mmol) was then added, 
followed by anhydrous magnesium chloride (1.063 g, 11.3 
mmol). The mixture was warmed to room temperature and stirred for a further 2.5 hours. 
The resultant off-white slurry was recooled to 0
o
C, and 3,4,5-trimethoxybenzoyl chloride 
499 (1.037 g, 4.5 mmol) in acetonitrile (5 mL) was added dropwise, over 15 minutes. 
Further triethylamine (0.13 mL, 0.9 mmol) was charged to the vessel and the overall mixture 
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was subsequently stirred at room temperature for 20 hours. Following solvent removal, 
toluene (10 mL) was added and evaporated in vacuo; the residue was redissolved in toluene 
(15 mL) and washed with 10% aqueous HCl (4 × 25 mL). The first acidic extract was 
extracted with a further volume of toluene (10 mL), and the combined toluene layers were 
then washed with water (3 × 120 mL), brine (150 mL), dried over magnesium sulfate and 
reduced under vacuum to the novel off-white solid β-ketoester 497, used without any further 
purification (0.927 g, 71%); m.p. 82-85
o
C; νmax/ cm
-1
 (KBr) 2969, 2938, 1741, 1666, 1583, 
1506, 1459; δH (300 MHz, CDCl3) 1.24-1.29 [3H, t, J 7.1, CO2CH2CH3], 3.91 [6H, s, 2 × m-
OCH3], 3.93 [3H, s, p-OCH3], 3.96 [2H, s, CH2], 4.18-4.25 [2H, q, J 7.1, CO2CH2CH3], 
7.22 [2H, s, aromatic C-H2,6]; δC (75 MHz, CDCl3) 14.1 (CH3, CO2CH2CH3), 46.1 (CH2, 
CO2CH2CH3), 56.3 (2CH3, 2 × m-OCH3),  61.0 (CH3, p-OCH3), 61.6 (CH2, COCH2CO), 
106.2 (2CH, aromatic C-H2 & aromatic C-H6), 131.2 (C, aromatic C), 143.3 (C, aromatic C), 
153.2 (2C, 2 × aromatic C), 167.5 (C, CO2CH2CH3), 191.2 (C, C=O); m/z (ES+) 283.1 
[M+H]
+
 (100%); HRMS - (ES+) requires: 283.1182. Found: 283.1180 (C14H19O6).  
 
5.2.3.3.9 6-(3,4,5-Trimethoxyphenyl) pyrimidin-2,4(1H,3H)-dione 500 
 
A mixture of precursor 497 (0.102 g, 0.36 mmol) and 
recrystallised urea (0.024 g, 0.39 mmol, 1.1 eq.) was pre-mixed 
thoroughly using a mortar and pestle, and heated in a closed vessel 
in a 300W microwave reactor, under solvent-free conditions. The 
reaction proceeded at 180
o
C over 15 minutes, preceded by a 5 
minute ramp interval, at a power of 300W, along with 
simultaneous cooling of the reaction vessel. The crude product melt (0.070 g), was 
suspended in water (2 × 5 mL), and then filtered to isolate the crude pyrimidin-2,4-dione 500 
residue, which was recrystallised from absolute ethanol, to afford novel 500 as an off-white 
crystalline solid (0.020 g, 20%); m.p. 246-250
o
C; νmax/ cm
-1
 (KBr) 3362, 2921, 2850, 1727, 
1668, 1645, 1587; δH (300 MHz, DMSO-d6) 3.71 [3H, s, p-OCH3], 3.86 [6H, s, 2 × m-
OCH3], 5.96 [1H, s, C=C-H], 7.05 [2H, s, aromatic C-H2 & aromatic C-H6], 11.10 [2H, bs, 2 
× NH]; δC (75 MHz, DMSO-d6) 56.0 (2CH3, 2 × m-OCH3), 60.1 (CH3, p-OCH3), 97.6 (CH, 
C=CH-C=O), 104.4 (2CH, 2 × aromatic CH), 126.6 (C, aromatic C), 139.5 (C, aromatic C), 
151.8 (C, C=O), 152.1 (C, aromatic C), 152.9 (2C, 2 × aromatic C), 164.2 (C, C=O); m/z 
(ES-) 277.1 [M-H]
-
 (100%); HRMS - (ES+) requires: 279.0981. Found: 279.0976 
(C13H15N2O5).  
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5.2.3.4 Cyclocondensation route to 5,6-bisindolylpyrimidinone synthesis 
5.2.3.4.1 1H-Indol-3-yl carboxaldehyde 121
20
 
 
To a 100 mL three-neck round-bottom flask, incorporating an addition 
funnel was added DMF (8 mL), which was initially cooled to –10oC, prior 
to addition of POCl3 (2 mL, 21.9 mmol) dropwise over approximately 15 
minutes, into the reaction vessel. The contents of the flask were then 
warmed to room temperature. Indole 171 (2.502 g, 21 mmol) was then placed in a dry 100 
mL addition funnel, with anhydrous DMF (10 mL). This solution was introduced into the 
reaction flask, at –10oC, at a slow regulated rate, allowing full addition to be complete within 
20 minutes. The reaction mixture was then stirred for a further 45 minutes, while gradual 
heating of the flask contents to >40
o
C was observed. The appearance of a yellow slurry was 
noted at this time. The reaction was then poured into ice, producing a cherry-red colour – 
made basic by the addition 5M NaOH (20 mL), to produce a biphasic yellow/red slurry. Hot 
deionised water (100 mL) was then added, followed by cooling to room temperature and 
then to 0
o
C. The product was filtered on a Buchner funnel and the light-orange crystals 
washed with ice-water. The crude product was then recrystallised from DMF/ H2O to afford 
121 (2.402 g, 79%) as light orange needles; m.p. 190-193
o
C (lit.
20
 188-189
o
C); νmax/ cm
-1
 
(KBr) 3150, 1647, 1608; δH (300 MHz, DMSO-d6) 7.19-7.29 [2H, m, aromatic C-H5,6], 7.51-
7.53 [1H, d, J 7.1, aromatic C-H7], 8.10-8.12 [1H, d, J 6.9, aromatic C-H4], 8.29 [1H, s, 
aromatic C-H2], 9.95 [1H, s, H-C=O], 12.15 [1H, s, NH]; δC (75 MHz, DMSO-d6) 112.4 
(CH, aromatic CH), 118.1 (CH, aromatic CH), 120.8 (CH, aromatic CH), 122.1 (CH, 
aromatic CH), 123.4 (CH, aromatic CH), 124.1 (C, aromatic C), 137.0 (C, aromatic C), 
138.4 (C, aromatic C), 184.9 (CH, H-C=O); m/z (ES+) 146.0 [M+H]
+
 (100%). (ES-) 144.0 
[M-H]
-
 (100%). 
5.2.3.4.2 1-Methyl-1H-indol-3-yl carboxaldehyde 483
21
 
Method A:  
NaH (60% mineral oil dispersion) (1.038 g, 15.5 mmol, 1.5 eq.) was 
washed with portions of hexane (2 × 5 mL), under inert atmosphere. 1H-
Indole-3-carboxaldehyde 121 (1.507 g, 10.3 mmol) was then added to the 
reaction flask along with dry DMF (20 mL) and stirred for 20 minutes, 
noting the rapid evolution of hydrogen gas at this point. Iodomethane (1 
mL, 15.5 mmol, 1.5 eq.) was then added carefully, while stirring at room temperature 
overnight. Following removal of the solvent and washing of the ethyl acetate layers several 
times with water and brine, and drying over magnesium sulfate, the crude residue was 
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purified by flash chromatography, affording aldehyde 483 as a viscous brown oil, which 
solidified to a brown solid upon cooling (1.533 g, 92%); m.p. 62-65
o
C (lit.
21
 68-70
o
C); νmax/ 
cm
-1
 (KBr) 3106, 2937, 1657, 1537; δH (300 MHz, CDCl3) 3.87 [1H, s, CH3], 7.31-7.37 [3H, 
m, aromatic C-H5,6,7], 7.67 [1H, s, aromatic C-H2], 8.29-8.32 [1H, m, aromatic C-H4], 9.98 
[1H, s, H-C=O]; δC (75 MHz, CDCl3) 33.8 (CH3, N-CH3), 109.9 (CH, aromatic CH), 118.1 
(C, aromatic C), 122.1 (CH, aromatic CH), 123.0 (CH, aromatic CH), 124.1 (CH, aromatic 
CH), 125.3 (C, aromatic C), 137.9 (C, aromatic C), 139.3 (CH, aromatic CH), 184.5 (H-
C=O); m/z (ES+) 160.0 [M+H]
+
 (100%).  
 
Method B: 
Phosphorus oxychloride (6 mL, 10.009 g, 65.2 mmol) was slowly added to dry DMF (70 
mL) at 0
o
C. The solution was then stirred at 0
o
C for 30 minutes and N-methyl indole 456 
(5.012 g, 38.2 mmol) in DMF (15 mL) was added dropwise to the flask. Following stirring 
overnight, the solvent was evaporated prior to addition of water (70 mL) and basification to 
pH 12 by the addition of aqueous 20% NaOH solution. The product was extracted several 
times with ethyl acetate (3 × 200 mL), dried with magnesium sulfate and filtered. The title 
compound appeared as a dark brown viscous oil following removal of solvent under reduced 
pressure and N-methyl 3-formylindole 483 was isolated following column chromatography 
using ethyl acetate/hexane (2.917 g, 28%).    
5.2.3.4.3 1-Methyl-1H-indol-3-yl carboxylic acid 484 
 
N-Methyl indole-3-carboxaldehyde 483 (0.203 g, 1.25 mmol) was added 
to acetone (40 mL). Potassium permanganate (0.501 g, 3.3 mmol, 2.6 eq.) 
was then added to the resulting mixture and stirred overnight. Aqueous 
hydrogen peroxide solution (30%) (10 mL) was then added to the reaction 
flask and stirring continued for a further 30 minutes. The off-white slurry 
was filtered and the straw-yellow filtrate acidified by the addition of a few drops of 10% HCl 
solution. The insoluble acid 484 was then isolated by vacuum filtration, to afford on drying, 
an off-white powder (0.182 g, 83%); m.p. 192-194
o
C (lit.
22
 205-206
o
C); νmax/ cm
-1
 (KBr) 
3350, 1750, 1562; δH (300 MHz, DMSO-d6) 3.84 [1H, s, CH3], 7.17-7.28 [2H, m, aromatic 
C-H5,6], 7.50-7.53 [1H, d, J 8.1, aromatic C-H7], 8.01-8.04 [1H, overlapping d, aromatic C-
H4],  8.04 [1H, s, aromatic C-H2], 11.97 [1H, bs, CO2H]; δC (75 MHz, DMSO-d6) 32.9 (CH3, 
N-CH3), 106.1 (C, aromatic C), 110.6 (CH, aromatic CH), 120.7 (CH, aromatic CH), 121.2 
(CH, aromatic CH), 122.1 (CH, aromatic CH), 126.4 (C, aromatic C), 136.1 (CH, aromatic 
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CH), 137.0 (C, aromatic C), 165.6 [C, CO2H]; m/z (ES+) 175.0 [M+H]
+
 (75%), 130.0 
(45%).  
5.2.3.4.4 1-Methyl-1H-indol-3-yl carbonyl chloride 479
23,24
 
Method A:
23
  
Thionyl chloride (20 mL) was added to N-methyl indole-3-carboxylic acid 
484 (0.175 g, 1 mmol), followed by 3 drops of anhydrous DMF. The 
mixture was stirred at room temperature for 20 hours and then 
concentrated in vacuo to form a red solid in overall quantitative yield 
(0.190 g, 99%). However, formation of the 2-chloro derivative 485 was 
also observed, from mass spectral analysis; therefore, another method had to be employed 
for this step. 
 
Method B:
24
   
N-Methyl indole-3-carboxylic acid 484 (0.502 g, 2.85 mmol) was suspended in dry DCM 
(15 mL), followed by the careful addition of oxalyl chloride (0.25 mL, 2.86 mmol) over 
several minutes. Following stirring at ambient temperature for 75 minutes, gas evolution had 
ceased, and the solvent was evaporated under reduced pressure – yielding a light red solid 
479, (0.550 g, 99%), which was used without further purification; νmax/ cm
-1
 (KBr) 1850 
(C=O). 
5.2.3.4.5 Methyl-1H-indol-3-yl acetate 239
25
 
 
Indole-3-acetic acid 233 (10.803 g, 5.7 mmol) was stirred in the presence 
of distilled methanol (220 mL), and then cooled to 0
o
C. Thionyl chloride 
(21 mL, 273 mmol) was then charged slowly into the cooled reaction 
vessel over 10 minutes. The burgundy coloured reaction mixture was 
gradually allowed to attain room temperature and then stirred overnight. 
Following subsequent removal of solvent, the product residue was extracted with ethyl 
acetate (3 × 150 mL), and washed successively with saturated sodium bicarbonate solution 
(2 × 250 mL), water (3 × 250 mL) and brine (1 × 250 mL). The organic layer was dried 
using magnesium sulfate, filtered and thoroughly evaporated in vacuo; the ester intermediate 
239 was thus isolated as a crude violet oil, which was employed without any further 
purification (10.822 g, 100%); m.p. lit.
25
 47-48
o
C; νmax/ cm
-1
 (NaCl) 3410, 2957, 1730, 1490; 
δH (300 MHz, CDCl3) 3.70 [3H, s, O-CH3], 3.79 [2H, s, CH2], 7.11-7.16 [2H, m, aromatic C-
H2,5], 7.18-7.23 [1H, td, J 7.1, 1.3, aromatic C-H6], 7.33-7.36 [1H, d,  J 7.9, aromatic C-H7], 
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7.60-7.63 [1H, d, J 8.0, aromatic C-H4], 8.11 [1H, bs, NH]; m/z (ES+) 190.1 [M+H]
+
 
(100%). 
5.2.3.4.6 1-Methyl Methyl-1H-indol-3-yl acetate 480
26
 
Method A:
23
 
 
1H-Methyl indol-3-yl acetate 239 (0.504 g, 2.65 mmol) was added to NaH 
(0.160 g, 4 mmol, 1.5 eq.), under inert atmosphere, followed by the careful 
addition of anhydrous DMF (20 mL), while stirring in an appropriately 
sized ice-bath, with the rapid evolution of hydrogen gas from the mixture 
observed. Following stirring for 20 minutes at 0
o
C, iodomethane (0.25 mL, 
4 mmol, 1.5 eq.) was charged slowly into the flask and stirring was continued at 0
o
C 
overnight. The reaction was then allowed to warm to room temperature. Following solvent 
removal, the product residue was extracted with ethyl acetate (2 × 75 mL), which was 
washed with water (2 × 100 mL) and brine (1 × 100 mL). The combined organic layers were 
dried using magnesium sulfate, filtered and evaporated in vacuo. Flash chromatography of 
the crude residue was employed, to isolate product 480 as a clear oil (0.498 g, 92%); νmax/ 
cm
-1
 (KBr) 2951, 1732, 1616, 1556; δH (300 MHz, CDCl3) 3.70 [3H, s, O-CH3], 3.76 [3H, s, 
N-CH3], 3.77 [2H, s, CH2], 7.02 [1H, s, aromatic C-H2], 7.09-7.15 [1H, t, J 7.9, aromatic C-
H5], 7.20-7.25 [1H, t, J 8.0, aromatic C-H6], 7.27-7.30 [1H, d, J 8.1, aromatic C-H7], 7.58-
7.61 [1H, d, J 7.9, aromatic C-H4]; δC (75 MHz, CDCl3) 31.0 (CH2, CH2CO2Me), 32.7 (CH3, 
N-CH3), 52.0 (CH3, O-CH3), 106.7 (C, aromatic C), 109.3 (CH, aromatic CH), 118.9 (CH, 
aromatic CH), 119.2 (CH, aromatic CH), 121.8 (CH, aromatic CH), 126.6 (C, aromatic C), 
127.7 (CH, aromatic CH), 136.9 (C, aromatic C), 172.6 (C, CO2CH3); m/z (ES+) 204.1 
[M+H]
+
 (100%). 
 
Method B:
26
      
Dimethyl carbonate (8.6 mL, 101.6 mmol) was added to a mixture of indole-3-acetic acid 
233 (6.002 g, 29.6 mmol), anhydrous potassium carbonate (6.007 g, 43.2 mmol), and DMF 
(70 mL), which was then stirred at 130
o
C for 16 hours. Following solvent removal, the 
product residue was extracted with ethyl acetate (150 mL), which was washed with water (2 
× 150 mL) and brine (1 × 100 mL). The combined organic layers were dried using 
magnesium sulfate, filtered and evaporated in vacuo. The pure ester 480 was obtained, as a 
straw coloured oil, following column chromatography, using an 80:20 mixture of hexane and 
ethyl acetate (5.722 g, 82%).  
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5.2.3.4.7 Methyl 2,3-bis(1-Methyl-1H-indol-3-yl)-3-oxopropanoate 478           
 
A solution of LDA (36.2 mL, 65.1 mmol, 2.2 eq.) was added 
over 10 minutes to a flask containing dry THF (50 mL), 
followed by cooling to −78oC. A mixture of N-methyl ester 
480 (6.005 g, 29.6 mmol) in THF (3 mL) was then added 
slowly to the flask, while stirring, under inert atmosphere. The 
acid chloride 479 residue (38.5 mmol, 1.3 eq., based on corresponding acid 484) was 
dissolved in THF (10-15 mL), and then added dropwise to the reaction vessel. The reaction 
was allowed to warm up to room temperature, while stirring was maintained, overnight. 
Following solvent removal, the brown product residue was extracted with ethyl acetate (3 × 
150 mL), followed by washing with saturated ammonium chloride (250 mL), water (4 × 250 
mL) and brine (2 × 150 mL). The combined organic layers were dried using magnesium 
sulfate, filtered and evaporated in vacuo. The optimised yield of the novel product 478 - a 
dark yellow crystalline solid, following gradient column chromatography employing ethyl 
acetate/ hexane, was 8.530 g (80%); m.p. 142-144
o
C; νmax/ cm
-1
 (KBr) 2927, 1732, 1644, 
1529; δH (300 MHz, CDCl3) 3.74 [3H, s, N-CH3], 3.74 [3H, s, N-CH3], 3.76 [3H, s, O-CH3], 
5.70 [1H, s, C-Hα], 7.12-7.17 [1H, td, J 6.9, 1.4, aromatic C-H5], 7.19-7.25 [1H, td, J 8.2, 
1.3, aromatic C-H5‟], 7.28-7.30 [4H, m, aromatic C-H6,6‟,7,7‟], 7.32 [1H, s, aromatic C-H2], 
7.66-7.68 [1H, d, J 7.7, aromatic C-H4], 7.78 [1H, s, aromatic C-H2‟], 8.42-8.45 [1H, m, 
aromatic C-H4‟]; δC (75 MHz, CDCl3) 32.9 (CH3, N-CH3), 33.6 (CH3, N-CH3), 52.7 (CH3, 
O-CH3), 53.2 (CH, COCHCO2CH3) 107.5 (C, aromatic C), 109.6 (CH, aromatic CH), 109.7 
(CH, aromatic CH), 115.0 (C, aromatic C), 118.3 (CH, aromatic CH), 119.5 (CH, aromatic 
CH), 121.8 (CH, aromatic CH), 122.8 (CH, aromatic CH), 122.9 (CH, aromatic CH), 123.7 
(CH, aromatic CH), 126.8 (C, aromatic C), 127.2 (C, aromatic C), 129.0 (CH, aromatic CH), 
136.2 (CH, aromatic CH), 136.7 (C, aromatic C), 137.4 (C, aromatic C), 170.3 (C, 
CO2CH3)], 188.0 (C, C=O); m/z (ESI) 361.3 (M+H
+
, 100%), 259.3 (80); HRMS - (ESI+) 
requires: 361.1548. Found: 361.1552 (C22H21N2O3). 
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5.2.3.4.8 Attempted derivatisation of 2,3-bisindolyl methyl-3-oxopropionate 478 
 
 
 
 
 
                                            507                                        487                                                                    
                                                                                             490                                 
 
Representative microwave reactions*:                               
Table 5.2 
Reactant Reagent Additive  Power Temp/oC Time Product  Yield 
478 urea - 300W 160 20 min (507)  n.r 
478 urea p-TSA (2.2 eq.) 300W 160 25 min (507)  n.r 
478 urea Camphoric acid (2.2 eq.) 300W 160 25 min (507)  n.r 
478 
478 
(NH4)2CO3 
Bn-NH2 
AcOH (3 mL) 
Molecular sieves (4Å) 
300W 
300W 
120 
100 
20 min 
20 min 
(487)  
(490)  
n.r 
n.r 
        
*General microwave protocol: Intermediate β-ketoester 478 (0.100 g, 0.28 mmol) was added 
to a high pressure microwave vessel along with the appropriate reagent (10 eq.), along with 
corresponding reaction catalyst/ additive. Following extensive mixing of these components, 
the sealed tube was heated at the appropriate temperature for the given time (including ramp 
time = 5 min). Following addition of water (5 mL), formed solids were filtered and the 
filtrate was extracted with DCM (3 x 25 mL). In all cases, only starting material and 
decomposition products were isolated.   
  
5.2.3.4.9 N-Benzyl-3-(benzylamino)-2,3-bis(1-methyl-1H-indol-3-yl)acrylamide 491 
 
Heating of β-ketoester 478 (0.150 g, 0.42 mmol) and 
benzylamine (4 mL) at 110
o
C for 24 hours, afforded a dark 
brown mixture, which was found by TLC to contain a product 
with a high Rf value, along with full consumption of starting 
material 478. Following the addition of water (100 mL), the 
product was extracted with ethyl acetate (3 × 110 mL), and these 
combined layers were subsequently evaporated to yield the crude β-enaminoamide 491 as a 
viscous dark brown oil. This compound was determined by LCMS to be the dibenzylated 
derivative of interest and was used without purification at this point due to its rapid 
decomposition when subjected to silica gel chromatography; m/z (ES+) 525.2 [M+H]
+
 
(50%); HRMS - (ES+) requires: 525.2654. Found: 525.2632 (C35H33N4O).  
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Attempted synthesis of 488, 489 via reductive amination 
approach: To a flask containing 478 (0.150 g, 0.42 mmol) was 
added appropriate amine source, ammonium acetate (R1 = H 
(488); 10 eq.) or benzylamine (R1 = PhCH2 (489); 10 eq.), along 
with absolute ethanol (15 mL). To this orange solution was 
slowly added sodium triacetoxyborohydride (3 eq.), stirring at 
room temperature for a few minutes; the reaction was then heated 
to reflux and stirred overnight. After solvent removal, the crude residue was investigated and 
it was determined that conversion to the anticipated product did not occur in each case.  
5.2.3.4.10 Carbonylation reactions: Attempted synthesis of 492:  
Method A: A mixture of 491 (0.150 g, 0.42 mmol) and 
triphosgene (0.124 g, 0.42 mmol, 1 eq.) in 1,2-dichloroethane (20 
mL) was heated at 80
o
C, for 24 hours, under inert atmosphere. 
Only starting material 491 was detectable under these conditions. 
Method B: Heating of urea (0.252 g, 4.2 mmol, 10 eq.), along 
with 491 (0.150 g, 0.42 mmol) under solvent-free conditions, at 
170
o
C, for 16 hours, also did not afford any of the desired uracil derivative 492.  
5.2.3.4.11 (E/Z)-Methyl 3-chloro-2,3-bis(1-methyl-1H-indol-3-yl)acrylate 493 
 
Phosphorus pentachloride (0.158 g, 0.76 mmol, 1.1 eq.) was 
added to a mixture of β-ketoester 478 (0.250 g, 0.69 mmol) 
and dry methanol (15 mL). The reaction was then stirred at 
reflux for 20 hours. Following solvent removal under reduced 
pressure, the crude residue was extracted with ethyl acetate 
(70 mL), washed with water (2 × 100 mL), brine (70 mL), dried with magnesium sulfate and 
evaporated to dryness, to yield the novel chlorinated derivative 493 as an inseparable 
mixture of (E) and (Z)-isomers formed in a ratio of 2:1, as determined by 
1
H NMR 
comparison between the characteristic methyl group peaks occurring at 3.45 and 3.52 ppm, 
and isolated as a dark brown crystalline solid (0.170 g, 65%); m.p. 84-87
o
C; νmax/ cm
-1
 (KBr) 
2945, 1720, 1660, 1613, 1533, 1465; δH (300 MHz, CDCl3) 3.45 [3H, s, N-CH3 (major)], 
3.48 [3H, s, N-CH3 (minor)], 3.52 [3H, s, N-CH3 (minor)], 3.72 [3H, s, N-CH3 (major)], 3.75 
[3H s, O-CH3 (major)], 3.81 [3H, s, O-CH3 (minor)], 6.76 [1H, s, aromatic C-H2 (minor)], 
6.85-6.93 [2H, m, 2 × aromatic C-H (minor)], 6.98 [1H, s, aromatic C-H2‟ (minor)], 7.05-
7.34 [13H, m, 13 × aromatic C-H (7 × major; 6 × minor)], 7.41 [1H, s, aromatic C-H 
 489 
490 
Chapter 5                                                                                                                                    Experimental                         
__________________________________________________________________________ 
                                                                         229 
(major)], 7.48-7.51 [1H, m, aromatic C-H (major)], 7.75-7.77 [1H, m, aromatic C-H 
(major)]; δC (75 MHz, CDCl3) (mixture of minor/major product signals) 31.8 (CH3, N-CH3 
(minor)), 31.9 (CH3, N-CH3 (minor)), 32.1 (2CH3, 2 × N-CH3 (major)), 51.4 (2CH3, 2 × O-
CH3), 108.3 (2CH, 2 × aromatic CH), 108.6 (CH, aromatic CH), 108.7 (CH, aromatic CH), 
108.9 (C, aromatic C), 111.5 (C, aromatic C), 112.8 (C, aromatic C), 118.9 (CH, aromatic 
CH), 119.0 (2CH, 2 × aromatic CH), 119.1 (CH, aromatic CH), 119.2 (CH, aromatic CH), 
119.4 (CH, aromatic CH), 119.5 (CH, aromatic CH), 119.6 (C, aromatic C), 120.3 (CH, 
aromatic CH), 120.9 (2CH, 2 × aromatic CH), 121.1 (CH, aromatic CH), 121.5 (CH, 
aromatic CH), 123.5 (C, aromatic C), 123.7 (C, aromatic C), 124.7 (C, aromatic C), 125.2 
(C, aromatic C), 125.3 (C, aromatic C), 125.4 (C, aromatic C), 125.6 (C, aromatic C), 128.3 
(CH, aromatic CH), 129.0 (2CH, 2 × aromatic CH), 130.2 (CH, aromatic CH), 130.4 (C, 
aromatic C), 135.5 (C, aromatic C), 135.6 (C, aromatic C), 135.7 (C, aromatic C), 135.8 (C, 
aromatic C), 168.2 (C, CO2CH3 (minor)), 168.5 (C, CO2CH3 (major)); m/z (ES+) 379.1 
[M+H]
+
 (30%); HRMS - (ES+) requires: 379.1213. Found: 379.1208 (C22H20N2O2Cl). 
5.2.3.4.12 4,5-Bis(1-Methyl-1H-indol-3-yl)-1H-pyrazol-3(2H)-one 510
23
 
 
β-Ketoester 478 (0.960 g, 2.66 mmol) was placed in a 100 
mL round-bottom flask, along with camphoric acid (0.536 g, 
2.66 mmol) and dry methanol (30 mL). Hydrazine hydrate 
(50-60%) (0.26 mL, 2.66 mmol, 1 eq.), was then added to 
the reaction mixture, prior to heating for 2 hours at reflux 
temperature. After this interval, excess hydrazine hydrate (0.78 mL, 7.98 mmol, 3 eq.) was 
added to the reaction vessel, and the overall mixture was stirred at reflux for a further 20 
hours. Following removal of the reaction solvent, the product residue was dissolved in ethyl 
acetate (70 mL) and washed with 10% aqueous sodium bicarbonate solution (2 × 110 mL). 
Following washing of the ethyl acetate layer with water (3 × 100 mL), brine (2 × 100 mL), 
and drying with magnesium sulfate, the solvent was evaporated in vacuo. The crude 
pyrazolone 510 was purified by flash chromatography, employing a gradient from 70% 
hexane/ 30% ethyl acetate to 100% ethyl acetate as eluent. The product fractions were 
combined and evaporated to yield the desired compound 510 as dark brown flakes (0.620 g, 
68%); m.p. 177-180
o
C (lit.
23
 180-181
o
C); νmax/ cm
-1
 (KBr) 3400, 2923, 1602, 1462, 1327; δH 
(300 MHz, CDCl3) 3.50 [3H, s, N-CH3], 3.67 [3H, s, N-CH3], 6.87-6.92 [1H, t, J 7.5, 
aromatic C-H5‟], 6.89 [1H, s, aromatic C-H2‟], 7.02-7.07 [1H, t, J 7.0, aromatic C-H6‟], 7.11 
[1H, s, aromatic C-H2], 7.11-7.15 [1H, t, J 7.2, aromatic C-H5], 7.16-7.22 [1H, t, J 8.3, 
aromatic C-H6], 7.22-7.25 [2H, d,  J 8.0, aromatic C-H7,7‟], 7.29-7.32 [1H, d, J 7.9, aromatic 
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C-H4‟], 7.55-7.58 [1H, d,  J 8.0, aromatic C-H4]; δC (75 MHz, CDCl3) 32.8 (2CH3, 2 × N-
CH3), 97.1 (C, aromatic C), 104.8 (C, aromatic C), 105.3 (C, aromatic C), 109.0 (CH, 
aromatic CH), 109.6 (CH, aromatic CH), 118.8 (CH, aromatic CH), 120.0 (CH, aromatic 
CH), 120.4 (CH, aromatic CH), 121.2 (CH, aromatic CH), 121.3 (CH, aromatic CH), 122.1 
(CH, aromatic CH), 125.6 (C, aromatic C), 127.2 (C, aromatic C), 128.5 (CH, aromatic CH), 
128.9 (CH, aromatic CH), 136.6 (C, aromatic C), 137.0 (C, aromatic C), 138.1 (C, aromatic 
C), 162.4 (C, C=O); m/z (ES+) 343.0 [M+H]
+
, (100%), (ES-) 341.1 [M-H]
-
 (55%).      
5.2.3.4.13 6,7-Bis(1-methyl-1H-indol-3-yl)-2,3-dihydropyrazolo[5,1-b]oxazole 511 
 
Pyrazolone 510 (0.102 g, 0.29 mmol) was added to a mixture 
of anhydrous potassium carbonate (0.078 g, 0.58 mmol, 2 eq.), 
TBAB (0.028 g, 0.087 mmol, 0.33 eq.) and 1,4-dioxane (10 
mL). Dibromoethane (0.08 mL, 0.87 mmol, 3 eq.) was then 
added to the vigorously stirring reaction mixture in a single 
portion and allowed to react at 30
o
C for 20 hours. The dioxane 
solution was filtered to remove the potassium carbonate, and washed with DCM (10 mL). 
Following solvent removal, hexane (10 mL) was added to the residue. This mixture was then 
decanted in order to remove excess unreacted dibromoethane. The resultant light brown solid 
was then dissolved in hot absolute ethanol (8 mL), followed by cooling to room temperature 
and then to 0
o
C. The novel oxazoline-fused pyrazole derivative was then filtered under 
vacuum and dried to yield a light yellow powder. Chromatography of the evaporated mother 
liquor residue, employing ethyl acetate/ hexane also isolated a further crop of title compound 
511, and the total yield was 0.061 g (57%); m.p. 132-135
o
C; νmax/ cm
-1
 (KBr) 3412, 2930, 
1710, 1612, 1568, 1521, 1467; δH (300 MHz, CDCl3) 3.58 [3H, s, N-CH3], 3.74 [3H, s, N-
CH3], 4.41-4.46 [2H, t, J 7.5, N-CH2CH2-O], 5.04-5.10 [2H, t, J 7.5, N-CH2CH2-O], 6.96 
[1H, s, aromatic C-H2‟], 6.96 [1H, s, aromatic C-H2], 7.02-7.07 [1H, t, J 8.0, aromatic C-
H5‟], 7.08-7.14 [1H, td, J 8.0, 1.5, aromatic C-H5], 7.18-7.27 [3H, m, aromatic C-H6,6‟,7‟], 
7.31-7.33 [1H, d, J 8.2, aromatic C-H7], 7.51-7.54 [1H, d, J 7.9, aromatic C-H4‟], 8.07-8.10 
[1H, d, J 7.9, aromatic C-H4]; δC (75 MHz, CDCl3) 32.8 (2CH3, 2 × N-CH3), 45.9 (CH2, N-
CH2CH2-O), 74.9 (CH2, N-CH2CH2-O), 87.3 (C, aromatic C), 105.5 (C, aromatic C), 108.8 
(CH, aromatic CH), 109.1 (CH, aromatic CH), 109.6 (C, aromatic C), 119.1 (CH, aromatic 
CH), 119.8 (CH, aromatic CH), 120.8 (CH, aromatic CH), 121.6 (CH, aromatic CH), 121.7 
(CH, aromatic CH), 122.2 (CH, aromatic CH), 126.6 (C, aromatic C), 127.6 (C, aromatic C), 
127.7 (CH, aromatic CH), 128.3 (CH, aromatic CH), 136.7 (C, aromatic C), 136.9 (C, 
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aromatic C), 151.4 (C, aromatic C), 157.3 (C, aromatic C); m/z (ES+) 369.1 [M+H]
+
 
(100%); HRMS - (ES+) requires: 369.1716. Found: 369.1722 (C23H20N4O).   
5.2.3.4.14 S-Methyl isothiouronium hemisulfate 534
27
 
 
Dimethyl sulfate (6.303 g, 49.95 mmol) was slowly added to a 
mixture of thiourea (7.604 g, 99.84 mmol) in water (150 mL). On 
vigorous stirring of the reaction at room temperature, for 5 
minutes, heating to 30
o
C was initiated and stirring was continued for 2 hours. Following 
heating to 100
o
C, reflux of the reaction contents proceeded for 16 hours, at which point, it 
was concentrated to dryness. Treatment of the off-white residue with a mixture of EtOH/ 
water (10:1) (50 mL), prior to stirring for 5 minutes, then afforded S-methyl isothiouronium 
hemisulfate 534 following filtration and drying in vacuo (14.815 g, 53%); m.p. 243-245
o
C 
(dec.) (lit.
27
 235
o
C (dec.)); νmax/ cm
-1
 (KBr) 3096, 1664, 1429; m/z (ES+) 90.8 [M]
+
 (100%). 
5.2.3.4.15 4-Morpholinocarboxamidine hemisulfate 535
28
 
 
Morpholine (0.35 mL, 3.96 mmol, 1.1 eq.) was added to a 
suspension of S-methyl isothiouronium hemisulfate salt 534 (1.006 
g, 3.60 mmol), stirring in EtOH and then heated at reflux for 20 
hours. Filtration of the milky slurry yielded a single crop of pure hemisulfate salt 535 was 
isolated following washing successively with water (2 × 15 mL), EtOH (2 × 15 mL) and 
drying under vacuum (1.003 g, 78%); m.p. >300
o
C (lit.
29
 306
o
C (dec.)); νmax/ cm
-1
 (KBr) 
3330, 3108, 2857, 1664; m/z (ES+) 130.1 [M]
+
 (100%).     
5.2.3.4.16 5,6-Bis(1-methyl-1H-indol-3-yl)-2-thioxo-2,3-dihydropyrimidin-4(1H)-one 
514  
 
To a sodium methoxide solution (sodium metal (1.595 g, 69 
mmol, 10 eq.)) in dry methanol (120 mL), under inert 
atmosphere, was added thiourea (2.627 g, 35 mmol, 5 eq.), 
followed by vigorous stirring for 15 minutes. Methyl 2,3-bis(1-
methyl-1H-indol-3-yl)-3-oxopropanoate 478 (2.508 g, 6.9 
mmol) was then charged to the reaction mixture and heated at 
70
o
C for 24 hours. Following solvent evaporation, water (100 mL) was added to the complex 
residue, prior to acidification with 10% HCl to pH 3. Filtration of the resultant dark brown 
solid, followed by trituration of the crude pyrimidinone 514 with boiling absolute ethanol 
(40 mL), produced a slurry, which, following filtration and successive washing of the yellow 
powder with water and diethyl ether, was identified as the pure thiouracil product 514 (0.640 
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g, 24%); m.p. 317-320
oC; νmax/ cm
-1
 (KBr) 2922, 1651, 1541 1452; δH (300 MHz, DMSO-
d6)  3.63 [3H, s, N-CH3], 3.70 [3H, s, N-CH3], 6.74-6.80 [2H, m, aromatic C-H5,5‟], 6.96-7.01 
[2H, m, aromatic C-H7,7‟], 7.02-7.07 [2H, t, J 7.9, aromatic C-H6,6‟], 7.21 [1H, s, aromatic C-
H2], 7.24-7.27 [1H, d,  J 8.2, aromatic C-H4], 7.30-7.33 [1H, d, J 8.2, aromatic C-H4‟], 7.65 
[1H, s,  aromatic C-H2‟]; 12.15 [1H, bs, C=C-NHCS]; 12.51 [1H, bs, NHCO]; δC (75 MHz, 
DMSO-d6)  32.4 (CH3, N-CH3), 32.7 (CH3, N-CH3), 105.7 (C, aromatic C), 106.3 (C, 
aromatic C), 109.1 (C, aromatic C), 109.4 (CH, aromatic CH), 110.0 (CH, aromatic CH), 
118.5 (CH, aromatic CH), 119.5 (CH, aromatic CH), 119.6 (CH, aromatic CH), 119.7 (CH, 
aromatic CH), 120.6 (CH, aromatic CH), 121.4 (CH, aromatic CH), 125.1 (C, aromatic C), 
127.0 (C, aromatic C), 130.7 (CH, aromatic CH), 132.4 (CH, aromatic CH), 135.9 (C, 
aromatic C), 136.0 (C, aromatic C), 144.9 (C, aromatic C), 161.3 (C, C=O), 174.3 (C, C=S); 
m/z (ES+) 387.2 [M+H]
+
 (20%), 115.0 (75), 73.9 (100); HRMS - (ES+) requires: 387.1280. 
Found: 387.1272 (C22H19N4OS).   
5.2.3.4.17 5,6-Bis(1-Methyl-1H-indol-3-yl)pyrimidin-4(3H)-one 537 
 
 Thiouracil 514 (0.105 g, 0.26 mmol) was added to a flame-
dried flask along with nickel bromide (0.290 g, 1.3 mmol, 5 
eq.) and dry methanol (10 mL). Sodium borohydride (0.152 g, 
3.89 mmol, 15 eq.) was added cautiously to the reaction 
mixture portionwise, and the reaction was allowed to stir for 2 
hours at room temperature. TLC analysis indicated full 
consumption of starting material had occurred at this point. Following stirring at room 
temperature for a further 14 hours, only the desired pyrimidin-4(3H)-one 537 could be 
detected. The reaction mixture was then filtered through a pad of celite
®
, and washed with 
additional methanol (2 × 20 mL), followed by ethyl acetate (3 × 15 mL). Following 
evaporation of these combined extracts, the light orange residue was redissolved in ethyl 
acetate (70 mL). This material was then washed with water (75 mL), and the aqueous layer 
further extracted with ethyl acetate (2 × 25 mL). The ethyl acetate layers were combined and 
washed with water (3 × 100 mL) and brine (100 mL). The organic layer was dried with 
magnesium sulfate, filtered and evaporated in vacuo, and the residue was purified by flash 
chromatography (1% methanol/DCM), to afford novel pyrimidin-4(3H)-one derivative 537 
as a dark brown powder (0.051 g, 55%); m.p. 218-221
oC; νmax/ cm
-1
 (KBr) 3426, 2926, 1633, 
1528, 1465, 1372; δH (300 MHz, DMSO-d6) 3.38 [3H, s, N-CH3], 3.74 [3H, s, N-CH3], 6.68-
6.73 (1H, t, J 7.1, C-H5), 6.80 (1H, s, C-H2), 6.84-6.86 (1H, d, J 7.9, C-H7), 6.88-6.93 (1H, t, 
J 7.8, C-H5‟), 6.96-7.01 (1H, t, J 7.6, C-H6), 7.01-7.06 (1H, t, J 7.0, C-H6‟), 7.23-7.25 (1H,d, 
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J 8.0, C-H7‟), 7.33-7.35 (1H, d, J 5.9, C-H4), 7.35 (1H, s, C-H2‟), 7.95-7.98 (1H, d, J 7.9, C-
H4‟), 8.13 (1H, s, N=CH-NHCO), 12.23 (1H, bs, NH); δC (75 MHz, DMSO-d6) 32.5 (CH3, 
N-CH3), 32.6 (CH3, N-CH3), 107.5 (C, aromatic C), 109.6 (CH, aromatic CH), 109.7 (CH, 
aromatic CH), 112.7 (C, aromatic C), 114.7 (C, aromatic C), 118.6 (CH, aromatic CH), 
119.8 (2CH, 2 × aromatic CH), 120.8 (CH, aromatic CH), 121.4 (CH, aromatic CH), 122.3 
(CH, aromatic CH), 126.1 (C, aromatic C), 126.6 (C, aromatic C), 130.5 (CH, aromatic CH), 
132.5 (CH, aromatic CH), 136.3 (C, aromatic C), 136.5 (C, aromatic C), 146.3 (C, aromatic 
C), 155.7 (C, N=C-H(NH)), 161.7 (C, C=O(NH)); m/z (ES+) 355.1 [M+H]
+
 (100%); HRMS 
- (ES+) requires: 355.1559. Found: 355.1569 (C22H19N4O).  
 
5.2.3.4.18 Oxidative desulfurisation study 
 
 
 
 
 
                                       514                                                           507                            
Table 5.3 
Reaction No. Reactant Amount Solvent Reaction Time Product¥ 
1 ClCH2CO2H 10% w/v H2O 72h/ reflux 514+507   
2 ClCH2CO2H 10% w/v AcOH 72h/ reflux 514+507 
3 ClCH2CO2H 10% w/v DMF 72h/ 110
o
C 514+507 
4 
5 
ClCH2CO2H 
aq. H2O2 
5 eq. 
30% w/v 
MeOH 
H2O2 
72h/ reflux 
20h/ 70
o
C 
514+507 
514 
6 
7 
BrCH2CO2Et 
BrCH2CO2Et 
1.1 eq. 
1.5 eq. 
MeOH 
DMF 
20h/ reflux 
24h/ 110
o
C 
507 (17%) 
514 
8 BrCH2CO2Et 2.5 eq. MeOH/H2O 48h/ reflux 507 (45%) 
 
¥ Reactions were monitored by 13C NMR, based on observed chemical shift differences between C=O and C=S signals.   
 
General reaction (1-7): A mixture of 514 and the haloacetic acid derivative was heated at 
high temperature for 24-72 hours. On cooling to 0
o
C, the precipitated solid was filtered, to 
afford a mixture of starting material 514, along with detection of a small amount of 507, in 
each case (Table 5.1).    
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5.2.3.4.19 5,6-Bis(1-methyl-1H-indol-3-yl)-2-oxo-2,3-dihydropyrimidin-4-one 507     
 
Bisindolyl 2-thiopyrimidin-4-one derivative 514 (0.100 g, 0.26 
mmol) was stirred in the presence of methanol (15 ml) and ethyl 
bromoacetate (0.108 g, 0.07 mL, 0.65 mmol, 2.5 eq.) at 70
o
C, for 
24 hours, prior to the addition of a few drops of water and heating 
for a further 24 hours. Following solvent evaporation, a hot 
DMF/H2O solution (5:1) (15 mL) was added to the light-yellow 
residue, and the resultant milky slurry was allowed to cool to room temperature and then 
filtered. The off-white powder was washed with water and diethyl ether successively, prior 
to drying under high vacuum overnight, to afford the pure 5,6-bisindolyl uracil 507 (0.044 g, 
45%); m.p. >320
oC; νmax/ cm
-1
 (KBr) 3425, 2925, 1703, 1639, 1555, 1453; δH (300 MHz, 
DMSO-d6)  3.63 [3H, s, N-CH3], 3.67 [3H, s, N-CH3], 6.75-6.81 [2H, m,  aromatic C-H5,5‟], 
6.96-7.08 [4H, m, aromatic C-H6,6‟,7,7‟], 7.11 [1H, s, aromatic C-H2], 7.24-7.27 [1H, d,  J 8.2, 
aromatic C-H4], 7.30-7.33 [1H, d, J 8.3, aromatic C-H4‟], 7.50 [1H, s,  aromatic C-H2‟], 
10.69 [1H, bs, amide NH], 11.12 [1H, bs, imide NH]; δC (75 MHz, DMSO-d6)  32.3 (CH3, 
N-CH3), 32.7 (CH3, N-CH3), 103.8 (C, aromatic C), 106.6 (C, aromatic C), 107.4 (C, 
aromatic C), 109.2 (CH, aromatic CH), 109.9 (CH, aromatic CH), 118.3 (CH, aromatic CH), 
119.5 (CH, aromatic CH), 119.6 (CH, aromatic CH), 119.8 (CH, aromatic CH), 120.5 (CH, 
aromatic CH), 121.5 (CH, aromatic CH), 125.1 (C, aromatic C), 127.6 (C, aromatic C), 
130.5 (CH, aromatic CH), 131.6 (CH, aromatic CH), 136.0 (2C, 2 × aromatic C), 145.2 (C, 
aromatic C), 151.1 (C, NHC=ONH), 164.2 (C, C-C=ONH); m/z (ES+) 371.1 [M+H]
+
 (80%). 
(ES-) 369.1 [M-H]
-
 (40%); HRMS - (ES+) requires: 371.1508. Found: 371.1506 
(C22H19N4O2).  
5.2.3.4.20 5,6-Bis(1-methyl-1H-indol-3-yl)-2-(methylthio)pyrimidin-4(3H)-one 515     
 
Distilled methanol (15 mL) was added to a flask containing 
anhydrous potassium carbonate (0.203 g, 1.42 mmol, 1.1 eq.), 
along with compound 514 (0.507 g, 1.29 mmol). Iodomethane 
(0.16 mL, 2.58 mmol, 2 eq.) was then added and the mixture was 
stirred vigorously at 30
o
C for a further 20 hours. Following solvent 
removal, the residue was taken up in ethyl acetate (15 mL), and 
filtered, to remove any unreacted base. This ethyl acetate solution was evaporated to yield a 
light beige solid, which was subjected to column chromatography, employing a gradient 
from 100% ethyl acetate, to 90% ethyl acetate/ 10% methanol, and finally with the addition 
of a few drops of Et3N, to release polar 515, following elution of the thiouracil starting 
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material 514. The product fractions were then combined and evaporated to a light yellow 
powder, under vacuum (0.180 g, 35%); m.p. 273-276
oC; νmax/ cm
-1
 (KBr) 3434, 2923, 1628, 
1521, 1461; δH (300 MHz, DMSO-d6) 2.66 [3H, s, S-CH3], 3.46 [3H, s, N-CH3], 3.82 [3H, s, 
N-CH3], 6.76-6.81 [1H, t, J 7.7, aromatic C-H5], 6.87 [1H, s, aromatic C-H2], 6.93-6.95 [1H, 
d, J 7.9, aromatic C-H7], 7.00-7.05 [1H, t, J 7.4, aromatic C-H5‟], 7.05-7.10 [1H, t, J 7.3, 
aromatic C-H6], 7.10-7.15 [1H, t, J 7.0, aromatic C-H6‟], 7.32-7.35 [1H, d, J 8.1, aromatic C-
H7‟], 7.37 [1H, s, aromatic C-H2‟], 7.41-7.44 [1H, d, J 8.2, aromatic C-H4]; 8.06-8.09 [1H, d, 
J 8.0, aromatic C-H4‟], 12.50 [1H, bs, NH]; δC (75 MHz, DMSO-d6) 12.92 (CH3, S-CH3), 
32.5 (CH3, N-CH3), 32.6 (CH3, N-CH3), 107.5 (C, aromatic C), 109.6 (CH, aromatic CH], 
109.8 (CH, aromatic CH), 112.7 (C, aromatic C), 118.6 (CH, aromatic CH), 119.7 (CH, 
aromatic CH), 119.7 (C, aromatic C), 119.9 (CH, aromatic CH), 120.7 (C, aromatic C), 
120.8 (CH, aromatic CH), 121.5 (CH, aromatic CH), 122.1 (CH, aromatic CH), 126.3 (C, 
aromatic C), 126.7 (C, aromatic C), 130.3 (CH, aromatic CH), 132.7 (CH, aromatic CH), 
136.3 (C, aromatic C), 136.5 (C, aromatic C), 156.6 (C, N=C(SCH3)), 161.9 (C, C=O); m/z 
(ES+) 401.1 [M+H]
+
 (30%); HRMS - (ES+) requires: 401.1436. Found: 401.1430 
(C23H21N4OS).  
 
 
 
 
 
 
                   515                                                 524                                               507                      
Scheme 5.1 
5.2.3.4.21 Attempted oxidative hydrolysis of 515 to 507:  
 
(a) Potassium peroxymonosulfate (Oxone
®
) (0.307 g, 0.50 mmol, 2 eq.) was added 
portionwise to a flask containing a suspension of novel sulfide 515 (0.100 g, 0.25 mmol) in a 
1:1 mixture of water/1,4-dioxane (15 mL). It was observed that no reaction had occurred 
after 72 hours at reflux (Scheme 5.1).  
 
(b) Addition of 10% aq. NaOH (10 mL) or 5% aq. HCl (10 mL), to compound 515 (0.100 g, 
0.25 mmol), followed by heating at 70
o
C for a further 72 hours also afforded no reaction. 
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5.2.3.4.22 6,7-Bis(1-Methyl-1H-indol-3-yl)-2H-thiazolo[3,2-a]pyrimidin-5(3H)-one 516        
 
To a solution of compound 514 (0.101 g, 0.26 mmol) in 1,4-
dioxane (10 mL), was added anhydrous potassium carbonate 
(0.072 g, 0.52 mmol, 2 eq.) and TBAB (0.025 g, 0.078 mmol, 
0.33 eq.). 1,2-Dibromoethane (0.07 mL, 0.78 mmol, 3 eq.) was 
then syringed into the reaction flask, with vigorous stirring of the 
mixture allowed to proceed overnight. The dioxane solution was 
filtered, prior to washing with DCM (10 mL). The clarified filtrate was evaporated in vacuo, 
and the residue was then washed with a small volume of hexane, to remove any excess 
starting reagent. The resultant beige solid was dissolved in hot absolute ethanol (8 mL), 
followed by cooling to room temperature and subsequently to 0
o
C. The novel thiazolo 
heterocyclic product 516 was then filtered and isolated as a light yellow powder (0.071 g, 
66%); m.p >300
oC; νmax/ cm
-1
 (KBr) 2923, 1644, 1562, 1520, 1479, 1460; δH (300 MHz, 
DMSO-d6) 3.52 [3H, s, N-CH3], 3.64-3.69 [2H, t, J 7.6, S-CH2-CH2-N], 3.87 [3H, s, N-
CH3], 4.46-4.51 [2H, t, J 7.6, S-CH2-CH2-N], 6.84-6.89 [1H, t, J 7.6, aromatic C-H5], 6.89 
[1H, s, aromatic C-H2], 7.02-7.04 [1H, d, J 7.9, aromatic C-H7], 7.02-7.07 [1H, t, J 7.6, 
aromatic C-H5‟], 7.11-7.17 [1H, t, J 9.0, aromatic C-H6], 7.14-7.19 [1H, t, J 7.2, aromatic C-
H6‟], 7.36-7.39 [1H, d, J 8.2, aromatic C-H7‟], 7.39 [1H, s, aromatic C-H2‟], 7.47-7.50 [1H, d, 
J 8.2, aromatic C-H4], 7.97-8.00 [1H, d, J 8.0, aromatic C-H4‟]; δC (75 MHz, DMSO-d6) 26.3 
(CH2, N-CH2CH2-S), 32.5 (CH3, N-CH3), 32.7 (CH3, N-CH3), 49.0 (CH2, N-CH2CH2-S), 
107.4 (C, aromatic C), 109.0 (C, aromatic C), 109.6 (CH, aromatic CH), 109.8 (CH, 
aromatic CH), 112.2 (C, aromatic C), 118.6 (CH, aromatic CH), 119.7 (CH, aromatic CH), 
119.9 (CH, aromatic CH), 120.8 (CH, aromatic CH), 121.5 (CH, aromatic CH), 122.1 (CH, 
aromatic CH), 126.4 (C, aromatic C), 126.5 (C, aromatic C), 130.3 (CH, aromatic CH), 
132.7 (CH, aromatic CH), 136.2 (C, aromatic C), 136.6 (C, aromatic C), 155.5 (C, aromatic 
C), 160.8 (C, N-C=N), 161.1 (C, C=O); m/z (ES+) 413.0 [M+H]
+
 (100%); HRMS - (ES+) 
requires: 413.1436. Found: 413.1432 (C24H21N4OS).  
5.2.3.4.23 Attempted oxidation of 6,7-bis(1-methyl-1H-indol-3-yl)-2H-thiazolo[3,2-
a]pyrimidin-5(3H)-one 516  
 
A mixture of 2H-thiazolo[3,2-a]pyrimidin-5(3H)-one 516 
(0.149 g, 0.36 mmol) and m-CPBA (0.180 g, 0.80 mmol, 2.2 
eq.) was stirred in DCM at 35
o
C, for 72 hours. The reaction 
mixture was initially filtered, prior to solvent removal and 
addition of DCM (40 mL). Following repeated washing with 
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saturated aq. NaHCO3 solution (3 x 70 mL), the aqueous component was extracted with 
further DCM (40 mL); the combined DCM layers were washed successively with brine (3 x 
100 mL) and water (100 mL) and dried with magnesium sulfate. Upon usual work-up, TLC 
and MS analysis of the crude residue indicated oxidation to the corresponding sulfone 517 
had not occurred and only starting material 516 was present. 
5.2.3.4.24 2-Amino-5,6-bis(1-methyl-1H-indol-3-yl)pyrimidin-4(3H)-one 445      
 
Sodium metal (1.742 g, 76 mmol, 20 eq.) was dissolved in dry 
methanol (60 mL), under an inert atmosphere, followed by 
stirring at room temperature for 20 minutes. Guanidine carbonate 
(3.421 g, 19 mmol, 5 eq.) was then added to the flask in a single 
portion, and the heterogeneous mixture was stirred vigorously for 
25 minutes at ambient temperature.  Methyl 2,3-bis(1-methyl-1H-
indol-3-yl)-3-oxopropanoate 478 (1.366 g, 3.8 mmol) was carefully added to this suspension 
and the dark orange reaction was then heated to reflux for 24 hours. Following solvent 
removal under reduced pressure, the residue was dissolved in a minimum volume of water 
(30 mL), and subsequently acidified with 10% HCl to pH 3. The crude 2-amino-5,6-bis(1-
methyl-1H-indol-3-yl)pyrimidin-4(3H)-one 445 was then filtered, washed successively with 
water and diethyl ether, and dried. Gradient chromatography afforded a fraction, eluting with 
0.5% methanol/ DCM, which was evaporated to provide the novel isocytosine derivative 445 
as a light brown amorphous powder (0.627 g, 45%); m.p. 195-197
oC; νmax/ cm
-1
 (KBr) 3384, 
2925, 1686, 1627, 1517, 1462; δH (300 MHz, DMSO-d6)  3.40 [3H, s, N-CH3], 3.80 [3H, s, 
N-CH3], 6.41 [2H, bs, NH2], 6.65 [1H, s, aromatic C-H2], 6.78-6.83 [1H, t, J 7.5, aromatic 
C-H5], 6.98-7.13 [4H, m, aromatic C-H5‟,6,6‟,7], 7.17 [1H, s, aromatic C-H2‟], 7.27-7.29 [1H, 
d, J 8.0, aromatic C-H7‟], 7.39-7.42 [1H, d, J 8.2, aromatic C-H4], 8.32-8.35 [1H, d, J 8.0, 
aromatic C-H4‟], 10.83 [1H, bs, NH]; δC (75 MHz, DMSO-d6)  32.4 (CH3, N-CH3), 32.7 
(CH3, N-CH3), 105.5 (C, aromatic C), 106.6 (C, aromatic C), 109.0 (2C, 2 × aromatic C), 
109.5 (CH, aromatic CH), 110.0 (CH, aromatic CH), 118.5 (CH, aromatic CH), 119.6 (CH, 
aromatic CH), 119.9 (CH, aromatic CH), 120.7 (CH, aromatic CH), 121.2 (CH, aromatic 
CH), 121.8 (CH, aromatic CH), 125.6 (C, aromatic C), 127.1 (C, aromatic C), 130.5 (CH, 
aromatic CH), 132.2 (CH, aromatic CH), 136.2 (C, aromatic C), 136.3 (C, aromatic C), 
152.7 (C, C=N(NH2)), 161.8 (C, C=O(NH)); m/z (ES+) 370.1 [M+H]
+
 (100%); HRMS - 
(ES+) requires: 370.1677. Found: 370.1668 (C22H20N5O).  
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5.2.3.4.25 Attempted hydrolytic dediazoniation reactions: 
 
 
 
 
                                      445                                                           507                                                                      
Representative reactions: 
(1) NaNO2: (a) To a flask containing 445 (0.200 g, 0.54 mmol), was added 10% aq. HCl 
(10 mL), and the mixture was heated to 70
o
C. A solution of NaNO2 (0.075 g, 0.59 
mmol, 1.1 eq.) in water (3 mL) was added dropwise over 10 minutes; the solution 
was cooled to room temperature and stirring was maintained overnight. 
 (b) On cooling of a suspension of 445 (0.200 g, 0.54 mmol) in AcOH (7 mL) or aq. 
2M HCl (7 mL) to 0
o
C, an ice-cold 10% w/v aq. NaNO2 solution (2 mL) was slowly 
added, with stirring at 0
o
C. Following protection from light and vigorous stirring at 
this temperature for 2 hours, the reaction was warmed to room temperature overnight.   
(2) tert-Butyl nitrite: To a mixture of 445 (0.200 g, 0.54 mmol) and tert-butyl nitrite 
(0.280 g, 2.7 mmol, 5 eq.), protected from light and cooled to 0
o
C, was added a 
solution of 1:1 IPA/ water (10 mL). On stirring at this temperature for 20 hours, the 
reaction was then allowed to warm to room temperature and allowed to stand for 24 
hours. 
(3) Nitrosylsulfuric acid: Preparation of the nitrosating reagent was accomplished by 
dissolving NaNO2 (1.003 g, 14 mmol) in conc. H2SO4 (5 mL), at −5
o
C, maintained 
by means of an ice-salt bath, followed by slow stirring of the clear solution at this 
temperature for 45 minutes. At this point, a suspension of 445 (0.100 g, 0.27 mmol) 
stirred in a 1:1 mixture of conc. sulphuric acid/ water (7 mL), was cooled to 0
o
C. 
Addition of nitrososylsulfuric acid solution (1 mL, 2.8 mmol) dropwise over 10 
minutes was followed by stirring of the heterogeneous dark brown mixture at this 
temperature for 3 hours, with the appearance of some foaming. The reaction was then 
heated to 70
o
C overnight.  
 
 In all cases, IR analysis failed to identify a characteristic product peak at 1702 
cm
-1
. TLC and MS evidence corroborated this result and identified only starting 
material/ unidentifiable side-products from this series of reactions.  
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5.2.3.4.26 N-(4,5-Bis(1-methyl-1H-indol-3-yl)-6-oxo-1,6-dihydropyrimidin-2-yl)-2,2,2-
trifluoroacetamide 528 
 
Bisindolyl aminopyrimidinone 445 (0.053 g, 0.14 mmol) was 
suspended in a mixture of trifluoroacetic anhydride (15 mL) 
and trifluoroacetic acid (3 mL). The reaction was then heated 
at 80
o
C and a steady reflux of the reaction contents was 
established and maintained overnight. The dark brown 
suspension was then cooled, prior to evaporation of the solvent 
in vacuo. The crude trifluoroacetamide 528 (0.035 g) was 
subjected to flash chromatography with 100% ethyl acetate, and the final product 528 was 
isolated as a dark orange powder (0.029 g, 45%); m.p. 177-180
o
C (dec.); νmax/ cm
-1
 (KBr) 
3377, 3173, 2929, 1629, 1612, 1520, 1464; δH (300 MHz, DMSO-d6) 3.36 [3H, s, N-CH3], 
3.87 [3H, s, N-CH3], 6.63 [1H, s, aromatic C-H2],  6.71 [1H, s, aromatic C-H2‟], 6.79-6.84 
[1H, t, J 7.3, aromatic C-H5], 7.00-7.10 [4H, m, aromatic C-H5‟,6,6‟,7], 7.21-7.24 [1H, d, J 8.2, 
aromatic C-H7‟], 7.27-7.29 [1H, d, J 7.4, aromatic C-H4], 7.53-7.56 [1H, d, J 8.5, aromatic 
C-H4‟], 8.42 [1H, bs, NHCOCF3], 11.04 [1H, bs, N=C-NHCO]; δC (75 MHz, DMSO-d6) 
32.2 (CH3, N-CH3), 32.6 (CH3, N-CH3), 109.6 (CH, aromatic CH), 111.1 (CH, aromatic 
CH), 119.9 (CH, aromatic CH), 120.2 (CH, aromatic CH), 120.6 (CH, aromatic CH), 121.6 
(CH, aromatic CH), 121.9  (C, CF3), 122.0 (CH, aromatic CH), 122.2 (C, aromatic C), 123.2 
(CH, aromatic CH), 123.8 (C, aromatic C), 125.1 (C, aromatic C), 126.8 (CH, aromatic CH), 
127.0 (C, aromatic C), 127.1 (C, aromatic C), 129.0 (C, aromatic C), 132.4 (CH, aromatic 
CH), 136.2 (C, aromatic C), 140.2 (C, aromatic C), 154.2 (C, N=C-NHCOCF3), 174.9 (C, 
NH-CO), 175.4 (C, COCF3); m/z (ES+) 466.2 [M+H]
+
 (85%). (ES-) 464.3 [M-H]
-
 (80%); 
HRMS - (ES+) requires: 466.1491. Found: 466.1473 (C24H19N5O2F3). 
5.2.3.4.27 N-(4,5-Bis(1-methyl-1H-indol-3-yl)-6-oxo-1,6-dihydropyrimidin-2-yl) 
acetamide 527 
 
5,6-Bisindolyl-2-aminopyrimidin-4-one 445 (0.080 g, 0.21 mmol) 
was suspended in dry pyridine (8 mL), to which was added acetic 
anhydride (0.05 mL, 0.32 mmol, 1.5 eq.), in a single portion. The 
reaction was then heated at 90
o
C for 20 hours. The resultant dark 
brown suspension was cooled and evaporated in vacuo. The crude 
acetamide 527 was subjected to flash chromatography with 
gradient elution from 100% DCM to 98:2 DCM/methanol, and 
fractions containing product 527 were combined and reduced under vacuum to a dark orange 
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powder (0.030 g, 35%); m.p. 195-198
o
C (dec.); νmax/ cm
-1
 (KBr) 3431, 3194, 2932, 1695, 
1633, 1608, 1512, 1462; δH (300 MHz, DMSO-d6) 2.26 [3H, s, COCH3], 3.43 [3H, s, N-
CH3], 3.84 [3H, s, N-CH3], 6.74 [1H, s, aromatic C-H2], 6.78-6.83 [1H, t, J 7.6, aromatic C-
H5], 6.93-6.96 [1H, d, J 7.8, aromatic C-H7], 7.04-7.18 [3H, m, aromatic C-H5‟,6,6‟], 7.32-
7.35 [1H, overlapping d, J 8.0, aromatic C-H7‟], 7.35 [1H, s, aromatic C-H2‟], 7.43-7.46 [1H, 
d, J 8.2, aromatic C-H4], 8.36-8.38 [1H, d, J 8.0, aromatic C-H4‟], 11.49 [1H, bs, 
NHCOCH3], 11.90 [1H, bs, N=C-NHCO]; δC (75 MHz, DMSO-d6) 24.0 (CH3, COCH3), 
32.5 (CH3, N-CH3), 32.7 (CH3, N-CH3), 107.7 (C, aromatic C), 109.7 (2CH, 2 x aromatic 
CH), 112.1 (C, aromatic C), 118.6 (CH, aromatic CH), 119.6 (CH, aromatic CH), 120.0 
(CH, aromatic CH), 120.9 (CH, aromatic CH), 121.6 (CH, aromatic CH), 123.1 (CH, 
aromatic CH), 126.3 (C, aromatic C), 126.8 (C, aromatic C), 130.1 (CH, aromatic CH), 
132.6 (C, aromatic C), 132.8 (CH, aromatic CH), 136.2 (C, aromatic C), 136.6 (C, aromatic 
C), 147.9 (C, aromatic C), 160.8 (C, N=C-NH), 173.6 (C, NHCOCH3), 173.7 (C, NH-CO); 
m/z (ES+) 412.1 [M+H]
+
 (65%). (ES-) 410.2 [M-H]
-
 (100%); HRMS - (ES+) requires: 
412.1774. Found: 412.1783 (C24H22N5O2). 
5.2.3.4.28 Chloroacetyl chloride 520
30
 
 
Chloroacetic acid (15.006 g, 160 mmol) was refluxed for 2 hours, in the 
presence of neat SOCl2 (150 mL). This solution was cooled to room 
temperature and subsequently reduced to a final volume of approximately 
30 mL, in vacuo; this oil was then employed as the title compound 520, without any further 
purification; νmax/ cm
-1
 (film) 1732 (COCl). 
5.2.3.4.29 Chloroacetamide 523
31
 
 
 To a solution of chloroacetyl chloride 520 (0.8 mL, 10 mmol), in CHCl3 (25 
mL), was added aqueous ammonia (33% w/v) (0.7 mL, 12 mmol), along 
with Et3N (2.8 mL, 20 mmol). The reaction was then stirred at room 
temperature for 16 hours, prior to addition of DCM (100 mL) and water (150 mL). The 
organic layer was then separated and dried over anhydrous magnesium sulfate, affording a 
light straw-coloured solution which was evaporated to dryness and the title chloroacetamide 
523 (0.285 g, 30%) was used as a beige powder without further purification; m.p. 114-117
o
C 
(lit.
32
 114-116
o
C); νmax/ cm
-1
 (KBr) 3384, 1742; m/z (ES-) 94.9, 92.9 [M-H]
-
 (30%, 100%).   
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5.2.3.4.30 2-[(1-(2-Amino-2-oxoethyl)-4,5-bis(1-methyl-1H-indol-3-yl)-6-oxo-1,6-
dihydropyrimidin-2-yl)thio]acetamide 522 
 
To a solution of thiouracil 514 (0.050 g, 0.13 mmol) in 1,4-
dioxane (7 mL), was added potassium carbonate (0.040 g, 0.29 
mmol, 2.2 eq.) and TBAB (0.013 g, 0.039 mmol, 0.33 eq.). 
Upon addition of α-chloroacetamide 523 (0.036 g, 0.39 mmol, 3 
eq.), the reaction was stirred at room temperature overnight and 
monitored by TLC analysis. On completion, the crude residue 
was filtered, washed with DCM (10 mL) and methanol (5 mL), 
and the combined organic extracts were evaporated in vacuo. The title 2-[(1-(2-amino-2-
oxoethyl)-4,5-bis(1-methyl-1H-indol-3-yl)-6-oxo-1,6-dihydropyrimidin-2-yl)thio]acetamide 
522 was purified by column chromatography, initially employing 100% DCM and finally 
collected over a small number of fractions applying 0.5% MeOH/ DCM as eluent. On 
solvent removal, the pure 2-thiopyrimidinone derivative 522 was isolated as a light brown 
amorphous powder (0.026 g, 40%); m.p. >300
o
C; νmax/ cm
-1
 (KBr) 3444, 2929, 1673, 1526, 
1471, 1379; δH (300 MHz, DMSO-d6) 3.47 [3H, s, N-CH3], 3.84 [3H, s, N-CH3], 3.91 [2H, s, 
S-CH2CONH2], 4.69 [2H, s, N-CH2CONH2], 6.78 [1H, s, aromatic C-H2], 6.87-6.92 [1H, t, J 
7.1, aromatic C-H5], 7.05-7.10 [1H, t, J 7.1, aromatic C-H5‟], 7.12-7.26 [3H, m, aromatic C-
H6,6‟,7], 7.35-7.37 [1H, d, J 8.0, aromatic C-H7‟], 7.39 [1H, s, aromatic C-H2‟], 7.48-7.51 [1H, 
d, J 8.4, aromatic C-H4], 8.13-8.16 [1H, d, J 7.8, aromatic C-H4‟]; δC (75 MHz, DMSO-d6) 
32.6 (CH3, N-CH3), 32.8 (CH3, N-CH3), 34.3 (CH2, S-CH2CO2NH2), 64.3 (CH2, N-
CH2CO2NH2), 105.7 (C, aromatic C), 106.0 (C, aromatic C), 109.9 (2CH, 2 × aromatic CH), 
111.7 (C, aromatic C), 119.1 (CH, aromatic CH), 119.5 (CH, aromatic CH), 120.5 (CH, 
aromatic CH), 121.2 (CH, aromatic CH), 121.8 (CH, aromatic CH), 122.2 (CH, aromatic 
CH), 126.4 (2C, 2 × aromatic C), 129.7 (CH, aromatic CH), 133.1 (CH, aromatic CH), 136.2 
(C, aromatic C), 136.7 (C, aromatic C), 161.2 (C, aromatic C), 166.3 (C, aromatic C), 166.8 
(C, C=O), 169.5 (C, CONH2), 169.8 (C, CONH2); m/z (ES+) 501.1 [M+H]
+
 (60%); HRMS - 
(ES+) requires: 501.1709. Found: 501.1706 (C26H25N6O3S).  
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5.2.3.4.31 Ethyl 2-[(1-(2-ethoxy-2-oxoethyl)-4,5-bis(1-methyl-1H-indol-3-yl)-6-oxo-1,6-
dihydropyrimidin-2-yl)thio]acetate 521 
 
1,4-Dioxane (7 mL) was added to a flask containing thiouracil 
514 (0.051 g, 0.13 mmol), and vigorously stirred at room 
temperature overnight, following addition of potassium 
carbonate (0.040 g, 0.29 mmol, 2.2 eq.), TBAB (0.013 g, 0.039 
mmol, 0.33 eq.) and ethyl bromoacetate (0.04 mL, 0.39 mmol, 3 
eq.). Following identical work-up as for 522, the combined 
DCM/MeOH extracts were evaporated to dryness and the 
resultant residue was investigated by gradient chromatography from 100% DCM to 0.5% 
methanol/ DCM, in order to cleanly provide title compound 521 as a characteristic light 
brown powder (0.032 g, 45%); m.p. >300
o
C; νmax/ cm
-1
 (KBr) 2929, 1741, 1528, 1474, 1378; 
δH (300 MHz, DMSO-d6) 1.15-1.20 [3H, t, J 7.1, O-CH2CH3], 1.20-1.25 [3H, t, J 7.1, O-
CH2CH3], 3.47 [3H, s, N-CH3], 3.84 [3H, s, N-CH3], 4.08 [2H, s, S-CH2CO2Et], 4.08-4.18 
[4H, m, 2 × O-CH2CH3], 4.87 [2H, s, N-CH2CO2Et], 6.73 [1H, s, aromatic C-H2], 6.89-6.65 
[1H, td, J 7.9, 0.75 Hz, aromatic C-H5], 7.06-7.11 [1H, td, J 8.0, 1.0, aromatic C-H5‟], 7.13-
7.21 [3H, m, aromatic C-H6,6‟,7], 7.32 [1H, s, aromatic C-H2‟], 7.36-7.39 [1H, d, J 8.1, 
aromatic C-H7‟], 7.49-7.52 [1H, d, J 8.2, aromatic C-H4], 8.16-8.19 [1H, d, J 7.9, aromatic 
C-H4‟]; δC (75 MHz, DMSO-d6) 13.9 (CH3, CO2CH2CH3), 14.0 (CH3, CO2CH2CH3), 32.6 
(CH3, N-CH3), 32.8 (CH3, N-CH3), 32.8 (CH2, S-CH2CO2Et), 60.6 (CH2, CO2CH2CH3), 61.1 
(CH2, CO2CH2CH3), 62.6 (CH2, N-CH2CO2Et), 105.6 (C, aromatic C), 105.8 (C, aromatic 
C), 109.9 (CH, aromatic CH), 110.0 (CH, aromatic CH), 111.4 (C, aromatic C), 119.2 (CH, 
aromatic CH), 119.3 (CH, aromatic CH), 120.5 (CH, aromatic CH), 121.3 (CH, aromatic 
CH), 121.9 (CH, aromatic CH), 122.2 (CH, aromatic CH), 126.5 (2C, 2 × aromatic C), 129.4 
(CH, aromatic CH), 133.2 (CH, aromatic CH), 136.2 (C, aromatic C), 136.7 (C, aromatic C), 
161.7 (C, aromatic C), 165.8 (C, N-C(SCO2Et)=N), 166.6 (C, N-C=O), 168.2 (C, CO2Et), 
169.1 (C, CO2Et); m/z (ES+) 559.2 [M+H]
+
 (100%); HRMS - (ES+) requires: 559.2015. 
Found: 559.2015 (C30H31N4O5S).  
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5.2.3.4.32 Indolocarbazole aromatisation study 
 
 
 
 
 
 
Table 5.4  
Compound 
(R1) 
Oxidant Solvent  
Product 
No. 
445 (NH2) K3[Fe(CN)6]/ KOH, air H2O  n.r 
445 (NH2) 500 mol% Pd(OAc)2, N2 DMF  n.r 
445 (NH2) 100 mol% Pd(OAc)2, air AcOH  n.r 
445 (NH2) 100 mol% Pd(CO2CF3)2, N2 DMF  n.r 
507 (OH) 
507 (OH) 
445 (NH2) 
537 (H) 
 
300 mol% Pd(COCF3)2, N2 
hυ/ I2, air 
hυ/ I2, air 
hυ/ I2, air 
DMF 
3:2 MeCN/ MeOH 
3:2 MeCN/ MeOH 
3:2 MeCN/ MeOH 
 n.r 
n.r 
442 (55%) 
538 (60%) 
 
 Reaction 1: To a solution of 445 (0.100 g, 0.27 mmol) in 10% aqueous KOH (10 
mL), was added K3[Fe(CN)6] (5 eq.) and reflux was initiated for 24 hours. No 
product (442)  was identified, and only starting material was present by TLC analysis 
(Table 5.2). 
 Reactions 2-5: A suspension of 445 or 507 (0.100 g) in the appropriate solvent was 
stirred for 24 hours at reflux, along with the corresponding Pd(II) complex, either in 
the presence or absence of air. Upon cooling, the reaction mixture was filtered 
through a pad of celite and washed with methanol (3 × 10 mL). Evaporation to 
dryness prior to MS investigation of the resulting residue yielded a complex mixture 
of decomposition products and starting material (Table 5.2). 
5.2.3.4.33 2-Amino-9,10-dimethylindolo[2,3-a]pyrimido[5,4-c]carbazol-4(3H)-one 442 
 
Bisindolyl 2-aminopyrimidin-4-one 445 (0.070 g, 0.19 mmol) 
was allowed to stir in a mixture of acetonitrile (100 mL) and 
methanol (50 mL), in the presence of a catalytic amount of 
iodine. The reaction was efficiently irradiated, employing a 
medium pressure mercury lamp, in the presence of air, for 16 
hours. The dark brown suspension was then evaporated under 
reduced pressure. The final product residue was then purified by redissolving in ethyl acetate 
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(60 mL), washing with 10% sodium thiosulfate solution (3 × 50 mL), water (3 × 100 mL) 
and brine (100 mL), drying with magnesium sulfate and evaporation of the crude product 
mixture. Flash chromatography employing a mixture of ethyl acetate and methanol yielded 
the desired novel  indolocarbazole 442 as a dark brown amorphous solid (0.052 g, 55%); 
m.p. 202-204
o
C; νmax/ cm
-1
 (KBr)  3331, 2922, 1639, 1440, 1321; δH (300 MHz, DMSO-d6)  
4.15 [3H, s, N-CH3], 4.23 [3H, s, N-CH3], 6.41 [2H, bs, NH2], 7.19-7.24 [1H, t, J 7.0, 
aromatic C-H6], 7.31-7.36 [1H, t, J 7.0, aromatic C-H13], 7.45-7.52 [2H, m, aromatic C-
H7,12], 7.64-7.67 [1H, d, J 8.8, aromatic C-H8], 7.71-7.74 [1H, d, J 8.8, aromatic C-H11], 
9.06-9.09 [1H, d, J 10.5, aromatic C-H5], 9.68-9.70 [1H, d, J 7.0, aromatic C-H14], 10.93 
[1H, bs, NH]; δC (75 MHz, DMSO-d6) 36.1 (CH3, N-CH3), 36.8 (CH3, N-CH3), 105.0 (C, 
aromatic C), 110.3 (CH, aromatic CH), 110.4 (CH, aromatic CH), 115.2 (C, aromatic C), 
119.0 (CH, aromatic CH), 119.3 (C, aromatic C), 120.3 (CH, aromatic CH), 123.6 (CH, 
aromatic CH), 124.2 (C, aromatic C), 124.6 (CH, aromatic CH), 124.7 (C, aromatic C), 125.0 
(CH, aromatic CH), 126.2 (C, aromatic C), 127.2 (CH, aromatic CH), 133.1 (C, aromatic C), 
142.7 (C, aromatic C), 144.1 (C, aromatic C), 147.1 (C, aromatic C), 151.5 (C, N=C-NH2), 
162.0 (C, NH-C=O); m/z (ES+) 368.1 [M+H]
+
 (40%); HRMS - (ES+) requires: 368.1515. 
Found: 368.1511 (C22H18N5O). 
5.2.3.4.34 9,10-Dimethylindolo[2,3-a]pyrimido[5,4-c]carbazol-4(3H)-one 538 
 
5,6-Bis(1-methyl-1H-indol-3-yl)pyrimidin-4(3H)-one 537 
(0.050 g, 0.14 mmol) was added to a solution of acetonitrile 
and methanol (3:2) (150 mL), along with a catalytic amount 
of iodine. The dilute reaction mixture was irradiated with 
U.V. light, under open-vessel conditions, until TLC analysis 
displayed the absence of any starting material (16 hours). Following solvent evaporation, the 
crude fluorescent pyrimidin-4(3H)-one  ring-fused indolocarbazole 538 was purified by 
standard chromatography employing DCM, containing a few drops of methanol, resulting in 
elution of the pure aromatised product in a small number of fractions - isolated as a dark 
brown amorphous solid (0.030 g, 60%); m.p. 229-231
oC; νmax/ cm
-1
 (KBr) 3428, 2924, 1636, 
1566, 1464, 1322; δH (300 MHz, DMSO-d6) 4.24 [3H, s, N-CH3], 4.28 [3H, s, N-CH3], 7.28-
7.33 [1H, t, J 7.2, C-H6], 7.38-7.43 [1H, t, J 7.3, C-H13], 7.52-7.57 [1H, t, J 7.1, C-H7], 7.55-
7.60 [1H, t, J 7.1, C-H12], 7.71-7.74 [1H, d, J 8.2, C-H8], 7.76-7.79 [1H, d, J 8.2, C-H11], 
8.32-8.33 [1H, d, J 3.6, N=CH-NHCO], 8.98-9.01 [1H, d, J 7.8, C-H5], 9.72-9.75 [1H, d, J 
8.3, C-H14], 12.33 [1H, bs, NH]; δC (75 MHz, DMSO-d6) 36.4 (CH3, N-CH3), 36.8 (CH3, N-
CH3), 110.5 (CH, aromatic CH), 110.8 (CH, aromatic CH), 111.5 (C, aromatic C), 116.7 (C, 
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aromatic C), 118.4 (C, aromatic C), 119.5 (CH, aromatic CH), 120.9 (CH, aromatic CH), 
123.5 (CH, aromatic CH), 124.1 (2C, 2 × aromatic C), 125.4 (CH, aromatic CH), 125.5 (CH, 
aromatic CH), 127.3 (CH, aromatic CH), 128.6 (C, aromatic C), 132.6 (C, aromatic C), 
143.0 (C, aromatic C), 143.7 (C, aromatic C), 143.9 (C, aromatic C), 144.0 (C, N=C-H), 
160.7 (C, NH-C=O); m/z (ES+) 353.1 [M+H]
+
 (100%); HRMS - (ES+) requires: 353.1402. 
Found: 353.1396 (C22H17N4O). 
   
5.2.4 Synthesis of a 3,4-bisindolyl-5-aminopyrazole compound series  
5.2.4.1 3-Diethylaminomethyl-1H-indole (Gramine) 542
33
 
 
To a 250 mL 2-neck round-bottomed flask was charged 37% 
formaldehyde solution (7 mL, 86 mmol), 98% diethylamine (8.9 mL, 86 
mmol), along with indole 171 (10.012 g, 86 mmol), absolute ethanol (120 
mL), and zinc chloride (17.462 g, 128 mmol). The resultant straw coloured 
slurry was then stirred at room temperature for 2 hours. The reaction 
mixture was then poured into a mixture of ethyl acetate (150 mL) and water (150 mL). 
Following addition of aqueous 20% NaOH solution to reach pH 9, extraction was performed 
with 3 × 150 mL volumes of ethyl acetate; the resultant organic layers were evaporated 
under reduced pressure, diluted with water (120 mL), and acidified with conc. HCl to pH 3. 
The slurry thus formed was then filtered under vacuum and the pH of the mother liquor was 
readjusted to pH 9, by addition of aqueous 20% NaOH solution. The turbid mixture was then 
cooled to 0
o
C, and the resultant light orange precipitate 542 was filtered and washed with 
water, prior to drying (10.612 g, 62%); m.p. 105-107
o
C (lit.
34
 109-110
o
C); νmax/ cm
-1
 (KBr) 
3051, 2971, 1619, 1543, 1500, 1452; δH (300 MHz, CDCl3) 1.06-1.11 [6H, t, J 7.1, 2 × 
NCH2CH3], 2.54-2.61 [4H, q, J 7.1, 2 × NCH2CH3], 3.79 [2H, s, CH2], 7.05-7.06 [1H, d, J 
2.3, C-H2], 7.07-7.13 [1H, td, J 7.5, 1.3, C-H5], 7.14-7.19 [1H, td, J 7.8, 1.4, C-H6], 7.29-
7.32 [1H, d, J 8.0, C-H7], 7.72-7.74 [1H, d, J 7.8, C-H4], 8.32 [1H, bs, NH]; δC (75 MHz, 
CDCl3) 12.0 (2CH3, 2 × NCH2CH3), 46.7 (2CH2, 2 × NCH2CH3), 48.0 (CH2, CH2N(C2H5)2), 
111.0 (CH, aromatic CH), 113.6 (C, aromatic C), 119.3 (CH, aromatic CH), 119.5 (CH, 
aromatic CH), 121.8 (CH, aromatic CH), 123.5 (CH, aromatic CH), 128.1 (C, aromatic C), 
136.3 (C, aromatic C); m/z (ES+) 203.1 [M+H]
+
 (100%).   
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5.2.4.2 1H-Indol-3-yl acetonitrile 229
35
         
 
To a solution of N,N-diethyl-3-aminomethyl indole 542 (0.370 g, 1.83 
mmol), in methanol (10 mL) was added  a solution of potassium cyanide 
(0.245 g, 3.77 mmol) in water (2 mL). Iodomethane (0.3 mL, 4.79 mmol) 
was added dropwise and the reaction mixture was then stirred vigorously at 
room temperature for 16 hours. Following evaporation of the solvent, the 
crude residue was dissolved in ethyl acetate (100 mL) and successively washed with 
saturated aqueous sodium bicarbonate solution (100 mL), water (3 × 100 mL) and brine (2 × 
100 mL). Following chromatography employing ethyl acetate/hexane, the title compound 
229 was dried, and isolated as a beige amorphous solid (0.191 g, 67%); m.p. 32-34
o
C (lit.
36
 
34-36
o
C); νmax/ cm
-1
 (KBr) 3412, 2252, 1621, 1458, 1420; δH (300 MHz, CDCl3) 3.82 [2H, s, 
CH2], 7.15-7.21 [2H, m, C-H2,5], 7.22-7.28 [1H, td, J 7.1, 1.1, C-H6], 7.37-7.40 [1H, d, J 8.0, 
C-H7], 7.57-7.60 [1H, d, J 7.8, C-H4], 8.19 [1H, bs, NH]; δC (75 MHz, CDCl3) 14.4 (CH2, 
CH2CN), 104.7 (C, aromatic C), 111.6 (CH, aromatic CH), 118.1 (CH, aromatic CH), 118.2 
(C, aromatic C), 120.3 (CH, aromatic CH), 122.8 (CH, aromatic CH), 122.9 (CH, aromatic 
CH), 126.0 (C, CH2CN), 136.3 (C, aromatic C); m/z (ES+) 130.0 [M+H-HCN]
+
 (100%). 
5.2.4.3 1-Methyl-1H-indol-3-yl acetonitrile 454
6
      
Method A:  
To a suspension of NaH (60% dispersion in mineral oil) (3.331 g, 83.3 mmol) 
in anhydrous DMF (25 mL), was added dropwise a solution of 3-
indolylacetonitrile 229 (10.022 g, 64 mmol) in DMF (50 mL). After stirring 
for 30 minutes, at room temperature, the flask was then cooled to 0
o
C. 
Iodomethane (6 mL, 95.8 mmol) was added dropwise in solution with DMF 
(30 mL). The reaction was then allowed to warm, and was stirred at ambient temperature for 
3 hours. The reaction was then quenched by pouring it into a mixture of ethyl acetate (300 
mL) and 5% aq. HCl (400 mL). Following extraction of the dark brown ethyl acetate layer, it 
was washed with water (2 × 250 mL) and brine (1 × 300 mL), dried over magnesium sulfate 
and filtered. The resultant solution was then evaporated thoroughly, under reduced pressure, 
to afford the N-methyl acetonitrile 454 in quantitative yield (11.087 g, 100%) as a viscous 
brown oil which gradually solidified following cooling; m.p. 54-56
o
C (lit.
37
 59-60
o
C); νmax/ 
cm
-1
 (KBr) 2954, 2247, 1657, 1553, 1464; δH (300 MHz, CDCl3) 3.73 [3H, s, NCH3], 3.78 
[2H, s, CH2], 7.04 [1H, s, C-H2], 7.14-7.19 [1H, td, J 8.0, 1.5, C-H5], 7.23-7.38 [2H, m, C-
H6,7], 7.54-7.57 [1H, d, J 7.9, C-H4]; δC (75 MHz, CDCl3) 14.3 (CH2, CH2CN), 32.9 (CH3, 
NCH3), 103.0 (C, aromatic C), 109.6 (CH, aromatic CH), 118.2 (CH, aromatic CH), 119.7 
Chapter 5                                                                                                                                    Experimental                         
__________________________________________________________________________ 
                                                                         247 
(CH, aromatic CH), 122.4 (CH, aromatic CH), 126.2 (C, CH2CN), 126.5 (C, aromatic C), 
127.3 (CH, aromatic CH), 137.1 (C, aromatic C); m/z (ES+) 171.1 [M+H]
+
 (100%). 
 
Method B:  
To a suspension of powdered KOH (0.538 g, 9.6 mmol, 1.5 eq.) in anhydrous DMF (10 mL), 
was added dropwise a solution of 3-indolylacetonitrile 229 (1.005 g, 6.4 mmol) in DMF (5 
mL). After stirring for 30 minutes, at 0
o
C, iodomethane (0.44 mL, 7.04 mmol, 1.1 eq.) in 
DMF (3 mL) was added dropwise. The reaction was then allowed to warm, and was stirred 
at ambient temperature for 1.5 hours. The reaction was then quenched by pouring it into a 
mixture of ethyl acetate (70 mL) and 10% HCl (70 mL). Following extraction of the dark 
brown ethyl acetate layer, it was washed with water (2 × 150 mL) and brine (1 × 100 mL), 
dried over magnesium sulfate and filtered. The resultant solution was then evaporated 
thoroughly, to yield the pure N-methyl acetonitrile 454 in quantitative yield (1.075 g, 99%). 
5.2.4.4 2,3-Bis(1-Methyl-1H-indol-3-yl)-3-oxopropanenitrile 541        
 
 To a flask containing dry THF (40 mL), was added LDA 
solution (2 M) (19.4 mL, 38.7 mmol, 2.2 eq.) at −78oC, under 
nitrogen atmosphere. 1-Methyl indole-3-acetonitrile 454 (3.002 
g, 17.6 mmol) in THF (4 mL) was then added slowly to the 
stirring reaction mixture and maintained at −78oC for 1.5 hours. 
N-Methyl indole-3-carbonyl chloride 479 was dissolved in THF (15 mL), and added 
dropwise to the cooled reaction mixture. The reaction was then allowed to warm to room 
temperature and stirred for a further 16 hours. Following solvent evaporation, the crude β-
ketonitrile 541 was taken up in ethyl acetate (100 mL) and washed with saturated ammonium 
chloride solution (2 × 150 mL). These were then combined and further extracted with ethyl 
acetate (2 × 75 mL); the combined ethyl acetate layers were then washed with water (3 × 150 
mL) and brine (2 × 150 mL), dried with magnesium sulfate and evaporated to a light brown 
residue. Following chromatography, employing a 10-25% ethyl acetate/ hexane gradient, 
intermediate 541 was isolated as a brown crystalline solid (4.424 g, 76%); m.p. 104-107
o
C; 
νmax/ cm
-1
 (KBr) 2925, 2202, 1717, 1645, 1531, 1463; δH (300 MHz, CDCl3) 3.66 [3H, s, N-
CH3], 3.68 [3H, s, N-CH3], 5.46 [1H, s, COCHCN], 7.08-7.14 [2H, m, aromatic C-H5,5‟], 
7.18 [1H, s aromatic C-H2], 7.21-7.26 [4H, m, aromatic C-H6,6‟,7,7‟], 7.63-7.66 [1H, d, J 7.9, 
aromatic C-H4], 7.75 [1H, s, aromatic C-H2‟], 8.29-8.32 [1H, m, aromatic C-H4‟]; δC (75 
MHz, CDCl3) 32.0 (CH3, N-CH3), 32.8 (CH3, N-CH3), 38.7 (CH), 104.2 (C, aromatic C), 
108.8 (2CH, 2 × aromatic CH), 111.9 (C, aromatic C), 116.8 (C, aromatic), 117.6 (CH, 
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aromatic CH), 119.2 (CH, aromatic CH), 121.5 (CH, aromatic CH), 121.6 (CH, aromatic 
CH), 122.3 (CH, aromatic CH), 123.0 (CH, aromatic CH), 124.8 (C, aromatic C), 125.8 
(C≡N), 127.0 (CH, aromatic CH), 135.1 (CH, aromatic CH), 136.1 (C, aromatic C), 136.3 
(C, aromatic C), 182.1 (C, C=O); m/z (ES+) 328.1 [M+H]
+
 (100%); HRMS - (ES+) requires: 
328.1450. Found: 328.1452 (C21H18N3O). 
5.2.4.5 3,4-Bis(1-methyl-1H-indol-3-yl)-1H-pyrazol-5-amine 447       
 
Hydrazine hydrate (0.4 mL, 6 mmol, 4 eq.) was added to a 
stirred mixture of β-ketonitrile 541 (0.511 g, 1.5 mmol), along 
with distilled ethanol (15 mL), and heated to 80
o
C. A catalytic 
amount of glacial acetic acid was then added to the reaction, 
followed by stirring at reflux temperature for 20 hours. 
Following solvent removal, the residue was taken up in ethyl acetate (70 mL) and washed 
with saturated sodium bicarbonate solution (2 × 100 mL). These aqueous bicarbonate layers 
were added together and subsequently extracted with ethyl acetate (2 × 50 mL); the 
combined ethyl acetate layers were then washed with water (3 × 100 mL) and brine (2 × 100 
mL), dried with magnesium sulfate, filtered and evaporated to form a crude golden brown 
solid. Following purification by gradient flash chromatography from 30% ethyl 
acetate/hexane to 95% ethyl acetate/5% methanol, the novel fluorescent aminopyrazole 447 
was isolated as golden brown crystals (0.235 g, 45%); m.p. 255-258
o
C; νmax/ cm
-1
 (KBr) 
3418, 3198, 2928, 1607, 1480, 1378; δH (300 MHz, CDCl3)  3.57 [3H, s, N-CH3], 3.75 [3H, 
s, N-CH3], 5.05 [2H, bs, NH2], 6.91 [1H, s, aromatic C-H2], 6.99 [1H, s, aromatic C-H2‟], 
7.02-7.04 [1H, d, J 7.9, aromatic C-H7], 7.09-7.12 [1H, t, J 8.0, aromatic C-H5], 7.18-7.27 
[3H, m, aromatic C-H5‟,6,6‟], 7.32-7.35 [1H, d, J 8.2, aromatic C-H7‟], 7.40-7.43 [1H, d, J 7.9, 
aromatic C-H4], 7.69-7.71 [1H, d, J 7.9, aromatic C-H4‟]; δC (75 MHz, CDCl3) 32.8 (2CH3, 2 
× N-CH3), 97.7 (C, aromatic C), 105.2 (C, aromatic C), 106.2 (C, aromatic C), 109.2 (CH, 
aromatic CH), 109.5 (CH, aromatic CH), 119.2 (CH, aromatic CH), 120.0 (CH, aromatic 
CH), 120.2 (CH, aromatic CH), 120.6 (CH, aromatic CH), 121.7 (CH, aromatic CH), 122.1 
(CH, aromatic CH), 122.7 (C, aromatic C), 125.9 (C, aromatic C), 127.7 (C, aromatic C), 
128.1 (CH, aromatic CH), 128.2 (CH, aromatic CH), 136.7 (C, aromatic C), 137.1 (C, 
aromatic C), 137.6 (C, aromatic C); m/z (ES+) 342.1 [M+H]
+
 (100%); HRMS - (ES+) 
requires: 342.1719. Found: 342.1715 (C21H20N5). 
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5.2.4.6 1-(5-Amino-3,4-bis(1-methyl-1H-indol-3-yl)-1H-pyrazol-1-yl)ethanone 543 
        
To a solution of aminopyrazole 447 (0.150 g, 0.44 mmol) in 
acetonitrile (10 mL), was added acetic anhydride (0.06 mL, 
0.53 mmol, 1.2 eq.) and the reaction mixture was heated to 
80
o
C, with stirring, for 16 hours, at which point full 
consumption of the starting material 447 was observed by TLC. 
Following solvent removal, the crude acetylated product 543 
was dissolved in ethyl acetate (30 mL), washed with 10% aqueous sodium bicarbonate 
solution (50 mL), followed by water (3 × 50 mL) and brine (50 mL). The organic layer was 
then dried with magnesium sulfate, prior to filtration and evaporation of the filtrate to a 
crude residue. Chromatography with 15% ethyl acetate/ hexane, followed by concentration 
of the product fractions, generated the pyrazolic acetamide derivative 543 as off-white plate-
like crystals (0.096 g, 57%); m.p. 141-144
o
C; νmax/ cm
-1
 (KBr) 3468, 3360, 2931, 1702, 
1567, 1460; δH (300 MHz, CDCl3) 2.85 [3H, s, COCH3], 3.52 [3H, s, N-CH3], 3.86 [3H, s, 
N-CH3], 5.40 [2H, bs, NH2], 6.85 [1H, s, aromatic C-H2], 7.06-7.11 [1H, t, J 7.7, aromatic 
C-H5], 7.07 [1H, s, aromatic C-H2‟], 7.16-7.24 [1H, m, aromatic C-H5‟], 7.26-7.33 [3H, m, 
aromatic C-H6,6‟,7], 7.40-7.43 [1H, d, J 8.3, aromatic C-H7‟], 7.42-7.45 [1H, d, J 8.0, 
aromatic C-H4], 8.42-8.45 [1H, m, aromatic C-H4‟]; δC (75 MHz, CDCl3) 23.4 [CH3, 
COCH3], 32.9 [CH3, N-CH3], 33.0 [CH3, N-CH3], 94.0 [C, aromatic C], 105.2 [C, aromatic 
C], 107.5 [C, aromatic C], 109.0 [CH, aromatic CH], 109.5 [CH, aromatic CH], 119.6 [CH, 
aromatic CH], 120.5 [2CH, 2 × aromatic CH], 122.1 [CH, aromatic CH], 122.2 [CH, 
aromatic CH], 122.6 [CH, aromatic CH], 126.5 [C, aromatic C], 127.7 [C, aromatic C], 
128.6 [CH, aromatic CH], 129.9 [CH, aromatic CH], 136.8 [C, aromatic C], 137.3 [C, 
aromatic C], 147.9 [C, aromatic C], 150.5 [C, aromatic C], 173.6 [C, C=O]; m/z (ES+) 384.1 
[M+H]
+
 (100%); HRMS - (ES+) requires: 384.1824. Found: 384.1807 (C23H22N5O). 
 
5.2.4.7 5-Amino-N-methyl-3,4-bis(1-methyl-1H-indol-3-yl)-1H-pyrazole-1-           
carbothioamide 544 
   
Methyl isothiocyanate (0.012 g, 0.15 mmol) was applied to a 
stirred solution of aminopyrazole 447 (0.050 g, 0.29 mmol) in 
acetonitrile (7 mL). The reaction was then heated to reflux 
temperature, and the dark orange suspension was stirred for 16 
hours. The reaction was initially allowed to cool to room 
temperature, and subsequently, to 0
o
C, and maintained for 30 
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minutes at this temperature. The formed slurry was then filtered to afford the pure thiourea 
derivative 544 as light orange crystals (0.023 g, 30%); m.p. 163-166
o
C; νmax/ cm
-1
 (KBr) 
3396, 3329, 3277, 2925, 1607, 1567, 1519; δH (300 MHz, CDCl3)  3.34-3.35 [3H, d, J 5.0, 
NH-CH3], 3.53 [3H, s, N-CH3], 3.86 [3H, s, N-CH3], 6.30 [2H, bs, NH2], 6.86 [1H, s, 
aromatic C-H2], 7.07 [1H, s, aromatic C-H2‟], 7.08-7.11 [1H, d, J 7.7, aromatic C-H7], 7.19-
7.31 [4H, m, aromatic C-H5,5‟,6,6‟], 7.40-7.43 [1H, d, J 7.7, aromatic C-H7‟], 7.42-7.44 [1H, d, 
J 7.7, aromatic C-H4], 8.26-8.28 [1H, d, J 6.9, aromatic C-H4‟], 9.36 [1H, bs, NH-CH3]; δC 
(75 MHz, CDCl3) 30.9 (CH3, NH-CH3), 32.9 (CH3, N-CH3), 33.0 (CH3, N-CH3), 94.4 (C, 
aromatic C), 105.4 (C, aromatic C), 107.0 (C, aromatic C), 109.2 (CH, aromatic CH), 109.4 
(CH, aromatic CH), 119.6 (CH, aromatic CH), 120.4 (CH, aromatic CH), 120.5 (CH, 
aromatic CH), 122.1 (CH, aromatic CH), 122.2 (2CH, 2 × aromatic CH), 126.3 (C, aromatic 
C), 127.7 (C, aromatic C), 128.8 (CH, aromatic CH), 130.4 (CH, aromatic CH), 136.8 (C, 
aromatic C), 137.3 (C, aromatic C), 147.8 (C, aromatic C), 149.0 (C, aromatic C), 176.8 (C, 
C=S); m/z (ES+) 415.1 [M+H]
+
 (100%); HRMS - (ES+) requires: 415.1705. Found: 
415.1696 (C23H23N6S). 
5.2.4.8 N-(3,4-Bis(1-methyl-1H-indol-3-yl)-1H-pyrazol-5-yl)methanesulfonamide 545 
    
To a solution of the aminopyrazole 447 (0.108 g, 0.29 mmol) in 
pyridine (7 mL), was added methanesulfonyl chloride (0.02 mL, 
0.29 mmol), along with triethylamine (0.04 mL, 0.29 mmol). 
The reaction was refluxed overnight and then evaporated in 
vacuo. The residue was dissolved in ethyl acetate (80 mL), then 
washed with 10% HCl (5 × 70 mL), aqueous saturated sodium 
bicarbonate solution (100 mL), water (3 × 100 mL) and brine (100 mL), dried over 
magnesium sulfate and evaporated. Chromatography employing 25% ethyl acetate/ hexane 
yielded sulfonamide 545 as a dark brown solid (0.042 g, 35%); m.p. 93-96
o
C; νmax/ cm
-1
 
(KBr) 3389, 2926, 1718, 1615, 1465, 1378, 1319, 1152; δH (300 MHz, CDCl3)  3.27 [3H, s, 
SO2CH3], 3.60 [3H, s, N-CH3], 3.81 [3H, s, N-CH3], 6.91 [1H, s, aromatic C-H2], 6.99-7.03 
[1H, t, J 7.7, aromatic C-H5], 7.13 [1H, s, aromatic C-H2‟], 7.15-7.18 [1H, d, J 8.0, aromatic 
C-H7], 7.20-7.23 [1H, d, J 7.8, aromatic C-H7‟], 7.26-7.31 [3H, m, aromatic C-H5‟,6 & 
NHSO2], 7.31-7.37 [2H, m, aromatic C-H4,6‟], 7.67-7.70 [1H, d, J 7.9, aromatic C-H4‟]; δC 
(75 MHz, CDCl3) 30.9 (CH3, N-CH3), 33.0 (CH3, N-CH3), 41.4 (CH3, SO2CH3), 91.2 (C, 
aromatic C), 103.9 (C, aromatic C), 109.5 (CH, aromatic CH), 109.8 (CH, aromatic CH), 
119.5 (CH, aromatic CH), 119.7 (CH, aromatic CH), 120.0 (CH, aromatic CH), 120.6 (CH, 
aromatic CH), 122.0 (CH, aromatic CH), 122.4 (CH, aromatic CH), 125.0 (C, aromatic C), 
Chapter 5                                                                                                                                    Experimental                         
__________________________________________________________________________ 
                                                                         251 
125.6 (C, aromatic C), 127.4 (2C, 2 × aromatic C), 128.5 (CH, aromatic CH), 128.8 (CH, 
aromatic CH), 133.9 (C, aromatic C), 136.7 (C, aromatic C), 137.1 (C, aromatic C); m/z 
(ES+) 420.1 [M+H]
+
 (100%); HRMS - (ES+) requires: 420.1494. Found: 420.1488 
(C22H22N5O2S). 
5.2.4.9 (N,N’-Di-tert-butoxycarbonyl)-thiourea 54638 
 
To a stirred solution of NaH (1.352 g, 33.8 mmol) (60% 
suspension in mineral oil) in dry THF (150 mL), under inert 
conditions at 0
o
C, was added thiourea (0.570 g, 7.5 mmol) 
portionwise over 5 minutes, and left to stir at room temperature 
for 15 minutes. Following cooling to 0
o
C, di-tert-butyl carbonate (3.604 g, 16.5 mmol) was 
added, and stirring was continued for 40 minutes, prior to warming to room temperature over 
3 hours. The reaction was subsequently quenched via addition of saturated aqueous NaHCO3 
solution (10 mL), water (200 mL) and the product was extracted with ethyl acetate (3 × 75 
mL). On drying with magnesium sulfate, the filtrate was evaporated to dryness to afford 546 
as an off-white solid, used successfully without further purification (1.913 g, 93%); m.p. 
115-117
o
C (lit.
38
 127-129
o
C); νmax/ cm
-1
 (KBr) 3365, 3173, 2925, 1771, 1724, 1609, 1542; 
δH (300 MHz, CDCl3) 1.48 [9H, s, (CH3)3], 1.53 [9H, s, (CH3)3], 8.26 [1H, s, NH], 9.23 [1H, 
s, NH]; δC (75 MHz, CDCl3) 28.0 (6CH3, 6 × CH3), 84.1 (2C, 2 × C(CH3)3), 151.3 (C, C=S), 
177.9 (C, C=O), 182.1 (C, C=O); m/z (ES+) 157.0 [M+H]
+
 (50%). (ES-) 155.0 [M-H]
- 
(45%). 
5.2.4.10 Tert-butyl [5-amino-3,4-bis(1-methyl-1H-indol-3-yl)-1H-pyrazol-1-yl][({tert-
butoxycarbonyl}imino)methyl]carbamate 547 
 
Aminopyrazole 447 (0.150 g, 0.44 mmol) was treated with 
HgCl2 (0.143 g, 0.48 mmol, 1.1 eq.) and N,N‟-di-tert-
butoxycarbonyl thiourea 546 (0.110 g, 0.44 mmol), in 
distilled DCM (10 mL), at 0
o
C. Triethylamine (0.2 mL, 1.36 
mmol, 3.1 eq.) was then added to the flask and allowed to stir 
at 0
o
C for a further 1 hour, followed by stirring for 12 hours at 
room temperature. The reaction was then poured into ethyl acetate (30 mL), and filtered 
through a pad of celite
® 
in order to remove the yellow mercury sulfide by-product. The filter 
cake was washed with ethyl acetate (3 × 15 mL), and the combined organic phases were then 
washed with water (3 × 100 mL) and brine (100 mL), dried over magnesium sulfate and 
concentrated under vacuum. Chromatography employing 15% ethyl acetate/hexane yielded 
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the pure di-protected pyrazole derivative 547 as an off-white crystalline solid (0.095 g, 
37%); m.p. 140-142
o
C; νmax/ cm
-1
 (KBr) 3452, 3337, 2978, 1768, 1707, 1657, 1567, 1494; 
δH (300 MHz, CDCl3) 1.56 [18H, s, 2 × CO2C(CH3)3], 3.55 [3H, s, N-CH3], 3.84 [3H, s, N-
CH3], 5.65 [2H, bs, pyrazole NH2], 6.87 [1H, s, aromatic C-H2], 7.04 [1H, s, aromatic C-
H2‟], 7.06-7.12 [1H, t, J 7.8, aromatic C-H5], 7.19-7.28 [3H, m, aromatic C-H5‟,6,7], 7.26-7.31 
[1H, t, J 7.9, aromatic C-H6‟], 7.39-7.43 [2H, m, aromatic C-H4,7‟], 8.20-8.22 [1H, d, J 7.4, 
aromatic C-H4‟], 9.40 [1H, s, NH-CO2C(CH3)3]; δC (75 MHz, CDCl3) 28.1 [3CH3, 
{CO2C(CH3)3}], 28.2 [3CH3, {CO2C(CH3)3}], 32.9 [CH3, N-CH3], 33.0 [CH3, N-CH3], 80.8 
[C, {CO2C(CH3)3}], 82.8 [C, {CO2C(CH3)3}], 94.7 [C, aromatic C], 105.1 [C, aromatic C], 
107.2 [C, aromatic C], 109.2 [CH, aromatic CH], 109.4 [CH, aromatic CH], 119.6 [CH, 
aromatic CH], 120.4 [2CH, 2 × aromatic CH], 122.1 [2CH, 2 × aromatic CH], 122.2 [CH, 
aromatic CH], 126.3 [C, aromatic C], 127.6 [C, aromatic C], 128.7 [CH, aromatic CH], 
129.9 [CH, aromatic CH], 136.8 [C, aromatic C], 137.2 [C, aromatic C], 143.5 [C, aromatic 
C], 147.7 [C, aromatic C], 149.1 [C, C=O], 149.8 [C, C=O], 157.6 [C, C=N]; m/z (ES+) 
584.3 [M+H]
+
 (100%). (ES-) 582.5 [M-H]
-
 (50%); HRMS - (ES+) requires: 584.2985. 
Found: 584.2965 (C32H38N7O4). 
5.2.4.11 5-Amino-3,4-bis(1-methyl-1H-indol-3-yl)-1H-pyrazole-1-carboximidamidium 
trifluoroacetate 548 
 
 Boc-protected derivative 547 (0.100 g, 0.17 mmol) was 
stirred along with a solution of 10% TFA in DCM (15 
mL), at 30
o
C, for 16 hours. Following solvent evaporation 
under reduced pressure, the corresponding trifluoroacetate 
salt 548 was generated in quantitative yield; m.p. 115-
117
o
C; νmax/ cm
-1
 (KBr) 3382, 1684, 1480, 1379; m/z 
(ES+) 384.2 [M]
+
 (100%), (ES-) 112.9 [CF3CO2]
-
 (100%). 
5.2.4.12 2,3-Bis(1-methyl-1H-indol-3-yl)-5,7-bis(trifluoromethyl)pyrazolo[1,5-
a]pyrimidine 549 
 
Hexafluoroacetylacetone (2.74 mL, 5.8 mmol, 20 eq.) was 
added to a mixture of aminopyrazole 447 (0.106 g, 0.29 mmol) 
and acetic acid (10 mL), with stirring, at room temperature. 
The reaction was then heated to 80
o
C for 20 hours, at which 
point, full consumption of the starting material 447 had 
occurred. Following removal of acetic acid under vacuum, the 
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crude pyrimidine derivative was purified by column chromatography and the pure residue 
was then dried under high vacuum overnight, to yield the product 549 as a dark red powder 
(0.080 g, 54%); m.p. 215-217
o
C; νmax/ cm
-1
 (KBr) 2930, 1615, 1569, 1480, 1270, 1188; δH 
(300 MHz, CDCl3) 3.55 [3H, s, N-CH3], 3.91 [3H, s, N-CH3], 6.98-7.03 [1H, t, J 7.8, 
aromatic C-H5], 7.10 [1H, s, aromatic C-H2], 7.22-7.25 [2H, d, J 8.7, aromatic C-H7,7‟], 7.26-
7.33 [4H, m, aromatic C-H4,5‟,6,6‟], 7.35 [1H, s, aromatic C-H2‟], 7.41-7.44 [1H, d,  J 8.2, 
aromatic C-H4‟], 8.57-8.61 [1H, m, (CF3)C-CH=C(CF3)]; δC (75 MHz, CDCl3) 33.0 (CH3, 
N-CH3), 33.1 (CH3, N-CH3), 100.6 (C, 2 × CF3), 100.7 (CH, CF3-C=CH-C(CF3)), 103.8 (C, 
aromatic C), 104.5 (C, aromatic C), 107.0 (C, aromatic C), 109.2 (CH, aromatic CH), 109.6 
(CH, aromatic CH), 119.5 (CH, aromatic CH), 121.1 (CH, aromatic CH), 121.3 (CH, 
aromatic CH), 121.9 (CH, aromatic CH), 122.6 (CH, aromatic CH), 122.7 (CH, aromatic 
CH), 126.6 (C, aromatic C), 126.8 (C, aromatic C), 129.4 (CH, aromatic CH), 131.4 (CH, 
aromatic CH), 136.9 (C, aromatic C), 137.4 (C, aromatic C), 144.2 (C, aromatic C), 144.7 
(C, aromatic C), 146.8 (C, N=C(CF3)- C), 154.4 (C, N-N-C(CF3)=C); m/z (ES+) 514.2 
[M+H]
+
 (100%); HRMS - (ES+) requires: 514.1466. Found: 514.1466 (C26H18N5F6). 
5.2.4.13 7,8-Bis(1-methyl-1H-indol-3-yl)pyrazolo[1,5-a][1,3,5]triazine-2,4(1H,3H)-dione 
539 
 
Chlorocarbonyl isocyanate (0.05 mL, 0.645 mmol, 1.1 eq.) was 
added to a dark solution of aminopyrazole 447 (0.200 g, 0.587 
mmol) in doubly distilled DCM (7 mL), containing three drops 
of triethylamine, at 0
o
C. The reaction was then allowed to stir at 
room temperature overnight, at which point, water (1 mL) was 
added carefully to the flask and slight effervescence was 
observed. The resultant brown slurry was filtered, washed with water (2 × 5 mL), ether (2 × 
5 mL), and the isolated tan-coloured solid was then air-dried for 1 hour to afford the pure 
triazinedione congener 539 (0.202 g, 84%); m.p. 280-283
o
C; νmax/ cm
-1
 (KBr) 3228, 3105, 
2936, 1739, 1705, 1654, 1563, 1478; δH (300 MHz, DMSO-d6)  3.51 [3H, s, N-CH3], 3.88 
[3H, s, N-CH3], 6.90 [1H, s, aromatic C-H2], 6.95-7.00 [1H, t, J 7.6, aromatic C-H5], 7.14-
7.16 [1H, d, J 7.6, aromatic C-H7], 7.14-7.25 [3H, m, aromatic C-H5‟,6,6‟], 7.39-7.42 [1H, d, J 
7.6, aromatic C-H7‟], 7.45 [1H, s, aromatic C-H2‟], 7.52-7.55 [1H, d, J 8.2, aromatic C-H4], 
8.36-8.39 [1H, d, J 7.2, aromatic C-H4‟], 11.48 [2H, bs, 2 × NH]; δC (75 MHz, DMSO-d6) 
31.5 (2CH3, 2 × N-CH3), 93.2 (C, aromatic C), 100.7 (C, aromatic C), 105.4 (C, aromatic C), 
108.7 (CH, aromatic CH), 108.9 (CH, aromatic CH), 117.9 (CH, aromatic CH), 118.3 (CH, 
aromatic CH), 119.0 (CH, aromatic CH), 120.2 (CH, aromatic CH), 120.9 (CH, aromatic 
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CH), 121.0 (CH, aromatic CH), 124.6 (C, aromatic C), 126.4 (C, aromatic C), 128.6 (CH, 
aromatic CH), 129.6 (CH, aromatic CH), 135.2 (C, aromatic C), 135.8 (C, aromatic C), 
137.8 (C, aromatic C), 143.2 (C, aromatic C), 147.6 (C, NH-C=O(NH)), 150.6 (C, NH-
C=O(N-N)); m/z (ES+) 411.1 [M+H]
+
 (20%). (ES-) 409.2 [M-H]
-
 (100%); HRMS - (ES+) 
requires: 411.1569. Found: 411.1567 (C23H19N6O2). 
 
5.2.5 Derivatisation of 4-(indol-3-yl)-3-(trimethoxyphenyl)-5-aminopyrazoles 
5.2.5.1 3,4,5-Trimethoxybenzoyl chloride 499
39
 
 
To a stirred suspension of 3,4,5-trimethoxybenzoic acid (1.000 g, 4.7 
mmol) in DCM (15 mL), was added thionyl chloride (1.7 mL, 23.6 
mmol, 5 eq.), dropwise over 5 minutes. The resultant mixture was then 
refluxed for 20 hours prior to being cooled to room temperature. The 
reaction solvent and excess thionyl chloride was removed in vacuo to yield the 
corresponding acid chloride 574 as a colourless oil, in quantitative yield, and used without 
any further purification; νmax/ cm
-1
 (KBr) 1750, 1590, 1457. 
5.2.5.2 2-(1-Methyl-1H-indol-3-yl)-3-oxo-3-(3,4,5-trimethoxyphenyl)propanenitrile 556 
 
LDA solution (2 M) (19.4 mL, 38.7 mmol, 2.2 eq.) was added, 
under nitrogen, to a flask containing THF (30 mL), cooled to 
−78oC, and equilibriated at this temperature for 35 minutes, with 
stirring. Nitrile 454 (3.009 g, 17.6 mmol) in THF (4 mL) was 
then added slowly to the reaction flask and maintained at −78oC 
for 2 hours. 3,4,5-Trimethoxybenzoyl chloride 499 (6.011 g, 
26.4 mmol, 1.5 eq.) was then dissolved in THF (15 mL), and added dropwise to the reaction 
vessel, at −78oC. The reaction was allowed to warm to room temperature and stirred 
overnight. Following solvent evaporation, the crude residue was taken up in ethyl acetate 
(100 mL) and washed with saturated ammonium chloride solution (2 × 150 mL). These were 
then combined and further extracted with ethyl acetate (2 × 75 mL); the aggregate ethyl 
acetate layers were then washed with water (3 × 150 mL) and brine (2 × 150 mL), dried with 
magnesium sulfate and evaporated in vacuo. Celite
®
 was added to the crude dark brown 
ketonitrile 556, along with DCM (40 mL), and the product adsorbed under reduced pressure. 
Employing a gradient from 15-30% ethyl acetate/hexane, the product was eluted rapidly, and 
following combination and evaporation of the fractions, was isolated as a dark orange 
crystalline solid (2.221 g, 35%); m.p. 73-76
oC; νmax/ cm
-1
 (KBr) 3433, 2938, 1684, 1584, 
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1504, 1127; δH (300 MHz, CDCl3)  3.75 [3H, s, N-CH3], 3.76 [6H, s, 2 × m-OCH3], 3.86 
[3H, s, p-OCH3], 5.82 [1H, s, CH], 7.15 [1H, s, C-H2], 7.18-7.24 [1H, t, J 7.3, C-H5], 7.21 
[2H, s, C-H2‟,6‟], 7.26-7.31 [1H, t, J 6.8, C-H6], 7.32-7.35 [1H, d, J 7.5, C-H7], 7.71-7.74 
[1H, d, J 7.8, C-H4]; δC (75 MHz, CDCl3) 33.1 (CH3, N-CH3), 38.4 (CH, CHCN), 56.3 
(2CH3, 2 × m-OCH3), 61.0 (CH3, p-OCH3), 103.9 (C, aromatic C), 106.7 (2CH, 2 × aromatic 
CH), 110.1 (CH, aromatic CH), 116.9 (C, aromatic C), 118.1 (CH, aromatic CH), 120.6 
(CH, aromatic CH), 122.9 (CH, aromatic CH), 125.6 (C, CN), 128.4 (CH, aromatic CH), 
128.6 (C, aromatic C), 137.1 (C, aromatic C), 143.4 (C, aromatic C), 153.0 (2C, 2 × aromatic 
C), 187.5 (C, C=O); m/z (ES+) 365.1 [M+H]
+
 (60%). (ES-) 363.1 [M-H]
-
 (100%); HRMS - 
(ES+) requires: 365.1501. Found: 365.1486 (C21H21N2O4). 
5.2.5.3  4-(1-Methyl-1H-indol-3-yl)-3-(3,4,5-trimethoxyphenyl)-1H-pyrazol-5-amine 553 
    
Hydrazine hydrate (0.14 mL, 1.5 mmol) and camphoric acid 
(0.180 g, 0.88 mmol, 1.2 eq.) were added to a suspension of the 
β-ketonitrile 556 (0.265 g, 0.73 mmol), in dry methanol (10 
mL). The reaction mixture was then stirred at reflux 
temperature for 3 hours, prior to addition of excess hydrazine 
hydrate (0.42 mL, 4.5 mmol) and heating for a further 20 hours. 
Following solvent removal, the residue was taken up in ethyl acetate (50 mL) and washed 
with saturated aqueous sodium bicarbonate solution (2 × 70 mL). These aqueous bicarbonate 
layers were added together and subsequently extracted with ethyl acetate (2 × 30 mL); the 
combined ethyl acetate layers were then washed with water (3 × 70 mL) and brine (2 × 70 
mL), dried with magnesium sulfate, filtered and evaporated to yield a crude golden brown 
solid. Following chromatography, initially with 100% ethyl acetate, to complete full elution 
of the starting material, and then with 98:2 ethyl acetate/methanol, the novel 5-
aminopyrazole 553 was isolated as light brown crystals (0.170 g, 62%); m.p. 117-120
o
C; 
νmax/ cm
-1
 (KBr) 2930, 1583, 1511, 1465, 1422, 1124; δH (300 MHz, CDCl3)  3.42 [6H, s, 2 × 
m-OCH3], 3.77 [3H, s, N-CH3], 3.81 [3H, s, p-OCH3], 4.75 [2H, bs, NH2], 6.68 [2H, s, C-
H2‟,6‟], 7.01-7.06 [3H, m, C-H2,5 & NH], 7.20-7.25 [1H, t, J 8.0, C-H6], 7.30-7.33 [1H, d, J 
7.8, C-H7], 7.33-7.36 [1H, d, J 8.2, C-H4]; δC (75 MHz, CDCl3) 32.9 (CH3, N-CH3), 55.7 
(2CH3, 2 × m-OCH3), 60.8 (CH3, p-OCH3), 104.0 (2CH, 2 × aromatic CH), 104.4 (C, 
aromatic C), 105.7 (C, aromatic C), 109.3 (CH, aromatic CH), 119.6 (CH, aromatic CH), 
120.4 (CH, aromatic CH), 122.0 (CH, aromatic CH), 126.1 (C, aromatic C), 127.9 (C, 
aromatic C), 128.0 (C, aromatic C), 128.4 (CH, aromatic CH), 137.1 (C, aromatic C), 137.8 
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(C, aromatic C), 153.1 (C, aromatic C), 153.3 (2C, 2 × aromatic C); m/z (ES+) 379.1 
[M+H]
+
 (100%); HRMS - (ES+) requires: 379.1770. Found: 379.1765 (C21H23N4O3). 
5.2.5.4 1-(5-Amino-4-(1-methyl-1H-indol-3-yl)-3-(3,4,5-trimethoxyphenyl)-1H-pyrazol-
1-yl)ethanone 557 
 
To a solution of parent aminopyrazole 553 (0.150 g, 0.397 
mmol) in acetonitrile (10 mL), was added acetic anhydride 
(0.05  mL, 0.476 mmol, 1.2 eq.) and the reaction mixture was 
heated to 80
o
C, with stirring, for 16 hours. Following solvent 
removal, the crude acetylated product was dissolved in ethyl 
acetate (30 mL), washed with 10% aqueous sodium 
bicarbonate solution (50 mL), followed by water (3 × 50 mL) 
and brine (50 mL). The organic layer was then dried with magnesium sulfate, prior to 
filtration and evaporation of the filtrate to a crude residue. Chromatography with 15% ethyl 
acetate/ hexane, followed by concentration of the product fractions, generated the pure 
pyrazolic acetamide derivative 557 as off-white plate-like crystals (0.067 g, 40%); m.p. 182-
184
o
C; νmax/ cm
-1
 (KBr) 3449, 3338, 2935, 1710, 1608, 1572, 1485, 1126; δH (300 MHz, 
CDCl3) 2.79 [1H, s, COCH3], 3.45 [6H, s, 2 × m-OCH3], 3.78 [3H, s, N-CH3], 3.82 [3H, s, p-
OCH3], 5.46 [2H, bs, NH2], 6.87 [2H, s, C-H2‟,6‟], 6.99 [1H, s, C-H2], 7.06-7.11 [1H, td, J 
8.0, 0.9, C-H5], 7.23-7.28 [1H, td, J 8.1, 1.1, C-H6], 7.35-7.38 [1H, d, J 8.0, C-H7], 7.38-7.40 
[1H, d, J 7.6, C-H4]; δC (75 MHz, CDCl3) 23.2 (CH3, COCH3), 32.9 (CH3, N-CH3), 55.6 
(2CH3, 2 × m-OCH3), 60.8 (CH3, p-OCH3), 94.5 (C, aromatic C), 104.7 (C, aromatic C), 
105.0 (2CH, 2 × aromatic CH), 109.4 (CH, aromatic CH), 119.8 (CH, aromatic CH), 120.2 
(CH, aromatic CH), 122.2 (CH, aromatic CH), 127.9 (C, aromatic C), 128.0 (C, aromatic C), 
128.7 (CH, aromatic CH), 137.2 (C, aromatic C), 138.4 (C, aromatic C), 148.7 (C, aromatic 
C), 152.8 (2C, 2 × aromatic C), 153.3 (C, aromatic C), 173.8 (C, C=O); m/z (ES+) 421.2 
[M+H]
+
 (100%); HRMS - (ES+) requires: 421.1876. Found: 421.1862 (C23H25N4O4). 
5.2.5.5 2,2,2-Trifluoro-N-(4-(1-methyl-1H-indol-3-yl)-3-(3,4,5-trimethoxyphenyl)-1H-
pyrazol-5-yl)acetamide 558 
 
Trifluoroacetic anhydride (0.10 mL, 0.63 mmol, 1.2 eq.) was 
added in a single portion, to a mixture of parent aminopyrazole 
553 (0.200 g, 0.53 mmol) and acetonitrile (10 mL). The 
temperature was then adjusted until a steady reflux of the dark-
brown reaction was attained; stirring was continued for 16 
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hours. The solvent was then evaporated in vacuo, to yield the trifluoroacetylated product 558 
as a light orange solid  (0.100 g, 40%), following column chromatography (30% ethyl 
acetate/hexane) of the crude residue; m.p. 113-116
o
C; νmax/ cm
-1
 (KBr) 3270, 2939, 1729, 
1585, 1504, 1466, 1126; δH (300 MHz, CDCl3) 3.43 [6H, s, 2 × m-OCH3], 3.78 [3H, s, N-
CH3], 3.86 [3H, s, p-OCH3], 6.75 [2H, s, C-H2‟,6‟], 7.05-7.11 [2H, m, C-H5,6], 7.26 [1H, s, C-
H2], 7.26-7.31 [1H, t, J 7.0, C-H7], 7.39-7.41 [1H, d, J 8.3, C-H4], 8.17 [2H, bs, NHCOCF3 
& pyrazole NH]; δC (75 MHz, CDCl3) 33.1 (CH3, NCH3), 55.6 (2CH3, 2 × m-OCH3), 60.9 
(CH3, p-CH3), 103.2 (C, aromatic C), 104.2 (2CH, 2 × aromatic C-H), 105.2 (CH, aromatic 
CH), 109.6 (CH, aromatic CH), 119.9 (CH, aromatic CH), 120.3 (CH, aromatic CH), 122.7 
(CH, aromatic CH), 127.5 (C, aromatic C), 128.5 (2C, 2 × aromatic C), 133.6 (C, aromatic 
C), 137.3 (2C, 2 × aromatic C), 143.3 (C, aromatic C), 153.1 (2C, 2 × aromatic C); m/z 
(ES+) 475.1 [M+H]
+
 (100%); HRMS - (ES+) requires: 475.1593. Found: 475.1591 
(C23H22N4O4F3). 
5.2.5.6 5-Amino-N-methyl-4-(1-methyl-1H-indol-3-yl)-3-(3,4,5-trimethoxyphenyl)-1H-
pyrazole-1-carbothioamide 559 
 
Methyl isothiocyanate (0.040 g, 0.55 mmol, 1.05 eq.) was 
applied to a stirred solution of aminopyrazole 553 (0.200 g, 
0.53 mmol) in acetonitrile (10 mL). The reaction was then 
heated to reflux temperature, and the dark orange suspension 
was stirred for 16 hours. The reaction was initially allowed to 
cool to room temperature, and subsequently, to 0
o
C, and 
maintained for 30 minutes at this temperature. The formed 
slurry was then filtered to yield the pure thiourea derivative 559 as light orange crystals 
(0.080 g, 34%); m.p. 186-188
o
C; νmax/ cm
-1
 (KBr) 3418, 3272, 2931, 1624, 1519, 1423, 
1117; δH (300 MHz, CDCl3) 3.28-3.30 [3H, d, J 4.9, NHCH3], 3.43 [6H, s, 2 × m-OCH3], 
3.78 [3H, s, N-CH3], 3.82 [3H, s, p-OCH3],  6.35 [2H, s, NH2], 6.85 [2H, s, C-H2‟,6‟], 7.01 
[1H, s, C-H2], 7.06-7.11 [1H, t, J 7.3, C-H5], 7.23-7.28 [1H, t, J 8.9, C-H6], 7.35-7.38 [1H, d, 
J 8.1, C-H7], 7.38-7.40 [1H, d, J 7.8, C-H4], 9.38 [1H, s, NHCH3]; δC (75 MHz, CDCl3) 29.0 
(CH3, NHCH3), 31.1 (CH3, N-CH3), 53.8 (2CH3, 2 × m-OCH3), 59.0 (CH3, p-OCH3), 93.1 
(C, aromatic C), 103.1 (C, aromatic C), 103.2 (2CH, 2 × aromatic CH), 107.5 (CH, aromatic 
CH), 118.0 (CH, aromatic CH), 118.4 (CH, aromatic CH), 120.4 (CH, aromatic CH), 125.7 
(C, aromatic C), 126.2 (C, aromatic C), 127.1 (CH, aromatic CH), 135.3 (C, aromatic C), 
136.6 (C, aromatic C), 148.1 (C, aromatic C), 148.5 (C, aromatic C), 151.0 (2C, 2 × aromatic 
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C), 175.1 (C, C=S); m/z (ES+) 452.1 [M+H]
+
 (50%); HRMS - (ES+) requires: 452.1756. 
Found: 452.1742 (C23H26N5O3S). 
5.2.5.7 N-(4-(1-Methyl-1H-indol-3-yl)-3-(3,4,5-trimethoxyphenyl)-1H-pyrazol-5-yl) 
methanesulfonamide 560 
 
To a solution of the aminopyrazole 553 (0.108 g, 0.29 mmol) 
in pyridine (8 mL), was added methanesulfonyl chloride 
(0.023 mL, 0.29 mmol), along with triethylamine (0.04 mL, 
0.29 mmol). The reaction was refluxed overnight and then 
evaporated under reduced pressure. The residue was 
dissolved in ethyl acetate (80 mL), then washed with 10% 
HCl (5 × 70 mL), aqueous saturated sodium bicarbonate 
solution (100 mL), water (3 × 100 mL) and brine (100 mL), dried over magnesium sulfate 
and evaporated under reduced pressure. Chromatography employing 25% ethyl 
acetate/hexane yielded the title product 560 as a dark brown solid (0.048 g, 35%); m.p. 129-
132
o
C; νmax/ cm
-1
 (KBr) 3307, 2930, 1584, 1465, 1424, 1125; δH (300 MHz, CDCl3) 3.24 
[3H, s, SO2CH3], 3.42 [6H, s, 2 × m-OCH3], 3.78 [3H, s, N-CH3], 3.82 [3H, s, p-OCH3], 6.61 
[2H, s, C-H2‟,6‟], 7.00-7.05 [1H, t, J 7.4, C-H5], 7.08 [1H, s, C-H2], 7.17-7.19 [1H, d, J 7.8, 
C-H7], 7.19-7.24 [1H, t, J 7.5, C-H6], 7.26 [1H, s, pyrazole NH], 7.33-7.35 [1H, d, J 8.16, C-
H4]; δC (75 MHz, CDCl3) 33.0 (CH3, N-CH3), 41.4 (CH3, SO2CH3), 55.8 (2CH3, 2 × m-
OCH3), 60.9 (CH3, p-OCH3), 103.4 (C, aromatic C), 103.5 (C, aromatic C), 104.0 (2CH, 2 × 
aromatic CH), 109.5 (CH, aromatic CH), 119.9 (CH, aromatic CH), 120.0 (CH, aromatic 
CH), 122.3 (CH, aromatic CH), 124.6 (C, aromatic C), 127.6 (C, aromatic C), 128.9 (CH, 
aromatic CH), 137.1 (C, aromatic C), 138.3 (C, aromatic C), 141.8 (C, aromatic C), 145.2 
(C, aromatic C), 153.3 (2C, 2 × aromatic C); m/z (ES+) 457.1 [M+H]
+
 (100%); HRMS - 
(ES+) requires: 457.1546. Found: 457.1550 (C22H25N4O5S). 
5.2.5.8 Tert-butyl [(5-amino-4-(1-methyl-1H-indol-3-yl)-3-(3,4,5-trimethoxyphenyl)-1H-
pyrazol-1-yl){(tert-butoxycarbonyl)imino}methyl]carbamate 561  
 
Aminopyrazole 553 (0.150 g, 0.397 mmol) was treated with 
HgCl2 (0.130 g, 0.437 mmol, 1.1 eq.) and N,N‟-di-tert-
butoxycarbonylthiourea 546 (0.109 g, 0.397 mmol), in distilled 
DCM (10 mL), at 0
o
C. Triethylamine (0.2 mL, 1.23 mmol, 3.1 
eq.) was then added to the flask and allowed to stir at 0
o
C for a 
further 1 hour, followed by stirring for 12 hours at room 
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temperature. The reaction was then poured into ethyl acetate (30 mL), and filtered through a 
pad of celite
® 
in order to remove the yellow mercury sulfide by-product. The filter cake was 
washed with ethyl acetate (3 × 15 mL). The combined organic phases were then washed with 
water (3 × 100 mL) and brine (100 mL), dried over magnesium sulfate and concentrated 
under vacuum. Chromatography employing 15% ethyl acetate/ hexane yielded the pure di-
protected pyrazole derivative 561 as an off-white crystalline solid (0.085 g, 35%); m.p. 153-
156
o
C; νmax/ cm
-1
 (KBr) 3487, 3360, 2975, 1766, 1751, 1712, 1656, 1587, 1126; δH (300 
MHz, CDCl3) 1.55 [9H, s, CO2C(CH3)3], 1.56 [9H, s, CO2C(CH3)3], 3.47 [6H, s, 2 × m-
OCH3], 3.78 [3H, s, N-CH3], 3.82 [3H, s, p-OCH3], 5.72 [2H, bs, NH2], 6.81 [2H, s, C-
H2‟,6‟], 6.98 [1H, s, C-H2], 7.07-7.12 [1H, td, J 7.8, 0.7, C-H5], 7.23-7.28 [1H, t, J 7.7, C-H6], 
7.35-7.38 [1H, d, J 8.3, C-H7], 7.36-7.39 [1H, d, J 7.9, C-H4], 9.25 [1H, s, NHCO2C(CH3)3]; 
δC (75 MHz, CDCl3) 28.1 (3CH3, CO2C(CH3)3), 28.2 (3CH3, CO2C(CH3)3), 32.9 (CH3, N-
CH3), 55.7 (2CH3, 2 × m-OCH3), 60.8 (CH3, p-OCH3), 81.0 (C, CO2C(CH3)3), 83.1 (C, 
CO2C(CH3)3), 95.2 (C, aromatic C), 104.7 (C, aromatic C), 105.2 (2CH, 2 × aromatic CH), 
109.4 (CH, aromatic CH), 119.9 (CH, aromatic CH), 120.1 (CH, aromatic CH), 122.2 (CH, 
aromatic CH), 127.6 (C, aromatic C), 127.9 (C, aromatic C), 128.8 (CH, aromatic CH), 
137.1 (C, aromatic C), 138.5 (C, aromatic C), 143.2 (C, aromatic C), 148.6 (C, aromatic C), 
149.7 (C, NH-C=N), 152.0 (C, C=O), 152.9 (2C, 2 × aromatic C), 157.3 (C, C=O); m/z 
(ES+) 621.3 [M+H]
+
 (100%); HRMS - (ES+) requires: 621.3037. Found: 621.3033 
(C32H41N6O7). 
 
5.2.5.9 5-Amino-4-(1-methyl-1H-indol-3-yl)-3-(3,4,5-trimethoxyphenyl)-1H-pyrazole-1-
carboximidamidium trifluoroacetate 562 
 
As for synthesis of compound 548, Boc-protected N
1
-
guanylated derivative 561 (0.05 g, 0.08 mmol) was treated, at 
30
o
C, with a 10% v/v solution of TFA in DCM (10 mL), for 16 
hours. After stirring for this time, the solvent was evaporated in 
vacuo to generate the corresponding trifluoroacetate salt 562 in 
quantitative yield; m.p. 118-120
o
C; νmax/ cm
-1
 (KBr) 3369, 
1698, 1551, 1421; m/z (ES+) 421.2 [M]
+
 (100%), (ES-) 112.9 [CF3CO2]
-
 (100%). 
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5.2.5.10  3-(1-Methyl-1H-indol-3-yl)-5,7-bis(trifluoromethyl)-2-(3,4,5-
trimethoxyphenyl)pyrazolo[1,5-a]pyrimidine 563 
 
Hexafluoroacetylacetone (1.50 mL, 10.6 mmol, 20 eq.) was 
added to a mixture of aminopyrazole 553 (0.200 g, 0.53 
mmol) and acetic acid (10 mL), prior to heating at 80
o
C for 
20 hours, at which point, full consumption of the starting 
material had occurred. Following acetic acid removal, the 
crude hexafluoropyrimidine derivative 563 was purified by 
chromatography employing a gradient from 20-50% ethyl 
acetate/ hexane. Product fractions were then combined prior to solvent evaporation and 
drying under high vacuum overnight, to yield the product 563 as a brick-red crystalline solid 
(0.130 g, 45%); m.p. 217-220
o
C; νmax/  cm
-1
 (KBr) 2940, 1577, 1485, 1467, 1420, 1170; δH 
(300 MHz, CDCl3) 3.48 [6H, s, 2 × m-OCH3], 3.84 [3H, s, N-CH3], 3.90 [3H, s, p-OCH3], 
6.97-7.02 [1H, t, J 7.2, aromatic C-H5], 7.10-7.13 [1H, d, J 7.8, aromatic C-H7], 7.12 [2H, s, 
aromatic C-H2‟,6‟], 7.19-7.25 [1H, t, J 7.2, aromatic C-H6], 7.35 [1H, s, (CF3)C-CH=C(CF3)], 
7.36-7.39 [1H, d, J 8.3, aromatic C-H4], 7.42 [1H, s, aromatic C-H2]; δC (75 MHz, CDCl3) 
33.1 (CH3, N-CH3), 55.7 (2CH3, 2 × m-OCH3), 60.9 (CH3, p-OCH3), 102.1 (CH, aromatic 
CH), 103.3 (C, aromatic C), 106.1 (2CH, 2 × aromatic CH), 106.7 (C, aromatic C), 109.4 
(CH, aromatic CH), 117.4-124.6 (2C, m, 2 × CF3), 119.8 (CH, aromatic CH), 121.0 (CH, 
aromatic CH), 122.1 (CH, aromatic CH), 126.9 (C, aromatic C), 127.3 (C, aromatic C), 129.5 
(CH, aromatic CH), 134.0-135.4 (C, q, JF-C 38.6, aromatic C), 137.2 (C, aromatic C), 139.2 
(C, aromatic C), 143.5-144.9 (C, q, JF-C 37.8, aromatic C), 147.1 (C, aromatic C), 153.1 (2C, 
2 × aromatic C), 156.0 (C, aromatic C); m/z (ES+) 551.2 [M+H]
+
 (100%); HRMS - (ES+) 
requires: 551.1518. Found: 551.1514 (C26H21N4O3F6). 
5.2.5.11 8-(1-Methyl-1H-indol-3-yl)-7-(3,4,5-trimethoxyphenyl)pyrazolo[1,5-
a][1,3,5]triazine-2,4(1H,3H)-dione 540 
 
Chlorocarbonyl isocyanate (0.05 mL, 0.582 mmol, 1.1 eq.) 
was added to a stirred solution of aminopyrazole 553 (0.100 
g, 0.265 mmol) in doubly distilled DCM (5 mL), containing 
two drops of triethylamine, at 0
o
C. The reaction was then 
allowed to stir at room temperature overnight. Water (1 mL) 
was added carefully to the flask; the resultant dark brown 
slurry was then filtered and the isolated brown solid product 
540 (0.075 g, 64%) was washed successively with water, ether, and air-dried for 1 hour; m.p. 
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268-271
o
C, νmax/ cm
-1
 (KBr) 3433, 3213, 2939, 1763, 1710, 1587, 1419, 1125; δH (300 MHz, 
DMSO-d6) 3.38 [6H, s, 2 × m-OCH3], 3.65 [3H, s, NCH3], 3.90 [3H, s, p-OCH3], 6.93 [2H, 
s, C-H2‟,6‟], 7.02-7.06 [1H, t, J 7.6, C-H5], 7.17-7.19 [1H, d, J 7.8, C-H7], 7.22-7.27 [1H, t, J 
8.1, C-H6], 7.48 [1H, s, C-H2], 7.55-7.58 [1H, d, J 8.3, C-H4], 11.67 [2H, bs, 2 × NH]; δC (75 
MHz, DMSO-d6) 32.5 (CH3, N-CH3), 55.1 (2CH3, 2 × m-OCH3), 60.0 (CH3, p-OCH3), 94.8 
(C, aromatic C), 101.8 (C, aromatic C), 104.5 (2CH, 2 × aromatic CH), 109.8 (CH, aromatic 
CH), 119.1 (CH, aromatic CH), 119.4 (CH, aromatic CH), 121.4 (CH, aromatic CH) , 127.3 
(C, aromatic C), 127.8 (C, aromatic C), 130.7 (CH, aromatic CH), 136.8 (C, aromatic C), 
137.8 (C, aromatic C), 139.9 (C, aromatic C), 144.3 (C, aromatic C), 148.5 (2C, 2 × aromatic 
C), 152.4 (C, C=O), 153.5 (C, C=O); m/z (ES+) 448.1 [M+H]
+
 (40%); HRMS - (ES+) 
requires: 448.1621. Found: 448.1611 (C23H22N5O5). 
5.2.5.12 Methyl 2-(1-Methyl-1H-indol-3-yl)-3-oxo-3-(3,4,5-trimethoxyphenyl) 
propanoate 555 
 
To a flame dried 100 mL round-bottomed flask, was added dry 
THF (40 mL), cooled and stirred at −78C. LDA solution 
(1.8M) (15.2 mL, 27.3 mmol, 2.2 eq.) was then added slowly to 
the reaction mixture and allowed to equilibriate, with stirring, 
for 30 minutes. N-Methyl indole ester 480 (2.513 g, 12.4 
mmol) in THF (3 mL) was added dropwise, maintaining an 
internal temperature of −78C, and allowed to deprotonate for 90 minutes. 3,4,5-
Trimethoxybenzoyl chloride 499, (4.228 g, 18.6 mmol, 1.5 eq.) was dissolved in THF (10-15 
mL), and added dropwise, over 10 minutes, to the dark reaction mixture. The reaction was 
then allowed to warm up to room temperature, while stirring of the flask was maintained 
overnight. Following solvent removal, the crude product residue was extracted with ethyl 
acetate (3 × 150 mL), which was washed with saturated ammonium chloride (250 mL), 
water (4 × 250 mL) and brine (2 × 150 mL). The combined organic layers were dried using 
magnesium sulfate, filtered and evaporated in vacuo. The pure product β-ketoester 555 was 
isolated as a light brown solid following gradient column chromatography, utilising 10-30% 
ethyl acetate/hexane as eluent (1.721 g, 35%); m.p. 70-74
oC; νmax/ cm
-1
 (KBr) 2941, 1739, 
1678, 1584, 1453, 1415, 1333, 1126; δH (300 MHz, CDCl3) 3.75 [9H, s, CO2CH3 & 2 × m-
OCH3], 3.78 [3H, s, N-CH3], 3.85 [3H, s, p-OCH3], 5.85 [1H, s, COCHCO2CH3], 7.14-7.18 
[1H, t, J 6.8, aromatic C-H5], 7.18 [1H, s, aromatic C-H2], 7.21-7.24 [1H, d, J 8.2, aromatic 
C-H7], 7.26 [2H, s, aromatic C-H2‟,6‟], 7.27-7.32 [1H, t, J 8.0, aromatic C-H6], 7.69-7.72 [1H, 
d, J 7.7, aromatic C-H4]; δC (75 MHz, CDCl3) 33.0 (CH3, N-CH3), 51.6 (CH, 
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COCHCO2CH3), 52.7 (CH3, CO2CH3), 56.2 (2CH3, 2 × m-OCH3), 60.9 (CH3, p-OCH3), 
106.2 (C, aromatic C), 106.4 (2CH, aromatic C-H2‟ & aromatic C-H6‟), 106.9 (C, aromatic 
C), 109.8 (CH, aromatic CH), 118.0 (CH, aromatic CH), 119.8 (CH, aromatic CH), 122.1 
(CH, aromatic CH), 126.8 (C, aromatic C), 129.3 (CH, aromatic CH), 130.5 (C, aromatic C), 
136.9 (C, aromatic C), 142.7 (C, aromatic C), 153.0 (C, aromatic C), 169.9 (C, CO2CH3), 
192.3 (C, C=O); m/z (ES+) 398.1 [M+H]
+
 (100%); HRMS - (ES+) requires: 398.1604. 
Found: 398.1613 (C22H24NO6).  
5.2.5.13 4-(1-Methyl-1H-indol-3-yl)-5-(3,4,5-trimethoxyphenyl)-1H-pyrazol-3(2H)-one 
552 
 
β-Ketoester precursor 555 (0.250 g, 0.63 mmol) was initially 
placed in a 100 mL round-bottom flask, along with camphoric 
acid (0.128 g, 0.63 mmol) and distilled ethanol (20 mL). To 
the stirring mixture, was then added hydrazine hydrate (50-
60% commercial solution) (0.07 mL, 0.65 mmol) and the 
temperature was adjusted to maintain reflux of the flask 
contents for 2 hours. Further hydrazine hydrate solution (0.20 mL, 1.90 mmol, 3 eq.) was 
then added to the heated reaction vessel, and the overall mixture was stirred at 80
o
C for a 
further 20 hours. Following removal of the reaction solvent, the product residue was 
dissolved in ethyl acetate (70 mL) and washed with 10% aqueous sodium bicarbonate 
solution (2 × 80 mL). Following washing of the ethyl acetate layer with water (3 × 100 mL), 
brine (2 × 100 mL), and drying with magnesium sulfate, the solvent was evaporated in 
vacuo. The crude pyrazolone 552 was then purified by flash chromatography, employing a 
gradient from 70% hexane/ 30% ethyl acetate to 95% ethyl acetate/5% methanol. The 
pyrazolone fractions were then combined, evaporated under reduced pressure, and triturated 
with boiling methanol in order to afford the novel title compound 552, indicated by NMR 
analysis to exist as two atropisomers, and isolated as a yellow powder (0.146 g, 60%); m.p. 
198-201
o
C; νmax/ cm
-1
 (KBr) 3334, 2936, 1700, 1586, 1519, 1458, 1251, 1125; δH (300 MHz, 
DMSO) 3.39 [6H, s, 2 x m-OCH3], 3.42 [3H, s, p-OCH3], 3.59 [3H, s, N-CH3], 3.82 [1H, s, 
NH-NH-CO, D2O exchangeable], 6.75 [2H, s, aromatic C-H2‟,6‟], 6.84-6.93 [1H, m, aromatic 
C-H5], 7.02-7.15 [2H, m, aromatic C-H6,7], 7.30 & 7.31 [1H, 2 × overlapping s, aromatic C-
H2], 7.38-7.45 [1H, m, aromatic C-H4]; δC (75 MHz, DMSO) (mixture of signals not 
deconvoluted) 32.3 (2CH3, 2 × N-CH3), 55.1 (4CH3, 4 x m-OCH3), 59.9 (2CH3, 2 × p-
OCH3), 103.5 (2CH, aromatic C-H2‟ & aromatic C-H6‟), 103.5 (2CH, aromatic C-H2‟ & 
aromatic C-H6‟), 105.1 (2C, aromatic C), 105.8 (C, aromatic C), 105.8 (C, aromatic C), 
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109.5 (CH, aromatic CH), 111.2 (CH, aromatic CH), 111.3 (C, aromatic C), 118.3 (CH, 
aromatic CH), 118.4 (CH, aromatic CH), 119.8 (CH, aromatic CH), 120.0 (CH, aromatic 
CH), 120.8 (CH, aromatic CH), 120.9 (CH, aromatic CH), 124.7 (CH, aromatic CH), 124.9 
(C, aromatic C), 124.9 (C, aromatic C), 125.8 (C, aromatic C), 125.9 (C, aromatic C), 125.9 
(C, aromatic C), 126.8 (C, aromatic C), 129.1 (CH, aromatic CH), 135.9 (C, aromatic C), 
136.1 (C, aromatic C), 136.5 (C, aromatic C), 136.5 (C, aromatic C), 136.6 (C, aromatic C), 
136.7 (C, aromatic C), 152.4 (C, C=O), 152.5 (C, C=O); m/z (ES+) 380.2 [M+H]
+
 (100%); 
HRMS - (ES+) requires: 380.1610. Found: 380.1601 (C21H22N3O4). 
 
5.2.6 Synthesis of imidazo[4,5-c]indolo[2,3-a]carbazoles 
5.2.6.1 1H-Indol-3-yl glyoxylyl chloride 231
40
  
 
Indole 171 (1.001 g, 8.6 mmol) was placed in a 50 mL round-bottomed 
flask, along with diethyl ether (20 mL). Oxalyl chloride (1.1 mL, 11.46 
mmol) was then added carefully to the flask over 10 minutes and the 
straw coloured slurry was allowed to stir at room temperature for a 
further 30 minutes. The product was filtered on a Hirsch funnel and washed with cool 
mother liquor (5-10 mL). The glyoxalyl chloride 231 produced, yielded a crop of yellow 
crystals (1.623 g, 90 %); m.p. 120-122
o
C (lit.
40
 128
o
C); νmax/ cm
-1
 (KBr) 3400, 1730, 1680, 
1590  
5.2.6.2 1,2-Bis(1H-indol-3-yl)ethane-1,2-dione 565
41
 
 
Indole-3-glyoxylyl chloride 231 (4.164 g, 20 mmol) was added 
in portions over a period of 5 minutes, to a suspension of 
aluminium chloride (12.076 g, 90 mmol), in a mixture of 
dichloroethane (20 mL) and heptane (10 mL), with stirring, and 
at room temperature. A solution of indole 171 (3.863 g, 33 mmol) in dichloroethane (20 
mL), was added dropwise under vigorous stirring, to the dark brown slurry, and then stirred 
for a further 3 hours. The reaction mixture was poured into an ice-water (100 mL), and 
extracted into ethyl acetate (3 × 120 mL). The combined extracts were dried over 
magnesium sulfate, filtered, and evaporated under vacuum. The formed residue was 
triturated with ether/ absolute ethanol (20:1) (150 mL), and the final product was collected 
by vacuum filtration, dried and title compound 565 isolated as a brown powder (2.614 g, 
45%); m.p. 267-270
o
C (lit.
41
 278-280
o
C); νmax/ cm
-1
 (KBr) 3305, 1709, 1603, 1511; δH (300 
MHz, DMSO-d6) 7.26-7.32 [4H, m, aromatic C-H5,5‟,6,6‟], 7.54-7.57 [2H, m, aromatic C-
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H7,7‟], 8.23 [2H, aromatic C-H2,2‟], 8.27-8.30 [2H, m, aromatic C-H4,4‟], 12.24 [2H, s, 2 × 
NH]; δC (75 MHz, DMSO-d6) 112.5 (2C, 2 × aromatic C), 112.5 (2CH, 2 × aromatic CH), 
121.3 (2CH, 2 × aromatic CH), 122.4 (2CH, 2 × aromatic CH), 123.4 (2CH, 2 × aromatic 
CH), 125.6 (2C, 2 × aromatic C), 136.7 (2C, 2 × aromatic C), 137.3 (2CH, 2 × aromatic 
CH), 188.8 (2C, 2 × C=O); m/z (ES+) 289.1 [M+H]
+
 (100%). (ES-) 287.1 [M-H]
-
 (100%).  
 
5.2.6.3 Synthesis of 2-substituted 8,9-dihydro-1H-imidazo[4,5-c]indolo[2,3-a]carbazoles 
 
 
 
 
                      565                                               564                                               449                    
Table 5.5: Characteristic data for crude compounds 566, 569, 567, 570, 568 and 571 
Compound R1 IR (cm
-1
) HRMS (m/z) Formula 
566
# thien-2-yl 3396, 3055, 1619, 1572, 
1456 
381.1172 C23H17N4S 
(381.1174) 
569
¥ thien-2-yl 3394, 3055, 2922, 1640, 
1583, 1456 
379.1006 C23H15N4S 
(379.1017) 
567
# isopropyl 3390, 2919, 1557, 1410 341.1772 C22H21N4 
(341.1766) 
570
¥ isopropyl 3374, 3269, 2964, 1706, 
1619, 1456 
339.1607 C22H19N4 
(339.1610) 
568
# 3,4,5-
trimethoxyphenyl 
3368, 2936, 1589, 1503, 
1457 
465.1931 C28H25N4O3 
(465.1927)  
571
¥ 3,4,5-
trimethoxyphenyl 
3333, 2936, 1589, 1502, 
1457 
463.1768 C28H23N4O3 
(463.1770) 
 
General reaction schemes: 
#
(i) Aldehyde (1 eq.) was added to a mixture of dione 565 and 
ammonium acetate (10 eq.), along with acetic acid (10 mL/ mmol), and heating of the red 
mixture at 110
o
C was commenced for 24 hours. The reaction was then concentrated in 
vacuo, prior to washing with aqueous saturated NaHCO3 and extraction with DCM. The 
crude imidazole derivative 564 was isolated by flash chromatography (100% DCM – 2% 
methanol/DCM), but could not be satisfactorily purified, as confirmed by NMR 
spectroscopy.  
 
¥
(ii) 3,3'-(2-Substituted 1H-imidazol-4,5-diyl)bis(1H-indole) (564) was stirred in acetonitrile 
(0.8 mL/ µmol substrate), along with a catalytic amount of iodine. U.V. irradiation of the 
dark red mixture, in the presence of air, then proceeded overnight. Following concentration 
of the reaction mixture, flash chromatography (0.5% MeOH/DCM) afforded the fluorescent 
product (449) as a single intense spot in TLC, in moderate to good yields. As for the 
corresponding unaromatised series, several inseparable impurities present prevented clean 
isolation of the desired indolocarbazole product in each case. 
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5.2.6.3.1 
#
3,3'-(2-(Thiophen-2-yl)-1H-imidazol-4,5-diyl)bis(1H-indole) 566 
 Applying general scheme (i) starting from dione 565 (1.002 g, 3.47 mmol), ammonium 
acetate (2.682 g, 34.72 mmol, 10 eq.) and thiophene-2-carboxaldehyde (0.33 mL, 3.47 
mmol), afforded 566 as an amorphous red powder (0.460 g, 35%). 
5.2.6.3.2 
#
3,3'-(2-Isopropyl-1H-imidazol-4,5-diyl)bis(1H-indole) 567 
Applying general scheme (i) starting from dione 565 (0.580 g, 2.01 mmol), ammonium 
acetate (1.550 g, 20.1 mmol, 10 eq.) and isobutyraldehyde (0.2 mL, 2.01 mmol) afforded 567 
as a crystalline light brown solid (0.258 g, 37%). 
5.2.6.3.3 
#
3,3'-(2-(3,4,5-Trimethoxyphenyl)-1H-imidazol-4,5-diyl)bis(1H-indole) 568 
Applying general scheme (i) starting from dione 565 (0.700 g, 2.43 mmol), ammonium 
acetate (1.901 g, 24.3 mmol, 10 eq.) and 3,4,5-trimethoxybenzaldehyde (0.487 g, 2.43 
mmol), afforded imidazole analogue 568 as an amorphous red powder (0.905 g, 80%). 
 
5.2.6.3.4 
¥
2-(Thiophen-2-yl)-8,9-dihydro-1H-imidazo[4,5-c]indolo[2,3-a]carbazole 569 
According to general scheme (ii), 3,3'-(2-(thiophen-2-yl)-1H-imidazol-4,5-diyl)bis(1H-
indole) 566 (0.100 g, 0.26 mmol) was irradiated in the presence of acetonitrile (150 mL) for 
16 hours, to afford imidazo[3,4-c]carbazole 569 as a crystalline red solid (0.024 g, 25%). 
5.2.6.3.5 
¥
2-Isopropyl-8,9-dihydro-1H-imidazo[4,5-c]indolo[2,3-a]carbazole 570  
Procedure outlined in general scheme (ii), employing 3,3'-(2-isopropyl-1H-imidazol-4,5-
diyl)bis(1H-indole 567 (0.100 g, 0.29 mmol), irradiated in acetonitrile (250 mL) for 16 
hours, provided indolocarbazole 570 as a crystalline red solid (0.032 g, 33%). 
5.2.6.3.6 
¥
2-(3,4,5-Trimethoxyphenyl)-8,9-dihydro-1H-imidazo[4,5-c]indolo[2,3-
a]carbazole 571 
 
As outlined in general scheme (ii), 3,3'-(2-(3,4,5-trimethoxyphenyl)-1H-imidazol-4,5-
diyl)bis(1H-indole) 568 (0.200 g, 0.43 mmol), irradiated along with acetonitrile (300 mL) for 
16 hours, produced novel indolocarbazole 571 as a dark red powder (0.182 g, 92%). 
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5.2.7 Synthesis of miscellaneous 3-substituted indole compounds  
5.2.7.1 1H-Indol-3-yl carbonitrile 481
42
 
  
1H-Indole-3-carboxaldehyde 121 (2.004 g, 13.8 mmol) was dissolved in dry 
DMF (30 mL), forming a reddish solution which was heated to reflux and 
maintained at this temperature for 15 minutes. Hydroxylamine 
hydrochloride (1.163 g, 16.6 mmol, 1.2 eq.) was then added to the vessel 
and reflux continued for a further 30 minutes. The heating source was removed and the 
reaction cooled to room temperature. Water (100 mL) was then added and the resultant 
slurry cooled to 0
o
C for several minutes. The precipitated 3-cyanoindole 481 was then 
filtered and dried (1.202 g, 61%); m.p. 177-179
o
C (lit.
43
 176-177
o
C); νmax/ cm
-1
 (KBr) 3225, 
2227, 1525, 1429, 1380; δH (300 MHz, DMSO-d6) 7.21-7.26 [1H, td, J 7.2, 1.2, aromatic C-
H5], 7.26-7.32 [1H, td, J 7.1, 1.4, aromatic C-H6], 7.55-7.58 [1H, d, J 7.4, aromatic C-H7], 
7.63-7.65 [1H, d, J 7.5, aromatic C-H4], 8.25-8.26 [1H, d, J 3.0, aromatic C-H2], 12.23 [1H, 
bs, NH]; δC (75 MHz, DMSO-d6) 84.1 (CN), 112.9 (CH, aromatic CH), 116.4 (C, aromatic 
C), 118.4 (CH, aromatic CH), 121.6 (CH, aromatic CH), 123.3 (CH, aromatic CH), 126.7 
(C, aromatic C), 134.5 (CH, aromatic CH), 135.2 (C, aromatic C); m/z (ES-) 141.0 [M-H]
-
 
(100%).  
5.2.7.2 2-(1H-Indol-3-yl)-N-methoxy-N-methylacetamide 575
44
 
 
1,1-Carbonyldiimidazole (3.392 g, 18.8 mmol, 1.1 eq.) was added 
portionwise to a mixture of indole-3-acetic acid 233 (3.008, 17.2 mmol) 
and DCM (40 mL), and stirred under nitrogen for 2 hours, at room 
temperature. N,O-Dimethylhydroxylamine hydrochloride (1.871 g, 18.8 
mmol, 1.1 eq.) was then added to the reaction mixture and stirred for 16 
hours. The reaction contents were then poured into an ice-water mixture (200 mL) and 
adjusted to pH 10 with 30% NaOH, prior to extracting with ethyl acetate (2 × 120 mL). 
These organic layers were combined, washed with 10% HCl (150 mL), dried over 
magnesium sulfate, filtered and evaporated under reduced pressure to yield the Weinreb 
amide 575 as dark pink plates (3.429 g, 91%); m.p. 118-120
o
C (lit.
44
 125-127
o
C); νmax/ cm
-1
 
(KBr) 3281, 2972, 2936, 1656, 1460; δH (300 MHz, CDCl3) 3.21 [3H, s, N-CH3], 3.65 [3H s, 
O-CH3], 3.90 [2H, s, CH2], 7.08 [1H, s, aromatic C-H2], 7.11-7.18 [2H, m, aromatic C-H5,6], 
7.28-7.31 [1H, d, J 7.5, aromatic C-H7], 7.63-7.65 [1H, d, J 7.3, aromatic C-H4], 8.29 [1H, 
bs, NH]; δC (75 MHz, CDCl3) 29.0 (CH2, CH2CO), 32.3 (CH3, N-CH3), 61.4 (CH3, N-
OCH3), 108.9 (C, aromatic C), 111.2 (CH, aromatic CH), 118.8 (CH, aromatic CH), 119.5 
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(CH, aromatic CH), 122.0 (CH, aromatic CH), 123.2 (CH, aromatic CH), 127.4 (C, aromatic 
C), 136.1 (C, aromatic C), 172.9 (C, C=O); m/z (ES+) 219.1 [M+H]
+
 (100%).  
5.2.7.3 1-Methyl-1H-indol-3-yl acetic acid 225
45
 
Method A:  
To a suspension of NaH (0.377 g, 11.3 mmol, 1.5 eq.) (60% dispersion in 
mineral oil) in dry THF (25 mL), at 0
o
C, was initially added a solution of 
indole-3-acetic acid 233 (1.312 g, 7.5 mmol) in THF (10 mL). After 
stirring for 30 minutes, a solution of iodomethane (0.4 mL, 6.25 mmol) in 
THF (5 mL) was then added dropwise over 5 minutes. The reaction was 
slowly warmed to room temperature and allowed to stir overnight. The reaction was 
subsequently cooled to 0
o
C, prior to quenching by the slow addition of MeOH (2 mL), along 
with vigorous stirring. Water (50 mL) was then carefully added until the appearance of a 
clear yellow solution. Ether (100 mL) was also delivered and the separated aqueous phase, 
acidified with 10% HCl (150 mL) and extracted with DCM (3 × 70 mL). On drying with 
magnesium sulfate, filtration and concentration of the reaction to dryness, the crude residue 
was recrystallised from EtOH to afford 1-methyl-1H-indol-3-yl acetic acid 225, as a pale 
brown solid (1.33 g, 94%), which was used without further purification; m.p 123-126
o
C 
(lit.
46
 127-129
o
C); νmax/ cm
-1
 (KBr) 3064, 2976, 2934, 1710, 1632, 1526; δH (300 MHz, 
CDCl3) 3.73 [3H, s, N-CH3], 3.78 [2H, s, CH2], 7.02 [1H, s, aromatic C-H2], 7.09-7.14 [1H, 
td, J 7.9, 1.1, aromatic C-H5], 7.20-7.25 [1H, td, J 7.7, 0.9, aromatic C-H6], 7.27-7.30 [1H, d, 
J 8.1, aromatic C-H7], 7.57-7.59 [1H, d, J 7.9, aromatic C-H4]; δC (75 MHz, CDCl3) 31.0 
(CH2, CH2CO2H), 32.7 (CH3, N-CH3), 106.1 (C, aromatic C), 109.4 (CH, aromatic CH), 
119.0 (CH, aromatic CH), 119.3 (CH, aromatic CH), 121.9 (CH, aromatic CH), 127.6 (C, 
aromatic C), 127.9 (CH, aromatic CH), 136.9 (C, aromatic C), 178.4 (C, C=O); m/z (ES+) 
190.2 [M+H]
+
 (100%).  
 
Method B:  
Methyl 1H-indol-3-yl acetate 480 (1.012 g, 4.99 mmol) was initially suspended in EtOH (50 
mL), and vigorously stirred in the presence of an aqueous LiOH solution (1M, 200 mL). 
Following reaction at 35
o
C for 20 hours, the solution was recooled to room temperature and 
adjusted to pH 4 with aqueous 10% HCl. On further cooling to 0
o
C, the slurry was filtered 
and subsequently dried, to yield the title compound 225 as a light brown powder (0.670 g, 
71%).  
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5.2.7.4 1-Benzyloxycarbonyl-1H-indol-3-yl acetic acid 576
47
 
 
A solution of indole-3-acetic acid 233 (1.004 g, 5.70 mmol) was 
stirred in THF at −78oC along with 1.8M LDA (7.0 mL, 12.54 
mmol, 2.2 eq.), which was added dropwise, under inert 
atmosphere. Following continued stirring at this temperature for 
1 hour, benzyl chloroformate (1.0 mL, 6.84 mmol, 1.2 eq.) was 
added and the reaction contents vigorously stirred for 2 hours. 
Following solvent evaporation, the dark residue was redissolved in water (150 mL) and 
extracted with ether (2 × 120 mL). Acidification of the aqueous phase to pH 3 with 10% HCl 
resulted in the formation of a precipitate, which was filtered and dried to afford the protected 
acid 576, as an off-white amorphous powder (1.235 g, 70%); m.p. 145-148
o
C (lit.
47
 152
o
C); 
νmax/ cm
-1
 (KBr) 3140, 3030, 1733, 1696, 1454; δH (300 MHz, CDCl3) 3.72 [2H, s, 
CH2CO2H], 5.47 [2H, s, O-CH2Ph], 7.24-7.30 [1H, t, J 8.4, aromatic C-H5], 7.32-7.37 [1H, t, 
J 8.3, aromatic C-H6], 7.39-7.44 [1H, t, J 6.8, aromatic C-H4‟], 7.42-7.46 [2H, t, J 7.6, 
aromatic C-H2‟ & aromatic C-H6‟], 7.52-7.55 [2H, d, J 7.5, aromatic C-H3‟ & aromatic C-
H5‟], 7.57-7.60 [1H, d, J 7.7, aromatic C-H7], 7.68 [1H, s, aromatic C-H2], 8.08-8.10 [1H, d, 
J 8.1, aromatic C-H4], 12.41 [1H, bs, CO2H]; δC (75 MHz, CDCl3) 30.2 (CH2, CH2CO2H), 
68.3 (CH2, O-CH2), 114.5 (CH, aromatic CH), 115.1 (C, aromatic C), 119.7 (CH, aromatic 
CH), 122.8 (CH, aromatic CH), 124.0 (CH, aromatic CH), 124.6 (CH, aromatic CH), 128.3 
(2CH, phenyl C-H3‟ & phenyl C-H5‟), 128.5 (CH, phenyl C-H4‟), 128.6 (2CH, phenyl C-H2‟ 
& phenyl C-H6‟), 130.2 (C, phenyl C1‟), 134.7 (C, aromatic C], 135.4 (C, aromatic C), 150.1 
(C, N-CO2CH2Ph), 172.0 (C, CO2H); m/z (ES+) 310.1 [M+H]
+
, (20%), 266.0 [M+H-CO2]
+
, 
(100%), (ES-) 617.2 [2M-H]
-
 (100%), 308.1 [M-H]
-
 (20%). 
5.2.7.5 1-Ethoxycarbonyl-1H-indol-3-yl acetonitrile 577
48
   
 
Ethyl chloroformate (1.08 mL, 10.9 mmol) was slowly added to a rapidly 
stirring mixture of 3-indolylacetonitrile 229 (1.503 g, 9.6 mmol), TBAB 
(0.054 g, 0.17 mmol) and 30% NaOH solution (30 mL) in dry DCM (30 
mL). The reaction mixture was initially stirred for 1 hour at 0
o
C, and 
allowed to stir at ambient temperature overnight. Stirring was ceased, and 
the distinct layers were permitted to separate; extraction of the aqueous 
layer was performed with DCM (2 × 100 mL), and the combined DCM layers were then 
washed successively with water (3 × 150 mL) and brine (250 mL), dried with magnesium 
sulfate and evaporated in vacuo. The crude acetonitrile 577 was then purified by column 
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chromatography, with 20% ethyl acetate/ hexane as eluent, to afford derivative 577 as a 
colourless oil, which solidified to an off-white residue on further drying (0.522 g, 23%); m.p. 
56-58
o
C; νmax/ cm
-1
 (KBr) 2910, 2252, 1729, 1612; δH (300 MHz, CDCl3) 1.45-1.50 [3H, t, J 
7.1, N-CO2CH2CH3], 3.76 [2H, s, CH2CN], 4.46-4.53 [2H, q, J 7.1, N-CO2CH2CH3], 7.28-
7.33 [1H, td, J 7.5, 1.0, aromatic C-H5], 7.37-7.42 [1H, td, J 7.7, 1.0, aromatic C-H6], 7.50-
7.53 [1H, d, J 7.8, aromatic C-H7], 7.68 [1H, s, aromatic C-H2], 8.19-8.21 [1H, d, J 8.2, 
aromatic C-H4]; δC (75 MHz, CDCl3) 14.4 (CH2, CH2CN), 14.4 (CH3, N-CO2CH2CH3), 63.6 
(CH2, N-CO2CH2CH3), 110.3 (C, aromatic C), 115.6 (CH, aromatic CH), 117.0 (C, C≡N), 
118.3 (CH, aromatic CH), 123.3 (CH, aromatic CH), 123.9 (CH, aromatic CH), 125.5 (CH, 
aromatic CH), 128.5 (C, aromatic C), 135.6 (C, aromatic C), 150.6 (C, C=O); m/z (ES+) 
229.0 [M+H]
+
 (100%), (ES-) 227.1 [M-H]
-
 (60%).  
5.2.7.6 1-Ethoxycarbonyl methyl 1H-indol-3-yl acetate 578
48
  
 
Ethyl chloroformate (4.83 mL, 48.8 mmol) was cautiously added over a 15 
minute period, to a rapidly stirring mixture of methyl indole-3-acetate 239 
(8.018 g, 42.4 mmol), TBAB (0.238 g, 0.768 mmol) and 30% NaOH 
solution (150 mL) in dry DCM (150 mL). Following vigorous stirring of 
the bi-phasic mixture for 1 hour at 0
o
C, both layers were allowed to 
separate. Following extraction of the aqueous layer with DCM (2 × 200 mL), the combined 
organic layers were washed successively with water (3 × 250 mL) and brine (300 mL), dried 
with magnesium sulfate and evaporated in vacuo. The crude carbamate 578 was then 
purified by column chromatography, with 20% ethyl acetate/ hexane as eluent, yielding a 
colourless oil (8.532 g, 77%); νmax/ cm
-1
 (KBr) 2983, 1738, 1732, 1613, 1574, 1455; δH (300 
MHz, CDCl3) 1.44-1.48 [3H, t, J 7.1, N-CO2CH2CH3], 3.72 [3H, s, CO2CH3], 3.73 [2H, s, 
CH2CO2CH3], 4.44-4.51 [2H, q, J 7.1, N-CO2CH2CH3], 7.24-7.30 [1H, td, J 7.6, 1.0, 
aromatic C-H5], 7.32-7.38 [1H, td, J 7.4, 1.2, aromatic C-H6], 7.52-7.55 [1H, d, J 7.5, 
aromatic C-H7], 7.62 [1H, s, aromatic C-H2], 8.17-8.19 [1H, d, J 8.0, aromatic C-H4]; δC (75 
MHz, CDCl3) 14.4 (CH3, O-CH2CH3), 30.9 (CH2, C-CH2CO2CH3), 52.2 (CH3, CO2CH3), 
63.2 (CH2, CO2CH2CH3), 113.8 (C, aromatic C), 115.3 (CH, aromatic CH), 119.1 (CH, 
aromatic CH), 122.9 (CH, aromatic CH), 124.1 (CH, aromatic CH), 124.8 (CH, aromatic 
CH), 130.1 (C, aromatic C), 135.4 (C, aromatic C), 150.9 (C, N-CO2CH2CH3), 171.4 (C, 
CO2CH3); m/z (ES+) 262.1 [M+H]
+
 (55%).  
 
Chapter 5                                                                                                                                    Experimental                         
__________________________________________________________________________ 
                                                                         270 
5.2.7.7 Ethyl 3-(1-methoxy-1,3-dioxo-3-(3,4,5-trimethoxyphenyl)propan-2-yl)-1H-
indole-1-carboxylate 579 
 
LDA solution (1.8M) (37.4 mL, 67.5 mmol, 2.2 eq.) was added 
dropwise over a period of 20 minutes, to dry THF (30 mL), at        
−78oC, under nitrogen atmosphere. A mixture of carbamate 
protected ester 578 (8.014 g, 30.7 mmol) in THF (3 mL) was 
then added to the reaction vessel, at a sufficient rate to 
maintain the internal reaction temperature below −65oC, during 
addition. The dark brown solution was then stirred vigorously for 90 minutes. 3,4,5-
Trimethoxybenzoyl chloride 499 (10.502 g, 46.1 mmol, 1.5 eq.) was then dissolved in dry 
THF (15 mL) and added to the reaction vessel slowly, over 15 minutes. Stirring of the dark 
mixture proceeded at room temperature overnight. Following solvent removal, the product 
residue was extracted with ethyl acetate (3 × 150 mL), and washed with saturated 
ammonium chloride (250 mL), water (4 × 250 mL) and brine (2 × 150 mL). The combined 
organic layers were dried using magnesium sulfate, filtered and evaporated in vacuo. The 
optimized yield of the product β-ketoester 579, a light brown solid, following column 
chromatography (4.325 g, 31%); m.p. 117-120
o
C; νmax/ cm
-1
 (KBr) 2958, 1751(s), 1679, 
1583, 1505; δH (300 MHz, CDCl3) 1.43-1.47 [3H, t, J 7.1, N-CO2CH2CH3], 3.79 [6H, s, 2 × 
m-OCH3], 3.80 [3H, s, p-OCH3], 3.88 [3H, s, CO2CH3], 4.43-4.50 [2H, q, J 7.1, N-
COCH2CH3], 5.79 [1H, s, CH3CO2CHCO], 7.25 [2H, s, aromatic C-H2‟,6‟], 7.27-7.33 [1H, t, 
J 7.6, aromatic C-H5], 7.35-7.39 [1H, t, J 7.9, aromatic C-H6],  7.64-7.67 [1H, d, J 7.3, 
aromatic C-H7], 7.77 [1H, s, aromatic C-H2], 8.20-8.23 [1H, d, J 8.0, aromatic C-H4]; δC (75 
MHz, CDCl3) 14.4 (CH3, CO2CH2CH3), 51.5 (CH, CH3CO2CHCO), 53.0 (CH3, CO2CH3), 
56.2 (CH3, 2 × m-OCH3), 61.0 (CH3, p-OCH3), 63.5 (CH2, CO2CH2CH3), 106.3 (2CH, 2 × 
aromatic CH), 113.2 (C, aromatic C), 115.6 (CH, aromatic CH), 118.5 (CH, aromatic CH), 
123.2 (2CH, 2 × aromatic CH), 125.2 (CH, aromatic CH), 125.7 (C, aromatic C), 129.0 (C, 
aromatic C), 130.2 (C, aromatic C), 135.4 (C, aromatic C), 143.1 (C, N-CO2CH2CH3), 153.1 
(2C, 2 × aromatic C), 168.9 (C, CO2CH3), 191.4 (C, CH3CO2CHCO); m/z (ES+) 456.1 
[M+H]
+
 (100%); HRMS - (ES+) requires: 456.1658. Found: 456.1656 (C24H26NO8).  
5.2.7.8 1,2-Bis(1-methyl-1H-indol-3-yl)ethane-1,2-dione 580
22
 
 
To a suspension of sodium hydride (60% dispersion in mineral 
oil) (0.822 g, 12.2 mmol, 5 eq.) in DMF (15 mL), cooled to 0
o
C, 
was slowly added a solution of 1,2-bis(1H-indol-3-yl) ethane-
Chapter 5                                                                                                                                    Experimental                         
__________________________________________________________________________ 
                                                                         271 
1,2-dione 565 (0.701 g, 2.4 mmol) in DMF (10 mL), along with vigorous stirring of the dark 
brown reaction mixture. Following stirring for 45 minutes, a solution of iodomethane (0.5 
mL, 7.3 mmol, 3 eq.) in DMF (3 mL) was added dropwise over 10 minutes and reacted for 
an additional 15 minutes, prior to attaining room temperature and proceeding overnight. At 
this point, the reaction was diluted with ethyl acetate (250 mL) and poured into an aqueous 
solution of HCl (0.5M, 300 mL). Following initial extraction, the crude product was then 
washed with further portions of 10% HCl (2 x 250 mL). The final organic extract was then 
dried over magnesium sulfate, filtered and evaporated in vacuo, prior to chromatographic 
purification employing 20%-100% ethyl acetate/ hexane, in order to afford 580 as a brown 
powder (0.600 g, 78%); m.p. 255-259
o
C (lit.
22
 268-269
o
C); νmax/ cm
-1
 (KBr) 1607, 1524, 
1460; δH (300 MHz, DMSO-d6) 3.89 [6H, s, 2 x N-CH3], 7.34-7.39 [4H, m, aromatic C-
H5,5‟,6,6‟], 7.59-7.62 [2H, m, aromatic C-H7,7‟], 8.30-8.33 [2H, m, aromatic C-H4,4‟], 8.31 [2H, 
s, aromatic C-H2,2‟]; δC (75 MHz, DMSO-d6) 33.2 (2CH3, 2 × N-CH3), 111.0 (2CH, 2 × 
aromatic CH), 111.3 (2C,  2 × aromatic C), 121.4 (2CH, 2 × aromatic CH), 122.8 (2CH, 2 × 
aromatic CH), 123.5 (2CH, 2 × aromatic CH), 126.0 (2C, 2 × aromatic C), 137.4 (2C, 2 × 
aromatic C), 140.8 (2CH, 2 × aromatic CH), 188.2 (2C, 2 × C=O); m/z (ES+) 317.1 [M+H]
+
 
(100%). 
5.2.7.10 1,2-Bis(1H-indol-3-yl)ethane-1,2-dione dioxime 581
49
 
 
To a mixture of dione 565 (0.259 g, 0.90 mmol) and 
hydroxylamine hydrochloride (1.260 g, 1.80 mmol, 2 eq.), 
stirred in absolute ethanol (10 mL) at room temperature, was 
added pyridine (0.4 mL). The reaction was then heated at 90
o
C 
for 16 hours. Following solvent evaporation, the residue was 
dissolved in ethyl acetate (3 × 80 mL), washed with brine (3 × 70 mL), dried over 
magnesium sulfate and filtered. The crude product was subsequently purified by ethyl 
acetate/hexane gradient chromatography to yield the target compound 581 as a white powder 
(0.153 g, 53%); m.p. 186-190
o
C (lit.
49
 189-192
o
C); νmax/ cm
-1
 (KBr) 3327, 1614, 1541, 1458, 
1425, 1245; δH (300 MHz, DMSO-d6) 7.09-7.19 [6H, m, 6 × aromatic C-H2,2‟,5,5‟,6,6‟], 7.40-
7.42 [2H, d, J 7.7, aromatic C-H7,7‟], 8.14-8.17 [2H, d, J 7.6, aromatic C-H4,4‟], 10.57 [2H, 
bs, 2 × NH], 11.26 [2H, bs, 2 × N-OH]; m/z  (ES+) 319.1 [M+H]
+
 (50%), 115.0 (100%).  
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5.2.8 Single crystal X-ray diffraction studies in 5-aminopyrazole series 
 
Instrumentation 
 
Single crystal X-ray data was collected at University College Cork on a Bruker APEX II 
DUO diffractometer at temperatures between 100 – 293 K or on a Bruker X2S at a 
temperature of 293 K using graphite monochromatic Mo Kα (λ = 0.7107 Å) radiation. The 
structures were solved using direct methods and refined on F
2
 using SHELXL-97. Analysis 
was undertaken with the SHELX suite of programs and diagrams prepared with Mercury 2.3. 
All non-hydrogen atoms were located and refined with anisotropic thermal parameters. 
Hydrogen atoms were included in calculated positions or they were located and refined with 
isotropic thermal parameters.  
5.2.8.1 3,4-Bis(1-methyl-1H-indol-3-yl)-1H-pyrazol-5-amine 447    
 
  Experimental Reference: 5.2.4.5 
Crystal Data: C21H19N5, M = 341.41, monoclinic, a = 
9.6026(18) Å, b = 16.309(3) Å, c = 11.000(2) Å, β = 
105.049(4) 
o
, V = 1663.6(5) Å
3
, T = 100.0(2) K, space group 
P21/n, Z = 4, 12307 reflections measured, 2962 unique (Rint = 
0.1267). The final R1 values were 0.0557 (I > 2σ(I)) and 0.1315 (all data). The final wR(F
2
) 
values were 0.1062 (I > 2σ(I)) and 0.1305 (all data).  
 
5.2.8.2 2,3-Bis(1-methyl-1H-indol-3-yl)-5,7-bis(trifluoromethyl) pyrazolo[1,5-
a]pyrimidine 549 
 
                                                                 Experimental Reference: 5.2.4.12  
Crystal Data: C26H17F6N5, M = 513.45, monoclinic, a = 
8.1163(15) Å, b = 14.851(4) Å, c = 18.933(5) Å, β = 
95.576(8) 
o
, V = 2271.3(10) Å
3
, T = 150.0(2) K, space 
group P21/n, Z = 4, 21091 reflections measured, 4027 
unique (Rint = 0.0455). The final R1 values were 0.0402 (I > 
2σ(I)) and 0.0752 (all data). The final wR(F2) values were 
0.0871 (I > 2σ(I)) and 0.1011 (all data). 
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5.3.8.3  1-(5-Amino-4-(1-methyl-1H-indol-3-yl)-3-(3,4,5-trimethoxyphenyl)-1H-pyrazol-
1-yl)ethanone 557 
 
                                                                    Experimental Reference: 5.2.5.4 
Crystal Data: C23H24N4O4, M = 420.46.43, triclinic, a = 
10.027(4) Å, b = 10.830(5) Å, c = 10.880(6) Å, α = 
89.654(15) 
o, β = 71.175(15) o, γ = 81.995(15) o, V = 
1106.4(9) Å
3
, T = 300.0(2) K, space group P-1, Z = 2, 
2659 reflections measured, 2110 unique (Rint = 0.0238). 
The final R1 values were 0.0550 (I > 2σ(I)) and 0.0939 
(all data). The final wR(F
2
) values were 0.1183 (I > 2σ(I)) and 0.1367 (all data).  
 
5.3.8.4 5-Amino-N-methyl-4-(1-methyl-1H-indol-3-yl)-3-(3,4,5-trimethoxyphenyl)-1H-
pyrazole-1-carbothioamide 559 
 
                                                          Experimental Reference: 5.2.5.6 
Crystal Data: C23H25N5O3S, M = 451.54, monoclinc, a = 
16.1052(17) Å, b = 9.5800(11) Å, c = 14.6359(15) Å, β = 
92.806(4) 
o
, V = 2255.4(4) Å
3
, T = 300.0(2) K, space group 
P21/c, Z = 4, 20990 reflections measured, 3961 unique (Rint = 
0.0448). The final R1 values were 0.0552 (I > 2σ(I)) and 0.0768 
(all data). The final wR(F
2
) values were 0.1532 (I > 2σ(I)) and 
0.1699 (all data).  
 
5.2.8.3 3-(1-Methyl-1H-indol-3-yl)-5,7-bis(trifluoromethyl)-2-(3,4,5-pyrazolo[1,5-
a]pyrimidine 563  
 Experimental Reference: 5.2.5.10 
Crystal Data: C26H20F6N4O3, M = 550.45, triclinic, a 
= 13.960(2) Å, b = 14.052(2) Å, c = 14.580(2) Å, α = 
114.173(3) 
o, β = 108.342(4) o, γ = 93.100(4) o, V = 
2420.7(7) Å
3
, T = 100.0(2) K, space group P-1, Z = 
4, 51437 reflections measured, 9691 unique (Rint = 
0.0758). The final R1 values were 0.0550 (I > 2σ(I)) 
and 0.1108 (all data). The final wR(F
2
) values were 
0.1295 (I > 2σ(I)) and 0.1661 (all data).  
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6.0 Biological Results and Discussion 
 
Realisation of successful routes to diverse new chemical entities within a number of novel 
hydrogen-bonding families afforded access to a large library of compounds with the 
potential for unique modes of bioactivity based on the potent anti-cancer properties of 
structurally related bisindolylmaleimides and indolocarbazoles (Section 1.0, Biological 
Introduction). Biological evaluation of these congeners is critical in order to profile specific 
anti-cancer molecular targets for these derivatives, and in SAR endeavours, in order to assess 
how distinct bioactivity may be correlated with structural variation within our test panel. 
Topoisomerase II decatenation assays were undertaken in order to determine the in vitro 
inhibitory activity of these compounds against a highly clinically relevant cancer target, 
while growth inhibition studies on 60 cultured human tumour cell lines relayed important 
efficacy data concerning design of 5,6-bisindolylpyrimidin-4(3H)-one, indolo[2,3-
a]pyrimido[5,4-c]carbazol-4(3H)-one and related 3,4-bisaryl-5-aminopyrazole analogues as 
exciting new templates for medicinal research.      
6.1 Agarose DNA Gel Electrophoresis 
Standard agarose gel electrophoresis is a simple, reproducible and inexpensive bioanalytical 
separation technique for purification and characterization of DNA fragments ranging in size 
from 0.5 – 25 kB. Agarose is a linear polysaccharide composed of supercoiled helical fibres 
of D- and L-galactose joined by glycosidic linkages, comprising a three-dimensional mesh of 
channels whose pore sizes range from 50 nm to >200 nm.
1
 Electrophoretic separation 
achieved by this method depends upon the electrostatic phenomenon of DNA possessing an 
overall negative charge due to its surface phosphodiester backbone, the magnitude of which 
is also affected by factors such as matrix ionic strength, pH and specific nucleotide 
composition. Voltage applied at the ends of the gel apparatus completes an electric circuit 
with a field strength defined by gel length and potential difference (V/cm). Therefore, 
charged DNA fragments loaded at the cathode (negative) migrate within this applied electric 
field towards the anodic (positive) end, according to their characteristic electrophoretic 
mobility. Migration velocity is only determined by the shape and size of DNA fragments, 
due to the identical charge : mass ratio of DNA of different lengths; small gel pore sizes 
generate frictional forces that impede rates of movement and thus, efficiently resolves DNA 
fragment-length mixtures according to a differential size gradient through the gel.
1,2
  
  
The experimental protocol can be divided into three phases: (a) gel preparation utilizing an 
appropriate agarose concentration, usually 0.8-1.5%, for discrete DNA fragment separation; 
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(b) DNA samples and tracking dye (e.g. bromophenol blue or xylene cyanol) are loaded in 
marked sample wells and gel is run at optimal voltage (1-10 V/cm) and time, in order to 
resolve all molecular weight DNA bands present, and (c) gel is stained and visualized under 
U.V light (>2500 µW/cm
2
), or, if ethidium bromide is incorporated in the electrophoresis 
buffer (~0.5 µg/mL), illuminated directly following removal of DC power source. 
Prior to interpreting the results of any electrophoretic separation, several critical parameters 
affecting the migratory aptitude of DNA in agarose require discussion.
1
 These factors were 
also optimized during the course of our topoisomerase II decatenation study: 
 Agarose concentration: Linear DNA fragments migrate through agarose at a 
rate inversely proportional to log10 MW; 1-1.5% agarose content = separation 
of small 0.2-0.5 kB fragments, 0.5-1.0% = separation of larger 0.5-30 kB 
fragments and 0.3-0.5% = optimal for large 20-60 kB fragment resolution.  
 Applied voltage: DNA generally travels through agarose at a rate proportional 
to the applied voltage. A potential difference of 2-8 V/cm across the gel is 
optimal, as undesirable heating effects occur at high field strengths (>10 
V/cm). Large DNA molecules also co-migrate at higher applied voltages, thus 
reducing resolution of supercoiled and nicked topoisomers (improved by low 
agarose concentration and field strength (0.5%, ~1 V/cm).  
 DNA conformation: Closed (superhelical) circular (form I), nicked circular 
(form II), and linear (form III) DNAs of identical weight migrate through 
agarose matrix at different rates.
3
 Supercoiling reduces the hydrodynamic 
radius of DNA and enhances electrophoretic migration through gel pores, 
whereas nicked or relaxed circular molecules are significantly retarded. 
 Electrophoresis buffer: The two most commonly employed buffers are 
Tris/acetate (TAE) and Tris/borate (TBE). TBE is generally avoided for 
purification of DNA from gels, as it may form complexes with deoxyribose 
sugars. Similarly, denaturing pH ranges and thermogenic high ionic strength 
buffers capable of efficient electrical conductance leads to deformation of the 
agarose gel matrix.     
 
6.2 Influence of DNA topology in topo II inhibition 
 
Due to the acute importance of topoisomerase inhibition as a privileged anti-cancer target, 
powerful, fast and selective gel electrophoresis topo II inhibition assays have attained a 
status as indispensable tools within current molecular biology.
3-8
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The enviable clinical success of topo II inhibition derives from its essential topological role 
in mammalian DNA metabolism, e.g. chromosome segregation and selective over-
expression in rapidly proliferating cells (α isoform).7,9-13 The mechanism of action of diverse 
clinical drugs such as etoposide and amsacrine involves negligible effect on catalytic topo II 
activity, but elicit accumulation of 5‟-covalently bound catalytic intermediates, which are 
subsequently transformed into cytotoxic permanent double strand breaks, resulting in 
illegitimate chromosomal translocation and catastrophic cell damage.
4,14,15
  
 
 
 
 
 
 
 
 
 
 
Scheme 6.1: Key topological reactions of topo II, illustrating unlinking of intact circular DNA.  
  
Prokaryotic cells possessing double-stranded covalently closed DNA must also resolve 
significant topological challenges related to replication of circular bacterial chromosomes 
and plasmids. Following initial replication, these interwound, non-covalently linked circles 
or „catenanes‟ must physically traverse through another double-stranded segment, and thus 
require intrinsic topoisomerase activity to transiently break both DNA strands of one 
chromosome and allow the daughter chromosome to pass through the break 
(decatenation).
2,16
 In biochemical assays, eukaryotic topo II has been demonstrated to 
efficiently unlink parental strands by relaxing positive supercoils within superhelical circular 
DNA (Scheme 6.1).
17,18
 The topological versatility of supercoiled closed circular DNA in the 
presence of topo II also results in increased populations of nicked circular DNA and relaxed 
DNA, which migrate through agarose gels at different rates, due to their differing size and 
shape. DNA supercoiling is thus an essential mechanism of topo II-mediated decatenation 
that can be measured in agarose gel electrophoresis by determining relative populations of 
topoisomers. 
 
A well known anti-topo II agent, ellipticine 582 can be used as a negative control in the 
decatenation assay, due to its ability to intercalate into DNA, thus promoting persistent 
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strand cleavage by increasing levels of mutagenic cleavable complexes and strongly 
inhibiting topo II decatenation activity (c.f. Table 6.1).
19
 Alternatively, etoposide, a front-
line NSCLC topo II poison acts by strongly inhibiting the reverse DNA ligation step; 
however, this drug does not abrogate the decatenation process to any degree as this step is 
reversible.
20
 Therefore, to fully verify the extent to which non-intercalative compounds can 
inhibit topo II, the decatenation assay should be used in conjunction with a topo II cleavage 
assay.
21
 
 
In this investigation, topo II-mediated decatenation of supercoiled closed kinetoplast kDNA 
circles or catenanes, obtained from the mitochondrial DNA of Crithidia fasciculate, in the 
presence of ATP, represented the most specific assay to determine enzyme inhibition by a 
panel of our novel compounds by agarose gel electrophoresis.
2,22,23
 In the absence of an 
inhibitor (positive control), decatenation proceeds with concomitant removal of positive 
supercoils - accounting for the most distant covalently closed circular „relaxed‟ (CCC) band, 
while a population of open „nicked‟ circular (OC) monomers migrates slower, due to its 
frictional resistance. However, in the presence of a topo II inhibitor, decatenation is 
effectively suppressed and consequently, release of DNA mini-circles cannot occur. Due to 
the large hydrodynamic radius of covalently linked kDNA, it cannot enter the gel, and forms 
a single characteristically intense band at the top of the gel.       
6.3 NCI-60 cancer cell-line screen 
 
The U.S National Cancer Institute‟s Developmental Therapeutics Program (DTP) 60 human 
tumour cell line service (NCI-60) was developed in the late 1980‟s as a strategic high-
throughput screening tool for in vitro anti-cancer drug activity. Cytotoxicity data for in 
excess of 100,000 compounds across diverse cancer lineages (lung, renal, colorectal, 
ovarian, breast, prostate, central nervous system, melanoma and hematological 
malignancies) has been collated, following this approach.
24,25
 Initial interest in this critical 
research tool encompassing a functional repository of proteomic and genomic data 
assembled for this cell line panel was garnered due to the failure of anti-leukemic activity 
within in vivo animal models to yield efficacy in human solid tumours (e.g. lung, colon, 
breast and prostate). The broad scope of the present-day cell-based NCI-60 evolved from the 
original in vitro chemosensitivity testing of compounds with growth-inhibitory or toxic 
effects on lung cancer cell lines („disease-oriented concept‟) to a data-rich multiscreen 
inferring knowledge of expressed molecular targets within the NCI-60, as well as employing 
modern informatic tools for integrating information on modes of tumorigenesis and cancer 
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progression.
24,26-28
 Patterns of relative drug sensitivity and resistance were generated with 
standard anticancer drugs using three response parameters: GI50 (concentration at which 
growth of 50% of cells present is fully arrested), TGI (concentration for total inhibition or 
0% cell growth) and LC50 (lethal concentration causing death in 50% of cells originally 
present), were rapidly found to reflect mechanisms of drug action; thus, similar activity 
profiles for screening candidates allows for formulation of mechanistic hypotheses based on 
COMPARE algorithm.
24-26
  
 
Following initial NCI-60 screening, compounds which exhibit an interesting pattern of 
inhibition are assessed by the Data Review Committee, prior to a 5-dose investigation, 
performed by  5 × 10-fold serial dilution of a 100 µM stock solution prepared at the same 
time as the one-dose sample. Following recommendation by the Biological Review 
Committee, compounds which generate useful activity profiles via potent and selective 
cytotoxicity across tumour cell lines may progress to in vivo hollow-fibre testing in mouse 
models and further xenograft assays, with successful drug candidates eventually authorised 
by the Drug Development Group to enter NCI clinical development.
24,29
 It took only 8 years 
from initial NCI-60 hit identification of the novel proteasome inhibitor bortezomib – a 
COMPARE-negative (distinct anti-cancer mode of action) agent in 1995 to full FDA 
approval. Additional data returned to the compound supplier is also often important for 
licensing purposes or perhaps, lead-hopping and rational 2
nd
 generation drug design.
30,31
 
 
Fulfilling non-duplication criteria prescribed for NCI-60 compound selection, a preliminary 
panel of 3 novel 5,6-bisindolylpyrimidin-4-one analogues (507, 514, 445) synthesised during 
this work, planar isocytosine-fused indolocarbazole 442, as well as parent 3,4-bisindolyl-5-
aminopyrazole 447 and attractive pyrazolo[1,5-a]pyrimidine 549 derivatives were chosen as 
representative chemotypes for biological screening in the Developmental Therapeutics 
Program. These putative anti-cancer scaffolds were successfully investigated for initial one-
dose tumour cell line activity, and the pattern of quantifiable growth inhibition of these 
agents on the NCI-60 human tumour cell line panel is outlined.  
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6.4 Panel of key derivatives for biological investigation 
 
Table 6.1 Abridged list of 28 synthetic congeners within novel bisaryl and ICZ series†  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
                   
 
 
 
 
 
 
 
†A comprehensive library screen of 45 compounds was performed in topo II decatenation 
study (For synthesis, see Chemical Results and Discussion (Section 4.0) and Experimental 
(Section 5.0); assay results, Section 6.5). 
 
*see Appendix 6.8.1-6 (NCI cytotoxicity data). 
 
                                      
 
                                    
                  172                                  582                 
Compound 
No. 
Substituents NCI Accession No.* 
Topo II       
Gel Fig. No. 
Novel 
R1 R2    
445 NH2 H D-754605/1 6.3  
527 NHCOCH3 H - 6.4  
507 OH H D-754607/1 6.3  
514 SH H D-754608/1 6.3  
515 SCH3 H - 6.4,7  
516 -SCH2CH2- - 6.6,7  
521 SCH2CO2CH3 CH2CO2CH3 - 6.6,7  
522 SCH2CONH2 CH2CONH2 - 6.6,7  
537 H H - 6.4  
    1  
447 H NH2 D-754609/1 6.1  
544 CSNHCH3 NH2 - 6.6,7  
543 COCH3 NH2 - 6.1  
548 C=NH(NH3)
+
 NH2 - 6.7  
545 H NHSO2CH3 - 6.5  
549 -C(CF3)=CH-C(CF3)=N- D-754610/1 6.5  
539 -CONHCONH- - 6.4  
510 H OH - 6.1 X 
      
553 H NH2 - 6.2  
559 CSNHCH3 NH2 - 6.2  
557 COCH3 NH2 - 6.3  
563 -C(CF3)=CH-C(CF3)=N- - 6.2  
540 -CONHCONH- - 6.2  
552 H OH - 6.3  
      
468 -CONHCO- - 6.5,7,8 X 
467 -(CO)2O- - 6.1,8 X 
473 -CONHNHCO- - 6.5,7,8  
442 NH2 H D-754606/1 6.1  
538 H H - 6.5  
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6.5 Topoisomerase II Decatenation Assay 
 
Materials:  
Decatenation assay kit supplied by Inspiralis, Norwich Bioincubator, Norwich Research 
Park, Colney, Norwich, UK. The kit comprised of the following: Assay Buffer (supplied as 
10X stock) containing 50 mM Tris.HCl (pH 7.5), 125 mM NaCl, 10 mM MgCl2, 5 mM DTT 
and 100 µg/mL albumin; Dilution buffer containing 50mM Tris. HCl (pH 7.5), 100 mM 
NaCl, 1 mM DTT, 0.5mM EDTA, 50% (v/v) glycerol, 50 µg/ml albumin; ATP (30X stock) 
30 mM ATP; kDNA (100ng/µl); 10U/µL Human topoisomerase II in dilution buffer; 5X 
stop buffer containing 2.5% SDS, 15% Ficoll-400, 0.05% bromophenol blue, 0.05% xylene 
cyanol and 25 mM EDTA.  Tris-Acetate-EDTA Buffer (supplied as 10X buffer) and agarose 
supplied by Sigma Life Sciences (Dublin, Ireland) and Safe View Stain supplied by NBS 
Biologicals, Cambridgeshire, England. 
 
Method: 
Agarose gel preparation: 
Agarose (2 g) was added to 1X Tris-Acetate buffer (200 mL) and brought to the boil using a 
microwave. When the agarose had cooled to between 60-70
o
C, Safe View Stain (40 µL) was 
added and gently mixed. Hot agarose solution (100 mL) was added to each of two gel 
formers (15 cm x 10 cm) containing a 20 well sample comb. When the agarose gel had set 
the gel was placed in the gel rig and submerged in 1X Tris-Acetate-EDTA Buffer. 
Topo II Assay Preparation:  
The methodology used was adapted from the instructions supplied by Inspiralis for the 
Decatenation Assay and optimised for use with the Safe View Stain. A stock solution 
sufficient for 40 samples containing Assay buffer, 3X ATP, 3X kDNA and 6X Topo II 
enzyme was prepared on ice as described below. 10X Topo II was diluted with dilution 
buffer to provide a 1X working stock containing 1U/µL Topo II.  
 
Stock solution containing: Quantity (µL) 
Water 360 
Assay Buffer (10 X stock) 120 
ATP (30 X stock) 120 
kDNA (100 g/µL) 240 
Topo II (1 U/µL) 240 
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Preparation of Chemical Samples:  
All samples to be tested were made up to a concentration of 1 mM in DMSO (≤10% v/v) and 
a combination of water, methanol, and acetonitrile in various proportions depending on the 
solubility of the compound in question. The chemicals were screened at an initial 
concentration of 100 µM (3 µL of chemical preparation in a total sample volume of 30 µL) 
and any potential hits (i.e. inhibition of topo II activity – no mini circles produced) were 
retested at 100 µM, 10 µM and 1 µM concentration. 
 
The assay protocol involved initial addition of 27 µL of the above stock solution to 
Eppendorf tubes containing 3 µL of the chemicals to be screened, prior to incubation at 37
o
C 
for 1 hr. At this point, the reaction was stopped by addition of either 5X stop buffer (12 µL) 
or 2X stop buffer (30 µL). A standard volume of each assay preparation (20 µL) was then 
added to a sample well in the prepared agarose gel and run at 50 V for 2 hrs using a Consort 
EV243 power pack. Positive controls (containing 3µL water), and negative controls (3 µL 
ellipticine (EPT) 582, at a final concentration of 100 µM) were included in all gels. The 
solvent combinations employed to dissolve the chemicals under investigation were also 
tested to confirm that any observed hits were due to the chemicals and not inhibition by the 
solvents. The resulting gels were viewed under U.V. light using a DNR Bio-Imaging System 
and photographed using GelCapture software. 
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 - 
 Nicked circular DNA 
 
         Relaxed DNA 
 Decatenation products 
 
       Catenated kDNA 
(negative topo II control) 
6.5.1 Results of Topoisomerase II Decatenation Assay 
 
 
* 
In the following section, the experimental results associated with each of the gel assays are 
first presented followed by a discussion of the significant conclusions based on these data. It 
should be noted in each case that these results are preliminary. 
 
6.5.1.1 Topo II inhibition of screening panel at 100 µM concentration 
 
            Lane     A     B      1     2      3     4     5     6     7     8     9    10   11   12   13   14    15   16     A    B    
 
Fig. 6.1 
 
Lane No.
*
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
Compound 
No.
†
 
 
543 
 
C 
 
467 
 
C 
 
478 
 
C 
 
510 
 
442 
 
C 
 
447 
 
543 
 
C 
 
571 
 
583 
 
573 
 
566 
Topo II 
inhibition
¥
 - - + - - - - - - - - - - - - - 
 
*A = Positive control: cDNA + ATP + topo II. 
*B = Negative control: cDNA + ATP + topo II + 100 µM topo II inhibitor (ellipticine 582/+). 
† C = Dilution solvent/blank; N = Not from this compound class. 
¥Inhibitory activity: (-) = not active against topo II at 100 µM level; (+) = topo II inhibition at 100 µM level.  
 
 
 
               A     B     1      2     3     4     5      6     7     8     9    10   11   12   13   14   15     x     x     x 
 
Fig. 6.2 
 
Lane No.
*
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
Compound 
No.
†
 
 
568 
 
C 
 
584 
 
570 
 
C 
 
569 
 
567 
 
C 
 
565 
 
553 
 
563 
 
540 
 
558 
 
559 
 
C 
Topo II 
inhibition
¥
 - - - - - - - - - - - - - - - 
 
*A = Positive control: cDNA + ATP + topo II. 
*B = Negative control: cDNA + ATP + topo II + 100 µM topo II inhibitor (ellipticine 582/+). 
† C = Dilution solvent/blank; N = Not from this compound class. 
¥Inhibitory activity: (-) = not active against topo II at 100 µM level; (+) = topo II inhibition at 100 µM level.  
 
 
Direction            
of Gel 
+ 
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              A     B     1     2     3      4     5     6     7     8     9    10   11   12   13   14    15   16     A     B 
 
Fig. 6.3 
 
Lane No.
*
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
Compound 
No.
†
 
 
557 
 
C 
 
556 
 
C 
 
555 
 
C 
 
552 
 
N 
 
C 
 
541 
 
507 
 
C 
 
514 
 
C 
 
445 
 
C 
Topo II 
inhibition
¥
 - - - - - - - N - - - - - - - - 
 
*A = Positive control: cDNA + ATP + topo II. 
*B = Negative control: cDNA + ATP + topo II + 100 µM topo II inhibitor (ellipticine 582/+). 
† C = Dilution solvent/blank; N = Not from this compound class. 
¥Inhibitory activity: (-) = not active against topo II at 100 µM level; (+) = topo II inhibition at 100 µM level.  
 
 
 
               A     B     1     2     3      4     5     6     7     8     9    10    11   12   13   14   15   16     A    B 
 
                Fig. 6.4 
 
Lane No.
*
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
Compound 
No.† 
 
537 
 
C 
 
515 
 
C 
 
527 
 
539 
 
547 
 
C 
 
N 
 
N 
 
C 
 
N 
 
N 
 
N 
 
C 
 
N 
Topo II 
inhibition
¥
 - - + - - + - - N N - N N N - N 
 
*A = Positive control: cDNA + ATP + topo II. 
*B = Negative control: cDNA + ATP + topo II + 100 µM topo II inhibitor (ellipticine 582/+). 
† C = Dilution solvent/blank; N = Not from this compound class. 
¥Inhibitory activity: (-) = not active against topo II at 100 µM level; (+) = topo II inhibition at 100 µM level.  
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               A     B    1      2     3     4     5     6      7     8     9    10   11   12   13   14   15    16    A    B 
 
Fig. 6.5 
 
Lane No.
*
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
Compound 
No.† 
 
N 
 
C 
 
580 
 
C 
 
473 
 
N 
 
468 
 
549 
 
C 
 
C 
 
172 
 
C 
 
545 
 
C 
 
581 
 
538 
Topo II 
inhibition
¥
 N - - - + N + + - - + - - - - + 
 
*A = Positive control: cDNA + ATP + topo II. 
*B = Negative control: cDNA + ATP + topo II + 100 µM topo II inhibitor (ellipticine 582/+). 
† C = Dilution solvent/blank; N = Not from this compound class. 
¥Inhibitory activity: (-) = not active against topo II at 100 µM level; (+) = topo II inhibition at 100 µM level.  
 
 
               A     B    1      2     3     4     5     6      7     8     9    10   11   12   13   14   15    16    A    B 
 
Fig. 6.6 
 
Lane No.
*
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
Compound 
No.† 
 
544 
 
N 
 
516 
 
C 
 
522 
 
C 
 
521 
 
N 
 
C 
 
N 
 
C 
 
N 
 
N 
 
N 
 
N 
 
N 
Topo II 
inhibition
¥
 + N + - + - + N - N - N N N N N 
 
*A = Positive control: cDNA + ATP + topo II. 
*B = Negative control: cDNA + ATP + topo II + 100 µM topo II inhibitor (ellipticine 582/+). 
† C = Dilution solvent/blank; N = Not from this compound class. 
¥Inhibitory activity: (-) = not active against topo II at 100 µM level; (+) = topo II inhibition at 100 µM level.  
 
Figs. 6.1–6.6: Observed effects of a full panel of novel bioactive compounds, on the decatenation of 
kinetoplast DNA by topoisomerase II, following incubation at 37
o
C for 1 hour. Lanes 1–16 in displayed gels 
contained selected compound at 100 µM concentration, along with catenated DNA, ATP and topo II. The 
synthesis of this panel of compounds is discussed in Section 4.0 (Chemical Results and Discussion), and 
experimental details are provided in Section 5.0 (Experimental).  
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6.5.1.2 Topo II inhibition of selected compounds at 1, 10 and 100 µM 
Following identification of attractive inhibitory activity within several novel synthetic 
compounds against topo II at 100 µM concentration, the inhibitory potency of selected active 
compounds was investigated by incubation under identical assay conditions, at individual 
concentrations of 100, 10 and 1 µM, respectively (Section 6.4, Table. 6.1).    
 
              µM             100    10     1    100    10     1   100   10     1     100   10    1    100  100  100  100  100  100   
              A     B     1      2     3     4      5     6     7     8     9     10   11   12   13   14    15   16   17   18 
 
Fig. 6.7 
 
Lane No.
*
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 
Compound 
No.
†
 
 
515 
 
515 
 
515 
 
516 
 
516 
 
516 
 
522 
 
522 
 
522 
 
521 
 
521 
 
521 
 
473 
 
468 
 
172 
 
544 
 
N 
 
548 
Topo II 
inhibition
¥
 
+ - - - - - + ++ - + ++
*
 - + + + + N - 
 
*A = Positive control: cDNA + ATP + topo II; B = Negative control: cDNA + ATP + topo II + 100 µM topo II 
inhibitor (ellipticine 582/+) † N = Not from this compound class. 
¥Inhibitory activity: (-) = not active against topo II at tested concentration; (+) = topo II inhibition at 100 µM 
level; (++) = topo II inhibition at 10 µM; ++* = partial inhibition at 10 μM; (+++) = topo II inhibition (1 µM)  
 
 
              µM            100    10      1   100   10     1     100   10    1   100   100   10      1   100  100  100  100   100                        
            A    B     1      2     3     4     5     6      7     8    9    10    11   12    13   14   15   16    A     B 
 
Fig. 6.8 
 
Lane No.
*
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
Compound 
No.† 
 
467 
 
467 
 
467 
 
473 
 
473 
 
473 
 
468 
 
468 
 
468 
 
172 
 
N 
 
N 
 
N 
 
N 
 
N 
 
N 
Topo II 
inhibition
¥
 + - - + ++  - - - - - 
 
N 
 
N 
 
N 
 
N 
 
N 
 
N 
 
*A = Positive control: cDNA + ATP + topo II; B = Negative control: cDNA + ATP + topo II + 100 µM topo II 
inhibitor (ellipticine 582/+) † N = Not from this compound class. 
¥Inhibitory activity: (-) = not active against topo II at tested concentration; (+) = topo II inhibition at 100 µM 
level; (++) = topo II inhibition at 10 µM; (+++) = topo II inhibition at 1 µM level.    
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6.5.2 Discussion of Topoisomerase II inhibition results  
 
In this investigation, a synthetic library of 45 compounds were initially screened for their 
ability to inhibit topo II-mediated circular kinetoplast DNA (kDNA) decatenation, at 100 
μM, following incubation at 37oC for 30 minutes.2,22 The intrinsic ability of these agents to 
disrupt the catalytic activity of this cancer-related topological enzyme was compared with a 
standard topo II inhibitor ellipticine 582; small molecule stabilisation of intermediate 
cleavage complexes rapidly increases equilibrium levels of these potent intracellular poisons 
and closely correlates with anti-proliferative activity and mitotic catastrophe due to extensive 
DNA fragmentation.
32,33
 In our single-dose and multi-concentration studies, large molecular 
weight kDNA samples were loaded on a 1% agarose gel containing Safe View Stain, 
purified topo II enzyme and ATP, containing either no drug (A), or 100 μM ellipticine 582 
(B) controls, along with 18 lanes comprising the compound of interest or dilution solvent 
(C), exposed to topo II under identical conditions.
1
 Decatenation of interlocked closed 
circular DNA has been reported to be the most specific assay for evaluation of in vitro topo 
II inhibition, and the exciting results of this experimental study suggest several attractive 
structural inhibitory leads for ongoing development of new bioactive heterocyclic scaffolds 
within this research group.
2
  
The electrophoretic features of topo II activity illustrated in Figs. 6.1-6.8 clearly 
demonstrates a number of important principles which require elucidation prior to 
interpretation of these biochemical data. The absence of any drug in Lane A provided a 
positive control for native topo II activity under our assay conditions. In this case, catenated 
kDNA cannot enter a typical agarose gel unless monomeric „mini-circles‟ are released via a 
gated double-stranded DNA passage mechanism (Section 6.2).
23,34
 In the presence of topo II, 
two distinct thermodynamically stable DNA populations are resolved in Lane A, 
corresponding to a proximal nicked (open circular) and more permeable relaxed (covalently 
closed circular) monomer bands. Electrophoresis within Lane B represents a negative 
decatenation control characterized by full suppression of mini-circle migration, via topo II 
inhibition by ellipticine 582 at 100 μM. Thus, for non-inhibitory compounds within Lanes 1-
18, topo II-induced DNA cleavage resulted in full conversion to nicked and relaxed circular 
DNA products, as clearly observed. Alternatively, compounds exhibiting topo II disruption 
inhibited kDNA fragmentation and retarded migration of DNA within the gel. At the outset, 
25 novel heterocyclic derivatives within 5 structural classes (I-V), exhibiting diverse H-
bonding characteristics were selected as attractive candidates to potentially exert new 
biological effects within the scope of this investigation (Table 6.1).    
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The results of the preliminary 45 compound screen performed at 100 µM are displayed in 
Figs. 6.1-6.8; attractive anti-topo II activity can now be reported to exist within several 
synthesized analogues encountered in this research. Unsurprisingly, in the case of the 
derivatives possessing the 4-(N-methyl-indol-3-yl)-3-(3,4,5-trimethoxyphenyl)-5-
aminopyrazole template (c.f. Table 6.1; class III) (Figs. 6.2 and 6.3), no inhibitory activity 
could be discerned, even at high concentration. Similarly, class V planar pyrimido[5,4-
c]carbazoles 442 (Fig. 6.1; Lane 8) and 538 (Fig. 6.5; Lane 16) were completely unable to 
arrest topo II-mediated decatenation at 100 μM. The inability of this novel ICZ chromophore 
to mimic the intercalative DNA base conformation of ellipticine 582 is an important 
observation, and future research into whether optimization of this template can effectively 
inhibit topo I activity will be necessary to determine how DNA base intercalation may 
account for the observed biological effects within this novel indolo[2,3-a]carbazole scaffold 
(Section 6.6). 
 
Interestingly, the tested panel of indolo[2,3-c]carbazole regioanalogues (class IV) afforded 
enviable activity at 100 µM concentration. To our knowledge, both maleimide 468 (Fig. 6.5; 
Lane 7) and furan-2,5-dione 467 (Fig. 6.1; Lane 3) derivatives have not been reported to 
inhibit topo II to an appreciable extent, so this activity may complement other novel 
biological functionalities within this relatively unexplored class. Interestingly, the novel 6-
membered pyridazinedione-fused  indolo[2,3-c]carbazole 473 was the most active congener 
and fully abrogated topo II decatenation activity at a concentration of 10 μM (Fig. 6.5; Lane 
5 and Fig. 6.8; Lanes 4-6). Similarly, anti-topo II activity mediated by bisindolylmaleimide 
172 (Fig. 6.5; Lane 11) represents an interesting inhibitory lead within that series. 
 
Two ring-condensed members of the 3,4-bisindolyl-5-aminopyrazole series (class II) also 
accomplished unique activity against topo II, derived from an inhibitory scaffold previously 
undisclosed in chemical literature. Further work is required to elucidate the origin of this 
inhibition, but it may be related to the ability of the bicyclic triazinedione moiety within 539 
(Fig. 6.4; Lane 6), and planar pyrazolo[1,5-a]pyrimidine 549 (Fig. 6.5; Lane 8) to adopt a 
purine-like conformation affording critical hydrophobic interactions with DNA bases 
adjacent to the topo II catalytic site. However, in the case of more flexible mono-N-
substituted analogues, only negligible inhibition could be determined, as confirmed by the 
presence of nicked and relaxed DNA bands within the agarose gel.  
 
During this work, an unusual pattern of anti-topo II activity also emerged within N-
substituted class I 5,6-bisindolylpyrimidin-4-ones, which permitted key insights into a 
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structural activity paradigm. The acetylated isocytosine derivative 527 was deemed to be 
completely inactive (Fig. 6.4; Lane 5); however, it was determined that certain alkylated 
derivatives of inactive parent 2-thiopyrimidin-4-one 514 (Fig. 6.3; Lane 13) resulted in 
potent in vitro enzyme inhibition. 
 
Sulfide 515 demonstrated effective topo II inhibition at 100 μM, but was inactive at 10 and 1 
μM (Fig. 6.4; Lane 3, Fig. 6.7; Lanes 1-3). Complex bifunctionalised thiouracil congeners 
exhibited complete efficacy at 100 μM; diacetate 521 was also partially inhibitory at 10-fold 
less concentration, but this activity was substantially diminished at 1 μM (Fig. 6.6; Lane 7, 
Fig. 6.7; Lanes 10-12). The most effective compound investigated within this series was 
novel S,N-diacetamidothiouracil 522 which obliterated topo II activity at 100 μM and also 
successfully inhibited decatenation at 10 μM (Fig. 6.6; Lane 5, Fig. 6.7; Lanes 7-9). It was 
hypothesized that key H-bonds extending from these flexible branched compounds effect 
important spatial H-bonding interactions with polar side-chains within the topo II active site. 
The length of (CH2)n linker employed, along with the size and shape of polar side-group 
(CO2R, CONR2R3) may be critical parameters, due to the conspicuous inability of non-H-
bonding, unbranched cycloalkylated analogue 516 to inhibit kDNA decatenation at 100 μM 
(Fig. 6.7; Lanes 4-6). The positive results of this study are outlined in Table 6.2. 
 
Table 6.2 New topo II inhibitors identified by kDNA decatenation assay. 
Structure Compound No. Activity/µM
†
 Fig. (Lane) 
 
R1=O; 467 - 6.8 (1-3) 
R1=NH-NH; 473 ++ 6.8 (4-6) 
R1=NH; 468 + 6.8 (7-9) 
 
R2=CH3, R3=H; 515 + 6.7 (1-3) 
R2=R3= -CH2CH2- ; 516 - 6.7 (4-6) 
R2=R3=CH2CONH2; 522 ++ 6.7 (7-9) 
R2=R3=CH2CO2Et; 521 ++
*
 6.7 (10-12) 
 
R5 = N, R4=R6=OH; 539
§ + 6.4 (6) 
R5 = CH, R4=R6=CF3; 549
§ + 
 
6.5 (8) 
†(-) = Inactive at 100 μM; (+) = 100 μM inhibition: inactive at 1 and 10 μM; (++) = 10 μM inhibition: no 
inhibition at 1 μM; ++* = partial inhibition at 10 μM. 
§Only tested at 100 µM. 
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6.6 NCI-60 cytotoxicity results 
 
The reported methodology employed for evaluation of growth inhibition for our selected 
compounds within the NCI-60 cell line panel involves initial formation of a 4 mM stock 
solution with DMSO, prior to dilution into RPMI 1640 medium containing 5% fetal bovine 
serum/ 2 mM L-glutamine, and exposure to each cell line previously cultured for 24 
hours.
24,26
 After 48 hour incubation, successive steps of media removal, cell fixation and 
sulforhodamine B (SRB) staining were performed, prior to 1% acetic acid wash, and air 
drying of these plates. The dye was dissolved in Tris buffer, and the colorimetric growth 
inhibition-dependent absorbance at 515 nm was measured and calibrated against DMSO 
control.
24,35
 In vitro activity of each compound in these human tumour cell lines was 
displayed by means of a „mean graph‟ comprising a series of horizontal bar graphs 
representing units of nominal growth percent, deviating from the arithmetic mean growth 
inhibition for the entire 60 cell line array, i.e. centre line or „0‟. In each case, graphs which 
extend to the right (-) denote more selective cytotoxicity or positive growth inhibition, while 
those which extend to the left (+) of centre line indicate a chemoprotective or non-cytotoxic 
effect on individual cell lines. Globally, patterns of total panel activity may also be 
correlated with those of over 100,000 compounds within a NCI-60 compound screen 
database, to reveal key mechanisms of action.
14,26,29,31
 
As demonstrated by supplementary data within Appendix 6.8, novel tested compounds 507, 
514, 445, 442, 447 and 549 exhibited extremely interesting cytotoxicity profiles within 60 
human tumours derived from 9 distinct tissue sites. In the case of novel bisindolyl 
derivatives 507, 514 and 445, similar patterns of tumour chemosensitivity were observed; 
however, critical differences in cytotoxicity profile could also be discerned based on small 
structural alterations. Based on one-dose data, all leukemic, colon, CNS, prostate and 
melanoma cell lines were deemed relatively refractory to growth arrest by these compounds. 
Interestingly, in contrast to isocytosine 445, a significant degree of selective cytotoxicity was 
expressed for closely analogous uracil derivatives 507 and 514 within EKVX (lung 
adenocarcinoma), SNB-75 (CNS glioma), CAKI-1 (renal cell carcinoma) and MDA-MB-
435 (melanoma) compared with related tissue cell lines. All three 5,6-bisindolypyrimidinone 
(BIP) agents (507, 514 and 445) also displayed enviable selective growth inhibition of 
IGROV1 carcinoma cell line compared with all other ovarian cancer types, and exhibited 
similar in vitro effects on MCF7 breast carcinoma cell line. Anti-cancer activity greater than 
the mean 60 cell line growth inhibition confirmed in several non-small cell lung cancers was 
also attributed to these novel congeners. Similarly, aminopyrazole derivative 447 displayed 
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useful cytotoxicity at 10 µM against EKVX lung cancer cells during this investigation. This 
novel bisindolyl-substituted heterocycle 447 also elicited a similar pattern of inhibition to the 
6-membered bisindolyl series, being ineffective across most leukemic, colon, prostate and 
melanoma cell lines, in addition to possessing unique cytotoxic properties represented by 
moderate activity towards glioma cell line U-251 (CNS) and especially, its strong inhibitory 
influence on HOP-92 lung large cell carcinoma. However, while retaining characteristic 
ovarian anti-cancer activity against IGROV1 cell line, as well as being selective for cultured 
UO-31 renal cell carcinoma, it was also apparent that compound 447 suffered attenuated 
activity on any breast cancer cell line tested in vitro, including MCF7, successfully targeted 
in the corresponding pyrimidin-4-one series.  
 
Pyrazolo[1,5-a]pyrimidine 549 was investigated as a novel topo II inhibitory candidate 
(Section 6.5), which was proposed to incorporate a more complex planar bicyclic structural 
motif at the biologically relevant 1,2-bisindolyl-cis-ethene bridgehead site, capable of 
mimicking hydrophobic interactions within an enzyme active site. Allied to a pattern of 
overall cytotoxic activity consistent with 3,4-bisindolyl-5-aminopyrazole 447, this derivative 
549 was also found to be selective for inhibition of a single HOP-92 NSCLC line within this 
array (NSC: D-754610/1; Appendix 6.8.6). In 2006, Ikediobi et al. characterized 24 
anomalous molecular targets based on acquired mutations present within the NCI-60 
screening panel. In addition to tumour suppressor p53 deficiency, HOP-92 was also 
characterized to possess mutations in CDK4-inhibitor proteins implicated in several primary 
tumours, e.g. familial atypical multiple melanoma.
25,36,37
 These evolving molecular insights 
afford the opportunity to target selective biological screens against relevant anti-cancer 
proteins; as a putative example of this rational approach applied to our topo II research, 
persistent DNA strand breakage induced by topo II inhibitors in mutated p53 colon or 
ovarian carcinoma cells has been disclosed to be effective in cancer therapy by eliciting 
rapid onset of apoptosis.
36,37
  
 
The most active anti-cancer agent within this NCI-60 test panel was novel pyrimido[5,4-
c]carbazole 442; inspection of the mean graph generated for this planar compound illustrated 
tumour growth inhibitory effects across 8 primary cancer zones, delivering an activity profile 
inconsistent with the pattern of differential cytotoxicity exhibited by the corresponding 
bisindolylpyrimidinone 445, or uracil derivatives 507 and 514 (NSC: D-754606/1; Appendix 
6.8.2). In addition, a chemoprotective effect (>100%) was only observed in CNS tumours, 
while 25 cell lines displayed greater than 50% growth inhibition following incubation with 
this novel indolocarbazole 442 at 10 µM for 48 hours. In comparison to its acyclic 
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counterpart 445, significant activity was observed across all haematological tumour cell 
lines, in addition to colorectal carcinomas (e.g. HT-29) and melanomas (e.g. MDA-MB-435 
cell line). In addition to its improved mean cytotoxicity, enhanced intra-tissue cell line 
selectivity was also discerned for MCF-7 breast cancer, in the absence of significant tumour 
growth inhibition within other breast cancer lines, while less marked differentiation 
phenomena also featured within melanoma lines and NSCLCs. Strong growth inhibition was 
also displayed by anti-cancer ICZ 442 against the SK-OV-3 cell line, which was completely 
unresponsive to other test compounds. These results infer a putative mode of action for class 
V indolo[2,3-a]pyrimido[5,4-c]carbazole analogues, distinct from mechanisms of anti-cancer 
bioactivity mediated by class I 5,6-bisindolylpyrimidin-4-one congeners in vitro (Table 6.3).  
 
Table 6.3 Novel in vitro cytotoxic anti-cancer leads following NCI-60 compound screen. 
Structure Compound 
no. 
NCI-60 cell 
line 
Tumour 
site 
% Growth after 
48h
§
 
Mean cell line 
growth 
 
442 
 
HT29 
UO-31 
CAKI-1 
colon 
kidney 
kidney 
17.58 
7.16 
-14.95 
 
58.90 
 
 
549 
 
 
HOP-92 
 
lung 
(NSCLC) 
 
32.74 
 
98.12 
§Cultured cells were tested on RPMI 1640 medium at an initial compound concentration of 10 μM.  
 
However, the most intriguing aspect of this initial screen concerned the potent and selective 
anti-cancer activity of 442 against kidney cancer lines CAKI-1 and UO-31.  
 
Subsequent testing of 442 against all 60 human cancer cell lines during exponential growth 
phase, was performed at 5 individual concentrations, ranging from 100 µM to 10 nM.
26
 
Based on these data, dose-response curves were generated for cell growth inhibition as a 
function of inhibitor concentration; it was observed that lower concentrations of 442 sharply 
impeded tumour growth inhibition across all cell lines, affording relatively modest growth 
inhibition at 10 nM and 100 nM concentration levels across these cell lines (Appendix 
6.8.7). The characteristic in vitro growth parameters, GI50, TGI, and LC50 were determined 
for each member of the NCI-60 panel and are collated in Appendix 6.8.8. Observing these 
growth response plots, it can be deduced that cell growth in all cases was arrested in a 
concentration-dependent manner, and predominantly elicited GI50 values within the low 
micromolar range, in this assay (Table 6.4).  
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Table 6.4 Selected targets of anti-cancer ICZ 442 following 5-dose growth inhibition study
†
  
Cell line Tumour 
type 
% Cell growth after 48h
§
 
GI50 
µM 
TGI 
µM 
LC50 
µM 10
 
nM 100 nM 1 µM 10 µM 100 µM 
SF-295 CNS 85 93 106 7 -57 3.68 12.9 76.7 
HCT-15 colon 96 99 61 24 9 1.98 >100 >100 
SK-MEL-2 melanoma 103 112 73 -10 -55 1.90 7.59 76.5 
SK-MEL-5 melanoma 89 98 87 15 -97 3.25 13.7 37.9 
UACC-257 melanoma 93 91 104 64 -62 12.8 32.0 79.7 
OVCAR-3 ovarian 112 107 120 47 -68 9.07 25.6 69.8 
ACHN kidney 94 92 51 25 12 1.11 >100 >100 
CAKI-1 kidney 93 85 53 29 3 1.33 >100 >100 
UO-31 kidney 85 72 55 19 17 1.37 >100 >100 
§ Cell growth refers to incubation with concentration of 442 in cultured cells on RPMI 1640 medium for 48 
hours. 
†See Appendix NCI Data for full details 
 
This investigation also confirmed the selective cytostatic anti-cancer activity of novel 2-
aminoindolo[2,3-a]pyrimido[5,4-c]carbazol-4(3H)-one 442 (ICZ analogue of 445) against 
colon, melanoma and renal cancers; GI50 values were displayed of 1.98 µM for HCT-15 
(colon), 1.90 µM for SK-MEL-2 (melanoma) and approximately 1 µM values for ACHN, 
CAKI-1 and UO-31 renal cell lines. A single-digit micromolar TGI value was also afforded 
for SK-MEL-2 melanoma, but most values were between 10-100 µM, in this study. The 
lethal concentration required for death of 50% of cell population (LC50) was >100 µM, in 
most instances, although acute cytotoxicity was observed for SK-MEL-2, SK-MEL-5 and 
UACC-257 melanoma, as well as ovarian OVCAR-3 carcinoma, with LC50 values of 76.9, 
37.5, 79.7 and 69.8 µM, respectively.  
 
These results can be compared with the anti-cancer activity previously discussed for K-252c 
6 and arcyriaflavin A 7, which induce high levels of apoptosis in the K562 CML cell line at 
100 µM and reported IC50 values against some cell lines in the low micromolar range (e.g. 
arcyriaflavin A 7, IC50 HCT-116 = 0.85 µM) (Fig. 6.9).
38,39
 The low cytotoxicity of 442 may 
also correlate with specific cell signaling effects consistent with a profile of kinase 
inhibition. Further insights into the molecular targets (kinase screening etc.) of anti-cancer 
activity by compound 442 will be essential to furnish a mechanism by which this selective 
tumour growth inhibition occurs, and to ascertain key structural requirements for refinement 
of bioactivity within this class. Valuable investigation into improved anti-cancer potential of 
more active indole demethylated analogues of 442 will also be undertaken within the 
research group. 
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6.7 Conclusion 
 
In the light of biological data accumulated from topo II decatenation electrophoretic assay, 
as well as NCI-60 testing of compounds generated from synthetic studies, proof of concept 
for anti-cancer activity within several novel chemical families has been firmly established.  
Due to its critical physiological role in rapidly proliferating cells, topo II intervention is a 
valid clinical target for cancer chemotherapy, with over half of all current drug regimens 
incorporating topo II-targeted agents. A ubiquitous feature of this therapeutic approach is the 
interaction of small-molecule inhibitors with DNA within the active site of the enzyme; the 
mode of DNA binding varies widely in the absence of enzyme, ranging from weak 
interactions to strong binding and intercalation.
4,40
 Interestingly, Lassota and co-workers 
described the ability of staurosporine 2 to block topo II-induced intermediate phosphotyrosyl 
bond formation in the presence of DNA, but little work has explored this inhibitory motif  to 
date.
41
 Based on present work, 9 tested compounds conferred new anti-topo II activity at 100 
µM, while a novel di-S,N-substituted bisindolylthiouracil class constitutes an attractive lead 
structure for refining topo II inhibition. Future work to probe the precise biological nature of 
this warhead, by altering linker size and polar functionality, as well as exploration of the 
flexibility of the ring system will also reveal valuable SAR data. Utilisation of hydroxylated 
indole starting materials and synthesis of substituted derivatives of these lead compounds 
will also be desirable, based on the ability of 1,11-dihydroxylated ICZ, BE-13793c 52 to 
inhibit both topo I and topo II with an IC50 value of 2 µM.
42
  
 
 
 
 
 
 
 
                                   521                                         522                                    473 
 
 
 
 
 
                                   6  
                                   7                                        539                                       549 
 
Fig. 6.9: Development of novel topo II inhibitors and structures of natural ICZs K-252c 6 and 
Arcyriaflavin A 7. 
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Similarly, the ascertained biological activity of the [1,5-a]pyrimidine-fused 3,4-
bisindolylpyrazole nucleus represented by triazinedione 539 and fluorinated derivative 549 
also infer a privileged inhibitor scaffold/pharmacophore capable of single digit micromolar 
inhibition. This may comprise a non-rigid bisindolyl molecular hinge region bound to a 5 or 
6-membered nitrogenated ring system comprising an extended polar moiety, which may be 
ring-constrained or linked via a short alkyl linker chain. In addition, a novel 6-membered, 
planar indolo[2,3-c]carbazole derivative 473 was observed to possess enviable in vitro topo 
II inhibition at concentrations as low as 10 µM, during this study.  
 
 
 
 
 
                               514                                    507                                    445 
 
 
 
 
                                                     447                                       442 
             
Fig. 6.10: Selected compounds tested for NCI-60 cancer cell growth inhibition  
 
Availing of a cell-based cytotoxicity assay provided by the NCI-60 human cancer screening 
service, growth inhibition rendered by highlighted synthetic compounds (507, 514, 445, 447, 
549 and 442) was collated by means of a standard mean graph output yielding important 
details regarding associated molecular targets and modes of action (Appendix 6.8.1-6.8.6). 
Relatively poor cancer cell growth arrest was observed following incubation with uracil 507, 
thiouracil 514, isocytosine 445 and 5-aminopyrazole 447, for 48 hours. Conversely, selective 
inhibition of HOP-92 NSCLC cell line was determined for pyrazolo[1,5-a]pyrimidine 549. 
In the case of 9,10-dimethyl-2-amino substituted pyrimidoindolocarbazole 442, an 
interesting pattern of anti-tumour activity was revealed, with enhanced growth inhibition of 
several melanoma and colorectal cancer lines, as well as attractive activity emerging against 
two renal cell carcinomas, CAKI-1 and UO-31 at 10 µM concentration. Future work will 
attempt to elucidate the cell machinery and growth pathway mechanisms mitigated by 442 
(e.g. COMPARE analysis). Development of this relatively selective therapeutic target will 
now proceed, and testing of the closely related novel pyrimidin-4(3H)-one indolocarbazole 
538 will also advance SAR within this novel indolo[2,3-a]carbazole series. 
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 The major limitation of this study was the relative data deficit regarding the specific 
mechanisms involved in cancer cell line cytotoxicity. The potential of these synthesized 
compounds as topo I inhibitors could not be investigated within the scope of this project; 
thus, future biological studies will comprise a topo I unwinding assay to investigate the 
intercalating or minor groove binding capacity of these compounds, as well as a topo I 
cleavage assay to determine the propensity of these compounds to introduce persistent single 
DNA strand breakage via stabilization of the topo I-DNA covalent complex.
43,44
 NCI-60 
testing also provides a tantalizing vista into anti-cancer activity operating at a cellular level, 
but is not practical for combinatorial screening of active analogues to extensively probe anti-
cancer SAR within these libraries. Essential kinase inhibition screening (e.g. anti-VEGFR2 
activity) and in silico molecular modeling techniques will also aid to identify and augment 
the pharmacological profiles of these novel anti-tumour agents.
45
 
 
Based on the results of biological studies on this reported panel of compounds, completed to 
date, a number of validated synthetic targets for small-molecule anti-cancer development 
have been successfully achieved. Critical successes in novel topo II inhibition across a series 
of 1,5-pyrimidine-fused bisindolylpyrazole derivatives, N
3
-derivatised 2-alkylthio-
substituted 5,6-bisindolylpyrimidin-4-ones and potent micromolar inhibition by a planar 
indolo[2,3-c]carbazole congener containing a new 6-membered pyridazinedione ring system 
sets the stage for future productive work in this field. Screening of representative 
chemotypes from our diverse synthetic library identified limited in vitro cancer cell growth 
inhibition at 10 µM, across a number of hydrogen-bonding bisindolyl „hit‟ compounds, 
while analysis of a novel pyrimido[5,4-c]indolo[2,3-a]carbazole F-ring isocytosine agent 
revealed an attractive spectrum of activity, conferring potent anti-tumour activity across 
several cancer cell lines, including renal cancers and melanoma. The strategy of diversity-
oriented synthesis has also been validated as a means of generating versatile biological leads 
and several new research pathways can be envisaged to arise from this work, based on 
optimization of the biological activity within each chemical class. 
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7.0 Current Perspectives 
7.1 Final Overview 
At this juncture, full synthetic methodology has been developed for a panel of over 50 novel 
aglycon compounds based on bioisosteric modification of the maleimide ring motif within 
the natural product arcyriarubin A 79. These successful routes were applied to yield new 
libraries of potential anti-cancer 5,6-bisindolylpyrimidin-4-one derivatives (class I) based on 
the clinical therapeutic agent and selective PKC-β inhibitor, ruboxistaurin 80, as well as 
structurally related isocytosine 442 and pyrimidin-4(3H)-one-fused indolocarbazole 538 
congeners (class V). Formation of previously undisclosed imidazo[4,5-c]indolo[2,3-
a]carbazoles (class VI) was also accomplished, although isolation within this series proved 
problematic. Design and subsequent synthesis of diverse 3,4-bisindolyl (class II) and 4-
(3,4,5-trimethoxyphenyl)-3-(N-methylindol-3-yl)-5-aminopyrazole analogues (class III) 
derived from PKC and VEGFR2 inhibitory templates respectively, were also fulfilled during 
this research (Fig. 7.1).   
 
  
                                                                                      
     
 
 
 
Fig. 7.1: Novel indolocarbazole-based anti-cancer scaffolds developed over the course of this work. 
 
In addition, preliminary biological screening of these compounds to assess putative in vitro 
anti-tumour activity was achieved. Unique topo II-targeting agents were identified following 
evaluation of novel pyridazinedione indolo[2,3-c]carbazole 473 (class IV), flexible di-
substituted 5,6-bisindolyl-2-thiopyrimidin-4-ones such as 522 (class I) and bicyclic 
pyrazolo[1,5-a]pyrimidine 549 (class II) (Fig. 7.2).      
 
                                     
 
 
 
  
  
 
                                                                            549                                            442                                                                                                                                                                                                                                               
                           522                                                
Fig. 7.2 
Chapter 7                                                                                                                         Current Perspectives                        
__________________________________________________________________________ 
                                                                         302 
Based on these results, it is postulated that low micromolar topo II inhibition may be 
achieved by derivatisation of lead compound 522. Successful NCI-60 anti-cancer screening 
of selected chemotypes generated through this research also ascertained that potent (GI50 
values of 1-2 M) and quite selective tumour growth inhibition comparable to established 
bioactive indolo[2,3-a]pyrrolo[3,4-c]carbazoles, was mediated by novel indolocarbazole 442 
within cultured colon, kidney and melanoma cancer cell lines, producing low cytotoxicity 
across the majority of tested cell lines, even at elevated concentrations (LC50 = >100 M).  
      
7.2 Future Work 
A number of attractive avenues for continued exploration of novel indolocarbazole 
bioactivity are clearly manifest at the conclusion of this work based on the confirmed in vitro 
anti-cancer activity identified within the novel pyrimido[5,4-c]carbazole template (Fig. 7.3). 
 
(A) Comprehensive SAR studies: Further heterocyclic elaboration of the indolo[2,3-
a]carbazole F-ring nucleus is an enduring topic within this research field. To this end, recent 
innovation within our group revealed 5-membered isoxazolone 585 derivatives to exhibit 
interesting anti-topo II activity. Development of demethylated bisindolylpyrimidin-4-one 
analogues should maximize biological activity, while also simplifying the terminal oxidative 
cyclisation step to form corresponding pyrimido[5,4-c]carbazoles 586 or 5-aminopyrazoles 
587. In addition, development of routes to other pyrimidine substitution patterns, as 
illustrated in Fig. 7.3, is highly desirable.  
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(B) Chemical diversity: In addition to enhancing bioactivity within classes formed during 
this work, additional focus will be directed towards introduction of further heterocyclic 
diversity. The three most important strategies in this respect are: (i) regioselective 
attachment of carbohydrate and alkyl moieties to the indole ring (590), and formation of N-
glycosidic analogues (591) of compound classes reported in this work; (ii) derivatisation of 
the indolo[2,3-a]carbazole nucleus, in order to explore pyridocarbazole and other 
heteroarylcarbazole systems (Ar) and (iii) investigation of indolocarbazole metal complexes 
589, as a privileged scaffold for potent kinase inhibition.  
 
(C) Oxidative cyclisation: Aromatisation of flexible bisindolyl precursors proved to be a 
challenging transformation throughout the course of this research. In addition to the 
increased reactivity of demethylated indole derivatives within various series, an alternative 
methodology via irradiative dehydrohalogenation of accessible 2-halo substituted bisindolyl 
substrates 592 has been previously reported to proceed in high yields, within analogous 
systems, and thus, may constitute an alternative route to novel planar ICZs (586). 
  
(D) Solubility: Resolution of issues associated with poor product solubility will assist 
compound isolation and purification, in addition to optimizing physico-chemical properties. 
Application of protecting group strategies will modulate the polarity of heterocyclic 
substituents, and suppress reactive nucleophilic ring sites, thus increasing the scope of 
derivatisation chemistry available. Peripheral A or E-ring ICZ substitution by incorporating 
hydroxylated or chlorinated indole starting materials 588 (X = OH, Cl) may also augment in 
vitro cell permeability and inhibitory properties within active classes.  
_________________________________________________________________________________
 
A systematic approach to new compound synthesis will also reinforce important biological 
themes demonstrated by these positive preliminary anti-cancer results. Molecular modeling 
data and molecular target characterization, as well as supplementary topo I, kinase and 
cytotoxicity screening should be employed in order to maximize the amount of mechanistic 
and structural data available for rational design of next-generation indolocarbazole 
derivatives (Fig. 7.4). As described in Section 7.1, improvement of anti-tumour activity by 
optimisation of key identified structural features will be crucial in the context of progressive 
synthetic and biological research in this area.  
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Fig. 7.4 
 
It is sincerely hoped that this report encapsulates a valuable contribution to future 
researchers within the field of anti-cancer indolocarbazole study, and to those who pursue 
these endeavours I wish continuing success and determined recognition of the innate virtues 
of patience and indomitable curiosity.    
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NCI-60 anti-cancer data 
NSC: D-754605/1 (445; 10 µM) 
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NSC: D-754606/1 (442; 10 µM) 
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NSC: D-754607/1 (507; 10 µM) 
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NSC: D-754608/1 (514; 10 µM) 
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NSC: D-754609/1 (447; 10 µM) 
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                                                                          VI 
NSC: D-754610/1 (549; 10 µM) 
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                                                                          VII 
Dose-response curves of a novel anti-cancer 2-aminoindolo[2,3-a]pyrimido[5,4-
c]carbazol-4(3H)-one (443) against NCI-60 tumour cell lines  
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                                                                          VIII 
Concentration-dependent in vitro cell growth inhibition within a new anti-cancer 
indolo[2,3-a]pyrimido[5,4-c]carbazole template (443)  
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